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Abstract!
 
C. difficile is the leading cause of antibiotic associated diarrhoea worldwide.  
A lack of available tools has hindered the investigation of the molecular 
pathogenicity of this important nosocomial organism.  A library of Tn916 
transconjugants has been generated and screened for phenotypes 
associated with virulence and colonisation.  Investigation of the insertion 
sites of Tn916 in the genomes of C. difficile strains R20291 and 630!erm 
revealed an insertion bias to intergenic regions.  A 15 bp consensus 
sequence has been identified as the preferential site of insertion in strain 
630!erm.  Analysis of the genome of strain 630 revealed that this motif is 
found predominantly in intergenic regions.  These results suggest that Tn916 
is not suitable as a random mutagen in these strains, however it may be 
used as a saturating mutagen to facilitate investigation of these poorly 
described genomic regions. 
 
The tolerance of C. difficile strains to bile salts was investigated revealing 
differences in the tolerance profile of the hypervirulent strain R20291 
comparred with strain 630!erm.  R20291 appears to be inherently more 
resistant to the actions of bile than 630!erm.  The transcriptional response of 
these strains was also investigated.  The results of this study lay the 
foundation for further investigation of the role of bile in the colonisation and 
virulence of C. difficile.   
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A novel potential tool for random mutagenesis of C. difficile was developed 
using the mini transposon, mini-Tn10.  Although it was possible to introduce 
the element into C. difficile, insertion of the element into the genome of 
several C. difficile strains was not demonstrated.  This study highlights the 
potential of this type of tool, which, with further refinement, may be suitable 
for random mutagenesis of C. difficile.  The development of a mini derivative 
of Tn916, mini-Tn916 is also described. 
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Chapter 1 
 
 
1. Introduction 
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1.1. Clostridium difficile  
 
1.1.1. The bacterium 
Clostridium difficile is a motile Gram-positive spore forming anaerobic 
bacterium identified in the 1930’s by Hall and O’Toole and was originally 
known as Bacillus difficilis (Figure 1.1) 1, 2.  The bacterium is commonly 
isolated from faecal samples of neonates and the elderly, its carriage is often 
asymptomatic and is found in 2-3% of healthy adults and a high proportion of 
neonates (up to 64%) 3, 4.  In the 1970’s an association of colitis and broad-
spectrum antibiotics was observed; characterization of cytotoxin production 
identified C. difficile as the primary cause of pseudomembranous colitis 
(PMC) and as an important emerging pathogen 2, 5.   
 
The genome of the pathogenic multidrug-resistant C. difficile strain 630 
isolated from a hospital patient with severe PMC in Zurich, Switzerland has 
been fully sequenced 6.  The genome consists of a circular chromosome of 
approximately 4.3 Mb in length and a plasmid, pCD630 of 7.8 Kb (Table 1.1 
& Figure 1.2) 6.  It encodes 3,776 predicted coding sequences (CDSs) with 
low G+C content with 82.1% of CDSs on the leading strand.  It shares 15% 
of the CDSs with other sequenced clostridial genomes including Clostridium 
acetobutylicum, Clostridium botulinum, Clostridium perfringens and 
Clostridium tetani, encoding mainly essential functions 6-10.  Over 50% of C. 
difficile’s genome is unique encoding many accessory functions and mobile 
elements.  The genome contains several, often C+G rich, mobile elements 
that account for over 11% of the genome.  These include six putative 
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conjugative elements and one proven conjugative transposon (CTn) 
(Tn5397), one mobilisable transposon (Tn5398) two prophages, a prophage-
like sigK intervening sequence element and IStrons 6, 11-13. 
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Figure 1.1  Coloured transmission electron micrograph of C. difficile 
forming an endospore (red).  Taken from Aslam et al., 2005 14 
Clostridium difficile is a Gram-positive rod-shaped bacillus approximately 4-5!m in 
length.  In this transmission electron micrograph image the spore can be seen clearly 
highlighted in red. 
Feature Chromosome Plasmid 
Size (bp) 4,290,252 7,881 
G + C content (mole %) 29.06 27.9 
Coding sequences 3,776 11 
Coding density  0.087 1.39 
Average gene size (bp) 943 563 
Pseudogenes 32 0 
rRNA operons 11 0 
tRNA 87 0 
Stable RNA 54 0 
Table 1.1  General features of the genome of C. difficile adapted 
from Sebaihia et al., 2006 6 
The table displays the features of the chromosome and plasmid, pCD630, of strain 
630.  
 
 
 
Image unavailable due to copyright restrictions 
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Figure 1.2  Circular representation of the genome of C. difficile taken 
from Sebaihia et al., 2006 6 
The entire chromosome is represented by a series of concentric circles with features 
annotated using specific colours and position.  Reading externally to internally the circles 
represent the following (adapted from Sebaihia et al., 2006): 1+2 = all CDSs (transcribed 
clockwise & anticlockwise); 3 = CDSs shared with other sequenced clostridia (blue); 4 = CDSs 
unique to C. difficile (red); 5 = mobile elements (red = conjugative transposons, pink = 
prophage, blue = skin element and unknown mobile element; magenta = genomic island 
carrying ethanolamine degradation genes, pale red = Tn5398, brown = partial prophage and 
CTns); 6 = RNA genes (blue = rRNAs, red = tRNAs, purple = stable RNAs); 7 = G+C content 
(plotted using a 10-kb window); 8 = GC deviation ((G–C)/(G+C) plotted using a 10-kb window; 
khaki indicates values >1, purple <1).  Genes are colour coded as follows: dark blue = 
pathogenicity/adaptation, black = energy metabolism, red = information transfer, dark green = 
surface-associated, cyan = degradation of large molecules, magenta = degradation of small 
molecules, yellow = central/intermediary metabolism, pale green = unknown, pale blue = 
regulators, orange = conserved hypothetical, brown = pseudogenes, pink = phage & IS 
elements, gray = miscellaneous. 
 
 
 
 
 
Image unavailable due to copyright restrictions 
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1.1.2. C. difficile infection (CDI) 
C. difficile symptomatic infection is almost always associated with the prior 
use of antimicrobial therapy which leads to disruption of the normal intestinal 
flora 15, 16.  In healthy individuals the normal gut flora provides an effective 
barrier to invading pathogens in a process known as colonisation resistance 
15.  When this barrier is disrupted by administration of antibiotics, C. difficile 
is able to colonise the gut, specifically in the colon 17.  The organism is 
generally acquired from an exogenous source directly from an infected 
individual or indirectly from a contaminated environment due to its ability to 
produce highly resistant endospores 18.  The ability of C. difficile to persist in 
the environment has allowed it to become common in healthcare facilities 
and is now the leading cause of infectious diarrhoea in hospitals in 
developed countries 19, 20. 
 
Infection with C. difficile leads to a spectrum of clinical outcomes ranging 
from asymptomatic colonisation to mild self-limiting diarrhoea and severe 
symptoms including abdominal pain, fever and leukocytosis 21.  In fulminant 
or severe disease, patients experience severe diarrhoea with inflammatory 
lesions and the formation of pseudomembranes in the colon (Figure 1.3) 17, 
21.  Collectively known as C. difficile infections or CDI, there is the potential 
for life-threatening complications such as toxic mega colon or perforation, 
sepsis shock and death 16-18, 21, 22.   
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Figure 1.3 Pseudomembranes formed on the internal wall of the colon. 
Taken from Rupnik et al., 2009 17. 
An endoscopic view of the pseudomembranes on the lining of the colon composed of 
destroyed intestinal cells and leukocytes. 
 
 
 
 
Image unavailable due to 
copyright restrictions 
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Symptoms appear abruptly with production of explosive watery diarrhoea 
accompanied by abdominal pain 18.  C. difficile is widely regarded as the 
aetiological agent of PMC with 95 - 100% of cases testing positive for C. 
difficile toxinogenic strains in stool samples 2, 23.  It is unclear why one patient 
will develop PMC while others merely suffer from uncomplicated mild 
diarrhoea.  It is suggested that host factors are more important in determining 
disease outcome than bacterial virulence factors since infants and 
asymptomatic carriers can be colonized with toxinogenic strains 2. 
 
CDI or asymptomatic carriage of C. difficile has been identified in several 
animals including pigs, horses, monkeys, cats, and dogs 24.  At present there 
is no direct evidence of zoonotic transmission, however the situation is being 
closely monitored 25, 26.  C. difficile has also been isolated from a range of 
foodstuffs from America, Canada and Europe 27-33.  However, there is no 
direct epidemiological evidence to support human infections resulting from 
ingestion of contaminated foodstuffs 27. 
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1.2. CDI epidemiology, treatment and prevention 
 
After its description in 1978, C. difficile was mainly associated with the 
development of antimicrobial-associated diarrhoea, colitis and PMC in the 
elderly with interest centred on its impact on morbidity and mortality in this 
group 5.  Over the last 10 years the incidence, clinical presentation, severity 
and epidemiology of CDI has changed significantly and C. difficile is now 
regarded as a major clinical problem 34, 35.  Healthcare associated infections 
(HCAIs) are a significant financial and social burden 36.  Methicillin-resistant 
Staphylococcus aureus (MRSA) was regarded as one of the most significant 
causes of HCAI-associated infections with mandatory surveillance introduced 
in 2001, shortly followed by glycopeptide resistant enterococci (GRE) in 2004 
37.  As a result of the increasing incidence of CDI and associated mortality, 
surveillance was declared mandatory in 2004 in the UK to facilitate 
epidemiological monitoring and analysis 38.  The number of deaths attributed 
to C. difficile over the last 10 years are approximately 5-fold higher than for 
MRSA (Figure 1.4) 39. 
 
Although the epidemiology of this important nosocomial pathogen has 
changed dramatically, it is important not to over interpret the data.  Serious 
outbreaks including two at Stoke Mandeville hospital in Buckinghamshire 
between 2003-6 have led to increased media attention and publicity of CDI 
40.  Consequently, the education of health professionals has improved and 
brought C. difficile to the forefront of HCAI monitoring and prevention.  The 
differing laboratory diagnosis methods and increased awareness may have 
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led to ascertainment bias during reporting 35.  Fortunately, the statistics 
issued for 2008-9 show that the incidence of CDI associated mortality is 
decreasing, although the rates are still relatively high compared to those of 
the early part of the century (Figure 1.4) 41.  
 
1.2.1. Emergence of hyper-epidemic strains 
The changing epidemiology of CDI highlighted the emergence of a new 
seemingly hypervirulent strain characterized as PCR ribotype 027, toxinotype 
III, REA group 1 (BI) and North American PFGE type 1 (NAP1) often referred 
to as 027/NAP1 isolates 42 43.  Severe outbreaks of CDI between 2000 and 
2005 in North America, in previously low-risk populations, have been 
attributed to these isolates, which prior to 2000 accounted for less than 1% of 
the isolates in the USA 20. 
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A   
B  
Figure 1.4  Deaths attributed to C. difficile (A) and MRSA (B). 
The graphs show the total number of deaths reported to be due to or associated with C. difficile 
(A) and MRSA (B) in England and Wales.  The reported rates for C. difficile are approximately 5-
fold greater than those attributed to MRSA.  Graphs taken from the Office for National Statistics 
.44. 
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Molecular characterisation of 027/NAP1 isolates revealed an 18 bp deletion 
(position 330-347) in the gene tcdC, a putative negative regulator of toxin 
gene expression (tcdA & tcdB) 43, 45.  This leads to an in-frame deletion of the 
tcdC transcript, however the protein encoded from this transcript is active in 
vitro and in vivo 46.  In addition to this in-frame deletion, a 1-base-pair 
deletion (!117) exists in the 5’ end of tcdC leading to a frameshift and a 
premature stop in the early part of the gene 45, 46.  The resulting 65-residue 
fragment is unlikely to be functional disrupting the regulatory functions of 
TcdC 45.  These strains have been shown to produce high levels of TcdA and 
TcdB in vitro and it has been suggested that this may account for the 
increased severity of CDI arising from infection with 027/NAP1 isolates 43.  
This theory was not supported by assessment of 027/NAP1 strains in a 
complex gut model; in these experiments the strain was shown to produce 
toxin for a longer period of time rather than producing more toxin per unit 
time 35, 47.  Consequently, some researchers term these strains as hyper-
epidemic rather than hypervirulent strains.  Furthermore, various deletions in 
tcdC have been observed in non-epidemic PCR-ribotypes, suggesting that 
disrupted toxin regulation is not solely responsible for the increased 
predominance of these strains 48. 
 
027/NAP1 strains also produce a binary toxin (CDT), whose role in 
pathogenesis is unclear, and possess greater resistance to fluoroquinolones 
and third generation cephalosporins than older isolates of the same type and 
contemporary non-outbreak strains 35, 45, 49, 50.  It has been observed that 
027/NAP1 strains have increased sporulation capacity, possibly aiding their 
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dissemination and persistence in the environment 51, 52.  027/NAP1 isolates 
have spread worldwide, with significant outbreaks in North America and 
Europe 35, 43, 53-55.  The features of these strains described above, seem to 
have contributed to their rapid and widespread dissemination, however, 
other, as yet unidentified, factors may also be involved. 
 
1.2.2. Risk factors for CDI 
Several risk factors have been associated with the development of antibiotic-
associated diarrhoea (AAD) (Figure 1.5), the foremost risk factor being 
disruption of the gastrointestinal (GI) flora.  This is generally attributed to 
antimicrobial therapy, which destroys the colonization resistance of the bowel 
by killing the normal gut flora.15, 56, 57.  Approximately 2-3% of healthy adults 
are asymptomatic carriers of C. difficile and this figure rises to 5-15% post 
antibiotic exposure, the subjects show no physical symptoms yet are positive 
for C. difficile toxins 42, 58. 
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Figure 1.5  Risk factors associated with development of antibiotic-
associated diarrhoea (AAD), adapted from McFarland, 2008 59. 
The major risk factors for the development of AAD, of which C. difficile is the leading 
cause, can be divided into 4 broad areas: medication, host factors, pathogen exposure 
and procedures which disrupt the natural colonic flora.  The diagram lists some of the 
factors that have been associated with increasing the risk of developing AAD. 
Host factors 
Age >65 years 
Female 
Co-morbidity 
Reduced immune responses 
Prior AAD history 
 
Risk factors for AAD 
Medication 
Antibiotics 
Chemotherapy 
Antacids (proton pump inhibitors)? 
Pathogen exposure 
Prolonged hospitalisation 
Type of institution 
Type of accommodation – infected room 
mate/sharing of lavatory facilities 
Prior admission to healthcare institution 
Colonisation pressure 
Procedures 
Surgery 
Nasogastric tube 
Enemas? 
Diagnostic endoscopy? 
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Almost all antibiotics have been associated with AAD and even short 
courses of antibiotics including perioperative prophylactic antibiotics, 
routinely given to patients undergoing surgery to prevent surgical site 
infections, can be associated with an increased risk of developing AAD 59-61.  
Longer durations of antibiotic therapy may increase the relative risk of 
developing AAD 62.  Higher rates of AAD are associated with broad-
spectrum antibiotics including penicillins (particularly ampicillin/amoxicillin), 
cephalosporins (particularly third generation), and clindamycin 56, 57, 63-66. 
Recently, there has been increased interest in the use of proton pump 
inhibitors (PPIs) and the risk of CDI.  However, there have been conflicting 
reports on whether there is a significant association 67-71. 
 
Host factors are also very important when evaluating the risk of developing 
CDI.  The predominant factor is age, CDI is more commonly associated with 
the elderly (>60 years) than with any other age group and the highest 
infection rates are seen in the over 65’s 56, 63.  Co-morbidity has been shown 
to be significantly associated with CDI and this is not limited to the treatment 
of underlying diseases with antibiotics 59.  It is likely that there is an 
association with the immune response of the patients, which may be 
reduced due to the underlying disease and poor general health 59.   
 
A strong association exists between hospital admission and C. difficile 
colonisation, with the duration of stay and stay in intensive care units 
increasing the chance of exposure to C. difficile 14.  It was thought that CDI 
occurred almost exclusively in healthcare associated environments, which 
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serve as a reservoir of infection due to the high density of at risk individuals.  
Recently, there have been increasing reports of community-acquired CDI, 
although the definition of such cases is not clear limiting the epidemiological 
information available 35.  Finally healthcare-associated procedures affecting 
the intestines can lead to disruption of the colonic flora and possibly 
introduction of C. difficile spores 59. 
 
One of the major issues surrounding CDI infections is ease with which spores 
disseminate in the healthcare environment.  Efficient and rapid isolation 
methods are imperative in containing the spread of the infection, however the 
eradication of spores and patient containment is a major problem in 
healthcare facilities.  It is crutial that the infection is identified as early as 
possible to isolate the patient, introduce barrier-nursing techniques and 
change the treatment regime accordingly 2, 21. 
 
1.2.3. Treatment and Recurrence 
Promiscuous mobile genetic elements have contributed to the dynamic 
nature of many bacterial genomes, facilitating the generation of multi-drug 
resistant strains 72, 73.  C. difficile is a prime example of a bacterium which 
contains a plethora of mobile genetic elements originating from a variety of 
bacterial strains and genera 6, 74.  Elements frequently contain antimicrobial 
resistance genes with clinical isolates often showing resistance to 
tetracycline, macrolide–lincosamide–streptogramin B (MLSB) and 
chloramphenicol 75.  Resistance to tetracycline in strain 630 is encoded by 
tet(M) found on CTn3/Tn5397 and resistance to erythromycin results form the 
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presence of two copies of ermB on Tn5398 6.  Metronidazole and oral 
vancomycin are both effective agents for treatment of C. difficile infection, 
however there are reports of treatment failure, particularly with metronidazole 
76.  Initially, the cumulative failure rates of these two drugs was almost 
identical (2.5% and 3.5% respectively), however since 2000 the cumulative 
failure rates for metronidazole have been reported as high as 18.2% 14, 34, 76, 
77.  The 027/NAP1 strains in particular show a significant level of resistance 
to metronidazole 34, 77.  However, the current recommendations are to 
administer metronidazole as a first-line agent for mild infection due to its low 
cost and the concern over the increase in vancomycin-resistant nosocomial 
bacteria, with vancomycin only recommended for severe CDI 34.  
 
An alternative treatment called tolevamer, a novel non-antibiotic polymer that 
binds and neutralises TcdA and TcdB, was compared with vancomycin and 
metronidazole treatment in two controlled phase 3 trials.  The results of only 
one of the trials are available and it concluded that tolevamer was inferior to 
antibiotic treatment although a reduction in recurrence was observed 78. 
 
A further complication of CDI pathology is the incidence of recurrence or 
relapse with reported rates between 8-25% of patients, although it has been 
suggested this may be as high as 50% 14, 21, 42.  Antibiotic treatment destroys 
the colonisation resistance of the colon facilitating recurrent infection, 
typically around 4 weeks after treatment 34.  The recurrence can result from 
reinfection or through persistence of the initial strain and may involve 
repeated episodes.  This has also been confounded by the increasing CDI 
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incidence in previously low risk populations including children and pregnant 
women 79, 80.  Host immune response is thought to be an important factor in 
recurrence with higher levels of antibodies against TcdA and TcdB present in 
individuals who do not develop recurrent CDI 81.   
 
Treatment with intravenous immunoglobulin has shown some success, 
although this has not been thoroughly investigated, and has prompted the 
development of a vaccine 14, 82.  Several vaccine types are being investigated 
including a toxoid vaccine, live vaccines with Salmonella typhimurium and 
Vibrio cholerae acting as vector strains expressing an attenuated TcdA, and 
conjugate vaccines combining the non-toxic peptide of TcdA with 
polysaccharides from other bacteria 83-86.  Finally, the use of probiotics as a 
preventative measure for CDI has also been investigated however, there is 
currently insufficient evidence to support their use, particularly due to the lack 
of standardization between the studies 87-89. 
 
1.2.4. Financial burden of CDI 
The increasing incidence of CDI along with other HCAI is a major burden 
worldwide both socially and economically 90.  It has been predicted that 
HCAI’s cost the UK over £1 billion in 2005 and led to a number of likely 
preventable deaths 91.  In the UK the National Health Service has taken 
steps to minimise and effectively control HCAI’s, including dedicated 
infection control staff to monitor and identify infections/risks, routine 
screening of patients for MRSA, the introduction of antimicrobial 
pharmacists, implementing intelligent hospital design and by the provision of 
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specialist isolation wards where possible 92, 93.  Attention has also been 
given to the further education of healthcare professionals to allow them to 
identify infections quickly and minimise risks. 
 
1.3. Molecular pathogenesis and virulence 
 
Bacterial pathogenesis relies on complex interactions between the host and 
the bacterium, with factors that aid the pathogenicity of an organism known 
as virulence factors 94.  Those factors that act directly to contribute to 
pathology are termed aggressins while others promote colonization thus 
enabling the production of aggressins 15.  Not all strains of C. difficile have 
the same pathogenic potential and it is estimated that 25% of strains are 
non-pathogenic and of those that produce toxins, a proportion do not cause 
disease 42. 
 
1.3.1. Cytotoxins and the PaLoc 
After colonisation, C. difficile can produce potent toxins, the enterotoxin TcdA 
and the cytotoxin TcdB, which are considered to be the bacterium’s foremost 
virulence factors 95.  These toxins are largely responsible for the intestinal 
damage seen in symptomatic cases of CDI 96, 97.  They belong to a family of 
large toxins found in various members of the genus Clostridium; including 
lethal toxin (TcsL) and hemorrhagic toxin (TcsH) from Clostridium sordellii, 
alpha toxin (TcnA) from Clostridium novyi; and TpeL from C. perfringens 98-
100.  Members are grouped due to their large size, between 250-308 KDa, 
and sequence identity ranging from 36-90% 101-104.  Both TcdA and TcdB are 
monoglucosyltransferases that act intracellularly leading to the inhibition of 
members of the Rho family of GTPases, including Rho, Rac and Cdc42.  
These small regulatory proteins of the eukaryotic actin cell cytoskeleton are 
inhibited by glucosylation of a threonine residue which locks these proteins in 
an inactive conformation blocking all downstream signalling pathways (Figure 
1.6) 101, 105, 106.  This leads to disruption of the actin cytoskeleton and tight 
junctions resulting in decreased transepithelial resistance, fluid accumulation 
cell rounding and eventually apoptosis of the exposed cell 97.  The toxins also 
cause the release of inflammatory mediators from intestinal epithelial cells, 
macrophages and mast cells.  The cytokines affect enteric nerves and 
sensory neurones promoting an influx of inflammatory cells adding to fluid 
secretion and inflammation 17, 107. 
 
Structurally, the toxins are formed of a C-terminal receptor binding domain, a 
central translocation domain and a catalytic N-terminal domain responsible 
for the toxic activity 97, 101, 105.  Originally this structure-function relationship 
was accepted due to similarity with the model of other AB-type toxins 
including diphtheria toxin, which included a biologically active domain and a 
binding or translocation domain 108.  However, Jank and Aktories (2008) 
propose that a multi-modular structure more accurately describes the 
structure function relationship of these toxins known as the ABCD domain 
structure model (Figure 1.7) 101.  The biologically active glucosyltransferase 
A-domain is located at the N terminus and includes the DXD motif involved in 
Mn2+ coordination.  The cysteine protease C-domain, similar to V. cholerae 
RTX toxin, is located adjacent to the glucosyltransferase domain (DHC). 
43
  
 
44 
 
 
Figure 1.6  Cartoon of the mechanism of action of TcdA and TcdB taken 
from Carter et al., 2010 101, 106. 
Rho GTPases that control a number of signalling pathways in the cell.  They are believed to 
be particularly important during host-pathogen interaction and considered essential for 
epithelial barrier functions, immune cell migration, adhesion, phagocytosis, superoxide 
production, cytokine secretion and immune cell signalling.  Thus the presence of TcdA and 
TcdB prevent the normal functions of Rho GTPases leading to a breakdown in cell signalling 
and eventually death of the cell. 
Figure 1.7  Proposed ABCD domain structure model of the clostridial 
glucosylating toxin TcdB taken from Jank and Aktories, 2008 101. 
The ABCD domain structure model of clostridial glucosylating toxin is shown for TcdB. The 
biologically active glucosyltransferase A-domain is located at the N terminus and includes the 
DXD motif involved in Mn2+ coordination.  The C terminus (domain B) consists of polypeptide 
repeats and is involved in receptor binding.  It is suggested that the DXG motif is possibly 
involved in processing of the toxins and that the hydrophobic region may be involved in pore 
formation and delivery of the catalytic domain into the cytosol of the target cell. 
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The central region (D-domain) contains a DXG motif, possibly involved in 
processing of the toxins, and a hydrophobic region that may be involved in 
pore formation and delivery of the catalytic domain into the cytosol of the 
target cell.  The C terminus (B-domain) consisting of polypeptide repeats is 
involved in receptor binding, processing and cutting of the toxin.  
Crystallization of a fragment of the C-terminal repeats revealed a solenoid-
like structure allowing the entire C-terminal structure to be deduced 101, 109.  
The toxins have different tropism for host cells, TcdA has been shown to use 
glycoprotein gp96 as a co-receptor and binds more effectively to the apical 
side, whereas TcdB binds to an unknown receptor on the basolateral side of 
the host cell 17, 102, 110.  After binding, the toxins are endocytosed into the cell 
where proteolytic cleavage of the catalytic domain from the holotoxin occurs 
aided by the host derived co-substrate inositol phosphate; the catalytic 
domain is then transferred to the cytoplasm through a toxin-mediated pore 17, 
111, 112. 
 
The toxin genes and their regulators are located within a 19.6 Kb 
chromosomal pathogenicity locus known as the PaLoc which is found in the 
same chromosomal integration site in all toxinogenic strains.  In non-
toxinogenic strains (A-B-) this locus is completely absent and replaced by 115 
bp of non-coding sequence 113, 114.  The PaLoc contains five genes, tcdA 
encoding toxin A, tcdB encoding toxin B, two regulatory genes tcdC and tcdR 
and, tcdE encoding a holin-like protein (Figure 1.8) 115.  TcdC is an acidic 
membrane associated protein thought to act as a negative regulator of toxin 
production 46.  It shares no homology with other previously described 
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regulatory proteins and recent investigations reveal a potentially unique 
mechanism of action 46.  TcdR, formerly known as TcdD, similar to the TetR 
and BotR regulators of tetanus and botulinum toxin respectively, is thought to 
be a positive regulator of toxin expression and activates toxin gene 
expression as an alternative RNA polymerase sigma factor 115, 116.  
Expression of TcdR is also controlled by environmental conditions that can 
trigger or repress toxin gene expression 6, 117.  The tcdE gene encodes a 
protein with similarity to bacteriophage holins, which are cytolytic proteins 
that lyse bacterial hosts to allow the release of progeny phages; it is 
suggested that TcdE may function as a lytic protein facilitating the release of 
TcdA and TcdB to the extracellular environment 118. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8  Cartoon of the PaLoc of C. difficile taken from Rupnik et al., 2009 17. 
The PaLoc of C. difficile contains 5 ORFs encoding the cytotoxins TcdA and TcdB, along with the two regulatory proteins TcdC 
and TcdR.  TcdE is thought to function as a lytic protein facilitating the release of TcdA and TcdB to the extracellular 
environment.   
47 
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The sequence of the PaLoc is variable and strains displaying changes in this 
region are defined as toxinotypes.  This method, developed by Rupnik et al. 
(1998) divides the PaLoc into ten regions of 2 Kb, PCR is used to amplify the 
regions which are subjected to restriction digest.  The restriction profile length 
polymorphisms for two of the ten fragments are then inspected and strains 
assigned to the appropriate toxinotype 119, 120.  There are currently 10 groups 
(I to X) in addition to the reference strain VPI 10463 classified as type 0.  It is 
not known whether this classification relates to disease outcome, with the 
exception of type III, which includes the 027/NAP1 isolates showing 
increased virulence 106, 121. 
 
The majority of strains that cause disease in humans produce both toxins, 
however CDI can also be caused by strains producing TcdB alone (A-B+) 49, 
122, 123.  Such strains account for a very small percentage of the C. difficile 
population, yet have been responsible for several hospital outbreaks in 
Europe and Japan 49.  They are able to cause the same spectrum of 
diseases, however, severe disease is more likely with high mortality rates 
(14-66%) 123.  It is not clear why these strains lead to a more severe disease 
although it has been postulated that this may be due to a lack of a TcdA-
specific immune response, a key determinant in controlling disease severity 
123.  TcdB has been shown to be more potent than TcdA in experiments on 
human tissue causing mucosal necrosis and decreasing barrier function 124.  
Early studies suggested that TcdA alone was able to cause an enterotoxic 
effect when applied intragastrically in the hamster model; conversely TcdB 
had no effect when applied alone, symptoms were only evident when TcdB 
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was supplemented with TcdA or applied to previously damaged gut mucosa 
125.  This suggested that TcdA was required as a co-factor for disease with 
the toxins acting synergistically 106. 
 
The ability of either TcdA or TcdB alone to cause disease is a contentious 
issue.  The Rood laboratory recently published a study suggesting that TcdB 
was essential for C. difficile virulence in the Golden Syrian hamster model, 
generally accepted as the most appropriate animal model for C. difficile 
pathogenesis 126-128.  Lyras et al. (2009) generated three isogenic mutants in 
an erythromycin sensitive derivative of strain 630, JIR8094, using a gene 
specific disruption system 126.  An unstable plasmid, designated as the 
recombination vector was introduced into C. difficile carrying homologous 
DNA sequence to a specific part of the genome.  Disruption of a gene is 
achieved through insertion, via homologous recombination, leading to 
specific inactivation.  Truncated, and inactive toxins were generated by 
insertion of the plasmid in the catalytic region of each of the toxin genes in 
multiple independent experiments.  Each TcdA and TcdB negative mutant 
was assessed in vitro and in vivo using the Golden Syrian hamster model.  
The TcdA mutants (A-B+) were found to be highly toxic producing the same 
cytotoxic phenotype as the wild type strain in vitro.  Challenge of the hamster 
model with this mutant led to colonisation and death (94% mortality) similar to 
that observed for the wild type strain, confirming that toxin B alone was able 
to cause disease and mortality.  The TcdB mutants (A+B-) were shown to be 
significantly less cytotoxic in vitro, comparable to the avirulent strain 
phenotype, although a low level of cytotoxicity attributed to TcdA was 
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observed.  Challenge of the hamster model with the TcdB negative mutants 
led to colonisation similar to that seen for the wild type strain however, 
colonisation did not lead to death in almost 80% of the animals.  Together the 
data presented in this study suggest that TcdB is required for virulence in C. 
difficile 126.   
 
A similar study by Kuehne et al. (2010) contradicts these results suggesting 
that both A+B- and A-B+ strains are able to cause colonisation and mortality in 
vivo 129.  In this study, the ClosTron, a targeted gene knock out system, was 
used to generate three isogenic mutants containing a single intron insertion 
in the catalytic domain of tcdA and/or tcdB rendering the toxins non-
functional.  Each mutant was examined in vitro using the cytotoxicity assay 
and in vivo using the Golden Syrian hamster model.  Both the A-B+ and A+B- 
strains produced a cytopathic effect in vitro and led to colonisation and 
mortality in vivo confirming that TcdA and TcdB both have the potential to 
cause significant damage to intestinal epithelium leading to mortality in the 
hamster model.  The double mutant (A-B-), with two intron insertions, showed 
a complete loss of toxicity in vitro and in vivo, as anticipated.  Both authors 
thoroughly investigated the results of the in vivo work confirming, with an 
exception in the Lyras et al. study, the presence of only the inoculated strain 
post mortem 126, 129.  Additionally, both groups state that gene inactivation is 
stable, although hamster deaths in the Lyras et al. study for the A+B- test 
group have been attributed to revertants where the plasmid insertion has 
been lost 126, 130.  The authors of the later study suggest that inherent 
differences between the hamsters used and the origin of the erythromycin 
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sensitive A+B+ strain investigated may account for the discrepancies 129.  
Both 630!erm and JIR8094 were generated through serial sub-culture of 
strain 630 meaning that either one could have obtained one or more 
secondary mutations in the toxin genes 129, 131, 132.  Neither of these groups 
has complemented the mutants meaning that definitive conclusions cannot 
be drawn from these conflicting reports.   
 
Interestingly both studies found that the TcdB mutants (A+B-) produced 
between 2.2-3.3-fold more TcdA than the wild type strains (A+B+), confirmed 
by cytotoxicity assays and quantitative real-time reverse transcriptase PCR 
(qRT-PCR).  Although the Kuehne et al. study suggested that expression of 
both toxins was required to kill hamsters in vivo, the authors point out that the 
DNA sequence of the toxin genes, particularly TcdB, is highly variable in 
naturally occurring strains and that as yet no naturally occurring A+B- strains 
have been isolated from clinical samples 129.  It is not clear whether this is 
because such strains have not yet evolved or, that due to the routine 
diagnostic techniques used to identify C. difficile in clinical samples, these 
cases have been missed 129. 
 
Toxin production varies from strain to strain and is influenced by 
environmental conditions 133, 134.  Expression is significantly increased during 
entry into stationary phase and can be regulated by environmental 
conditions; for example, an increase in temperture from 22oC to 37oC has 
been shown to increase toxin production 135.  It is postulated that toxin 
expression is autoregulated in response to environmental signals such as the 
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presence of nutrients in the growth medium including glucose, certain amino 
acids, butyric acids and butanol 97, 136.  The global regulator of gene 
expression, CodY, has been shown to negatively regulate toxin gene 
expression in C. difficile 117.  Inactivation of CodY led to repression of all five 
genes in the PaLoc during exponential growth and stationary phase in 
tryptone-yeast medium.  It is suggested that in vivo CodY acts as a direct 
repressor of tcdR expression leading to downstream effects on tcdB, tcdE 
and tcdA expression.  A link between toxin gene expression and nutrient 
limitation was also observed, GTP and branched-chain amino acids were 
shown to be co-repressors for CodY in C. difficile, as they are for CodY in B. 
subtilis 117.  Thus in nutrient limitation during colonisation, toxin expression 
may increase, leading to lysis of epithelial cells which release nutrients to 
support C. difficile growth 117.  Expression of CodY is high during the early 
exponential phase but declines during the stationary phase, a point at which 
expression of both toxin A and B increases 46, 134. 
 
1.3.2. Binary toxin 
In addition to the cytotoxins, a third toxin, binary toxin also known as C. 
difficile transferase (CDT), which is independent of the PaLoc, is produced by 
approximately 5-6% of identified strains, including the 027/NAP1 epidemic 
isolates 20, 43.  CDT is a two-subunit toxin which belongs to a family of binary 
actin-specific ADP-ribosyltransferases produced by a range of pathogenic 
clostridia including C. perfringens (iota toxin), Clostridium spiroforme (CST), 
and C. botulinum (C2 toxin) 137, 138.  The genes cdtA and cdtB encode the 
enzymatic and binding components respectively and together with the 
  
 
53 
regulatory gene cdtR are located chromosomally at the binary toxin locus 
(CdtLoc) (Figure 1.9) 17, 139.  The toxin acts through the binding of CdtB to 
host cells allowing the translocation of CdtA into the cytosol.  Here CdtA 
ADP-ribosylates actin molecules, blocking polymerisation, inhibiting 
elongation and favouring depolymerisation of F-actin resulting in disruption of 
the cytoskeleton 17, 140.  
 
Although the role of CDT in disease severity and clinical outcome is unclear, 
there is frequent co-expression of CDT in hypervirulent strains of C. difficile 
and CDT is usually produced by strains with variant yet functional tcdA and 
tcdB genes 140, 141. Purified CDT has been shown to cause fluid accumulation 
and haemorrhage in ligated ileal loops and is cytotoxic to Vero cells in vitro 50, 
142.  Additionally, the majority of isolates from animals have functional CDT, 
suggesting a role in the disease of animals 143.  However, naturally occurring 
CDT producing A-B- strains can colonise but are avirulent in the hamster 
model suggesting that CDT alone is unable to cause disease 50.  Recent 
investigation by the Aktories group demonstrated that CDT, iota toxin and C2 
toxin could induce the formation of a novel type of microtubule structure; 
these long, thin and dynamic microtubule-based structures protrude from 
epithelial cells aiding the adherence of clostridial cells 140. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9  Binary toxin locus (CdtLoc) and toxin structure taken from Rupnik et al., 2009 17. 
CDT is encoded on a chromosomal locus CdtLoc, which is not connected to the PaLoc.  CDT is composed of two 
unlinked proteins, CdtA the catalytic domain encoded by cdtA and CdtB the translocation and binding domain encoded by 
cdtB.  Expression of these genes is regulated by cdtR 139.  
54 
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1.3.3. Surface layer proteins and adhesion 
Adhesion to host tissue is an important step in virulence for many 
pathogens.  Successful colonisation by C. difficile requires adhesion of the 
cells to the gut mucosa to overcome host defence mechanism such as 
peristaltic movement and the associated flushing affects 15, 144. 
 
Some strains of C. difficile have peritrichous flagella, considered an 
important adhesin, with flagellated strains showing a 10-fold higher level of 
adherence to mouse caecum compared to non-flagellated strains 145, 146 
 
C. difficile cells also produce an S-layer, a paracrystalline array of proteins 
outside the cell wall, possibly involved in attachment and phenotypic 
variation required to evade host defences 18, 147, 148.  There is significant 
variability between the surface proteins of different strains, particularly in 
surface layer protein A (SlpA) 17.  The layer is composed of two protein 
subunits (one high- and one low-molecular weight) encoded by a single gene 
slpA; 28 paralogues of this gene exist in the genome including those 
encoding Cwp66, a heat-shock inducible adhesin and Cwp84, a cysteine 
protease 6, 149, 150.  Cwp66 has been shown to mediate binding to Vero cells 
(kidney epithelial) in vitro after heat-shock 151, 152.  It is hypothesised that 
SLPs may be involved in pathogen-host interactions critical to pathogenesis 
due to their abundance and localisation on the outer surface of the cell 153.  
Evidence for their role in the adhesion of C. difficile has been demonstrated 
in vitro and in vivo in the Golden Syrian hamster model 152, 154. 
 
  
 
56 
1.3.4. Sporulation and germination 
C. difficile produces highly resistant spores that are able to withstand 
desiccation, chemicals including alcohol and certain disinfectants, oxygen, 
and temperature extremes 155-158.  The metabolically dormant spores are 
responsible for person-to-person transmission due to their inherent ability to 
persist in the environment.  Sporulation occurs when vegetative growth 
cannot be maintained.  The process of sporulation in C. difficile is poorly 
understood, although some parallels have been drawn with the process in B. 
subtilis 155. Asymmetric cell division leads to the generation of thick 
concentric external layers - the spore coat and cortex, which protect the 
cytoplasm and allow the bacteria to survive in harsh environments (Figure 
1.10) 155.  The initiation of sporulation may be based on a range of 
environmental and physiological signals including nutrient limitation, cell 
density and DNA damage and synthesis 159.  
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Figure 1.10 Structure of the C. difficile spore taken from Lawley et al., 
2009 155. 
A transmission electron micrograph of a sectioned C. difficile spore.  The spore 
ultrastructure including the exosporium, coat, cortex, core, membrane, and ribosomes can 
be seen.  The black bar represents 100 nm.  
 
 
 
 
Image unavailable due to copryright restrictions 
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In B. subtilis two regulatory systems control spore formation, the transcription 
factor Spo0A and a series of alternative sigma factors of RNA polymerase, 
which appear to be conserved in all sequenced species of Bacillus and 
Clostridium 159-161.  True Spo0F and Spo0B homologues, based on protein 
sequence homology, have not been found in the genomes of sequenced 
clostridia 162.  It is believed that in the clostridia the sporulation initiation 
pathway has remained like a two-component signal transduction system 
where signals are sensed by sporulation associated sensor kinases that 
phosphorylate Spo0A directly, and has not evolved into a multicomponent 
phosphorelay present in Bacillus 162-164.  Spo0A is thought to be used by 
spore-forming bacterial pathogens to modulate their virulence and survival 
responses, for example in C. perfringens Spo0A is involved in sporulation 
and toxin production 163.  In C. difficile, however, the link between sporulation 
and toxin production has not been fully investigated 133, 165-167.  A recent study 
by Underwood and colleagues (2009) found that inactivation of Spo0A using 
the ClosTron led to a number of effects including a marked reduction in toxin 
production 162.   
 
Similarly, the process of spore germination is also poorly understood.  Once 
ingested, germination occurs in the anaerobic environment of the large 
intestine in response to external stimuli.  In Bacillus and many Clostridium 
species spores germinate in response to amino acids, nucleosides, 
carbohydrates or potassium ions.  Interestingly, C. difficile spores have 
shown an increased level of germination in response to cholate derivatives 
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found in bile, although this has been disputed (see chapter 3 for more details) 
168-171. 
 
Persistence is a major issue in healthcare environments, limiting effective 
control and confinement of infection 172.  Interestingly, sub-inhibitory 
concentrations of non-chlorine based cleaning agents actually increased 
sporulation capacity 51, 172.  Evidence suggests that epidemic strains of C. 
difficile including ribotype 027 and 001 have an increased inherent 
sporulation capacity which is likely to have contributed to the efficient 
dissemination and spread of these strains 51, 52, 162.  However, researchers at 
the Minton laboratory question these results, they did not observe a 
difference in sporulation of the epidemic strains compared to standard 
laboratory strains 173, 174. 
 
1.3.5. Additional putative virulence factors 
The role of other factors in C. difficile virulence is less well understood.  
These may include chemotaxis, presence of flagella and capsule, and 
processes involved in iron sequestration, hyaluronidase (hydrolytic activity), 
proteases and collagenase activity 15, 18.  Genomic analysis has revealed 
that C. difficile has the potential to utilize a wide range of carbohydrates due 
to the presence of various genes required for metabolism and transport 6.  
This may be an important feature enabling the bacteria to survive intestinal 
passage.  It has also been observed that C. difficile contains two orthologues 
of genes found in Listeria monocytogenes that are thought to be responsible 
for bile tolerance; these genes have not been identified in other sequenced 
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clostridia 6.  Resistance to bile is an essential feature of GI flora and similarly 
of enteric pathogens allowing colonization and survival 175.  Bile is a potent 
detergent enabling the solubilisation and emulsification of lipids.  It acts as 
an antimicrobial agent causing cell lysis by dissolving phospholipids, 
cholesterol and proteins of the cell membrane 175.  Therefore, the ability of C. 
difficile to avoid lysis and damage to the cell wall is an important colonisation 
factor.  Although the mechanism of this resistance is not fully understood, 
comparisons and suggested mechanisms can be inferred from other Gram-
positive bacteria.  It has also been postulated that the presence of bile and 
bile salts may trigger the germination of spores when entering the small 
intestine, as they have been shown to enhance germination in vitro 176. 
 
1.4. Tools for genetic analysis and manipulation 
 
Progress in understanding the molecular pathogenicity of CDI has been 
hindered by the lack of genetic tools for effective gene transfer 18.  
Historically, the genetic manipulation of C. difficile has been extremely 
difficult, it has not been possible to introduce DNA through electroporation or 
chemical transformation 177.  However, recent advances including genome 
sequencing projects and the development of genetic tools such as shuttle 
vectors and the ClosTron have resulted in some significant advances in C. 
difficile research 130, 132, 177. 
 
Advances have been made in the genomics field, facilitating rapid and cost 
effective sequencing of entire bacterial genomes.  Sequence information has 
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provided crucial insights into the make-up and organisation of the genome of 
C. difficile.  This has allowed comparisons with other well-studied organisms 
to identify putative virulence-associated genes and investigation of the 
evolution of C. difficile strains 6, 178. 
 
Like the genomes of many other bacteria, the clostridial genome exists in a 
fluid and dynamic state due to the presence of extra-chromosomal elements 
such as plasmids and the presence of mobile genetic elements such as 
transposons (Tns). Mobile genetic elements, mainly conjugative transposons 
(CTns) make up almost 11% of the genome of C. difficile strain 630 and are 
predominantly responsible for the varied and wide ranging antibiotic 
resistance phenotypes seen in this strain 6. 
 
1.4.1. Transposons (Tns) 
Tns are mobile genetic elements made from discrete fragments of DNA that 
are able to relocate from one genomic location to another 179.  Transposable 
elements, first observed by Barbara McClintock, are ubiquitous from bacteria 
to human cells and have significantly contributed to genome content, 
plasticity and evolution 180.  Their movement is tightly regulated and their 
presence can significantly influence gene expression.  Host organisms have 
developed a range of defence mechanisms to reduce their movement, which 
can be potentially harmful, such as DNA methylation and RNA interference to 
reduce the expression of transposon encoded proteins 181, 182. 
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Transposable elements and their transposition processes have been well 
studied in genetically amenable bacteria.  They have been used to develop 
molecular tools for random insertion mutagenesis, facilitating the study of 
specific genes and genome organisation 179.  The use of Tns as mutagens 
has been focused on well-characterised elements from Gram-negative 
bacteria, with those that insert at random or near random being preferred.  
Other mobile elements play a role in genome plasticity and evolution 
including plasmids, mutator bacteriophage, integrons, mobile introns, 
shufflons, conjugative transposons, integrative conjugative elements and 
pathogenicity islands.  
 
Transposable elements range in complexity; simple elements are known as 
insertion sequence (IS) elements consisting of a gene(s) for transposition 
bounded by inverted repeat sequences such as IS1.  Composite 
transposons, such as Tn5 and Tn10, contain additional genetic information 
such as antibiotic resistance genes, which are flanked by IS elements (Figure 
1.11).  More complex elements, including Tn916, have hybrid qualities of 
transposons, plasmids, and bacteriophages 179. 
 
The composite Tn, Tn5, contains genes for resistance to kanamycin, 
bleomycin, and streptomycin and two inversely orientated IS50 elements.  
The IS50 elements are not identical, with IS50R encoding functional proteins 
for transposition, while IS50L encodes non-functional truncated proteins 183.
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Figure 1.11  Schematic diagram of the genetic organisation of IS1, 
Tn5 and Tn10 adapted from Hayes, 2003 179 
IS1 is an example of a simple transposable element.  The triangles represent repeat 
sequences and the black arrows represent genes involved in the transposition of the 
element.  Tn5 and Tn10 are composite transposons, which have additional genes 
including antibiotic resistance genes (shown by coloured arrows) flanked by two inversely 
orientated copies of IS50 and IS10 elements, respectively.  
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The overlapping genes on IS50R produce transposase (Tnp) and a truncated 
version of Tnp (Inh) which downregulates Tnp, thus inhibiting transposition to 
promote movement of the transposon in the genome.  Each of the IS50 
elements contains a 19 bp repeat sequence at its termini, which are crucial 
Tnp binding sites.  Tn5 is an excellent model for understanding cut and paste 
transposition where the element is precisely excised from its current position 
and inserted into a new target location via a stepwise process 184, 185.  The 
composite transposon Tn10 will be discussed in detail in chapter 4.   
 
1.4.1. Conjugative transposons (CTns) 
CTns are a family of mobile genetic elements that are able to transfer 
themselves from the genome of a donor cell to another (recipient) via 
intimate contact using a conjugation-like mechanism.  The mechanism of 
transposition is unique to this group, moving by excision from the donor DNA 
molecule, circularization and insertion into the target site of the recipient 186-
188.  These elements are found extensively within bacteria and are highly 
promiscuous, spanning large phylogenetic distances 187.  CTns are 
considered to be one of the major vectors responsible for the spread of 
antibiotic resistance, by direct transfer and mobilization of other plasmids 
and Tns 189-191.  C. difficile strain 630 has six putative CTns, and the 
extensively studied Tn5397 which mediates tetracycline resistance 6. 
Tn916 (18.3 Kb) was the first CTn to be identified, it was found in the 
chromosome of haemolytic multidrug-resistant Enterococcus faecalis DS16; 
the transposon has a broad host range and is responsible for the transfer of 
the tetracycline-resistance determinant tet(M) 189.  A closely related CTn, 
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Tn1545 from Streptococcus pneumoniae, has been shown to behave 
similarly to Tn916, carrying the tet(M) determinant and additionally 
erythromycin (ermAM) and kanamycin (aphA-3) resistance determinants 191, 
192. 
 
Due to its broad host range Tn916 has been used as a mutagen in several 
different species and for the introduction of heterologous DNA 193.  Through 
filter-mating with Bacillus subtilis it is possible to introduce Tn916 and 
possibly other transposons into the C. difficile genome, although transfer 
frequencies are relatively low (10-8 per donor) 194.  It has been discovered 
that Tn916 preferentially inserts into AT-rich sites that have limited sequence 
homology with the ends of the element 195.  In C. difficile Tn916 was shown 
to insert into a single site in strain CD37 and multiple sites in strain 630 and 
CD79-685 193.  Due to the insertion site preferance, particularly in CD37, its 
suitability for random mutagenesis is limited 131, 195.  
 
1.4.2. Other transposon-based mutagenesis systems 
A number of Tns have been investigated for their use as mutagens of Gram-
positive bacteria, two examples are miniTn10 (a derivative of Tn10) and 
mariner-based Tns 196.  MiniTn10 is a composite transposon harbouring an 
antibiotic resistance cassette flanked by IS10 elements in inverted 
orientation (discussed in detail in chapter 4) 197.  The transposase gene is 
located outside the Tn ends allowing stable integration and they have been 
used to create insertion libraries in B. subtilis and Bacillus anthracis with high 
frequency random insertions 197, 198.  Mariner Tns are part of the mariner/Tc1 
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super family, the most widespread and diverse class II transposable 
elements, they have broad host range and are found extensively in 
eukaryotes including humans 199.  Mariner Tns such as Himar1 and their 
derivatives undergo in vitro and in vivo transposition into several bacterial 
chromosomes.  Random and disperse insertion libraries have been created 
in Escherichia coli, Campylobacter jejuni and Leptospira interrogans 199-202.  
 
1.4.3. Transfer of replication-deficient and replication-proficient 
plasmids 
Methods have also been developed to introduce heterologous DNA and 
recombinant DNA into C. difficile using Tn916.  The fact that Tn916 enters 
the genome at a hot spot in strain CD37 can be exploited for gene cloning, 
although the process is cumbersome and relatively inefficient 193.  This 
strategy can also be used to introduce antisense RNA in order to down-
regulate the expression of specific genes, however initial experiments have 
been disappointing 203.  Historically, conjugal transfer of DNA has been 
conducted using B. subtilis donors.  Research in other clostridial species has 
shown this strategy of using conjugative mobilization of oriT based vectors 
from E. coli donors to be extremely effective 204.  A number of shuttle vectors 
have been constructed by cloning clostridial replicons into the replication-
deficient ColE1-based vector pMTL31, which can act as suicide vectors and 
facilitate integration of the plasmid into the genome by single cross over.  By 
cloning a fragment of the recipients chromosome in the plasmid polylinker it 
is possible to obtain gene knockouts 132, 177.  The use of autonomously 
replicating (replication-proficient) plasmids has also been investigated.  An 
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efficient replicon has been identified on an indigenous C. difficile 7 Kb 
plasmid pCD6 originating from strain CD6.  This replicon contains an 
extensive repeat region thought to represent the origin of replication and 
allows replication of constructed plasmids within C. difficile 177, 205.  Original 
experiments to introduce such plasmids revealed that as with other 
clostridia, it is necessary to elucidate and overcome restriction modification 
systems.  This may be achieved through methylation of the vector DNA prior 
to transfer, however both strain CD37 and 630 seem to show no restriction 
barriers.  Overcoming these barriers in other strains is, however, proving 
difficult due to the presence of unique restriction systems, hindering the 
progression of this system in C. difficile.  Other aspects also warrant further 
investigation, including the development of efficient plasmid delivery systems 
to make this an effective strategy for gene-knockout 205.   
 
1.4.4. Use of a group II intron derivatives for targeted 
mutagenesis – The ClosTron 
A recent major development in the manipulation of clostridia is the ClosTron.  
This system, based on the TargeTron™, enables directed inactivation of 
specific genes.  The system exploits mobile group II introns from the ltrB 
gene of Lactococcus lactis (L1.ltrB) that are able to integrate at specific sites 
independently of host factors.  In-silico analysis of the potential target sites 
allows the ClosTron to be targeted to a specific gene of interest.  To enable 
screening of mutants the group II intron contains an erythromycin resistance 
gene itself disrupted with a group I intron.  The specific arrangement of the 
three elements ensures that expression of erythromycin resistance only 
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occurs when the group II intron is in the target site at which point the group I 
intron will have spliced out leaving an intact antibiotic resistance gene.  This 
is known as a Retrotransposition-Activated Marker (RAM) and is an 
important feature of the ClosTron.  This is a relatively rapid process allowing 
mutants to be generated in 10 to 14 days and has proved effective in a 
number of clostridia including C. difficile 130, 206. 
 
1.5. Future perspectives 
 
The changing epidemiology and emergence of hyper-epidemic strains has 
brought CDI to the forefront of nosocomial infection monitoring and 
prevention in the UK.  The increasing burden of infections has spurred 
increased interest in the study of the molecular basis of pathogenesis of C. 
difficile.  Recently, there have been significant breakthroughs in the 
generation of tools to allow the genetic manipulation of C. difficile.  The 
ClosTron and the development of recombination plasmids allow targeted 
gene disruption in clostridia, although these methods may still require 
refinement.  There is, however, a clear need for the development of 
techniques to enable random mutagenesis to allow the discovery of novel 
virulence factors and to elucidate the mechanisms of gene regulation.  This 
following study describes the investigation of existing and novel tools for 
random mutagenesis of C. difficile. 
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Chapter 2 
 
 
2.  Mutagenesis of C. difficile with Tn916  
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2.1. Abstract 
 
Transposon mutagenesis is an effective method for random mutagenesis of 
bacterial genomes.  In C. difficile the use of this routine technique has been 
hindered by the lack of genetic amenability shown by this important 
nosocomial pathogen.  The development of a CTn based system has, to 
some extent, overcome these difficulties.  Although not ideal, this tool has 
proved successful in the generation of an insertion library in strain 630!erm 
using Tn916!E.  This chapter describes the generation and analysis of a 
Tn916 insertion library in the hyper-epidemic, ribotype 027 strain, R20291. 
 
  
 
71 
2.2. Introduction 
 
2.2.1. Transposon mutagenesis 
Mutational analysis has been a popular and successful method for the 
identification of microbial virulence determinants.  The approach can be 
either directed or random.  Directed mutagenesis seeks to confirm the role of 
a putative virulence determinant identified as being important in pathogenesis 
using a reverse genetic approach.  In contrast, random mutagenesis is 
known as a forward genetic approach as no assumptions are made about the 
role of genes in pathogenesis.  Large libraries of mutants are generated 
using a mutagen that can then be screened for differential phenotypes 
associated with virulence.  Further characterisation of mutated genes can 
allow the identification of novel virulence factors 207.  Both approaches have 
advantages and disadvantages and the appropriate method should be 
determined based on the tools and facilities available to yield the best 
possible results (Table 2.1). 
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Mutation 
approach Advantages Disadvantages 
 Specific 
Relies on assumptions about the 
role of the gene in virulence, 
based on circumstantial evidence 
Directed Can enable identification of downstream effects 
Can be time consuming to obtain 
desired insertion 
 Can be designed to ensure minimal downstream effects Tools may not be readily available 
 
Potential to allow mutations in 
specific regulatory regions affecting 
the expression of multiple genes 
Unlikely to identify novel factors 
     Requires sequence information 
 
Numerous mutagens available e.g. 
Chemical (e.g. Base-Analog 
Mutagens, deamination), Physical 
(e.g. UV), Biological (e.g. 
transposons) 
Large libraries may need to be 
constructed - labour intensive, 
and may lead to time and storage 
issues 
 Potential to identify multiple genes associated with virulence 
Can lead to downstream effects 
particularly when transposons are 
used 
Random 
Potential to identify novel factors 
and genes involved in regulation of 
virulence factors 
Multiple mutations can be made 
leading to difficulties in 
characterisation 
 Transposon mutagens can be tagged to allow easy identification 
The choice of mutagen is 
important as some mutations may 
not be stable, or frequency of 
mutation can be low 
 Can be relatively inexpensive and quick 
Is a 'hit and miss' approach - there 
is no guarantee that the library will 
contain mutants associated with 
virulence 
 
Table 2.1  Examples of the possible advantages and disadvantages of 
directed and random mutagenesis approaches 94. 
The table highlights some of the advantages and disadvantages, which should be 
considered when designing a mutagenesis strategy. 
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Tn mutagenesis is a random (forward genetic) approach based on the ability 
of transposons to insert into the genomes of many bacterial species, often at 
random.  A wealth of knowledge about bacterial virulence factors, particularly 
in important human pathogens, has been generated through transposon 
mutagenesis 179, 207.  Tn mutagenesis offers the potential to generate random 
single-site mutations relatively quickly and cheaply, with the added benefit 
that each mutation is tagged by the Tn facilitating mapping and subcloning 
207. 
 
2.2.2. Conjugative transposons and C. difficile 
For C. difficile, the ability to use standard Tn-based random mutagenesis has 
been hindered by the apparent fragility of this bacterium.  Introduction of DNA 
through electroporation or natural competence has not been demonstrated in 
this organism; however, utilisation of the self-mobilising properties of CTns 
has been exploited to allow mutagenesis in C. difficile.  Mullany et al. (1991) 
developed a method for the introduction of the conjugative transposon Tn916 
into C. difficile through filter mating with a B. subtilis donor cell containing a 
Tn916 194.   
 
CTns are important determinants of antibiotic resistance, these promiscuous 
elements are able to conjugate between bacteria of different species and 
genus 187.  This ability to disseminate among bacteria, with carriage of 
antibiotic resistance genes, make CTns a major clinical problem. 
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CTns also referred to as integrative conjugative elements (ICEs), encode 
proteins required to promote their own transposition 208.  Unlike other 
common transposons including Tn5 and Tn10, their mechanism of excision 
and integration involves the generation of a covalently closed circular 
transposition intermediate before insertion at the target site (Figure 2.1) 188. 
 
2.2.2.1. Tn916 
Tn916 is an 18 Kb conjugative transposon originally discovered in the late 
1970’s when tetracycline resistance was found to be transferable from the 
haemolytic multidrug-resistant bacteria E. faecalis DS16 to E. faecalis JH2-2 
189, 209.  This well studied element is made up of four functional modules: 
conjugation, regulation, recombination and accessory genes, the last of 
which is not involved in conjugative transposition (Figure 2.2) 210.  Tn916 
encodes tetracycline-minocycline (tet(M)) encoding tetracycline resistance 
191.  The host range of this element is exceptionally broad and it is 
widespread among many commensal and pathogenic bacteria 189, 191.  
Sequence analysis of many bacterial species has resulted in the identification 
of numerous Tn916-like elements with a common core genome containing 
the conjugation and regulatory regions but with numerous variations in the 
surrounding regions 210. 
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Figure 2.1 Mechanism of 
intercellular transposition of 
conjugative transposons. Taken 
from Salyers et al., 1995 188. 
The integrated form excises to form a 
covalently closed circle – the transfer 
intermediate, by staggered nicks at each 
end of the transposon.  A single strand is 
nicked at the oriT site and is transferred 
to the recipient cell via a conjugation 
mechanism similar to plasmid transfer. A 
double-stranded form is then regenerated 
in each cell.  The transposon is then able 
to integrate into the recipient cell’s 
genome. 
Figure 2.2  Schematic representation of Tn916 taken from Roberts and 
Mullany, 2009 210. 
Tn916 contains 4 functional modules: recombination, regulation, conjugation and accessory 
genes. 
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Excision of Tn916 from its insertion site is mediated by staggered nicks at 
each end of the transposon leaving single stranded non-complementary 6-
nucleotide stretches called coupling sequences at each end.  This leads to 
the generation of a nonreplicative circular intermediate with mismatches at its 
joint (Figure 2.3) 187, 188, 211.  A single strand of the circular intermediate is 
transferred to a suitable recipient by a mechanism analogous to plasmid 
transfer 187, 188.  Cell to cell contact is required for transfer of the element, 
however the mechanism is not fully understood 208.  A second strand is 
synthesized in both the donor and recipient cell generating a double stranded 
circular molecule capable of insertion in both cells 210.  The latter process is 
mediated by the recombination module located at one end of the element, 
this contains a gene encoding a tyrosine recombinase, Int (required for 
integration and excision), and the accessory protein Xis (required for the 
directionality of the recombination reaction, usually promoting excision).  The 
element can insert into a large number of target sites, yet in general has 
preference for AT rich targets 210, 212.  In some hosts it has a highly preferred 
site, for example in C. difficile strain CD37 insertion occurs at a single 
particular site 194, 195.  Insertion site sequence is not the only determining 
factor, experiments in other C. difficile strains reveal no apparent specific 
insertion site preference even though the insertion site from CD37 is present 
210. 
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Figure 2.3  Proposed mechanism for excision and integration of 
Tn916.  Taken from Salyers et al., 1995 188, 211. 
Staggered cuts occur 6 nucleotides from each end of the element producing single 
stranded overhangs known as coupling sequences.  These ends are joined covalently 
to form a circular transposition intermediate.  The bulged area represents areas of non -
base pairing.  Staggered cuts then open the target site and the circular intermediate 
before ligation of the ends into the target site.  This generates regions of non-base 
pairing at each end, which are repaired by mismatch repair or by replication through the 
region. 
 
 
 
 
Image unavailable due to copyright 
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2.2.2.2. Tn1545  
The conjugative transposon Tn1545, originally identified in S. pneumoniae 
has ends identical to Tn916 and behaves in a similar manner 189, 191, 213, 214.  
Tn1545 is larger than Tn916 (25 Kb vs 18 Kb) and in addition to tet(M) 
contains erythromycin (ermAM) and kanamycin (aphA-3) resistance 
determinants 188, 189, 215.  It has been used successfully in Clostridium 
cellulolyticum although a low frequency of insertion was observed 
(transconjugants were obtained at frequencies of between 1.7 x 10!6 and 3.8 
x 10!8 per recipient) 216. 
 
2.2.3. Screening assays for C. difficile transposon libraries 
In C. difficile the production of toxins TcdA and TcdB is known to be 
important for virulence 18, 97.  Less definitive information is available to 
support the importance of other putative virulence factors involved in 
pathogenesis and survival in the gut.  A library of C. difficile Tn916 
transconjugants can be screened for a myriad of phenotypes in vitro and 
potentially assessed in vivo in the Golden Syrian hamster model.  High 
throughput and relatively simple assays are an effective method for 
screening large numbers of samples in a relatively short period of time.  
Ideally, the assays should provide definitive results quickly and reproducibly 
to avoid the requirement for duplication or speculative conclusions.   
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2.2.3.1. Detection of C. difficlle toxins 
Assessment of each transconjugant for alteration in toxicity is a useful and 
informative assay, potentially providing insights into the genes involved in 
toxin production and regulation.  The cytotoxicity assay is reputed to be the 
gold standard assay for the identification of C. difficile in clinical samples 
using cell lines including fibroblasts, CHO, Vero, HeLa, and other epithelioid 
lines 217-220.  The presence of the cytotoxins TcdA and TcdB can be easily 
visualised using an inverted microscope, confluent cell monolayers exposed 
to the cytotoxins produce a cytopathic effect (CPE) where cells round-up, 
detach and shrink loosing adherence (Figure 2.4) 221.  This relatively 
straightforward, yet labour intensive assay allows the clear identification of 
the presence of toxin, and with dilution series’ estimations of relative toxin 
quantities can be determined between samples.  Specific C. difficile or C. 
sordellii antitoxin is used to validate the assays specificity through 
neutralisation 218.  The presence of C. difficile toxins can also be assessed 
using an enzyme immunoassay (EIA).  These rapid and easy tests allow 
diagnosis more rapidly than with the cytotoxicity assay.  EIA also removes 
the need for tissue culture facilities, which are expensive and the results are 
also easier to standardise 222.  There are several commercial kits, proven to 
be both sensitive and specific, for the detection of TcdA and/or TcdB and 
current NHS recommendations are to use either of these assays in the 
clinical diagnosis of C. difficile 38, 222, 223 
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Figure 2.4  Visualisation of the cytopathic effect. 
Photos courtesy of H. Hussain, UCL Eastman Dental Institute. 
A – Healthy human foreskin fibroblasts (HFF-1) cells grown to a confluent monolayer viewed by 
a light microscope. 
B – HFF-1 cells treated with a 30-fold dilution of cell free growth medium taken from 630!erm 
cultures grown in rich growth medium for 24 hours.  Cells are displaying the typical cell 
rounding and detachment attributed to the cytopathic effect (CPE) of TcdB and TcdA of C. 
difficile. 
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2.2.3.2. Sporulation/germination 
The metabolically dormant C. difficile spore is responsible for person-to-
person transmission due to its high level of resistance to oxygen, desiccation, 
temperature extremes, alcohol and certain disinfectants 155-157.   It has been 
suggested that spores may also facilitate persistence in the host during 
antibiotic therapy and subsequent recurrence after cessation of treatment 224.  
Thus the ability of C. difficile to form spores is an essential component of the 
infectious cycle and therefore an important colonisation factor.  However, the 
processes of sporulation and germination are poorly understood.  Therefore, 
a screening assay to identify insertion mutants with non-wild type phenotypes 
may lead to important insights into these processes and their regulation. 
 
2.2.3.3. Bile tolerance 
During passage through the gastrointestinal tract (GIT) C. difficile comes into 
contact with the potent digestive secretion known as bile.  Bile is a complex 
mixture of bile acids required for the emulsification of fats during digestion.  
Microorganisms that colonise the GIT must overcome the deleterious effects 
of bile, which can lead to lysis of the cell membrane.  It is not clear how C. 
difficile counteracts the effects of bile and this may represent an additional 
colonisation factor (see chapter 3 for more details).   
 
2.2.3.4. p-cresol tolerance 
The phenolic compound p-cresol (4-methylphenol) is an end product of 
protein breakdown.  p-cresol is one of the metabolites of tyrosine and to a 
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small extent phenylalanine and under normal physiological conditions it is 
excreted in the urine.  Generation of p-cresol in the gut is primarily by aerobic 
bacteria, particularly enterobacteria, although anaerobes also play a role 225.   
 
C. difficile has been shown to produce p-cresol via the degradation of 
tyrosine 226.  Early investigations found that the bacteria were able to tolerate 
up to 0.5% p-cresol which inhibits other anaerobic bacteria 227.  It has been 
hypothesised that the production and tolerance of p-cresol may offer a 
competitive advantage to C. difficile over other intestinal microflora and 
consequently contribute to C. difficile-associated disease 228.  Sequencing of 
the C. difficile strain 630 genome revealed the genetic pathway to p-cresol 
production; it is produced from tyrosine via the intermediate p-
hydroxyphenylacetate (pHPA) by genes including those encoding 
components of pHPA decarboxylase (CD0153–CD0155, hpdBCA), which 
catalyses the decarboxylation of pHPA to yield p-cresol 6, 229.  Dawson et al. 
(2008) have further explored the ability of C. difficile to tolerate p-cresol 228.  
They found that two ribotype 027 strains the hyper-epidemic strain R20291, 
isolated from a severe outbreak at Stoke Mandeville Hospital in 2005-2006, 
and strain BI-16 were significantly more tolerant to p-cresol than historical 
isolates including 630.  They suggest that this increased level of tolerance 
may be a contributing virulence factor to the rapidly spreading epidemic 027 
strains 228.  This interesting observation suggests that there may be a link 
between p-cresol tolerance and virulence.  
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This chapter describes investigation of the behaviour of Tn1545 and Tn916 in 
the hyper-epidemic strain R20291 and the generation of a library of Tn916 
transconjugants in R20291.  The library was screened to identify mutants 
defective in cytotoxicity, sporulation/germination and tolerance of bile salts 
and p-cresol.   
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2.3. Aims and Objectives 
 
This study aims to generate an insertion library in the hyper-epidemic strain 
R20291 using a conjugative transposon.  The library can be screened for 
mutations affecting virulence-associated phenotypes to elucidate the 
molecular pathogenicity of C. difficile.  
 
Objectives: 
1. Determine whether Tn916 and Tn1545 can be introduced into R20291 
using a B. subtilis donor by filter mating. 
2. Investigate and characterise the insertions based on insertion site and 
frequency per cell. 
3. Generate a Tn916 insertion library in R20291.  
4. Identify the insertion sites of Tn916 in a sample of the library. 
5. Develop several assays to screen the library for defects in cytotoxicity, 
sporulation/germination and tolerance of bile salts and p-cresol. 
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2.4. Materials & methods 
 
2.4.1. Bacterial strains and growth conditions 
C. difficile was cultured on Brain Heart Infusion (BHI) agar (Oxoid, UK) 
supplemented with 5% defibrinated horse blood (BHIB) (E & O laboratories, 
UK) or in pre-reduced BHI broth at 37oC in an anaerobic chamber (Don 
Whitley Scientific Ltd, UK) with an atmosphere of 80% N2, 10% H2, 10% CO2.  
Where appropriate, medium was supplemented with C. difficile selective 
supplement containing D-cycloserine 250 mg lt-1 and Cefoxitin 8 mg lt-1 
(CDSS) (Oxoid, UK) and 10 !g ml-1 tetracycline (Tc).  C. acetobutylicum was 
cultured on pre-reduced Reinforced Clostridial Medium (RCM) with addition 
of 5% agar for solid medium and grown under the conditions described for C. 
difficile.  B. subtilis was cultured on BHIB agar or in BHI broth with 10 !g ml-1 
Tc at 37oC in aerobic conditions.  Table 2.2 describes the properties of the 
bacterial strains. 
 
2.4.2. Resuscitation of 630!erm::Tn916!E library 
Clones stored in Robertsons cooked meat medium (Oxoid, UK) were 
streaked onto BHIB agar containing CDSS and 10 !g ml-1 erythromycin (Em).  
Plates were incubated anaerobically for 48 hours at 37oC.  Cultures were 
streaked onto selective agar as described above and onto BHIB agar without 
supplements.  The selective plate was incubated anaerobically while the non-
selective plate was incubated aerobically at 37oC to detect contaminants. 
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Bacterial strains, plasmids and 
transposons 
Relevant 
characteristics Reference / Source 
Strains    
  Clostridium difficile R20291 EmR, TcS ribotype 012 
Stoke Mandeville Hospital outbreak isolate, 
NCTC 13366.  Jon Brazier, Anaerobe 
Reference Laboratory, Cardiff.   
  Clostridium difficile 630!erm Tc
R, EmS, ribotype 
012 
H. Hussain, UCL Eastman Dental Institute.   
Hussain et al., 2005 131 
 Clostridium difficile 630!erm::Tn916!E Tc
R, EmR H. Hussain, UCL Eastman Dental Institute.  Hussain et al., 2005 131 
 Clostridium difficile 37 RifR, toxin negative P. Mullany, Eastman Dental Institute, UCL Hächler, et al., 1987 230 
 Clostridium acetobutylicum  ATCC 824.  N Minton, University of Nottingham.  Weyer and Rettger, 1927 231 
 Bacillus subtilis BS34A 
B. subtilis::Tn916 
(CU2189 x FM12A), 
TcR 
A. Roberts, Eastman Dental Institute, UCL.  
Roberts et al., 2003 203 
  Bacillus subtilis SA315 Tn1545, Tc
R, EmR, 
KanR M. Young, Aberystwyth, UK. 
Plasmid    
 pAM120 pGL101::Tn916 Gawron-Burke & Clewell, 1984 232 
Conjugative 
transposons    
 Tn916 TcR Franke et al. 1981 209 
 Tn1545 TcR, EmR, KanR Courvalin & Catlier, 1987; Caillaud et al. 1987 213, 214 
 
Table 2.2  Bacterial 
strains, plasmids 
and transposons. 
Table Key: 
Tc = tetracycline 
Em = erythromycin 
Kan = kanamycin  
Rif = rifampicin 
R = resistant 
S = sensitive 
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2.4.3. Filter mating and transconjugant selection 
BHI broth was inoculated with an 18-24 hour culture (~ 2%) of C. difficile 
R20291 (recipient) and incubated for 16-20 hours in anaerobic conditions at 
37oC.  C. difficile cultures were centrifuged at 3000 x g for 15 min in 
anaerobic conditions to pellet the cells.  A single BS43A or SA315 B. subtilis 
colony (donor) was inoculated into BHI broth supplemented with 10 µg ml-1 
Tc and incubated for 4 hours at 37oC with shaking at 200 rpm.  The optical 
density (OD) of the culture was measured at 600 nm using a 
spectrophotometer (Thermo Fisher Scientific, UK), cultures with a reading of 
between 0.6-0.8 were considered to be in mid to late log phase growth and 
were centrifuged at 5000 x g for 5 min.  Cells were washed twice with 20 mls 
BHI broth.  The donor and recipient cell pellets were combined in anaerobic 
conditions and mixed gently but thoroughly with addition of 0.6 ml fresh BHI 
broth.  The mating mixture was spread over cellulose nitrate filters (0.45 !m 
pore size, Sartorius) placed on pre-reduced BHIB agar.  Plates were 
incubated for 24 hours at 37oC in anaerobic conditions.  Filters were 
transferred to sterile universals and thoroughly washed with 0.6 ml of BHI 
broth.  Cells were spread onto 10-20 BHIB agar plates containing CDSS 
(BHIBS) and 10 !g ml-1 Tc.  Plates were incubated for 72 to 96 hours before 
being examined for transconjugants.  Resulting transconjugants were 
restreaked onto BHIBS agar plus 10 !g ml-1 Tc. 
 
Control plates were also included in initial experiments containing either B. 
subtilis or C. difficile alone and incubated alongside experimental plates.  
They were processed in the same manner as experimental plates post 
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incubation to ensure the selection was appropriate and to test for the 
frequency at which spontaneous mutants appeared. 
 
2.4.4. Growth curve  
15 ml of BHI broth in a 20 ml universal was inoculated with R20291 or 
630!erm to an initial OD of 0.05-0.07 measured at 600 nm using a 
spectrophotometer (Thermo-Fisher, UK).  Triplicate cultures were incubated 
without shaking at 37oC in an anaerobic chamber.  At time intervals 0.8 ml 
samples were taken under anaerobic conditions and the absorbance 
measured.  The assay was repeated 3 times and the data was plotted 
graphically using Prism 5 (GraphPad Software Inc, v5.01). 
 
2.4.5. Storage of library 
Each individual transconjugant was inoculated into pre-reduced BHI broth 
containing 10 µg ml-1 Tc and CDSS, and incubated for 72 hours in anaerobic 
conditions in deep well microtiter plates (VWR International, UK).  Sterile 
glycerol was added to a final concentration of 30% and plates were frozen at 
-70oC. 
 
2.4.6. Characterisation of insertions 
2.4.6.1. DNA extraction 
DNA from cultured cells was extracted using the Gentra Puregene Yeast 
Bact. Kit (Qiagen, UK) with minor modifications to the supplied protocol.  All 
  
 
89 
additional reagents were from Sigma-Aldrich UK.  Approximately 3-4 ml of 18 
-20 hour culture was briefly placed on ice before centrifuging for 45 s at 
15,000 x g to recover the cells.  Cells were resuspended in 300 µl Cell 
Suspension Solution before addition of 5 µl Lytic Enzyme Solution and mixed 
by inversion.  Samples were incubated at 37°C for 30 min before centrifuging 
at 15,000 x g for 1 min.  Supernatant was discarded and the pellet was re-
suspended in 300 µl Cell Lysis Solution.  Samples were incubated at 80°C 
for 5 minutes and cooled before addition of 1.5 µl RNase A Solution.  
Samples were incubated at 37°C for 45-60 minutes.  Samples were cooled 
on ice, 100 µl ice cold Protein Precipitation Solution was added and samples 
were vortexed vigorously for 20 s.  Samples were incubated on ice for 45–60 
minutes before centrifuging at 15,000 x g. for 3 minutes.  Supernatant was 
added to 300 µl isopropanol and mixed by inversion before centrifuging at 
16,000 x g for 1 minute to recover the precipitated DNA.  The DNA pellet was 
washed with 70% ethanol and allowed to air dry.  DNA was suspended in 
molecular grade water (molH2O) (Sigma-Aldrich, UK) by incubation at 65°C 
for 1 h followed by 37oC for 12-18 hours. 
 
2.4.6.2. PCR 
PCR reactions were carried out using Taq DNA polymerase and standard 
buffer according to the manufacturer’s guidelines under the following 
conditions: [94oC 4 min] x 1 cycle, [94oC 30 sec, 55oC 1.5 min, 72oC 1 min] x 
25-35 cycles [72oC 10 min] x1, hold 4oC.  Primers specific for the xis and int 
genes of Tn916 were used to confirm the presence of Tn916 as described by 
Roberts et al., 2001 233: 
  
 
90 
xis/int1  5’ CGCCAAAGGATCCTGTATATG 3’  
xis/int2  5’ GCTGTAGGTTTTATCAGCTTTTGC 3’  
 
PCR products were separated by electrophoresis in 0.7-2% agarose gels 
made with 1X TAE buffer (Table 2.3) (Sigma-Aldrich, UK).  Gels were soaked 
in TAE buffer containing ethidium bromide for 5 min before visualisation of 
DNA using UV lamp.  
 
2.4.6.3. Southern blotting 
Wild type and transconjugants were grown in BHI broth or BHI supplemented 
with 10 !g ml-1 Tc, respectively, for 20-24 hours at 37oC under anaerobic 
conditions.  Southern blotting was carried out according to the manufacturer’s 
instructions using an ECL kit (GE Healthcare, UK).  Briefly, genomic DNA 
was extracted from Tn916 transconjugants and wild type R20291 using the 
PureGene Yeast/Bact DNA isolation kit.  Approximately 300-500 ng of 
genomic DNA was digested with 200 U HindIII for Tn916 transconjugants 
and R20291 at 37oC for 16 hours (unless stated otherwise, all enzymes are 
from New England Biolabs, UK).  Plasmid DNA containing Tn916 was 
extracted from pAM120 using a Mini-prep kit according to the manufacturer’s 
guidelines (Qiagen, UK) and digested with HincII at 37oC for 16 hours.  
Digested DNA was separated on a 0.8 % agarose gel with a size marker at 4 
V cm-1 for approximately 90 min.  The gel was processed according to the 
manufacturer’s instructions using depurination, denaturation, and 
neutralization buffers (Table 2.3).  The gel was placed on blotting paper atop 
a ridged scaffold soaked in excess of 20X SSC (Table 2.3).  Hybond-N 
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nitrocellulose membrane (GE Healthcare, UK) was placed on the gel before 
addition of paper towels, a glass plate and a suitable weight.  The DNA was 
allowed to transfer for 12-15 hours before the membrane was carefully 
removed from the gel and fixed in a UV cross linker (UV Stratalinker 1800, 
Stratagene, UK) for 10 seconds. 
 
2.4.6.4. Probe generation 
The 0.7 Kb xis/int probe has been designed to hybridise to the xis/int region 
of Tn916 232.  PCR was used to amplify the probe sequence from plasmid 
pAM120 using previously described primer intxis1 and intxis2 (Figure 2.5) 233.  
The conditions were as follows: [94oC 4 min] x 1 cycle, [94oC 30 sec, 56oC 
1.5 min, 72oC 1 min] x 30 cycles [72oC 10 min] x1, hold 4oC.  The PCR 
product was separated on a 0.8% agarose gel before extraction and 
purification using a Gel Extraction Kit according to the manufacturer’s 
guidelines (Qiagen, UK). 
 
2.4.6.5. Probe labelling  
Each probe was diluted to approximately 10 ng !l-1 and the ladder diluted to 
a final concentration of approximately 2-5 ng ul-1 before labelling with the 
Amersham ECL direct nucleic acid labelling and detection system according 
to the manufacturer’s instructions.  Briefly, the probe or marker DNA was 
denatured by boiling for 5 minutes in a water bath before cooling on ice.  An 
equivalent volume of DNA labelling reagent (for example 10 !l) was added to 
the DNA and mixed gently but thoroughly.  A volume equivalent to the 
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labelling reagent (10 !l) of glutaraldehyde was added and mixed thoroughly.  
The mixture was incubated for 10-15 minutes at 37oC and used immediately. 
 
2.4.6.6. Hybridisation and detection 
Membranes were soaked in 5X SSC and placed into rotisserie tubes, the 
SSC was removed and membranes prehybridised in pre-heated hybridisation 
buffer for 1 hour at 42oC in a rotisserie oven (Table 2.3).  Freshly labelled 
probe and marker were added to the pre-hybridisation buffer and incubated 
with continual rotation for 16-18 hours at 42oC in a rotisserie oven.  Following 
incubation the membrane was washed with 5X SSC for 5 minutes, the SSC 
was removed and replaced with pre-heated primary wash buffer and 
incubated for 20 minutes at 42oC, the wash was repeated with fresh pre-
heated primary wash buffer for 10 minutes.  The membrane was transferred 
to a clean container and incubated in secondary wash buffer at room 
temperature (20-22oC) with gentle agitation for 5 minutes.  The wash was 
repeated with fresh secondary wash buffer for 5-10 minutes. 
 
ECL detection reagents were mixed in equal quantities and applied to the 
membrane 1 min before removal.  The membrane was placed in a protective 
plastic wallet inside a photographic cassette.  In the absence of light, a high 
performance chemiluminescence film (Amersham, UK) was exposed to the 
labelled membrane, incubated for between 30 seconds and 12 hours and 
developed using an AGFA CURIX 260 (AGFA, UK).  Membranes were stored 
in a dust free environment at room temperature for at least 24 hours before 
being re-probed.  
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Solution Ingredients 
50x TAE buffer Tris (base) 2 M 
Adjusted to pH8 EDTA (disodium salt) 0.05 M 
Depurination solution HCl 250 mM  
NaCl 1.5 M 
Denaturation solution  
NaOH 0.5 M 
Neutralization solution  NaCl 1.5 M 
pH adjusted to 7.5 Tris HCl 0.5 M 
20x SSC Na3 citrate 0.3 M 
pH 7.0 NaCl 3 M 
Hybridisation solution 
(Amersham, UK) 50 ml 
NaCl 3% (w/v) Hybridisation buffer 
Blocking agent (milk 
powder) 5% (w/v) 
Urea 6 M 
SDS 0.40% Primary wash buffer 
20X SSC 0.1-0.5X SSC 
Secondary wash buffer 20XSSC 10% 
Table 2.3  Solutions used for Southern blotting and 
hybridisation. 
Figure 2.5  Schematic diagram of pAM120 
pAM120 contains a complete copy of Tn916. The features of this CTn are 
labelled including PtetM (red arrow), tet(M) (orange arrow), xis (turquoise arrow) 
and int (green arrow).  HincII and HindIII restriction sites and the location of 
intxis1 and intxis2 are also labelled. 
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2.4.6.7. Sanger sequencing (Pooled samples) 
DNA extraction 
100 individual transconjugants, picked at random from the frozen 
R20291::Tn916 library were plated on BHIB agar with 10 µg ml-1 Tc plus 
CDSS and incubated for 48 hrs at 37oC under anaerobic conditions.  Each 
transconjugant was inoculated into BHI broth with 10 µg ml-1 Tc and CDSS in 
96 deep-well plates and incubated for 24 hrs at 37oC under anaerobic 
conditions.  A 96-pin replicator was used to transfer a sample of the growth 
suspension to 2 non-selective BHIB agar plates, with one plate incubated in 
anaerobic conditions and one plate incubated under aerobic conditions at 
37oC for 24 hrs to check for contamination with aerobes.  20 µl of cell 
suspension from the original growth culture was inoculated into 1 ml of fresh 
BHI broth with 10 µg ml-1 Tc and CDSS in 96 deep well plates and incubated 
for 24 hrs at 37oC under anaerobic conditions.  The transconjugant broth 
suspensions were pooled and split into manageable volumes before genomic 
DNA extraction (described in section 2.4.6.1).  Purified DNA was stored at -
20oC and given to Dr Tim Perkins at the Wellcome Trust Sanger Institute, UK 
for sequencing. 
 
The following methods (1-4) are those of Dr Tim Perkins adapted from 
Langridge et al. (2009) and all sequencing was performed by Dr Tim Perkins 
and Dr Gemma Langridge at the Wellcome Trust Sanger Institute 234.  They 
describe the transposon directed insertion-site sequencing (TraDIS) method.  
Data were then returned to the Eastman Dental Institute, UCL for further 
analysis. 
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1. Nucleotide sequencing (Sequencing-by-synthesis) 
Five micrograms of genomic DNA was fragmented to an average size of 300 
bp by using a Covaris AFA (adaptive focused acoustics) Ultra Sonicator and 
Illumina library preparation was performed following the manufacturer’s 
instructions, but using 1.5x the recommended reagent volumes in each step 
(Covatis Inc; Illumina Inc, USA) 235.  Breifly, after shearing the DNA ends 
were repaired and A’s were added to the ends to facilitate ligation of the 
Illumina adapters. 
 
To amplify the transposon insertion site, 22 cycles of PCR were performed 
using a transposon-specific forward primer and a custom Illumina reverse 
primers (adapter-specific) and 100 ng of library DNA per reaction.   
Forward primer  
5’ AATGATACGGCGACCACCGAGATCTACACATAAGTCCAGTTTTTATGCGGATAAC 3’,     
Reverse primer  
5’ CAAGCAGAAGACGGCATACGAGATCGGTACACTCTTTCCCTACACGACGCTCTT 
CCGATCT 3’. 
 
Amplified libraries were cleaned up with a QiaQuick PCR product purification 
column following the manufacturer’s instructions and eluted in 30 !l elution 
buffer, and the libraries were quantified by qPCR 235.  
 
Ligated fragments (DNA frgments ligated to adapters) were separated on a 
12 cm 2 % agarose gel in 1 x TBE buffer (45 mM Tris-borate and 1 mM 
EDTA), at 6 V cm-1 without the preceding column clean up step.  After 45 
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minutes, fragments corresponding to an insert size of 250-350 bp were 
excised, and DNA was extracted from the gel slice without heating 235.  The 
DNA was quantified on an Agilent DNA1000 chip, using a bioanalyzer, 
following the manufacturer’s instructions (Agilent technologies, Germany).  
The libraries were sequenced on a single end Illumina flowcell using an 
Illumina GAII, 54 cycles of sequencing, using a custom sequencing primer 5’ 
TCTACACATAAGTCCAGTTTTTATGCGGATAACTAGAT 3’ and 2x Hybridization 
Buffer (0.2% Tween 20 in 10x SSC).  This primer was designed such that the 
first 14 bp of each read was Tn916 transposon sequence (TTTTATGCTATTTT). 
 
2. PCR  
Fragments were amplified using Jumpstart Taq with 100 ng DNA template 
using the following conditions 94°C 2 minutes; [94°C 30 seconds; 65°C 20 
seconds; 72°C 30 seconds] x 22 cycles; 72°C 10 minutes.  
 
3. Analysis of nucleotide sequence data 
Custom Perl scripts were written to identify sequence reads with a 100% 
identical match to the 14 bp transposon tag.  All qualifying reads had this tag 
removed, along with a further 10 bp to take into account any possible 
coupling sequence.  Maq-0.6.8 using the easyrun.pl option with all the default 
parameters was used to map the remaining 30 bp to the relevant C. difficile 
genome sequence; either strain 630 (Accession: AM180355) or R20291 6, 121, 
236.  Mapped reads were filtered for mapping quality and those with a score of 
>20 (630) or 10 (R20291) were taken forward.  Each read mapped to a 
particular nucleotide position in the genome, named a Tn916 insertion site.  
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All insertion sites were inspected for frequency of reads and sites with <20 
reads were excluded from the strain 630 list as potentially spurious.  Read 
depth of the R20291 library was much lower, hence sites with <10 reads 
were excluded as potentially spurious.  Due to the potential presence of a 
coupling sequence, these insertion sites are up to 10 bp away from the true 
insertion site.  
 
4. Insertion site motif in strain 630 
Using the reference genome sequence, twenty base pairs upstream and 
downstream of each mapped Tn916 insertion site in the 630!erm pool was 
retrieved.  All the 40bp regions were submitted to MEME specifying a 
distribution of 1 motif per sequence 237, 238.  The output from MEME was 
loaded into FIMO (also part of the MEME suite) to identify all occurrences of 
the predicted motif using C. difficile strain 630 as the reference genome 
sequence. 
 
Analysis of insertion sites 
Genes were assigned functional classes based on the C. difficile 630 
genome annotation and using the JGI Integrated Microbial Genomics 
database 6, 239.  
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2.4.7. Screening assays 
2.4.7.1. Tissue culture maintenance 
HFF-1 fibroblasts (ATCC SCRC-1041) were grown in Dulbecco’s Modified 
Eagle’s Medium (D-MEM low glucose, Gibco-Invitrogen, UK) supplemented 
with 10% foetal calf serum (FCS) (Hyclone, USA), 0.1% glutamine 
(Cambrex, Belgium), penicillin/streptomycin mix (100 U ml-1) (Lonza, 
Belgium) in T75 vented flasks (Sarstedt, Germany) and incubated at 37oC, 
5% CO2.  Cells were trypsinized (Cambrex, Belgium) and subcultured two to 
three times per week depending on confluence.  Frozen stocks were 
maintained in DMEM with 45% FCS and 5% Dimethyl sulfoxide (DMSO, 
Sigma-Aldrich, UK) in liquid nitrogen. 
 
2.4.7.2. Cytotoxicity assay 
Sample preparation 
Transconjugants and control cultures (wild type R20291, 630!erm and 
CD37) were inoculated into 1 ml BHI broth containing 10 µg ml-1 Tc and 
CDSS, in deep well microtiter plates to an initial OD of 0.05 at 590 nm.  
Cultures were incubated at 37oC without shaking for 48-60 hours under 
anaerobic conditions.  Cultures were centrifuged at 2500 x g for 10 minutes 
to pellet the cells.  A sample of cell free supernatant was diluted 50-fold in 
sterile PBS (Lonza, Belgium) under sterile conditions. 
 
Tissue culture assay 
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HFF-1 fibroblasts were seeded at a density of 1 x 105 cells per well in DMEM 
medium in flat-bottomed 96-well microtiter plates.  Plates were incubated for 
16 hours at 37oC, in 5% (vol/vol) CO2 to achieve confluence.  Cell free 
supernatant from bacterial cultures was diluted in PBS and added to cell 
monolayers.  BHI broth and PBS were included as negative controls.  Plates 
were incubated at 37oC in 5% CO2 for 24 hours.  Cells were assessed under 
an inverted microscope for a cytopathic effect (CPE) i.e. rounding of at least 
50% and loss of adherence. 
 
2.4.7.3. Sporulation/germination assay 
Bacterial cultures were grown for 48 hours in 1 ml BHI broth supplemented 
with 10 µg ml-1 Tc in deep well microtiter plates (without shaking) at 37oC 
under anaerobic conditions.  100 µl samples were transferred to round 
bottom microtiter plates and cultures were heated to 60oC in a water bath for 
25 min to kill vegetative cells.  Using a 96-pin replicator approximately 2 µl of 
heat-treated culture was plated onto BHIB agar.  Heated and unheated 
samples of wild type R20291 were included as positive controls.  Plates were 
incubated at 37oC in anaerobic conditions for 48-60 hours. 
 
2.4.7.4. Bile tolerance assay 
Bacterial cultures were grown for 24 hours in 1 ml BHI broth supplemented 
with 10 µg ml-1 Tc in deep well microtiter plates (without shaking) at 37oC 
under anaerobic conditions.  Using a 96-pin replicator approximately 2 µl of 
culture was spotted onto BHIB containing 5% bovine and ovine bile (B & O 
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bile) (Sigma-Aldrich, UK).  Wild type R20291 and C. acetobutylicum were 
spotted onto each plate as positive and negative controls, respectively.  
Plates were incubated at 37oC in anaerobic conditions for up to 72 hours 
before analysis. 
 
2.4.7.5. p-cresol tolerance assay 
Bacterial cultures were grown for 24 hours in 1 ml BHI broth supplemented 
with 10 µg ml-1 Tc in deep well microtiter plates (without shaking) at 37oC 
under anaerobic conditions. Using a 96-pin replicator approximately 2 µl of 
culture was spotted onto BHIB agar containing 0.1% p-cresol (4-
methylphenol) (Sigma-Aldrich, UK).  Wild type R20291 and C. 
acetobutylicum were spotted on to each plate as positive and negative 
controls, respectively.  Plates were incubated at 37oC in anaerobic conditions 
for up to 72 hours before analysis. 
 
2.4.7.6. Dot blot assay 
Bacterial cultures were grown for 48 hours in 10 ml BHI broth in 20 ml 
universals (without shaking) at 37oC under anaerobic conditions.  Cultures 
were centrifuged at 3000 x g for 5 min to pellet the bacteria.  10-30 µl of cell 
free supernatant was spotted onto Hybond C nitrocellulose and left to dry for 
10 min at 20-22oC (GE Healthcare, UK).  Membranes were blocked with 
blocking buffer (5% skimmed milk powder (Marvel, UK) in PBS) for 2 hours at 
20-22oC.  The membrane was washed for 5 min with wash buffer (PBS with 
0.2% Tween; both Sigma-Aldrich, UK) and washing was repeated 3 times.  
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The membrane was incubated with primary antibody: mouse IgG anti-C. 
difficile TcdB (Patricell Ltd, Nottingham UK) diluted 1:250 – 1:50000 for 2 
hours at 20-22oC on an orbital shaker.  The membrane was washed as 
described above and incubated with secondary antibody: rabbit anti-mouse 
IgG peroxidase conjugate (Sigma-Aldrich, UK) diluted to 1:500-1:50000 for 2 
hours on an orbital shaker.  The membrane was washed as described above 
before addition of the detection reagent Sigma Fast DAB peroxidase 
substrate (3,3’-diaminobenzidine tetrahydrochloride with metal enhancer, 
Sigma-Aldrich, UK).  The reaction was stopped by flooding the membrane 
with dH2O or PBS. 
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2.5. Results 
 
2.5.1. Library construction  
2.5.1.1. Tn916 
Filter mating is a standard method to facilitate the transfer of conjugative 
elements between bacteria.  This method has proved successful for the 
transfer of Tn916 from B. subtilis to C. difficile strains 630!erm and CD37 131, 
193.  B. subtilis containing Tn916 (donor) was mated with the hyper-epidemic 
C. difficile strain R20291 (recipient) to investigate its behaviour and potential 
as a random mutagen in this strain.  Tn916 entered the genome of 630!erm 
on multiple occasions with preference for AT rich sites; however it entered 
the genome of CD37 at a specific site (att916) 131, 194.  Mating of the donor 
with R20291 led to the generation of C. difficile transconjugants containing 
Tn916.  Transconjugants arose at an average frequency of 10-10 per donor 
cell, which in comparison with the frequencies observed for strains 630!erm 
and CD37 (10-7), is extremely low 195.  Generation of the library was therefore 
very inefficient; in total 1000 transconjugants were generated for the library 
from circa 100 independent mating experiments.  Attempts to optimise the 
mating procedure by sequential variation of experimental parameters, 
including time, growth phase and addition of cysteine failed to improve the 
conjugation frequency.  One parameter was changed for each mating and 
repeated three times.  Different ratios of donor to recipient cells were tested 
including ratios of approximately 1:1, 1:2, 1:3, 1:5, 2:1, 3:1, and 5:1.  This had 
no obvious effect on the efficiency of the mating and the frequency with 
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which transconjugants were produced remained at approximately 10-10 per 
donor.  The mating time was investigated with inoculated filters incubated for 
15, 20, 24 or 40 hours.  Again, no obvious increase in transconjugant 
generation was observed, the frequency of transconjugants production 
remained 10-10 per donor.  Cells were also tested at three growth phases – 
mid-log (~12 hours), late-log (~17 hours) and stationary phase (~24 hours) 
as determined from a growth curve (Figure 2.6).  The growth stage did not 
appear to have any obvious impact on the mating efficiency.  The addition of 
cysteine to the growth medium resulted in the production of no detectable 
transconjugants in four independent experiments with an average of 1010 C. 
difficile recipients. 
 
Each transconjugant was authenticated by its ability to grow in the presence 
of 10 µg ml-1 Tc, confirming the presence of tet(M) on Tn916.  Six randomly 
selected transconjugants were subjected to PCR analysis that confirmed the 
presence of the xis and int genes of Tn916 in all the transconjugants.  
Hybridisation analysis also confirmed the presence of Tn916 in 30 
transconjugants picked from the library (discussed in detail in section 2.5.3). 
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Figure 2.6  Growth of C. difficile strains R20291 and 
630!erm in BHI broth over time. 
The growth of R20291 and 630!erm was monitored over time by 
measurement of optical density (OD) at 600 nm.  The results represent 
the mean of three experiments and error bars show the standard 
deviation. 
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2.5.1.2. Tn1545 
The presence of Tn1545 in B. subtilis strain SA315 was confirmed by PCR 
using primers specific for the Xis and Int region of the transposon.  In total six 
matings, each with 5-10 filters, were performed between R20291 (recipient) 
and SA315 (donor).  Mating of R20291 with SA315 failed to lead to the 
generation of tetracycline resistant transconjugants from the mating of 
approximately 4.2 x 109-7.7 x 1010 SA315 donors with 3.2 x 109-8.3 x 109 
R20291 recipients in six independent experiments.  Due to these results 
Tn1545 was not selected for the generation of a library in R20291. 
 
2.5.2. Screening assays 
Before storage as frozen aliquots each R20291::Tn916 transconjugant was 
subjected to four screening assays.  These included three simple agar-based 
assays assessing: 1) sporulation/germination potential, 2) bile tolerance, and 
3) p-cresol tolerance.  A fourth assay, the cytotoxicity assay, was carried out 
to identify transconjugants with insertions that affect the production of TcdA 
and TcdB.  Each member (approximately 1000) of the library was screened 
in each of the four assays.  No mutants with defects in any of the screened 
phenotypes were identified, while the use of negative controls such as C. 
acetobutylicum and wild type strains R20291 and CD37 provided validation 
for the assays. 
 
As an alternative to the cytotoxicity assay an antibody based dot-blot assay 
was investigated, this may have represented a relatively quick and less 
  
 
106 
labour-intensive method for identification of toxin in growth media.  
Unfortunately, this assay failed to distinguish samples known to contain toxin 
and those that did not using a specific antibody for TcdB (data not shown).  
 
2.5.3. Characterisation of insertions 
2.5.3.1. Hybridisation analysis 
To determine if Tn916 entered the R20291 genome at multiple sites, thirty 
transconjugants were subjected to hybridisation analysis.  Digested DNA was 
probed with a xis/int fragment of Tn916.  Since there is one HindIII site in the 
transposon the probe will bind to only one of these fragments (Figure 2.5).  
Of the thirty transconjugants, fifteen represent colonies arising from a single 
filter (Figure 2.7 A).  The hybridisation pattern obtained from these 
transconjugants reveals that each individual is unique indicating that they are 
not siblings.  The remaining fifteen were derived from different filters and 
again show unique patterns of hybridisation.  The majority show multiple 
insertions, with only two possessing a single insertion (Figure 2.7 B lane 5 & 
11). 
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 M     1     2    3   4    5    6   7    8    9   10  11  12 13 14  15         +    M    -  
M    1     2    3    4    5    6    7    8   9   10  11  12  13  14  15        +    M     -  
Figure 2.7  Hybridisation analysis of 30 Tn916 transconjugants. 
DNA from 30 transconjugants was digested with HindIII and probed with a xis/int probe to 
identify Tn916 insertions.  Blot A shows 15 transconjugants arising from the same filter with 
each one showing a unique hybridisation pattern.  Blot B shows 15 transconjugants taken from 
different filters, again each one gives a unique hybridisation pattern.  All of the transconjugants 
except two (blot B lane 5 & 11) show multiple insertions.  M = 1kb marker, + = pAM120 HincII 
digested DNA, - = wild type R20291 HindIII digested DNA. 
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2.5.3.2. Sequencing of the Tn916 insertion site 
To identify the insertion site of Tn916 in R20291, DNA from 100 randomly 
picked transconjugants (10% of the library) was extracted, pooled and sent to 
The Wellcome Trust Sanger Institute for sequencing.  As the sequence of 
Tn916 is known, insertion sites can be easily identified.  Analysis of the 
sequence surrounding the insertion can identify the location of the insertion in 
the genome.  From hybridisation analysis it was known that each 
transconjugant is likely to contain multiple insertion sites.  Sequencing 
analysis revealed 102 unique insertion sites in R20291, with twenty-seven in 
CDSs, equating to approximately 25% of the total number of insertion sites 
(Table 2.4).  Therefore, approximately 75% of the insertions occurred in non-
coding intergenic regions of the genome even though only 18% of the 
genome is believed to be non-coding (Dr Gemma Langridge, personal 
communication).  Closer inspection of the listed insertion sites reveals that 
Tn916 appears to have inserted into the same gene on multiple occasions.  
In total five genes have more than one insertion; in one of these genes 
(CDR20291_2368) the two insertion sites have a 1 bp difference.  In the 
other three other genes (CDR20291_2033, CDR20291_2642 & 
CDR20291_2855) the difference between the two insertion sites is 14 bp.  
Finally, one gene (CDR20291_1737) appears to have three Tn916 insertions, 
the difference in insertion site ranges from 1 to 15 bp. 
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Insert 
position Gene 
630 
orthologue 
Start 
position 
End 
position 
Gene 
Length 
(bp) 
Strand Gene Product 
413027 CDR20291_0344 CD0339 412623 413360 737 + two-component response regulator 
487710 CDR20291_0404 CD0463 487466 487999 533 - TetR-family transcriptional regulator 
612747 CDR20291_0506 CD0579 612337 612915 578 - TetR-family transcriptional regulator 
620016 CDR20291_0512 CD0588 619824 620111 287 + hypothetical protein 
777896 CDR20291_0628 CD0702 777396 778079 683 + putative membrane protein 
944576 CDR20291_0773 CD0843 943977 945212 1235 + putative glycosyl transferase 
1080945 CDR20291_0886 CD1030 1080844 1082100 1256 + putative glycosyl transferase 
1433968 CDR20291_1206 CD1363 1432968 1434032 1064 + putative phage protein 
1645610 CDR20291_1389 CD1540 1643765 1645645 1880 + ABC transporter, permease protein 
1919051 CDR20291_1634 CD1737 1918970 1920235 1265 + putative gluconate permease 
1934900 CDR20291_1645 CD1751 1932770 1935157 2387 + 
cell surface protein (putative 
cell surface-associated 
cysteine protease) 
2037397 CDR20291_1737 CD1842 2037161 2037907 746 + putative membrane protein 
2037411 CDR20291_1737 CD1842 2037161 2037907 746 + putative membrane protein 
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Insert 
position Gene 
630 
orthologue 
Start 
position 
End 
position 
Gene 
Length 
(bp) 
Strand Gene Product 
2037412 CDR20291_1737 CD1842 2037161 2037907 746 + putative membrane protein 
2339670 CDR20291_2001 CD2094 2339541 2341475 1934 - putative restriction enzyme 
2382637 CDR20291_2033 CD2126 2382398 2382655 257 - putative membrane protein 
2382651 CDR20291_2033 CD2126 2382398 2382655 257 - putative membrane protein 
2771369 CDR20291_2368 CD2475 2771181 2772483 1302 - putative competence membrane protein 
2771370 CDR20291_2368 CD2475 2771181 2772483 1302 - putative competence membrane protein 
2850388 CDR20291_2431 CD2544 2849896 2851011 1115 - putative membrane protein 
2990751 CDR20291_2551 CD2663 2989423 2991702 2279 - putative signalling protein 
3110019 CDR20291_2642 CD2752 3109477 3110142 665 + hypothetical protein 
3110033 CDR20291_2642 CD2752 3109477 3110142 665 + hypothetical protein 
3379082 CDR20291_2855 CD3019 3378774 3379706 932 - putative transporter 
3379096 CDR20291_2855 CD3019 3378774 3379706 932 - putative transporter 
3677207 CDR20291_3079 CD3220 3677190 3678047 857 - putative methyltransferase 
3802783 CDR20291_3188 - 3802387 3803703 1316 - sensor histidine kinase VirS 
 
 
 
Table 2.4 Location of Tn916 insertions in the genome of R20291  
The insertion sites of Tn916 in 100 transconjugants was investigated by the Sanger Institute.  27 insertion sites were found to be in the coding regions of 
R20291.  Details of the location of the insertions are listed in the table alongside the putative products of each gene and the orthologue in strain 630. 
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From the 102 characterised insertion sites in R20291, there was evidence of 
some bias of insertion into intergenic regions.  This was also seen in the 
results obtained for 630!erm::Tn916!E library where only 19 out of 112 
unique insertion sites were found in genes.  To investigate further Dr. 
Gemma Langridge at the Wellcome Trust Sanger Institute used MEME 
(Multiple Em for Motif Elicitation), an on-line motif-based sequence analysis 
tool, to investigate the 40 bp sequence surrounding the insertion sites in the 
630!erm::Tn916!E sample pool to identify a common motif 237, 238.  She 
found that a 15 bp motif, TTTTTATATTAAAAA, was associated with all of the 
insertion sites (Dr Gemma Langridge, personal communication).  She used 
the MEME search results to find all occurrences of the 15 bp motif in the 630 
reference genome sequence using FIMO (Find Individual Motif Occurrences).  
Using a P-value cut-off of 0.01 (which finds all the insertion sites indentified 
by the TraDIS method), there were a total of 100,987 occurrences of the 15 
bp Tn916 insertion motif in the genome sequence of strain 630.  
Approximately 63,000 of these are genic and approximately 35,000 are 
intergenic (the remainder cross gene boundaries).  This shows a bias 
towards intergenic regions, as approximately 18,000 occurrences would be 
expected for randomly distributed motifs.  This suggests that Tn916 
preferentially inserts into a consensus sequence, TTTTTATATTAAAAA, a 
sequence found predominantly within the intergenic regions of strain 630. 
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2.6. Discussion 
 
The conjugative transposon Tn916 has been used to generate an insertion 
library in the epidemic strain R20291.  The frequency with which 
transconjugants arose was extremely low, meaning that the construction of 
the library was very time consuming.  In many mating experiments no 
transconjugants were generated from any of the filters.  In other experiments 
1-15 were produced using the same experimental parameters.  Attempts 
were made to optimise the filter mating procedure to promote transconjugant 
formation.  Almost all of the variables were assessed individually including 
the ratio of donor to recipient cells, the growth phase of the bacteria, the 
mating time, and the effect of addition of cysteine to the growth medium.  
Some parameters remained constant, for example the media, filters and cell 
strains, additionally C. difficile was not exposed to oxygen during mating at 
any point.  None of the changes improved the efficiency of the matings 
although these experiments were only repeated three times.  Given the low 
frequency of conjugation, further replicate experiments may have produced 
transconjugants, allowing comparison of the efficiencies.  The number of 
variables and the time required to carry out these different experiments 
precluded such investigation. 
 
The role of cysteine was however investigated in a further three experiments.  
In all six of the experiments performed transconjugants failed to be generated 
indicating that cysteine in the growth medium has a negative impact on 
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conjugation.  Despite attempts to increase the frequency of conjugation, the 
final size of the R20291::Tn916 library was 1000 members. 
 
Each of the 1000 transconjugants was assessed by each of the four 
screening assays before storage.  Three of the assays were agar-based and 
therefore a negative result was indicated by growth.  All of the samples 
tested were able to tolerate the same concentrations of p-cresol and bile as 
the wild type strain suggesting that insertion of the transposon had no effect 
on the tolerance mechanism of C. difficile to these two stresses.  No 
differences were seen in the ability of the transconjugants to sporulate or 
germinate; this relatively simple assay revealed that all of the samples were 
able to produce spores and to germinate efficiently.  Should colonies not 
have been observed the sample would have been investigated further to 
characterise the location of the insertion and which process was affected. 
 
The cytotoxicity assay is relatively time consuming and expensive, and is not 
specific, as both TcdA and TcdB can cause a CPE.  In general this assay will 
allow identification of strains able to produce toxins to a similar level as the 
wild type strain.  It would only be possible to see differences in the level of 
toxin produced if these differences were fairly large due to the fact that only 
one dilution of growth medium was examined.  All of the transconjugants 
tested were capable of causing a CPE at a 50-fold dilution.  Should time and 
resources permit, further dilutions of the growth medium and assessment at 
various time points may have revealed differences in the amount of the toxins 
produced or in their regulation.  Toxin production is believed to occur in 
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response to starvation 133.  By growing the bacteria in defined media it is 
possible to control the nutrients available allowing further monitoring of toxin 
production and potentially the identification of novel factors involved in 
production and regulation. 
 
In general none of these assays would be able to reveal subtle differences 
between the transconjugants and wild type samples, but as transposon 
libraries often contain thousands of members these high throughput and 
relatively cheap assays are invaluable for the identification of mutations in 
key genes involved in these processes. 
 
Other screening assays have also been devised to investigate this and the 
630!erm::Tn916!E library, and are to be conducted by a member of the 
Mullany group.  These included a bacitracin tolerance assay, this 
antimicrobial attacks the Gram-positive cell wall and has been investigated 
as an alternative to vancomycin in the treatment of CDI; an agar based 
motility assay and potentially, an adhesion assay 240, 241.  The library 
represents an important resource which can be screened numerous times 
with various assays to identify novel genes involved in a range of processes, 
particularly those associated with virulence. 
 
Insertion of Tn916 in the hyper-epidemic strain R20291 has been shown to 
be analogous to insertion into strain 630!erm.  Multiple insertions were seen 
in twenty eight (93%) of the transconjugants investigated by Southern 
hybridisation, again similar to the results observed for 630!erm with no 
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obvious ‘hot-spot’ 131.  On average, there were approximately three insertions 
of Tn916 per R20291 transconjugant based on hybridisation analysis of 30 
transconjugants. 
 
To further characterise the insertion sites of Tn916, DNA from a random 
sample of 100 R20291::Tn916 transconjugants was pooled and sent to the 
Sanger Institute for sequencing.  Sequencing revealed that the majority of the 
insertion sites were within intergenic regions, with 27 insertions in CDSs. A 
similar result was observed for the 630!erm::Tn916!E library where 100 
random transconjugants were also sequenced to determine the site of 
insertion.  From 112 unique insertion sites nineteen genes had a Tn916!E 
insertion, again the majority of insertions occurred in intergenic regions.  
Approximately 82% of the C. difficile genome is coding (personal 
communication; Dr. Gemma Langridge, The Wellcome Trust Sanger 
Institute).  If insertion of Tn916 occurs at random then one would expect an 
equivalent proportion of insertions in CDSs from this random sample of 
transconjugants.  The insertion bias was confirmed by the identification of a 
15 bp motif found at all of the Tn916 insertion sites which is found 
predominantly within intergenic regions of the genome of strain 630.  Thus, 
the usefulness of Tn916 as a random mutagen in C. difficile may be limited.  
As the insertion site motif is found at low frequency in coding regions only a 
small percentage of library insertion mutants will have disrupted CDSs.  
However, disruption of intergenic regions may provide vital clues about the 
regulation of genes and genome organisation. 
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Comparative analysis of several C. difficile strains (including R20291) by 
Stabler and colleagues revealed that the insertion of other transposons in 
strain 630 occurred mainly within CDSs 121.  Eight full-length functional 
transposons copies had inserted in CDSs.  Conversely, in both of the 
ribotype 027 strains examined, of the seventeen full-length transposon 
copies identified, only six had inserted into CDSs.  Clearly, each transposon 
has a different mechanism of integration and insertion site preference, which 
may vary between strains and genera.  Insertions in CDS and intergenic 
regions are likely to affect gene expression by direct inactivation or indirectly 
through downstream polar effects.  Although it is likely that insertions in 
coding sequences are less well tolerated, particularly those in essential 
genes, intergenic regions are important for gene regulation, disruption of 
these regions could therefore lead to effects on downstream genes 242. 
 
It may be possible to use Tn916 as a saturating mutagen to investigate the 
remaining 737,320 bp (18.21% of 4.049 Mb) of sequence whose function is, 
at present, not well understood.  Due to the preference of insertion into the 
15 bp motif this suggests that a maximum of 100,000 insertions are possible 
with Tn916.  Although limited, this may provide key insights into these poorly 
described regions, possibly elucidating the process of gene regulation and 
characterisation of genome architecture.  
 
Closer inspection of the Tn916 insertion sites in R20291 revealed that the 
transposon may have entered four genes on two occasions, and one on 
three occasions at seemingly unique sites with differences in the insertion 
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position of between 1 and 15 bp.  Limitations of the sequencing assay mean 
that the insertion site can only be determined to within approximately 10 bp.  
Therefore, it is possible that each of these multiple insertions actually 
represents one insertion, but due to slight errors in the sequencing they are 
annotated as separate insertions.  Thus, if this is indeed the case, the 
number of insertion sites in coding sequence is reduced to just twenty one.  
Screening of the library with the four screening assays failed to identify any 
putative mutants through phenotypic assays.  Thus it would appear that the 
twenty one genes with Tn916 insertions are not associated with toxin 
production, bile or p-cresol tolerance, or sporulation/germination. 
 
The functions of these genes could be further investigated through 
comparative analysis with other bacterial species and genera to develop 
assays to identify whether these insertions affect a measurable phenotype.  
For example three genes are annotated as being putative membrane 
proteins, therefore assays designed to assess the functionality of the 
membrane and its integrity may reveal the functions of these genes.  Assays 
may include the investigation of pH, osmolarity, heat/cold treatment and 
antibiotic susceptibility to assess whether phenotypic changes can be 
observed for these transconjugants.  However, the annotation of R20291’s 
genome is not definitive, the majority of gene functions have been inferred 
from other bacteria using in silico analysis, with putative protein function often 
assigned without experimental evidence 6, 121.  Consequently, the genes in 
this list may not be accurate, thus the benefits of developing further assays 
would need to be assessed.  Interestingly, one of the genes disrupted by 
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Tn916 was CDR20291_3188, which is not present in strain 630.  This gene is 
annotated as sensor histidine kinase VirS which is one member of a two 
component signal transduction system shown to control toxin production in C. 
perfringens 243.  No toxin deficient mutants were found during the cytotoxicity 
screening assay; therefore it is unclear whether VirS is involved in toxin 
production in C. difficile.  The screening assays investigated only one dilution 
of growth supernatant, therefore it is possible that the insertion in this gene 
could have affected the amount of toxin produced.  Since the cytotoxicity 
assay is not specific for either toxin A or B, detailed in vitro assays with a full 
dilution series, and the use of specific antitoxins could elucidate the effects of 
this insertion on toxin production. 
 
Finally, the ability of Tn1545 to act as a random mutagen in R20291 was 
assessed.  In these experiments, transconjugants containing this transposon 
and the associated tetracycline resistance were not observed.  In total six 
independent assays were performed in parallel with Tn916 mating.  As no 
transconjugants were seen in these experiments work with this transposon 
was not continued.  It is possible that there may be activity towards the 
transposon from host restriction systems or poor maintenance in this strain.  
This requires further investigation. 
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2.7. Conclusions & future work 
 
Conjugation of Tn916 into the hyper epidemic strain R20291 was 
successfully achieved, although the frequency of transfer was extremely low.  
This low conjugation efficiency for R20291 had a severe impact on the 
generation of an insertion library in this strain.  1000 transconjugants were 
screened successfully with four different assays, although no mutant 
phenotypes were observed.  This library has been stored to allow further 
assessment using a range of screening assays.  Further assays could 
include motility and adhesion assays, auxotroph screens and investigation of 
resistance to antimicrobial agents. 
 
Hybridisation analysis of members of this library indicated that there was no 
insertion hot spot.  Investigation of the insertion site of Tn916 in 
approximately 100 members of the library revealed that insertion occurred 
predominantly in intergenic regions.  Investigation of the insertion site of 
Tn916!E in 100 members of a 630!erm::Tn916!E library revealed a 15 bp 
consensus sequence at the transposon insertion site.  A search of the 630 
genome revealed that this motif was found predominantly in intergenic 
regions therefore Tn916 is more likely to insert into these regions.  Thus this 
insertion bias prevents the use of Tn916 or Tn916!E as random mutagens in 
both of these strains.  However, production of a saturating library in R20291 
could allow investigation of these poorly characterised regions and provide 
important information about gene regulation. 
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Chapter 3 
 
 
3. Investigation of the effects of bile on C. 
difficile growth and gene expression 
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3.1. Abstract 
 
C. difficile is GI pathogen which under certain conditions colonises the colon 
leading CDI.  During passage through the GI tract the bacterium in either 
vegetative or spore form encounters innate antimicrobial defence 
mechanisms evolved to prevent colonisation by microorganisms.  One of 
these natural defences is the production of a potent digestive secretion 
known as bile.  The major role of bile is to emulsify fats from ingested 
material to aid digestion. However, it is also an effective antimicrobial.  The 
tolerance of C. difficile and its interaction with bile has not yet been fully 
investigated.  The results obtained here describe the tolerance levels of two 
pathogenic strains, 630!erm and R20291, to bovine and ovine bile.   
Significant differences were seen in the tolerance of R20291 compared to 
630!erm, with R20291 showing tolerance of a much higher concentration of 
bile.  Analysis of genome-wide transcription levels using a microarray 
revealed differences in the expression of genes in 630!erm in response to 
bile exposure, although these were not statistically significant.  These 
preliminary investigations do however provide a foundation for further 
elucidation of the interaction of C. difficile with bile. 
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3.2. Introduction 
 
Microorganisms which colonise the GIT are subjected to a variety of stressful 
conditions and environmental extremes upon entering the body.  Natural 
antimicrobial defence mechanisms exist to control colonisation through 
changes in pH, limitation of nutrients, reduced oxygen levels and increased 
osmolarity.  Organisms that colonise these environments must have evolved 
mechanisms for surviving these conditions, which can be considered as 
colonisation factors.  
 
One host defence mechanism is the production and release of bile from the 
liver, this highly potent digestive secretion plays a major role in the 
emulsification and solubilisation of lipids 244.  Thus, evolution of mechanisms 
to evade the actions of this digestive secretion are essential to allow survival 
and colonisation of the GIT. 
 
3.2.1. Physiological role of bile and bile salts 
The main role of bile is to act as a biological detergent to emulsify and 
solubilise ingested fats to aid digestion by lipases.  This property also confers 
potent antimicrobial activity forming part of the body’s physiochemical 
defence system 245.  Bile facilitates the excretion of insoluble or protein bound 
substances, particularly cholesterol, which cannot be excreted in the urine. 
Bile acids can also act as regulatory and signalling molecules, including the 
regulation of hepatic lipid and glucose metabolism 246.  Bile has numerous 
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important physiological and pathological roles, many of which are not fully 
understood. 
 
Bile is an aqueous solution of organic and inorganic compounds including 
bile acids, cholesterol, phospholipids and the pigment biliverdin which 
provides the distinctive yellow/green appearance 244.  Bile has a pH between 
7.5-8 with an osmolality of 300 mOsm/kg, and contains immunoglobulin A 
and mucus to prevent growth and adhesion of bacteria 245.  Approximately 1 
litre of bile is synthesised by liver pericentral hepatocytes per day.  After 
secretion, bile is transported along the bile ducts for storage in the 
gallbladder 247.  Here, the bile is concentrated by 5–10-fold, water and 
electrolytes are removed and the bile is acidified by Na+/H+ exchange.  Not 
all bile is processed and stored in the gallbladder; approximately half of the 
bile is released directly into the duodenum and undergoes continuous 
enterohepatic cycling where bile acids are recycled in the liver 245.  Bile also 
facilitates enterohepatic cycling of many endogenous substances such as 
certain vitamins, hormones and trace metals.  Some exogenous substances 
are also secreted into bile for a degree of enterohepatic cycling including 
antimicrobial agents, and drugs 245.  Bile salts range in concentration from 3-
45 mM l-1 (0.2 -2% wt/vol) depending on the individual, and the type and 
amount of food ingested 248, 249.  High concentrations are found in the 
duodenum, jejunum and proximal ileum to facilitate fat digestion and 
absorption 250. 
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Bile salts are synthesised in the liver from cholesterol via a multienzyme 
process and represent approximately 50% of the organic components of bile 
(Figure 3.1).  Synthesis occurs through two main pathways, the “classical” 
and the “alternative” pathway.  The classical pathway occurs in the liver and 
leads to the generation of chenodeoxycholic acid (CDCA) and cholic acid 
(CA), two important human primary bile acids (Table 3.2) 245, 251, 252. 
 
Prior to secretion, the bile salts must first be conjugated by N-acyl amidates 
(peptide linkage) with glycine (glycoconjugated) or taurine (tauroconjugated), 
these are present in a ratio of 3:1 respectively in average human bile (Figure 
3.2).  Conjugation increases the water-solubility of the bile acids by lowering 
the pKa of the terminal acidic group 244.  The amidation also decreases the 
passive absorption of bile acids in the biliary tract and small intestine, 
ensuring high levels of bile are available to aid fat digestion and adsorption.  
When conjugated, bile acids are generally referred to as bile salts due to the 
fact that they are completely ionised at physiological pH 245.  The bile salts 
are amphipathic and thus can self-associate in water to form polymolecular 
aggregates known as micelles.  Micelles form when bile salts reach a 
sufficient concentration known as the critical micellar concentration (CMC) 
244.  Approximately 5% of bile salts evade absorption by epithelium and are 
extensively modified through specialised biotransformation reactions by the 
indigenous intestinal microflora 244, 245. 
  
 125 
Bile acids Abbreviation Conjugates Abbreviation Site of production  
     
Primary bile 
acids     
     
Cholic CA Taurocholic TCA Liver 
  Glycocholic GCA  
Chenodeoxycholic CDCA Taurochenodeoxycholic TCDCA Liver 
  Glycochenodeoxycholic GCDCA  
     
Secondary bile 
acids 
    
     
Deoxycholic DCA Taurodeoxycholic TDCA Intestine 
  Glycodeoxycholic GDCA  
Lithocholic LCA Taurolithocholic TLCA Intestine 
  Glycolithocholic GLCA  
Ursodeoxycholic UDCA Tauroursodeoxycholic TUDCA Intestine 
  Glycoursodeoxycholic GUDCA  
Sulpholithocholic SLCA Taurosulpholithocholic TSLCA Liver 
  Glycosulpholithocholic GSLCA  
 
 
 
Table 3.1  Major constituents 
of human hepatic bile.  
Table adapted from Begley et 
al., 2005 245. 
!"#$%&%'(#%)) **"+,+)
!"#$%&' ()*'
+,-".$#/' 01'
2$-/'34-53'' )1'
6,"37,"-$7$#3' 8'
6"5433$%&' )'
+,"-/35/."-' 9'
Table 3.2 Bile acids and their conjugates. Adapted from Floch, 2002 248. 
The common bile acids and their conjugates are shown in the table alongside common abbreviations.  Synthesis of 
primary bile acids occurs exclusively in the liver as does conjugation.  Deconjugation occurs in the intestine. 
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Figure 3.1 Chemical structure of cholesterol and the major primary and secondary bile acids found in human bile.   
Cholic acid and chenodeoxycholic acid are synthesised in the liver from cholesterol via a multienzyme process.  Indigenous intestinal microbiota carry out 
various biotransformation reactions to generate the secondary bile acids deoxycholic acid and lithocholic acid, both of which can be excreted in the faeces. 
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Figure 3.2 Structure 
of the common 
conjugated bile salts 
found in human bile 
primarily tauro and 
glyco conjugates of 
cholate and 
chenodeoxycholate.  
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3.2.1. Bacterial biotransformation/modification of bile salts 
During intestinal transit, particularly in the caecum and colon, bile salts undergo 
further modifications by the indigenous intestinal bacteria.  There are three main 
types of biotransformation i) deconjugation, ii) 7 !/"–dehydroxylation, and iii) 7 
!-dehydrogenation (Figure 3.3) 252.   
 
Deconjugation removes taurine or glycine by enzymatic hydrolysis of the C-24 
N-acyl amide bond which links the amino acid conjugate to the bile salts 250.  
This hydrolysis is catalysed by bile salt hydrolases (BSHs) produced by a broad 
spectrum of anaerobic intestinal bacteria including Clostridium, Bacteroides, 
Lactobacilus, Bifidobacterium and Enterococcus 245, 250, 251, 253.  BSHs are 
thought to improve bacterial colonisation of the lower GIT in higher mammals 
possibly by detoxification of the bile salts 250.   
 
Dehydroxylation (replacement of a hydroxyl group with a hydrogen) occurs at 
the 7 position in the nucleus converting the primary bile salt CA to the 
secondary bile salt DCA and similarly CDCA to LCA (Figure 3.1) 251.  This 
transformation is quantitatively the most important bacterial bile salt 
biotransformation in the colon 252.  Execution of this rapid multistep 
transformation is restricted to specific members of the Clostridium and 
Eubacterium (approximately 0.0001% of colonic microbiota) 245, 250.  
Dehydroxylation is limited to free bile acids and thus removal of glycine/taurine 
by BSHs is a prerequisite for 7 !/"–dehydroxylation by intestinal bacteria, with 7 
"–dehydroxylation appearing to be nonessential 250.  
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Figure 3.3 Biotransformation reactions of bile salts performed by 
bacteria in the human intestinal tract.  Taken from Ridlon et al., 
2006 250. 
Schematic diagrams show the bacterial bile salt-biotransforming reactions in the 
human intestinal tract. The hydroxy group carbons of cholate are numbered and the 
AB rings are identified. Nomenclature is that of Hofmann et al. (1992) 254.  (BSH = bile 
salt hydrolase; HSDH = hydroxysteroid dehydrogenase).  
 
 
 
 
Image unavailable due to copyright restrictions 
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Deconjugation and dehydroxylation increase the hydrophobicity and pKa of 
the bile salts enabling recovery via passive absorption across the colonic 
epithelium 250.  The increased hydrophobicity is also thought to be associated 
with increased toxicity of the bile acids; high levels of secondary bile acids 
have been linked to cholesterol gallstone disease and colon cancer 245, 251, 255 
 
7 !-dehydrogenation involves oxidation and epimerisation of bile acid 
hydroxy groups.  Oxidation of the A-ring of the steroid nucleus leads to 
conversion of CDCA to 7-oxolithocholic acid which then undergoes 
epimerisation by bacterial enzymes to form urodeoxycholic acid 251.  This 
reaction is carried out by hydroxysteroid dehydrogenase (HSDH) expressed 
by intestinal bacteria.  Performing 7 !-dehydrogenation leads to energy 
generation and lowers the hydrophobicity and concentration of potentially 
toxic bile acids 250.  The physiochemical properties of bile acids can also be 
affected by changes to the hydroxy group stereochemistry, notably 
epimerisation of the 7!–hydroxy group of CDCA decreases its hydrophobicity 
and toxicity 251. 
 
3.2.1. Antimicrobial action of bile 
Three important agents produced by the GIT, whose primary role is to aid 
digestion, also play a significant role in the prevention of infection; including 
gastric secretions, hydrochloric acid and bile.  Together gastric secretions 
and hydrochloric acid lower the pH in the stomach to between pH 1.5-2 which 
destroys the majority of ingested bacteria 247.  Bacteria which fail to be 
eradicated in the stomach then face high concentrations of bile in the small 
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intestine, which alongside rapid transit times, antimicrobial peptides (e.g. 
defensins), IgA and proteolytic enzymes, help defend the GIT against many 
invading pathogenic organisms 256.  
 
The most significant antimicrobial action of bile is to cause membrane 
damage.  Observations by electron microscopy, reveal that upon exposure to 
bile, cells become shrunken and empty, with leakage of intracellular material, 
this leakage has been confirmed by enzyme assays 245, 257.  Alteration of the 
membrane through environmental stimuli such as acid adaptation or 
increased osmolarity, and entry of the cell into stationary phase can increase 
a bacterium’s resistance to bile-associated damage.  Furthermore, mutants 
which are resistant to the deleterious effects of bile are in the majority of 
cases associated with mutations in loci linked directly or indirectly to 
membrane integrity 245. 
 
The effects of bile salts on cell membranes vary according to several 
parameters, including concentration, the type and structure of the bile salt 
and the membrane architecture of the affected cell 245.  Membranes are 
rapidly dissolved and integral membrane proteins dissociated by high bile 
concentrations, leading to leakage of cell contents and ultimately cell death 
245, 258.  Low or sub-micellar bile concentrations can subtly alter membrane 
integrity by leading to changes in fluidity and permeability 259.  Low 
concentrations can also alter the activity of membrane bound enzymes and 
affect the physical chemical properties of the cell surfaces such as 
hydrophobicity and zeta potentials (electrokinetic potential) 245, 260. 
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Binding of bile acids to membrane lipids is correlated to their hydrophobicity 
and therefore, the type of bile salt and its structure is a factor in the severity 
of membrane damage.  Conjugated bile acids are strong acids and generally 
fully ionised at physiological pH 244.  They are therefore maintained in the 
outer hemileaflet of the bilayer unless actively transported into the cell.  
Unconjugated bile acids are able to ‘flip-flop’ passively across the lipid bilayer 
into the cell at a rate dependent on the number of hydroxy groups; dihydroxy 
flip more rapidly than trihydroxy bile acids 245.  Porcine bile, closely related to 
human bile in composition, is composed of dihydroxy bile acids and is 
significantly more inhibitory to bacterial membranes than bovine bile, which is 
composed of trihydroxy bile acids 245, 261.  Membrane architecture and 
composition including alteration of membrane characteristics such as charge, 
hydrophobicity and lipid fluidity, also play a role in the resistance of 
membranes to bile-associated damage.  Additionally, structural damage to 
lipopolysaccharides caused by freezing has been shown to increase the 
sensitivity of E. coli to bile acids, and the presence of carbon dioxide can 
increase the permeability of membranes to bile acids 245, 262. 
 
Bile acids have been shown to have a number of other effects on bacterial 
cells by disturbing macromolecule stability.  Evidence suggests that they can 
induce DNA damage and activate DNA repair enzymes in bacterial and 
mammalian cells, and lead to secondary structure formation in RNA 245, 263, 
264.  Bile may also induce oxidative stress by generation of oxygen free 
radicals and intracellular bile salts may lead to pH stress and osmotic effects.  
Furthermore, the detergent actions of bile can alter protein conformation 
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leading to misfolding or denaturation 245.   Bile salts may also act indirectly to 
prevent bacterial growth.  Inagaki et al. (2006) present evidence that 
conjugated bile acids can regulate the expression of host genes involved in 
innate immune defence mechanisms in cells of the small intestine 265.  
 
3.2.2. Bacterial mechanisms for bile tolerance 
The human intestines contain a plethora of indigenous microflora which play 
a role in digestion, carrying out a wide range of metabolic actions and 
offering protection against invading pathogenic organisms through 
colonisation resistance (Figure 3.4) 266.  The small intestine is relatively 
poorly colonised with populations up to 105 bacteria, primarily aerobes 248.  
Conversely, the colon harbours over 1011 bacteria per gram of wet weight of 
faeces which are predominately anaerobes 250, 267-269.  High levels of 
deconjugated bile acids exist in the small intestines which require the 
colonising bacteria to possess specialised adaptations for survival 175, 244. 
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Figure 3.4 Cartoon of the anatomy of the human gastrointestinal tract.  
Adapted from Brock Biology of Microorganisms 269. 
The distribution of non-pathogenic bacterial classes usually present in the 
small and large intestine of normal individuals is indicated.  
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Due to the potentially catastrophic actions of bile acids on bacterial 
membranes, enteric bacteria have developed several, often specific, 
tolerance mechanisms in response to the presence of bile 175.  Experiments 
performed with E. faecalis and L. monocytogenes reveal that exposure to 
sub-lethal concentrations of bile acids has a protective effect, dependent on 
growth phase and bile concentration, leading to rapid adaptation of the cell 
allowing it to withstand typically lethal concentrations of bile 270-272.  
Assessment of protein expression by Salmonella spp. has also revealed 
significant differences in expression after exposure to bile 175.  How bacteria 
sense bile is not yet fully understood, it has been suggested that sensor 
kinases of two component regulatory systems may initiate a phosphorylation 
cascade with a cognate response regulator; or that bile may be sensed by 
‘AraC-like’ transcriptional regulators which are able to regulate a diverse 
range of virulence factors; or finally that the sensory mechanism is an indirect 
process where the actions of bile on the cell are sensed rather than the bile 
itself 175, 273.  Clearly, further investigation is required to fully understand the 
mechanisms behind the resistance of enteric bacteria to bile.  Such advances 
have the potential to aid the development of effective treatment strategies 
and the design of novel infection prevention methods 169. 
 
3.2.2.1. LPS 
Gram-negative bacteria are known to be inherently more resistant to the 
actions of bile, with bile salts often used for the selective enrichment of 
growth media 175, 245, 248.  Salmonella spp. show a high level of resistance to 
bile acids and are able to colonise the gallbladder.  This is thought to allow 
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the chronic asymptomatic carrier state which occurs in 2-5% of infected 
individuals 274.  Investigation of the interaction of Salmonella spp. with bile 
has revealed increased biofilm formation and invasive potential 245.  Similarly, 
E. coli and Campylobacter spp. are often isolated from the gallbladder and 
bile of animals and humans 175, 245.  The Gram-negative cell wall provides an 
excellent hydrophobic barrier to bile salts (Figure 3.5).  The 
lipopolysaccharide (LPS) represents the major portion of the outer leaflet of 
the outer membrane with the O-antigen providing a major barrier to external 
compounds 175. 
 
3.2.2.2. Efflux pumps  
Efflux of bile from the bacterial cytoplasm is the best characterised form of 
bile salt resistance.  These systems are also responsible for efflux of other 
toxic compounds including antibiotics, organic solvents and oxidative stress 
agents 175, 275.  The intrinsic resistance shown by E. coli to solvents, 
detergents, lipophilic antibiotics (for example erythromycin) and bile salts is 
mediated by the acrAB encoded efflux system.  In this well characterised 
system, AcrB is a proton motive force-dependent drug efflux transporter; 
AcrA bridges the inner and outer membrane to aid efflux directly from the 
cytoplasm to the environment 175, 275, 276.   
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Figure 3.5  Schematic diagram of the structure of the Gram-
negative and Gram-positive bacterial cell wall taken from Cabeen 
and Jacobs-Wagner, 2005 277.  
a) Gram-positive cell wall – a thick multilayered peptidoglycan sheath covers the 
cytoplasmic membrane, with teichoic acids embedded in the peptidoglycan, and 
lipoteichoic acids which extend into the cytoplasmic membrane.  
 
b) Gram-negative cell wall - the outer membrane is linked by lipoproteins to a thin, 
primarily single-layered peptidoglycan sheath, located within the periplasmic space. 
The outer membrane contains porins to allow passage of small hydrophilic 
molecules across the membrane, and lipopolysaccharide molecules that extend into 
extracellular space. 
 
 
 
 
 
 
Image unavailable due to copyright restrictions 
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So-called Omp proteins are found on the outer membrane of Gram-negative 
bacteria and are important in the host-pathogen interaction; they are involved 
in a wide range of different functions including transportation of various 
molecules (porins), adhesion (adhesins), signalling pathways, cell structure 
and invasion of host cells and bacterial defence 278.  In E. coli, disruption of 
ompF and ompC leads to a bile sensitive phenotype, a phenomenon mirrored 
by disruption of ompU in V. cholerae 279, 280.  TolC is an outer membrane 
protein thought to aid the Acr system 276, 281.  Mutations in tol genes can have 
a direct impact on bile resistance by destabilising the outer membrane 
allowing greater access to bile salts 245.  Mutations of tolC in V. cholerae 
significantly reduced the ability of the organism to grow and colonise in the 
presence of bile 282. 
 
In general Gram-positive bacteria are more sensitive to the effects of bile 
than Gram-negative bacteria.  Numerous studies have been carried out on 
Gram-positive bacteria which may be used as probiotics in the human GIT, 
notably Bifidobacteria and Lactobacillus, as bile salt tolerance is an essential 
criteria for their suitability 283-285.  Unfortunately, the majority of these studies 
are not comparable due to technical differences; therefore it is difficult to 
draw accurate conclusions from these data.  It is clear however, that the level 
of resistance to bile differs extensively between genus, species and strain 245. 
 
Biotransformation reactions carried out by the microflora of the GIT are 
postulated to lead to the detoxification of bile acids which would otherwise 
exert deleterious effects on certain bacterial species 250.  Several Gram-
positive indigenous bacteria have the ability to modify bile using BSHs to 
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render conjugated bile acids less toxic by removing the taurine/glycine 
conjugate 250, 286, 287. 
 
3.2.3. The interaction of bile with pathogenic bacteria  
Environmental conditions such as osmolarity, acidity and temperature are 
constantly sensed by bacteria during colonisation or infection of the host.  
These signals allow the organism to adapt to its environment by altering gene 
expression and regulation to aid survival, which in pathogenic bacteria 
includes regulation of virulence factors. 
 
Vibrio parahaemolyticus is a marine and estuarine bacterium that causes 
acute gastroenteritis in humans.  Several of this bacterium’s virulence factors 
are affected by bile including thermostable direct haemolysin (TDH) and 
capsule production, adherence to epithelial cells and Congo red binding 
(associated with increased adherence and invasive potential) 245, 273, 288, 289.  
Bacteria also show increased motility when grown in bile allowing them to 
reach the more favourable environment of the intestinal mucosal layer 245, 290.  
Finally, as bile acids are calcium chelators they may trigger a low calcium 
response, which has been shown to regulate virulence factors in Yersinia 
spp. 245, 273. 
 
The Gram-positive intracellular pathogen L. monocytogenes has been 
studied extensively with respect to bile tolerance.  Like S. typhimurium, L. 
monocytogenes is able to colonise the gallbladder (known as cholecystis) 
and thus has a very high tolerance to bile.  Begley et al. (2002) observed 
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growth of L. monocytogenes strain LO28 on agar supplemented with high 
bile concentrations of human (15%), porcine (2%), oxgall (15%) and bovine 
(15%) bile 245, 270.  Olier et al. (2004) demonstrated that clinical isolates from 
asymptomatic carriers, and food and environmental isolates could grow in 
broth supplemented with 5% porcine bile supporting the idea that L. 
monocytogenes is inherently resistant to bile salts 291.  Other studies have 
generated different results, and as seen with probiotic bacteria, there were 
major differences between strains.  Experimental differences may also 
support the differing findings, Begley et al. (2002) note that pH can be a 
significant factor in the potential toxicity of glycoconjugated bile salts 270.  L. 
monocytogenes was the first pathogenic species not considered to be part of 
the normal enteric flora to be shown to have BSH.  BSH is present in all 
pathogenic Listeria species and its expression in vitro in strain EGDe is 
positively regulated by PrfA, a transcriptional activator and the principal 
regulator of virulence genes in L. monocytogenes 287.  A PrfA-regulated bile 
exclusion system has also been identified as a virulence factor in L. 
monocytogenes 292.  The BilE operon contains two genes bilEA and bilEB, 
with significant homology to members of the betaine carnitine choline 
transporter family.  Sleator et al. (2005) demonstrated that functional 
inactivation of BilE leads to a significant reduction in the bacterium’s ability to 
withstand lethal concentrations of bovine bile (oxgall) and physiological 
concentrations of human bile.  Additionally, cells with this phenotype were 
significantly less virulent in murine models 292.  
 
E. faecalis is an important multidrug resistant nosocomial pathogen and is 
one of the most common lactic acid producing bacteria found in the GIT 293.  
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The bacterium has been isolated from bile, biliary drain devices used in 
biliary surgery, and, directly from the gallbladder, highlighting its high 
tolerance of bile 245, 294.  Alteration of the physiochemical surface properties 
of E. faecalis occurs after growth in bile (oxbile) resulting in increased 
invasion of biliary drain materials 295.  This property may enhance 
colonisation through increased adhesion 245, 295.  However in vitro analysis of 
E. faecalis by tolerance to bile showed the bacterium is rapidly killed after 
challenge with unconjugated bile acids 271.  This differential susceptibility to 
conjugated verses unconjugated bile acids highlights the potential drawback 
of in vitro analysis; the composition of the bile may not accurately reflect the 
in vivo conditions faced by the organism. 
 
3.2.4. The interaction of C. difficile with bile 
Clostridium spp., notably C. perfringens, are often found in the GIT and have 
been isolated from bile.  However, little is known about their interaction with 
and tolerance mechanisms to bile salts.  The ability of the clostridia to 
produce metabolically dormant highly resistant endospores enables them to 
avoid oxygen toxicity and to pass freely through the extremely acidic 
environment of the stomach 16.  Spores are therefore widely considered to be 
the aetiological agent of infection, however these spores must germinate in 
order to cause disease 296.  The process of germination and sporulation in 
clostridia has not been well studied, although parallels can be drawn from the 
model organism B. subtilis 169.  In particular, investigation of these processes 
in C. difficile has been limited by the lack of genetic tools. 
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A role for bile salts in the germination of C. difficile spores has been 
proposed suggesting that certain bile salts may act as cogerminants 169, 176.  
Germination is initiated after exposure to specific environmental cues termed 
germinants, these include nutrients, muropeptides, cationic surfactants, high 
pressures, salts and CaDPA (a 1:1 chelate of dipicolinic acid and Ca2+) 297.  
In B. subtilis, germination is initiated by nutrients which are sensed by three 
sensory receptors GerA, GerB and GerK, leading to a cascade of reactions 
culminating in the commencement of metabolism 169, 297.  Homologues of 
GerA, GerB and GerK identified in many Clostridium species are absent from 
C. difficile 169. 
 
After ingestion and passage through the acid stomach environment, C. 
difficile spores encounter high concentrations of primary bile salts such as 
CA in the small intestine.  Upon entry to the anaerobic environment of the 
large intestine, the spores will encounter bile that evaded absorption and 
recycling.  Under normal conditions, the indigenous microflora will convert 
these bile salts to secondary bile acids such as DCA through 
biotransformation reactions 244.  As observed for other bacteria that colonise 
the GIT, C. difficile may use bile acids as a signal to indicate its position in 
the GIT.  The anaerobic environment and presence of deconjugated bile 
acids in the colon may signal germination allowing colonisation 169.  If the 
spore were to germinate in the small intestine the high concentrations of bile 
are likely to destroy vegetative cells, preventing colonisation.  Sorg and 
Sonenshein (2008) have investigated the role of various bile salts in 
germination of C. difficile spores 169.  They confirmed previous research by 
Wilson et al. (1982 & 1983) who showed that spore recovery was enhanced 
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by the addition of the primary bile salt taurocholate to rich growth medium 168, 
176.  Several studies have also shown that taurocholate (TCA) can enhance 
colony formation by C. difficile spores isolated from environmental surfaces 
168, 298, 299.  Other cholate derivatives may act as germinants for C. difficile 
including cholate and glycocholate, although the authors failed to show that 
they were able to stimulate germination using their assays.169.  Glycine was 
also identified as a co-germinant; as the bacterial microbiota deconjugate 
primary bile salts, free glycine is released into the lower bowel, and therefore 
available to stimulate germination.  Sorg and Sonenshein (2009) also noted 
that the secondary bile salt deoxycholate could induce germination but that it 
prevented vegetative cell growth.  Additionally chenodeoxycholate was 
shown to be an inhibitor of both germination and growth 170.  The authors 
hypothesise that should the normal gut flora be disrupted, say after 
administration of antibiotics, then the relative concentrations of deoxycholate 
will be reduced, creating a favourable environment for growth of vegetative 
cells and colonisation of the colon 169, 300.  However, the role of bile as an 
environmental cue for germination has been disputed by Paredes-Sabja et al. 
(2008) who failed to observe an increase in spore germination following 
exposure to bile salts, either alone or in nutrient-rich medium 171.  There are 
major differences in the methods used in these two studies, particularly those 
used to generate spore preparations and their storage and activation, which 
could account for the differences in the results. 
 
Gene CD0065, from the 630 genome, is predicted by genome annotation to 
encode a bile acid inducible enzyme NADP-dependent 7-alpha-
hydroxysteroid dehydrogenase which converts the primary bile acid, 
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chenodeoxycholic acid, into 7-keto-lithocholic acid, a potentially toxic 
secondary bile acid, although this has not been confirmed experimentally 6.  
It is not clear how C. difficile might protect itself from lithocholic acid, and its 
role in germination has not been tested due to its poor solubility in water 169.  
Genes CD3215 and CD3216 have been identified as orthologs of bilEA and 
bilEB, which encodes a bile exclusion system in L. monocytogenes 6, 292.  C. 
perfringens is known to express BSH on its cell surface enabling 
deconjugation of bile salts, however open reading frames with homology to 
these enzymes have not been found in C. difficile 169.  Investigation of the 
interaction of bacteria with bile is being increasingly assessed by expression 
analysis 283, 301-306.  Microarray technology allows quantitative assessment of 
the global response to certain conditions such as bile stress 307.  Such 
analysis can produce large quantities of data and through appropriate 
scrutiny, can lead to the identification of novel genes and pathways involved 
in the stress response, potentially identifying virulence factors suitable for 
further investigation 308. 
 
Clearly, additional exploration of the interaction of bile with C. difficile is 
required.  Enhanced understanding of these interactions may aid treatment 
and control strategies through the development of bile acid based 
therapeutics or environmental cleansing agents 169. 
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3.3. Aims and Objectives 
 
To survive the GIT C. difficile must possess mechanisms to tolerate bile acid 
stress however, little research has been conducted to explore this important 
interaction.  Although in vitro analysis cannot recreate the conditions of the 
complex in vivo environment, assessment of the tolerance profile of C. difficile 
to bile represents an interesting avenue of research.  As C. difficile spores and 
vegetative cells interact with bile during passage in the human and animal GIT, 
there is a requirement to gain an understanding of how bile affects C. difficile 
and how C. difficile responds to this stress.  The genetics of bile resistance in 
Gram-positive organisms is also poorly understood.  Expression analysis of the 
bacterium’s response to bile and the screening of a random transposon 
insertion library for changes in bile tolerance may identify novel virulence factors 
in C. difficile.  
 
Objectives: 
1. Develop assays to investigate the tolerance of C. difficile to bile salts in 
solid and liquid media using bovine and ovine, and porcine bile 
preparations. 
2. Evaluate the tolerance shown by various C. difficile strains and by the 
soil dwelling non-pathogenic organism, Clostridium acetobutylicum. 
3. Investigate the effects of sub-lethal bile concentrations on C. difficile prior 
to exposure to high bile concentrations. 
4. Investigate the expression profile of C. difficile strain 630!erm after 
growth in the presence of bile. 
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3.4. Materials & methods 
 
3.4.1. Bile tolerance assays 
3.4.1.1. Preparation of bile mix and individual salts 
Dehydrated bile of bovine and ovine origin (B & O) (Oxoid, UK) was 
suspended in sterile distilled H2O or sterile RCM broth (Oxoid) at 50% wt/vol 
and incubated for a minimum of 12 hours at 2-8oC before use.  Dehydrated 
bile of porcine origin (PB) (Oxoid, UK) was ground to a fine powder in a 
pestle and mortar before being suspended in sterile RCM broth at 10% wt/vol 
and incubated for a minimum of 12 hours at 2-8oC before use.  For each 
experiment, as the bile preparations were viscous they were warmed to 37oC 
before use to aid pipetting. 
 
3.4.1.2. Bovine & Ovine bile broth assay 
50% B & O bile was added to RCM or BHI broth to generate the required 
percentage.  1 ml of each B & O bile solution was plated in to 96 deep well 
plates (ABgene, UK) in triplicate with appropriate controls and pre-reduced 
for a minimum of 3 hours (Figure 3.1).  C. difficile strains R20291, 630!erm 
and CD37 were grown in 10 ml BHI broth with or without addition of 0.05% 
cysteine in 20 ml universals for 18-20 hours under anaerobic conditions at 
37oC.  C. acetobutylicum was grown in 10 ml RCM broth in 20 ml universals 
for 18-20 hours in anaerobic conditions at 37oC.  Cultures were centrifuged to 
pellet the bacteria; 15 min at 3000 x g, pellets were re-suspended in 0.25 ml 
fresh RCM medium.  Wells were inoculated with C. difficile, C. 
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acetobutylicum or RCM broth as appropriate to establish a final OD at 600 
nm (OD600 nm) of 0.1 at (except broth control) and mixed thoroughly.  Plates 
were covered with an adhesive gas-permeable seal (ABgene, UK) and 
incubated for 24 hours in anaerobic conditions at 37oC.  After incubation a 
100 !l sample from each well was transferred to a 96 well flat bottomed plate 
and optical density was measured using a microplate reader (MRXTC II, 
Dynex Technologies Inc., UK) at 590 nm with a 3 second shake prior to 
measurement.  Appropriate (broth only) blank measurements were 
subtracted from each OD reading for data analysis.  Prism 5 (GraphPad 
Software Inc, v5.01) and SPSS v19 were used to plot the data and for 
statistical analysis.  Data were analysed for normality using a Q-Q plot and 
assessment of the Shapiro-Wilk statistic.  A Mann-Whitney test for 
nonparametric data was performed to assess the significance of the 
observed growth differences. 
 
Extended range assay 
Starting cultures were grown as stated above and inoculated into BHI broth 
containing 0.1%, 0.3%, 0.5% increasing in increments of 0.5% to 12% B & O 
bile.  Samples were taken and evaluated after 24 hours as described above. 
Data were analysed for normality as described above and found not to be 
normally distributed.  A Kruskal-Wallis test for nonparametric data, with a 
post-hoc Dunn’s multiple testing correction, was used to analyse the 
differences in growth under each condition. 
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3.4.1.3. Bovine & Ovine bile agar assay 
50% B & O bile was added to BHI or RCM agar to generate the required bile 
percentage (0, 0.1, 0.3, 0.5, 1, 3, 5 and 10%).  Cultures of C. difficile strains 
R20291, 630, 630!erm and CD37 were grown in 10 ml BHI broth in 20 ml 
universals for 18-20 hours at 37oC in anaerobic conditions.  Cultures were 
standardized to an OD600 nm of 0.8 and spotted in quadruplicate onto pre-
reduced agar using a multipoint replicator (Mast, Liverpool UK). C. 
acetobutylicum cultures, grown in 10 ml RCM broth in 20 ml universals for 
18-20 hours, were standardised to an OD600 nm of 0.9 was plated alongside 
C. difficile on each test plate with the addition of a broth control using the 
multipoint replicator.  Inoculated plates were incubated for 48 hours in 
anaerobic conditions at 37oC before analysis.  
 
3.4.1.4. Porcine bile agar assay 
PB was added to RCM agar to generate the required bile percentage (0.01, 
0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 2, 3, 4 and 5 %). C. 
difficile strains R20291, 630, 630!erm and CD37, grown in 10 ml BHI broth in 
20 ml universals for 18-20 hours, were standardized to an OD600 nm of 0.8, 
and spotted in quadruplicate onto pre-reduced agar using the multipoint 
replicator. C. acetobutylicum cultures, grown in 10 ml RCM broth in 20 ml 
universals for 18-20 hours, were standardised to an OD600 nm of 0.9.  
Cultures were plated alongside C. difficile on each test plate with the addition 
of a broth control using the multipoint replicator.  Inoculated plates were 
incubated for 48 hours in anaerobic conditions at 37oC before analysis.  
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Control plates without bile were also inoculated and incubated anaerobically 
and aerobically at 37oC. 
 
3.4.1.5. Growth curve 
10 ml BHI broth was supplemented with 0.05% cysteine and 0.1%, 1%, 
2.4%, or 5% B & O bile.  Bile broths, and matched broth only controls, were 
inoculated in triplicate to a starting OD600 nm of 0.1 with 630!erm culture 
grown in 10 ml BHI broth in a 20 ml universal for 18-20 hours.  At regular 
time intervals 1 ml samples were taken and the absorbance measured 
OD600 nm using a spectrophotometer (Thermo-Fisher, UK).  The data was 
plotted using Prism 5. 
 
3.4.1.6. Bile adaptation assay 
630!erm and R20291 cultures were grown in 10 ml BHI broth in 20 ml 
universals for 16-18 hours to an OD600 nm of between 0.9-1.2.  Cultures 
were supplemented with 0.1%, 1%, 2.4%, or 4% B & O bile in triplicate or 
with an equivalent volume of BHI broth.  Cultures were incubated 
anaerobically for 15 minutes at 37oC.  Pre-reduced and warmed BHI broth 
supplemented with 0.1%, 1%, 2.4%, 4%, 8%, 10% and 12% B & O bile or 
BHI broth only controls, were inoculated with each of the pre-exposed 
samples in triplicate to an approximate starting OD590 nm of 0.05 in 96 deep 
well microtiter plates.  Plates were incubated anaerobically for 24 hours 
without shaking at 37 oC.  After incubation absorbance was measured at 590 
nm using a microplate reader.  Prism 5 and SPSS v19 were used to plot the 
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data and for statistical analysis.  Data were analysed for normality as 
described previously and found not to be normally distributed.  A Mann 
Whitney test was used to analyse the growth under each condition. 
 
3.4.2. Expression profiling 
3.4.2.1. Bile exposure assay 
Vented 25 cm3 tissue culture flasks containing 10 ml of BHI broth with 0.05% 
cysteine were inoculated with C. difficile strain 630!erm to an initial OD600 
nm of 0.1.  Cultures were incubated with shaking (50 rpm) for 4 hours at 
37oC in anaerobic conditions (OD600 nm ~ 0.6-0.7) (cells determined to be 
at mid-log phase by growth curves performed by Nazilla Jafari, UCL Eastman 
Dental Institute).  Under anaerobic conditions B & O bile (50% vol/vol 
solution) was added to a final concentration of 0.1, 2.4 or 4% in triplicate.  For 
control cultures, also in triplicate, an equivalent volume of BHI broth was 
added.  Cultures were incubated for a further 15 min (long exposure) or 1 min 
(short exposure) before growth was stopped by addition of RNA protect 
bacterial reagent (Qiagen, UK). 
 
3.4.2.2. RNA extraction and assessment 
Under anaerobic conditions 2 volumes of RNAprotect bacterial reagent 
(Qiagen, UK) was added to 1 volume of culture and vortexed immediately for 
5 seconds.  Samples were removed from the anaerobic chamber and 
incubated for 5 min at 15-25oC and then centrifuged at 5000 x g for 10 min to 
pellet the bacteria.  The supernatant was removed and the tubes were 
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drained on absorbent paper prior to freezing at -70oC for 24-48 hours.  All 
further processing and handling of RNA was conducted in controlled 
environments, using disposable plastic ware, filter tips, molecular grade 
RNase and DNase free water (Sigma-Aldrich, UK), and by the use of an 
RNaseZap solution (Ambion, UK) to minimize contamination.  Two methods 
were used to extract the RNA, the first using an RNeasy kit (Qiagen, UK) 
involving enzymatic lysis and proteinase K digestion, and secondly, using a 
Fast RNA pro blue extraction kit (MP Biomedicals, USA) involving a 
phenol/chloroform based extraction method. 
 
Extraction of RNA using an RNeasy kit (Qiagen, UK) 
Extraction and purification of RNA were carried out according to the 
manufacturer’s protocol 4 – Enzymatic lysis and proteinase K digestion and 
protocol 8 - Purification of total RNA from bacterial lysate using the RNeasy 
Midi kit.  Briefly, frozen cell pellets were thawed on ice.  400 !g of Proteinase 
K (Qiagen, UK) was added to TE buffer, which contained 15 mg ml-1 of 
lysozyme (Sigma-Aldrich, UK).  The cell pellets were carefully re-suspended 
by pipetting and vortexing for 10 sec and incubated for 10 min at 15-25oC 
with periodical vortexing.  Samples were processed according to the 
manufacturer’s protocol without modification.  RNA was eluted in 200 !l of 
RNase-free molH2O passed though the column twice.  The concentration of 
RNA was estimated using a NanoDrop 1000 spectrophotometer (Thermo 
Fisher Scientific, UK).  
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RNA extraction using a Fast RNA pro blue extraction kit (MP Biomedicals, 
USA)  
1 ml of RNA pro solution was added to each bacterial cell pellet thawed on 
wet ice.  Samples were processed according to the manufacturer’s protocol 
without modification.  The resulting RNA pellet was re-suspended in 100 µl of 
RNase-free molH2O and the concentration estimated using a NanoDrop 1000 
spectrophotometer. 
 
3.4.2.3. DNase treatment 
RNase-Free DNase Set (Qiagen, UK): 
Before re-suspension of the RNA pellet in molH2O, 2 µl of 10X DNase buffer 
was added to the pellet (RNase-Free DNase Set Qiagen, UK).  10 U of the 
RNase inhibitor and 0.5 Kunitz U of DNase I was added, the volume was 
adjusted to 20 µl with molH2O.  The sample was incubated for 30 min at 37oC 
before addition of 2 µl 0.5 mM EDTA. The DNase I was inactivated by 
incubation at 65oC for 5 min.  RNA was stored at -70oC. 
 
DNA-free™ (Ambion, UK): 
Aqueous RNA was transfer to a 0.5 µl microcentrifuge tube, 0.1 volumes of 
10X DNase I buffer and 3 U of rDNase I was added and mixed gently. The 
sample was incubated at 37oC for 30 min before addition of a further 3 U of 
rDNase I and 30 min incubation for rigorous treatment of the sample. 0.2 
volumes of re-suspended DNase inactivation reagent was added, samples 
were vortexed and incubated at room temperature for 2 min with occasional 
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mixing.  Sample was centrifuged at 10000 x g for 1.5 min and RNA 
transferred to a fresh tube.  RNA was stored at -80oC.  
 
3.4.2.4. RNA quantification and quality assessment  
Before use, RNA was quantified and assessed for quality on a Nanodrop 
1000 spectrophotometer (Thermo Fisher, UK).  The purity of the RNA was 
assessed using the ratio of sample absorbance at 260 and 280nm, samples 
giving a ratio between 1.9 and 2.1 were considered to be pure (based on the 
extinction coefficient of nucleic acids at 260 nm and 280 nm) 309.  A 
secondary measure of purity, using the ratio of absorbance of 260 nm and 
230 nm was also taken, samples that gave a reading between 1.8 and 1.2 
were considered to be pure.  Some RNA samples were assayed using an 
Agilent 2100 Bioanalyzer using the RNA 6000 Nano Lab-Chip kit (Agilent 
Technologies, UK) to assess RNA integrity.  This was performed by Dr. R. 
Stabler at the London School of Hygiene and Tropical Medicine, UK 
according to the manufacturer’s guidelines.  
 
3.4.2.5. Microarray hybridization 
Sample labelling and hybridisation were carried out according to the BµG@S 
RNA vs DNA Labelling & hybridisation protocol (Bacterial Microarray Group 
at St. George’s, London UK) 310.  All reagents used for labelling were 
purchased from Invitrogen life technologies, UK, except Cy3/Cy5 dCTP 
Fluorolink which was purchased from GE Healthcare UK.  Microarray slides 
CDv1 were designed to include 3688 chromosomal predicted CDSs from 
strain 630.  Each CDS was represented by a PCR product designed to 
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maximise sensitivity and minimise cross hybridisation, multiple reporters 
were included for certain genes with each one spotted in duplicate by split pin 
onto amino-silane coated glass slides (GAPS II, Corning) (Figure 3.6) 310.  
 
Labelling: 
For DNA, 1 µg of wild type 630!erm DNA was added to 3 µg of random 
primers, H2O was then added to a final volume of 41.5 µl.  Samples were 
heated to 95oC for 5 min, snap cooled and briefly centrifuged.  To each 
sample the following were added; 10X React 2 buffer, 5 mM dA/G/TTP, 2 
mM dCTP, 25 nmol Cy5 dCTP and 3-9 U DNA polymerase 1 large fragment 
(Klenow) to a final volume of 50 µl.   Samples were incubated in the dark at 
37oC for 90 min. 
 
For RNA, 8-10 µg of RNA was added to 3 µg of random primers, H2O was 
then added to achieve a final volume of 11 µl.  Samples were heated to 95oC 
for 5 min, snap cooled and briefly centrifuged.  To each sample the following 
were added; 5X First Strand Buffer, 100 mM DTT, 5 mM dA/G/TTP, 2 mM 
dCTP, 25 nmol Cy3 dCTP and 500 U SuperScript II to a final volume of 50 µl. 
Samples were incubated in the dark at 25oC for 10 min followed by 
incubation at 42oC in the dark for 90 min.  After incubation DNA and cDNA 
samples were combined and purified using the MinElute PCR purification kit 
(Qiagen UK).  Samples were eluted with H2O to a final volume of 
approximately 29 µl. 
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Figure 3.6 Strain 630 version 1_0_0 microarray slide design 
The diagram represents the typical design of a grid found on the 630 microarray slide.  
Each blue spot represents a unique PCR product specific to genes found in C. difficile 
strain 630.  Various control spots are included on the microarray to allow validation of 
the fluorescence data obtained after hybridisation. 
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Hybridisation: 
Each microarray slide (Bµg@s, UK) was prehybridised in prehybridisation 
solution warmed to 65oC containing 3.5X SSC, 0.1% SDS, 10 mg ml -1 BSA 
Fraction V (all Sigma-Aldrich, UK) and H2O.  Slides were incubated in the 
prehybridisation solution for 20 min at 65oC.  After incubation, slides were 
rinsed thoroughly for 1 min with H2O followed by a rinse with propan-2-ol 
(Sigma-Aldrich, UK) for 1 min.  Slides were dried by centrifuging for 5 min at 
433 x g and stored in the dark before addition of labelled samples.  Purified 
Cy3/Cy5 labelled cDNA/DNA was mixed with 4X filtered SSC and 0.3% 
filtered SDS to a final volume of 46 µl before heating to 95oC for 2 min.  15 µl 
H2O was added to the wells in a hybridisation cassette (Telechem 
International, UK) and the prehybridised slide loaded.  Two 22 x 22 mm 
LifterSlips (Erie Scientific, Portsmouth, USA) were carefully placed over the 
microarray area.  The cooled sample/hybridisation solution mix was 
dispensed under one corner of each LifterSlip to cover each area by capillary 
action.  The hybridisation cassette was sealed and placed in a water bath at 
65oC in the dark for 16-20 hours.  After incubation, the slides were washed in 
a solution of 1X SSC & 0.05% SDS pre-warmed to 65oC with continual 
agitation for 2 min.  The slides were then transferred to a second wash 
solution of 0.06X SSC and washed with continual agitation for 2 min.  This 
second wash was repeated.  Slides were dried by centrifugation, 5 min at 
433 x g and stored in the dark before scanning. 
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3.4.2.6. Microarray analysis/statistical analysis 
Microarrays were scanned as soon as possible after washing by a GMS 418 
microarray Scanner (Genetic Microsystems) using the microarray scanner 
software.  Slides were initially scanned to ensure appropriate positioning and 
to identify the minimum gain required for maximum intensity but without 
signal intensity saturation.  Scanning was repeated with gains increasing by 
increments of 15 points until the gain reached close or equal to 100 points for 
the RNA channel, and three times only for the DNA channel.  16 bit TIFF 
images were saved after each scan.  Images for the Cy5 and Cy3 channels 
were uploaded into ImaGene 7.5 (Biodiscovery) for quantification and quality 
control.  Images were aligned to the grid template, each grid and spot was 
checked systematically to ensure correct positioning by the software, 
unusable spots were flagged manually to be questioned or ignored during 
analysis.  Raw data were combined using MAVI Pro v2.6.0 (MWG Biotech, 
UK) and paired datasets for Cy3 (RNA) and Cy5 (DNA) microarray 
fluorescence intensity quantifications were uploaded to GeneSpring GX 7.3.1 
(Agilent Technologies, UK).  Data were interpreted using the log2 ratios of the 
intensity of the RNA channel (Cy3) to that of the control DNA channel (Cy5).  
Data were initially normalised to each microarrays median (50th percentile) 
intensity ratio (of present and marginal microarray elements) using standard 
Bµg@s parameters.  Control and test samples were compared for statistical 
significance by parametric analysis using a one-way ANOVA welsh t-test with 
or without a Benjamini-Hochberg false discovery rate multiple testing 
correction at 5% confidence level. 
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3.5. Results 
 
3.5.1.  Bovine and Ovine bile broth assay 
The growth of two pathogenic C. difficile strains (630!erm & R20291) and C. 
acetobutylicum in bovine and ovine (B & O) bile was assessed after growth in 
a rich medium containing 0.08% to 16% bile (Figure 3.7).  C. acetobutylicum 
was found to be unable to grow in all of the concentrations tested, with an 
average optical density (OD) for these cultures of 0.015 (range = 0.009 – 
0.06, standard deviation = 0.008).  The average OD value observed for 
growth in the absence of bile was 0.606 (range = 0.567-0.677, standard 
deviation = 0.043).  The reduction in growth was found to be statistically 
significant in each of the concentrations tested with P!0.005 (Mann-Whitney 
test). 
 
The average growth, measured by OD, of R20291 in rich medium without the 
addition of bile was 0.371 (range = 0.341-0.387, standard deviation = 0.016), 
growth was observed in all of the bile concentrations tested except 16% 
where the average OD was 0.002.  There was significant inhibition of growth 
in all bile containing broths compared to growth in broth without bile 
(P!0.005, Mann-Whitney test).  The growth of R20291 in medium containing 
bile can be seen in Figure 3.8 where the growth of each culture is expressed 
as a percentage of the total growth observed in broth without bile.   
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Figure 3.7 Growth of R20291 and 630!erm in B & O bile 
The growth of 630!erm and R20291 in 0-16% bovine and ovine bile 
concentrations was measured using optical density (OD) at 590 nm 24 hours 
after inoculation.  The OD of 630!erm is represented in blue and the OD of 
R20291 in red.  Bidirectional error bars represent the standard deviation of 
three biological and three independent experimental replicates.  C. 
acetobutylicum (negative control) was included in each experiment; growth was 
observed in the no bile control and not observed in any of the bile test wells.  
Data was analysed using a Mann-Whitney test significance is denoted by ** 
(P!0.005). 
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A  
B  
Figure 3.8  Percent growth of R20291 and 630!erm in B & O bile 
compared to unexposed culture growth.  
The optical density (OD) values obtained for each test sample were compared to the OD 
obtained in the control samples and expressed as a percentage of total growth for both 
strains.  Error bars represent the standard deviation obtained from three independent 
experiments. 
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The greatest inhibition of growth occurred for cultures grown in 0.4% bile with 
bacteria showing a four-fold reduction in growth compared to those grown in 
the absence of bile, with average OD values of 0.09 and 0.371, respectively 
(Figure 3.8).  0.4% bile is significantly more inhibitory than 0.08% and 0.8% 
bile with significance of P=0.002 and P=0.044, respectively.  Growth in 2.4% 
to 8% bile ranged from 63-69% of the total possible growth observed for 
cultures grown in broth without bile, no significant differences were observed 
between the growth of 630!erm vs R20291 at these concentrations.   
 
The average growth of 630!erm, measured using OD, in the absence of bile 
was 0.487 (Figure 3.7).  Growth of 630!erm was observed in broth 
containing 0.08 to 4% bile, however there is significant inhibition of growth at 
all of the concentrations of bile tested compared to the cultures grown without 
bile (P!0.005).  There is evidence of some growth of 630!erm in 8% bile, an 
average OD of 0.027 was observed equating to 5.5% of the total growth 
observed in the unexposed control (Figure 3.8).  4% bile was significantly 
more inhibitory compared to 2.4% bile (P=0.015) and 0.8% bile was 
significantly more inhibitory than 2.4% bile (P=0.002).   
 
Both strains appear better able to adapt to growth in high bile concentrations 
than in low concentrations.  Growth in 0.4% bile was more inhibitory 
compared to 2.4% bile with an approximately three-fold reduction in growth 
for R20291 and a two-fold reduction for 630!erm (significance P=0.002).  
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To characterise the inhibition of bile on the growth of R20291 and 630!erm, 
particularly in low concentrations, an extended range bile broth assay was 
performed.  Both strains were grown in broths containing 0.1 to 12% bile 
alongside control samples with growth measured by optical density.  In 
general, the results of this assay support those observed in the initial 
experiment, revealing that growth in low bile concentrations (0.3-2% for 
R20291 and 0.3-1% for 630!erm) is significantly more inhibitory than in 
medium to high concentrations (2.5% to 7.5% for R20291 and 1.3% to 5% for 
630!erm) (Figure 3.9 & Figure 3.10).  However, growth in 0.1% bile was not 
found to be significantly inhibitory for either strain in this assay (see Appendix 
section 9.1). 
 
For R20291 as the bile concentration increased from 0.1% to 0.3 and 0.5% 
growth decreases significantly (P<0.001) (Figure 3.9).  Further increases in 
bile concentration are associated with increased growth, although this growth 
is significantly reduced compared to the no bile control up to bile 
concentrations of 2%.  When the concentration of bile exceeds 2% there is 
no significant difference in the growth of these cultures compared to the no 
bile control.  Bile concentrations over 7.5% led to significant inhibition of 
growth (P=0.05).  R20291 was shown to grow reproducibly at bile 
concentrations of 12%, growing to approximately 25% of the total growth of 
the no bile control.  The level of growth at 12% bile is comparable to the 
growth observed at 0.3% bile, suggesting that 0.3% and 12% B & O bile have 
a similar inhibitory effect on the growth of R20291 in broth culture. 
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Figure 3.9  Extended range B & O bile broth assay for R20291. 
A refined range bile assay was conducted to assess the growth of R20291 in bile concentrations ranging from 0.1 to 12%, with particular emphasis at 
the lower range of 0.1 to 1.5%.  OD590 nm was measured at 24 hours post inoculation; error bars represent data from three biological and three 
independent experimental replicates. Significance is denoted by asterisks (* = P<0.05, ** = P<0.01, *** = P<0.001). 
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The growth of 630!erm in the extended range B & O bile assay showed some 
similarities with the results obtained for R20291.  Addition of 0.1% bile did not 
significantly inhibit growth, however significant inhibition of growth was 
observed in low bile concentrations of 0.3% to 1% (P!0.05) (Figure 3.10).  As 
the concentration of bile increased the growth of 630!erm appeared to increase 
up to bile concentrations of 2%.  After this point, there is an apparent reduction 
in growth; however, there is no significant difference between growth observed 
in each of the bile concentrations from 2% to 8.5% (see Appendix section 9.1). 
Statistically significant inhibition of growth is seen for cultures grown in bile 
concentrations of 5.5% and above when compared to growth in broth without 
bile. 
 
Comparison of the tolerance of the two strains revealed that both strains were 
significantly inhibited at low bile concentration (<1.3% for 630!erm and <2.5% 
for R20291).  As the concentration of bile increased, both strains were able to 
grow in the bile broths with no significant inhibition.  For 630!erm this ability to 
tolerate increasing bile levels without a significant effect on growth, ceased as 
bile concentration reached 5.5%, for R20291 this point occurred at 8%.  
R20291’s growth in 12% bile was 25% of the growth observed in the no bile 
control culture whereas 630!erm was unable to grow at this concentration 
(2.2% growth).  
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Figure 3.10  Extended range B & O bile broth assay for 630!erm. 
A refined range bile assay was conducted to assess the growth of 630!erm in bile concentrations ranging from 0.1 to 12%, with particular emphasis at 
the lower range of 0.1 to 1.5%.  OD590 nm was measured at 24 hours post inoculation; error bars represent data from three biological and three 
independent experimental replicates. Significance is denoted by asterisks (* = P<0.05, ** = P<0.01, *** = P<0.001). 
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3.5.2. B & O bile agar assay 
To complement the broth assays, strains R20291, 630!erm and C. 
acetobutylicum were spotted onto agar containing B & O bile at 0.1%, 0.5%, 
1%, 3%, 5%, 10, and 20%.  The results of this assay support those obtained 
from the broth assay, showing that R20291 was able to tolerate higher bile 
concentrations than 630!erm (Table 3.3).  In the broth assay the highest 
concentration of B & O bile tested was 16%, neither 630!erm nor R20291 were 
able to grow in these broths, however, visible growth of R20291 was observed 
on agar containing 20% bile.  Growth of C. acetobutylicum was not observed in 
any of the bile agar plates supporting the findings of the broth assay. 
 
3.5.1. Growth curve 
The growth of 630!erm in the presence of various concentrations of B & O bile 
was assessed over time.  Addition of B & O bile to the growth medium severely 
inhibited the growth of 630!erm (Figure 3.11).  After 9 hours the exposed 
samples had reached a third of the cell density seen in the unexposed control. 
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% B & O 
bile  R20291 630!erm C. acetobutylicum  Key 
0 +++ +++ +++  -  No growth 
0.1 ++ ++ -  + Poor growth 
0.5 ++ ++ -  ++ Good growth 
1 ++ ++ -  +++ Full growth 
3 ++ ++ -    
5 ++ +/++ -    
10 ++ - -    
20 + - -    
 
Table 3.3 Growth of C. difficile and C. acetobutylicum on solid medium 
containing B & O bile 
Colony formation of C. difficile and C. acetobutylicum on RCM agar containing B & O bile was 
assessed after 48 hours incubation.  Growth was recorded according to the key above where 
poor growth = sporadic colonies observed in the inoculum area, good growth = colonies 
present in the majority of the inoculum area and full growth = dense colonies present over the 
entire inoculum area.  Results represent the average result of three independent experiments. 
Figure 3.11 Effect of B & O bile on the growth of 630!erm. 
The growth of C. difficile strain 630!erm was measured in 1%, 2.4% and 5% B & O bile and 
compared to growth in BHI medium without the addition of bile.  Samples of the culture 
were taken at regular time intervals and the optical density measured at 600 nm.  Cultures 
remained in an anaerobic environment during sample collection.  Error bars represent the 
standard deviation resulting from three independent experiments.   
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3.5.2. Bile adaptation assay 
It has been reported that several bacterial species, such as L. 
monocytogenes, show increased tolerance to high levels of bile after 
exposure to sub-lethal levels 270.  To investigate whether such a response 
could be observed in C. difficile, cells were exposed to 0.1%, 1%, 2.4% or 
4% B & O bile for 15 minutes before being used as inocula for a standard bile 
broth assay.  
 
R20291 pre-exposed to 0.1 - 4% B & O bile and grown in rich media without 
bile, showed a significant increase in growth compared to non pre-exposed 
cultures (Mann Whitney test P!0.04) (Figure 3.12, graph A).  No significant 
difference was observed between pre-exposed and non pre-exposed cultures 
grown in 0.1%, 2.4% and 4% bile concentrations (Figure 3.12, graphs B, D & 
E).  Pre-exposure to 0.1%, 1% and 2.4% led to significant increases in 
growth when cultured in broth containing 1% bile (P<0.05).  Pre-exposure to 
0.1% to 4% bile led to a significant increase in the growth of bacteria grown 
in 8% and 10% bile (P!0.004), for those grown in 8% bile this equated to an 
average increase of approximately 1.5-fold (Figure 3.12, graph F & G).  A 
small increase in growth was observed for bacteria pre-exposed to 2.4% bile 
grown in 12% bile broths (P=0.006) (Figure 3.12). 
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Figure 3.12  Comparison of the growth of R20291 in broth 
containing B & O bile after pre-exposure to B & O bile. 
Graph A shows the growth of C. difficile strain R20291 in BHI broth after a 15 minute 
pre-exposure to 0.1%, 1%, 2.4% and 4% B & O bile, a non pre-exposed control is 
also included.  Graphs B-H show the growth of R20291 in BHI broth containing 0.1 to 
12% bile after a 15 minute pre-exposure to 0.1%, 1%, 2.4% and 4% bile.  A non pre-
exposed control is included for each condition.  Growth was measured by optical 
density at 590 nm.  Bidirectional error bars indicate the standard deviation resulting 
from three independent experiments.  Significance is denoted by asterisks (* = 
P!0.05, ** = P!0.01, *** = P!0.001). 
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630!erm pre-exposed to 0.1% - 4% B & O bile in rich media without bile, 
showed a highly significant increase in growth compared to non pre-exposed 
cultures (Mann Whitney test P<0.0001).  Highly significant differences were 
seen for growth in broth containing 0.1%, 1% and 8% bile for all pre-exposure 
conditions compared to non pre-exposed cultures (P!0.004) (Figure 3.13, 
graphs B, C & F).  For growth in 1% and 8% there is an average increase in 
growth of approximately 2-fold.  For cultures grown in 2.4% bile only those pre-
exposed to 0.1% and 4% B & O bile showed a significant increase in growth 
compared to the non pre-exposed control (P=0.0002 and P=0.002, respectively) 
(Figure 3.13, graph D).  For cultures grown in 4% bile only those pre-exposed to 
0.1%, 2.4% and 4% B & O bile showed a significant increase in growth 
compared to the non pre-exposed control (P=0.0009, P=0.024 and P=0.01, 
respectively) (Figure 3.13, graph E). For cultures grown in 10% bile a significant 
increase in growth was observed for all of the pre-exposure condition compared 
to the non pre-exposed control (P<0.012) (Figure 3.13, graph G).  Finally, a 
significant difference was observed for cultures pre-exposed to 4% bile grown in 
broth containing 12% bile.  
 
3.5.1. Expression profiling in response to bile stress  
Bacteria often adapt to environmental stresses by altering expression of their 
genes to limit stress-induced damage 311-313.  To investigate the response of C. 
difficile strain 630!erm to B & O bile stress, RNA was extracted from three 
replicate of mid-log phase cultures grown under control and test conditions for 
analysis.  RNA was hybridised against a 630 genomic DNA control to allow 
multi-way comparisons between all RNA samples and to remove dye bias.
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Figure 3.13  Comparison of the growth of 630!erm in broth 
containing B & O bile after pre-exposure to B & O bile. 
Graph A shows the growth of C. difficile strain 630!erm in BHI broth after a 15 minute 
pre-exposure to 0.1%, 1%, 2.4% and 4% B & O bile, a non pre-exposed control is also 
included.  Graphs B-H show the growth of 630!erm in BHI broth containing 0.1 to 12% 
bile after a 15 minute pre-exposure to 0.1%, 1%, 2.4% and 4% bile.  A non pre-exposed 
control is included for each condition.  Growth was measured by optical density at 590 
nm.  Bidirectional error bars indicate the standard deviation resulting from three 
independent experiments.  Significance is denoted by asterisks (* = P!0.05, ** = 
P!0.01, *** = P!0.001). 
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Three experiments were performed, i) Long shock - bacteria were exposed to 
0.1% or 2.4% bile for 15 minutes, ii) High concentration - bacteria were 
exposed to 2.4% or 4% bile for 15 minutes, iii) Short shock - bacteria were 
exposed to 0.1% or 2.4% bile for 1 minute.  A non-exposed control was 
included to establish whether the presence of bile induced a change in gene 
expression. 
 
3.5.1.1. RNA quality assessment 
After extraction and purification, RNA was assessed spectrophotometrically 
for purity and concentration with some samples examined for RNA integrity 
using a bioanalyzer.  Figure 3.14 A shows the electropherogram for a control 
RNA sample (no bile exposure).  The 16S and 23S rRNA peaks are sharp 
and well defined, suggesting good RNA integrity.  The RNA from bacteria 
exposed to bile gave duel peaks for either the 16S rRNA (0.1% exposure 
samples only) (Figure 3.14 B) or both the 16S and 23S rRNA peaks (0.1% 
and 2.4% exposure samples) (Figure 3.14.C).  This was an anomalous result 
suggesting two similar sized fragments for each rRNA, however the peaks 
are defined and there was little background.  Twin peaks were not observed 
in any of the unexposed samples. 
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Figure 3.14  Electropherograms of sample RNA. 
To evaluate the integrity of the RNA extracted from C. difficile cultures grown with or 
without bile, samples of RNA treated with DNase were assessed using a bioanalyzer 
(Agilent Technologies).  Three examples of the electropherograms are shown, 
representing each of the different growth conditions.  Figure A represents an average 
profile generated by control RNA (unexposed).  The rRNA ratio (23S vs. 16S) = 1.1 
generating sharp defined peaks for each rRNA, 5S RNA was also visible (peak 
between 25 and 30 seconds).  Figure B represents an average profile generated by 
RNA from test samples exposed to 0.1% bile for 15 minutes.  The rRNA ratio (23S vs. 
16S) = 1.7.  A distinct double peak was seen for 16S rRNA and a single well defined 
peak is seen for 23S rRNA.  A larger peak is seen for 5S RNA compared to the control 
sample.  Figure C represents an average profile generated by RNA from test samples 
exposed to 2.4% bile for 15 minutes.  The rRNA ratio (23S vs. 16S) = 0.8.  A distinct 
double peak is seen for 16S rRNA and for 23S rRNA. A larger peak is again seen for 
5S RNA compared to the control sample. 
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3.5.1.2. Experiment 1 – Long exposure 
Analysis of the transcriptional response of C. difficile to bile stress has not 
been previously conducted; therefore the experimental design was based on 
preliminary data obtained in the bile assays and by assessment of similar 
experiments in other organisms 283, 314.  In the initial bile shock experiment, 
mid-log phase bacteria were exposed to two bile concentrations 0.1% and 
2.4% for 15 minutes.  0.1% was chosen due to its relatively small inhibitory 
effect on growth, 2.4% was chosen as the bacteria were able to grow to 
approximately half the optical density of unexposed cultures (Figure 3.10).  
These levels are physiologically relevant as bile concentrations in the human 
intestine range from 0.2-2% 315.  Test and control samples from triplicate 
experiments each with three biological replicates were labelled and 
hybridised to a C. difficile 630 microarray and quantification of gene 
expression was determined in silico.   
 
The data were normalised to the control RNA data from each experiment to 
control data of another, minimizing variability and allowing conclusions to be 
drawn from the different experiments.  After normalisation, each gene from 
the unexposed control RNA should give a normalisation value of 1 (Figure 
3.15).  Figure 3.15 shows the majority of the genes to be tightly arranged 
around the central line suggesting reproducibility. 
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Figure 3.15  Comparison of fluorescence of control verses control 
RNA samples.  
Normalised fluorescence generated by control RNA from experiment one is compared to 
that obtained in experiment two to assess reproducibility between the experiments.  Each 
data point represents a spot on the microarray that is specific for a unique gene.  The 
intensity of the colour of the data point gives an indication of the reliability of the data 
(based on fluorescence intensity), the points are colour coded according to their expression 
in comparison to the control data point with red representing increased expression and 
blue representing decreased expression.  In this plot almost all of the data points are tightly 
arranged around the central line (x=y) suggesting expression of the gene represented by 
that data point was the same in each experiment. 
R
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Robust statistical assessment of the changes in gene expression in control 
verses test samples in each experiment failed to reveal any significant 
changes in the level of expression in bile exposed samples.  Presented 
graphically, it is apparent that the majority of genes did not show differential 
expression under the test conditions compared to the control i.e. data points 
lie along the central midline (Figure 3.16).  There are however, a number of 
genes whose expression appears to have changed, these genes are shown 
as data points positioned away from the midline indicating increased 
expression (red) or decreased expression (blue) compared to the control 
sample.  The tramlines represent a 2-fold change in either direction.  The 
intensity of the colour conveys the confidence with which one can conclude 
that the expression of this gene was different to that of the control.  Several 
genes appear to show differential expression in the 0.1% test sample, 
however this was not supported when scrutinised statistically using the 
Benjamini-Hochberg false discovery rate multiple testing correction (Figure 
3.16).  A similar situation was true for the 2.4% test sample; although there 
was an increase in the number of genes apparently showing differential 
expression these were not statistically significant (Figure 3.17).  When 
represented in a line diagram the differences between the control and test 
samples from the two experimental conditions can be easily seen (Figure 
3.18).  Few differences were observed in the expression of genes after 
exposure to 0.1% bile compared to control conditions (horizontal yellow 
lines).  Exposure to 2.4% bile on the other hand revealed a number of genes 
that showed either an increase in expression (red lines) or a decrease in 
expression (blue line). 
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Figure 3.16  Scatter plot of the fluorescence profile of the 0.1% 
exposed test samples compared to unexposed controls. 
The normalised fluorescence generated by hybridisation of the 0.1% test RNA was directly 
compared to the fluorescence of the unexposed control.  Where fluorescence was identical 
a ratio of 1:1 was given and these samples lie along the x=y central line.  Where differences 
in the fluorescence exist in the test sample spots are plotted off this line.  The tramlines 
represent a 2-fold deviation from the x=y line thus, spots outside these lines represent 
genes whose expression was more than 2-fold increased (red spots) or decreased (blue 
spots).  The intensity of the colour of each spot also reveals the predicted confidence for the 
result generated; high intensity suggests a reliable result.  A small number of spots are 
found outside the 2-fold difference area, statistical analysis of these genes will confirm 
whether these differences are significant. 
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Figure 3.17  Scatter plot of the fluorescence profile of the 2.4% exposed 
test samples compared to unexposed controls. 
The normalised fluorescence generated by hybridisation of the 2.4% test RNA was directly 
compared to the fluorescence of the unexposed control.  Where fluorescence was identical a 
ratio of 1:1 was given, these samples lie along the x=y central line.  These differences in 
fluorescence are represented by spots outside this area (see Figure 3.16 for further details).  In 
comparison to the scatter plot generated for the 0.1% test sample, a significant increase in the 
number of genes whose expression is more than 2-fold different to that of the control was 
observed.  Additionally, a proportion of these spots suggest a high level of reliability. 
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Figure 3.18  Comparison of gene expression levels in control and test 
samples.  
The normalised fluorescence data from each of the 3723 genes was plotted as an individual 
line on a scale where all genes in the control sample should be 1 (normalised to themselves).  
After exposure to 0.1 or 2.4% bile the expression level is plotted and the points joined and 
colour coded.  Lines are coloured to indicate the level of expression, yellow indicates no 
change (=1), red indicates an increase in expression (>1) and blue represents a decrease in 
expression (<1).  In the 0.1% test condition the majority of genes seem to be represented by 
yellow lines indicating little or no change in expression under the two conditions.  The results 
obtained for the 2.4% test condition show a larger number of changes with several red and 
blue lines indicating increased and decreased levels of expression respectively.  Each of 
these lines was inspected to analyse the probability and fold-change in expression for each 
gene under the test and control conditions.  
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To extract useful information from the microarray data for future experiments 
the multiple testing correction was omitted from the ANOVA analysis.  This 
revealed a number of genes whose expression was notably different in the 
test samples compared to the control samples, but which did not fulfil the 
required statistical stringency (ANOVA with Benjamini-Hochberg false 
discovery rate multiple testing correction) (see appendix section 9.2).  This 
selection of genes was scrutinised to identify those which might show 
differential expression based on four parameters i) a relatively significant 
level of normalised fluorescence i.e. >2000 units (florescence is measured 
from 0 to 65535), ii) a DNA control normalisation value of between 0.9 and 
1.1, iii) a t-test P value of less than 0.025, and iv) a change in expression of 
at least +/- 1.4-fold. 
 
Analysis of samples exposed to 0.1% bile 
Table 3.4 shows a selection of genes whose expression has changed in the 
0.1% exposed test samples compared to the control samples.  Although 
these genes did not pass the stringent statistical parameters required to 
support their differential expression, they provide useful information regarding 
the response of the bacteria to bile challenge.  Samples with a positive fold 
change represent genes whose expression had increased, while negative 
values represent genes that showed a reduction in expression compared to 
the control, a summary of the results is shown in Table 3.5.  Three genes 
CD1661 (transposase-like protein B), CD1305 (DNA polymerase III PolC-
type) and CD2666 (PTS system, glucose-specific IIa component) showed the 
most significant increase in expression (1.7-1.8-fold).  Thre most significant 
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decrese in expression was seen in gene CD3089 (PTS system, IIabc 
component) in the 0.1% test sample compared to the control.  All the genes 
are grouped by their classification based on Cluster of Orthologous Groups 
(COG) analysis of the protein domains found in the protein sequence 239. 
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Functional category Code Gene Fold change P value Product 
Additional 
category/information 
Energy production and 
conversion C CD0716 -1.4 0.016 
putative bifunctional carbon monoxide 
dehydrogenase/acetyl-CoA synthase cooS 
Amino acid transport and 
metabolism E CD3670 1.4 0.004 putative selenocysteine lyase  
    CD0241  -1.4 0.023 phosphoserine phosphatase   
Nucleotide transport and 
metabolism F CD2335 1.5 0.002 inosine-5'-monophosphate dehydrogenase guaB 
  CD2438  -1.4 0.021 cytidine deaminase cdd 
    CD0186  -1.6 0.006 dihydroorotate dehydrogenase, catalytic subunit pyrD 
Carbohydrate transport 
and metabolism G CD2666 1.7 0.022 
PTS system, glucose-specific IIa 
component crr 
  CD1191 1.5 0.004 putative fructose-1,6-bisphosphatase fbp 
  CD2322 1.5 0.013 transketolase tkt 
    CD3089 -1.8 0.025 PTS system, IIabc component   
Coenzyme transport and 
metabolism H CD1709 -1.4 0.001 
putative molybdopterin-guanine 
biosynthesis protein  
    CD3421 -1.5 0.013 porphobilinogen deaminase hemC 
Transcription K CD0670 1.6 0.002 putative regulatory protein   
Replication, 
recombination and repair L CD1661 1.8 0.012 transposase-like protein B tlpB 
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    CD1305 1.7 0.024 DNA polymerase III PolC-type dnaF 
Cell 
wall/membrane/envelope 
biogenesis 
M CD3488 -1.5 0.014 
utp--glucose-1-phosphate 
uridylyltransferase (general stress protein 
33) 
gtaB 
    CD2796b -1.5 <0.001 putative cell surface protein   
Cell motility intracellular 
trafficking, secretion and 
vesicular transport 
NU CD0251 -1.5 0.015 flagellum-specific ATP synthase fliI 
    CD0247 -1.6 0.023 flagellar hook-basal body complex protein fliE 
Posttranslational 
modification, protein 
turnover, chaperones 
O CD3283 -1.6 0.02 putative pyruvate formate-lyase 3 activating enzyme pflE 
Inorganic ion transport 
and metabolism P CD3403 -1.4 0.009 putative formate/nitrite transporter   
General function 
prediction only R CD1176  1.4 0.006 conserved hypothetical protein  
  CD2173 -1.4 0.04 putative peptidase  
  CD2561 -1.4 0.012 putative phosphatase  
    CD2181 -1.6 0.017 putative aromatic compounds hydrolase  nox 
Function unknown S CD1404 1.5 0.006 putative oligopeptide transporter  
    CD1645 -1.4 0.006 putative membrane protein 
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No COG information  CD0939 1.4 0.017 hypothetical phage protein  
  CD1768 1.6 0.017 putative membrane protein  
    CD1219 -1.6 0.018 conserved hypothetical protein   
 
 
 
Table 3.4  List of genes showing differential expression after exposure to 0.1% B & O bile. 
Genes whose expression was altered in the test samples are listed in the table with their predicted function, the fold change in expression and P value.  
Selected genes were derived from a one-way ANOVA test without a multiple testing correction using GeneSpring and classified based on COG domains in the 
protein sequence using the JGI Integrated Microbial Genomics database.  Where multiple COG domains were present this information is also included in the 
additional information.  Genes in bold are referred to in the text. 
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Gene classification No. of genes differentially expressed during bile shock: 
  Overexpressed Underexpressed 
Energy production and 
conversion 0 1 
Amino acid transport and 
metabolism 1 1 
Nucleotide transport and 
metabolism 1 2 
Carbohydrate transport and 
metabolism 3 1 
Coenzyme transport and 
metabolism 0 2 
Transcription 1 0 
Replication, recombination and 
repair 2 0 
Cell wall/membrane/envelope 
biogenesis 0 2 
Cell motility intracellular 
trafficking, secretion and 
vesicular transport 
0 2 
Posttranslational modification, 
protein turnover, chaperones 0 1 
Inorganic ion transport and 
metabolism 0 1 
General function prediction only 1 3 
Function unknown 1 1 
No COG information 2 1 
Total 12 18 
Table 3.5  Classes and frequency of genes differentially expressed 
during 15 minute exposure to 0.1% B & O bile. 
Genes were classified based on COG domains found in the protein sequence using the JGI 
Integrated Microbial Genomics database.  Where multiple COG domains were present the 
gene was categorised in the predominant class. 
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Analysis of samples exposed to 2.4% bile 
Table 3.6 shows a selection of genes whose expression has increased or 
decreased in the 2.4% bile exposed test sample compared to the control, a 
summary of this information is shown in Table 3.7.  The most significant 
increase was seen for gene CD1693 annotated as a putative dinitrogenase 
iron-molybdenum cofactor, expression appears to have increased by 3.9-fold, 
closely followed by CD2444, a putative sigma 54 modulation protein (3.2-fold 
increase) and CD1692, an ArsR-family transcriptional regulator (3-fold 
increase).  The most significant decrease in expression was observed for 
genes CD2366 (putative exported protein) (4.2-fold), CD0231 (putative 
flagellar hook-associated protein) (4.1-fold) and CD0252 (flagellar protein) (4-
fold).  A greater number of genes showed potentially significant differences in 
expression with many showing a greater fold change in expression than 
those seen in the 0.1% samples (after removal of the multiple testing 
correction).  These differences can be visualised on a line diagram (Figure 
3.19).  Here, only the genes selected after statistical analysis of the data 
obtained from the 2.4% bile exposed samples are shown allowing visual 
assessment of the expression of the comparative genes in the 0.1% test 
sample.  Comparison of both gene lists from the two experiments revealed 
five genes whose expression was altered in both experiments (CD0241, 
CD2796, CD0247, CD2181 & CD1404).  Gene CD1404, annotated as a 
putative oligopeptide transporter which may act by facilitating transport of 
small oligopeptides into the bacterium, was up-regulated in the 0.1% and 
2.4% test samples by 1.5 and 1.4-fold respectively with highly significant P 
values.  Several motility associated genes showed a change in expression in 
  
 
190 
the 2.4% test samples (18 in total) and in all cases this was a reduction in 
expression compared to the control (from -1.5 to 4-fold).  Genes classed into 
the COG category ‘posttranslational modification, protein turnover and 
chaperones’ contained 8 genes whose expression was upregulated (between 
1.4-2.7-fold), additionally several putative membrane associated protein 
coding genes were also differentially expressed.  Finally, there was no 
evidence that genes annotated as being associated with bile resistance, 
specifically CD0065, CD3215 and CD3216, were differentially expressed 
under these experimental conditions 6. 
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Functional category Code Gene Fold change P value Product 
Additional 
category/information 
Energy production and 
conversion C CD0117  2.2 0.001 putative subunit of oxidoreductase  
  CD1157 1.6 <0.001 
putative anaerobic nitric oxide reductase 
flavorubredoxin norV 
  CD3467 1.5 0.007 ATP synthase epsilon chain (partial) atpC 
  CD0713 1.4 0.012 putative adenosylcobamide-dependent radical SAM superfamily protein  
  CD1655 -1.4 0.011 putative Na+/H+ antiporter  
  CD2171 -2.0 0.001 putative Sodium:dicarboxylate symporter  
  CD0394 -2.2 0.013 D-lactate dehydrogenase 
ldhA, Coenzyme transport and 
metabolism, General function 
prediction only 
  CD0395 -2.5 0.018 E-cinnamoyl-CoA:R-phenyllactate CoA transferase large subunit hadA 
Cell cycle control, cell 
division, chromosome 
partitioning 
D CD1143 -1.4 0.018 septum formation protein maf 
  CD1145 -1.9 0.021 rod shape-determining protein mreB2 
Amino acid transport 
and metabolism E CD0179 1.7 0.021 NAD-specific glutamate dehydrogenase gluD 
 
 CD2674 1.6 0.009 oligopeptide ABC transporter, permease protein 
appC, Inorganic ion transport 
and metabolism 
  CD1665 1.4 0.014 cysteine synthase A cysK 
  CD1279 -1.5 0.004 cysteine desulfurase iscS2 
 
 CD0853 -1.7 0.002 oligopeptide ABC transporter, permease protein 
oppB, Inorganic ion transport 
and metabolism 
  CD2172 -1.7 0.021 
probable amino-acid ABC transporter, 
ATP-binding protein cbiO 
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  CD0241 -2.5 <0.001 phosphoserine phosphatase  
  CD0855 -2.7 <0.001 
oligopeptide ABC transporter, substrate-
binding lipoprotein oppA 
  CD0888 -3.1 0.003 arginine decarboxylase speA 
Nucleotide transport and 
metabolism F CD1261 1.6 0.006 
putative ribonucleotide-diphosphate 
reductase   
 
 CD2447 1.5 0.01 histidine triad nucleotide-binding protein  
 
 CD0220 -1.9 0.019 amidophosphoribosyltransferase 
purF, Carbohydrate transport 
and metabolism, General 
function prediction only 
  CD0224 -1.9 0.025 phosphoribosylamine--glycine ligase purD 
Carbohydrate transport 
and metabolism G CD0582 2 <0.001 putative PEP-utilising kinase   
  CD3091 -2.5 0.005 trehalose-6-phosphate hydrolase treA 
Coenzyme transport and 
metabolism H CD0243 -2.8 0.013 conserved hypothetical protein   
Translation, ribosomal 
structure and 
biogenesis 
J CD2444 3.2 0.004 putative sigma 54 modulation protein   
  CD0103 1.7 0.01 tRNA pseudouridine synthase 1 truA1 
 
 CD1282 1.7 0.01 putative alanyl-tRNA synthetase alaS 
  CD2432 1.6 0.025 glycyl-tRNA synthetase beta chain glyS 
  CD1161 1.6 0.001 
50S ribosomal protein L21 
 rplU 
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Transcription K CD1692 3 <0.001 ArsR-family transcriptional regulator 
 
Cell 
wall/membrane/envelope 
biogenesis 
M CD2789 -1.4 0.007 cell surface protein cwp66 
  CD0242 -1.9 0.003 conserved hypothetical protein  
  CD0226 -2.1 <0.001 putative transglycosylase  
  CD2796 -2.3 0.001 putative cell surface protein  
  CD2768 -3.3 <0.001 putative cell-wall hydrolase  
Cell motility N CD0270 -1.6 0.013 putative flagellar motor switch protein fliM 
  CD0256 -1.9 0.005 chemotaxis protein motA 
  CD0254 -2.0 0.019 
putative basal-body rod modification 
protein flgD 
  CD0269 -2.1 0.001 putative flagellar basal-body rod protein  
  CD0249 -2.3 0.019 flagellar motor switch protein fliG 
  CD0268 -2.3 0.001 flagellar basal-body rod protein  flgG 
  CD0232 -2.6 0.007 flagellar hook-associated protein flgL 
  CD0253 -2.7 0.015 
putative flagellar hook-length control 
protein fliK 
  CD0245 -3.2 0.007 flagellar basal-body rod protein flgB 
  CD0264 -3.9 <0.001 
signal recognition particle complex, GTP- 
binding subunit flhF 
  CD0231 -4.1 <0.001 
putative flagellar hook-associated 
protein flgK 
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Cell motility intracellular 
trafficking, secretion 
and vesicular transport 
NU CD0262 -1.5 0.009 flagellar export protein flhB 
  CD0258 -1.7 0.024 flagellar basal body-associated protein fliL 
  
CD0250 -2.3 0.014 flagellar assembly protein fliH 
 
 
CD0246 -2.3 0.009 flagellar basal-body rod protein flgC 
  
CD0247 -2.6 <0.001 flagellar hook-basal body complex protein fliE 
  CD0263 -2.7 0.002 flagellar export protein flhA 
  CD0252 -4.0 0.007 flagellar protein fliJ 
O CD0881 2.7 0.003 putative membrane protein   
 CD3284 2.3 0.004 probable protease  
Posttranslational 
modification, protein 
turnover, chaperones 
 CD1828 1.9 0.007 cell division protein ftsH1 
  CD0194 1.9 <0.001 60 kDa chaperonin groEL 
  CD3157 1.8 0.005 SsrA-binding protein smpB 
  CD1690 1.6 0.011 thioredoxin trxA1 
  CD2461 1.4 0.022 chaperone protein dnaK 
  CD0703 1.4 0.008 protease  
Inorganic ion transport 
and metabolism P CD3377 1.8 0.023 
magnesium transporting ATPase, P-type 
1 mgtA 
  CD1695 1.5 0.008 
putative arsenical pump membrane 
protein  
  CD2365 -1.8 <0.001 putative sulfonate ABC transporter, solute-binding lipoprotein  
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  CD0324 -2.1 0.002 putative cobalt transport protein cbiM 
  CD0327 -2.3 0.021 
cobalt ABC transporter, ATP-binding 
protein  
  CD2361 -2.5 0.013 
putative aliphatic sulfonate ABC 
transporter, ATP-binding protein  
Intracellular trafficking, 
secretion, and vesicular 
transport 
U CD0059 -1.5 0.004 preprotein translocase SecE subunit secE 
Defence Mechanisms V CD2149 1.7 0.008 putative exported protein   
  CD1469 -2.0 0.002 putative penicillin-binding protein  
R CD0730 2.3 0.001 putative iron-sulfur protein   
 CD2540 1.6 0.022 NADH oxidase  
General function 
prediction only 
 CD3041 1.4 0.009 proline iminopeptidase  
  CD2181 -1.7 0.009 putative aromatic compounds hydrolase nox 
  CD0240 -1.8 0.009 putative glycosyltransferase pepI 
  CD0878 -1.8 0.005 ABC transporter, permease protein  
  CD2367 -2.2 <0.001 putative permease  
  CD0893 -2.5 0.003 iron-dependent hydrogenase  
Function unknown S CD1693 3.9 0.008 putative dinitrogenase iron-molybdenum cofactor   
  CD1590 2 <0.001 putative membrane protein  
  CD1404 1.4 0.007 putative oligopeptide transporter  
  CD1215 -1.4 0.016 putative pyrophosphokinase  
  CD2531 -1.5 0.005 putative membrane protein  
  CD0227 -2.3 0.006 conserved hypothetical protein  
  CD3100 -2.7 0.002 
putative C4-dicarboxylate anaerobic 
carrier  
No COG information   CD0910 1.7 0.009 putative phage protein   
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  CD3327 1.6 0.013 
conjugative transposon conserved 
hypothetical protein  
  CD0735 1.5 0.01 hypothetical protein  
  CD3674 1.5 0.009 
methyltransferase (putative glucose 
inhibited division protein B) (pseudogene)  
  CD2542 1.5 0.007 putative exported protein  
  CD3668 -1.5 0.001 putative transcriptional regulator  
  CD1720 -1.6 0.019 putative hydantoinase  
  CD2063 -1.6 0.002 putative membrane protein  
  CD2127 -1.8 0.01 putative membrane protein  
  CD2062 -1.8 <0.001 conserved hypothetical protein  
  CD2127 -1.8 0.01 putative membrane protein  
  CD1147 -1.9 0.017 putative membrane protein  
  CD2363 -2.0 0.02 hypothetical protein  
  
CD2362 -2.1 0.006 
putative aliphatic sulfonates ABC 
transporter, permease protein 
(pseudogene)  
  CD3145 -3.8 0.002 
putative serine-aspartate-rich surface 
anchored fibrinogen-binding protein  
    CD2366 -4.2 <0.001 putative exported protein   
 
Table 3.6  List of genes showing differential expression after exposure to 2.4% B & O bile. 
Genes whose expression was altered in the test samples are listed in the table with their predicted function, the fold change in expression and P 
value.  Selected genes were derived from a one-way ANOVA test without a multiple testing correction using GeneSpring and classified based on 
COG domains in the protein sequence using the JGI Integrated Microbial Genomics database. Where multiple COG domains were present this 
information is also included in the additional information. Genes in bold are mentioned in the text. 
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Figure 4.1 Schematic of TargeTron/ClosTron mechanism of action, 
taken from Brüggemann & Gottschalk, 2009 148 
A – An appropriate plasmid carrying the Group (Gp) II intron and RAM element (Gp I 
intron and antibiotic resistance gene) is transferred to the host organism, in C. difficile this 
is achieved through filter mating from an E. coli donor.  The relative orientations of the Gp 
I and the RAM element are crucial for this system. 
 
B – the plasmid borne RAM element does not confer antibiotic resistance due the 
interruption of the Gp I intron.  The Gp I intron cannot self-splice from the gene transcript 
as it is in the reverse orientation.   
 
C – The Gp II intron RNA is transcribed from a strong promoter on the plasmid.   The Gp I 
intron is in the forward orientation in this transcript and self splices however, antibiotic 
resistance is not conferred at the antibiotic resistance gene is in the reverse orientation.  
The mature Gp II intron then undergoes retrotransposition into the target gene (in some 
bacteria in the population). 
 
D – After retrotransposition into the target gene an intron containing a functional antibiotic 
resistance gene (lacking the Gp I intron) is present on the chromosome allowing selection 
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Figure 4.3.  Schematic representation of the mechanism of Tn10 
transposition taken from Haniford 2006 181. 
Transposase (striped ovals) binds to the OE (black rectangles) of Tn10 forming the 
transpososome.  The transposase then catalyses the chemical steps in excision of the 
transposon from the donor DNA.  After removal of the flanking DNA from the transposon 
ends the transpososome binds to the target DNA (grey rectangle) and catalyses the 
chemical steps in the strand transfer reaction.  Host repair mechanisms fill in the 9 bp gaps 
generated during strand transfer leading to a small duplication of the original target site 
(checked rectangle). 
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Primer Sequence (5' - 3') Product size bp Use/location 
Additional 
information 
KM1 F CTGGATCCGGCTCGTATAATGTG 
KM1 R CTGGATCCATGTATTGCGATATGC 
2980 Amplification of transposase and mini-Tn10 region 
Both primers 
include a BamH1 
site (italics) 
Tn10 F CAGGTTAGTGACATTAG 
Tn10 R CAGACAAGTAAGCCTCC 
762 Amplification of entire cat gene in mini-Tn10  
cat 1 CTGGTTACAATAGCGACGGAGAG 
cat 2 CCTGCTGTAATAATGGGTAGAAG 
304 Amplification of a section of the cat gene  
amp 1 CAGTGCTGCAATGATACCGC 
amp 2 CATCGAACTGGATCTCAACAGC 
610 Amplification of a section of the bla gene  
bla F CGCTCAGTGGAACGAAAACTC 
bla R CCCTGATAAATGCTTC 
1038 Amplification of entire bla gene  
ermB F CTGACTTGCACCATATC 
ermB R CATAGTGACTGGCGATGCTGTC 
1085 Amplification of entire ermB gene  
fac F CACAGCCATACCACAGCTTCC 
fac R CCCAATACGCAAACCGCCTC 
319 Amplification of entire Pfac region  
Tpase F CTTTCTAAGGCAGACCAACC 
Tpase R CGACATCATAACGGTTCTGGC 
1518 Amplification of entire transposase gene  
compTn10 F CGGCAAGCTCTTTTAGG 
compTn10 R CATTGTCAGCAAATTGATCC 
1394 Amplification of entire mini-Tn10 region  
KM6 F CCGGGATCATATGACAAGATGTG  
KM6A R CCCTATCCAAGAAGTGATGCC 
234 
Amplification of a region covering the 
HindIII site (position 4644 in 
pKM1048).   
Reverse primer located on plasmid 
backbone 
KM6B R CTTGCGGGCGTTCATGCTC 652 Reverse primer located in transposase gene paired with KM6F 
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RT-PCR 
Primer Sequence 
Product 
size bp Use/location 
Additional 
information 
qCat F ACCAACAAACGACTTTTAGTATAACCACAG 
qCat R CCTAACTCTCCGTCGCTATTGTAACC 
168 Amplification of a portion of cat in RT-PCR 
Designed by 
SigmaGenosis 
qTpase F ACTTGTTGACTGGTCTGATATTCGTGAG 
qTpase R GAATGCTCGCAAGGTCGGCTAG 
166 Amplification of a portion of transposase in RT-PCR 
Designed by 
SigmaGenosis 
q16S F GTAGCGGTGAAATGCGTAGATATTAG 
q16S R 
CGTGCCTCAGCGTCAGTTAC 
80 
Amplification of a portion of the 16S 
rRNA gene from C. difficile in RT-
PCR  
Designed by 
SigmaGenosis 
commissioned by 
Dr. C Clayton  
qGyrA F AACATCAGGAAGAGCACGTCCAGC 
qGyrA R 
TCCCTATTGAAATAGCGGAAGAAATG 
83 
Amplification of a portion of the 
GyrA gene from C. difficile in RT-
PCR 
Designed by 
SigmaGenosis 
commissioned by 
Dr. C Clayton  
     
Probe  Primer Pair Product size bp Use/location   
Pb-cat  cat 1 & cat 2 304   
Pb-catH  KM6 F & KM6B R 652   
Pb-amp  amp 1 & amp 2 610   
Pb-Tn10 KM6 F & KM6A R   
Southern blotting 
  
Table 4.2 Primer sequences and probe information 
The table lists the primers used for analysis of the construction of pKM1048/49, primers for RT-PCR, and primers used to 
create probes for Southern blotting.  All primers synthesised by SigmaGenosys, UK. 
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Figure 4.5 The E. coli-Clostridium shuttle plasmid pMTL5401F 
Schematic representation of plasmid pMTL5401F.  Important features are 
labelled including the antibiotic resistance genes ermB and bla providing 
resistance to erythromycin and ampicillin respectively.  The plasmid contains 
the Gram-negative replicon ColE1, the Gram-positive replicon repH from 
pCB102, the transfer gene traJ and the promoter Pfac (fac). 
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Restriction digestion 
Plasmid pHV1248 was digested with ClaI, SacI and ApaLI simultaneously for 
18 hours at 37oC.  Digests were separated on a 0.8% agarose gel and the 
appropriate band (3.4 Kb) extracted using the gel extraction kit and eluted in 
30 µl molH2O.  Fill-in of 3’ recessed ends was achieved by adding 5 U of 
DNA polymerase I, Large (Klenow) fragment and 1X supplied buffer to the 
DNA fragment.  The sample was incubated for 15 min at 25oC and the 
reaction stopped by addition of EDTA to a final concentration of 10 mM, and 
by heating to 75oC for 20 min.  The reaction was purified using the PCR 
clean-up kit and eluted in 30 µl molH2O.  In parallel approximately 3 µg of 
pMTL5401F was digested with SmaI at 25oC for 18 hours.  The digested 
plasmid was incubated with 10 U of CIP for 60 min at 37oC.  The reaction 
was purified using the PCR clean-up kit and eluted in 30 µl molH2O. 
 
An approximation of concentration was determined from band intensities in 
the agarose gel and a ratio of vector (pMTL5401F) to insert (mini-Tn10) of 
approximately 1:5 was established.  5 U of T4 DNA ligase and 1X T4 DNA 
ligase buffer with ATP was added and the fragment mixture and incubated for 
18 hours at approximately 20-22oC to generate pKM1048.  pKM1048 was 
transformed into ElectroSHOX electrocompetent and/or DH5! chemically 
competent E. coli (Bioline, UK) (Figure 4.6 A) (as described in section 4.4.2.3 
and 4.4.2.4). 
4.4.2.2. Generation of pKM1049 
pHV1249 was digested with the restriction enzymes ApaL1 and HpaI 
simultaneously at 37oC for 18 hours.  Digests were separated on a 0.8% 
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agarose gel and the appropriate band (3.9 Kb) extracted using the gel 
extraction kit and eluted in 30 µl molH2O.  Fill-in of 3’ recessed ends was 
achieved by adding 5 U of DNA polymerase I, Large (Klenow) fragment and 
1X supplied buffer to the DNA fragment.  The sample was incubated for 15 
minutes at 25oC and reaction stopped by addition of EDTA to a final 
concentration of 10 mM, and by heating to 75oC for 20 min.  The reaction 
was purified using the PCR clean-up kit and eluted in 30 µl molH2O.  In 
parallel approximately 3 µg of pMTL5401F was digested with SmaI at 25oC 
for 18 hours.  The digested plasmid was incubated with 10 U of CIP for 60 
min at 37oC before purification using the PCR clean-up kit. 
 
An approximation of concentration was made by assessment of products on 
agarose gels and a ratio of vector to insert of approximately 1:5 was 
established.  5 U of T4 DNA ligase and 1X T4 DNA ligase buffer with ATP 
was added and the fragment mixture and incubated for 18 hours at 20-22oC 
to generate pKM1049.  pKM1049 was transformed into !-select chemical 
competent E. coli (Figure 4.6 B) (se section 4.4.2.3). 
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Figure 4.6 Schematic cartoon of the generation of pKM1048 (A) & 
pKM1049 (B) delivery plasmids 
Plasmid pHV1248 was digested with restriction enzymes ApaLI, ClaI and SacI to allow 
isolation of the desired ~3.4 Kb fragment containing transposase and the mini-Tn10 
cassette.  The fragment was ligated with pMTL5401F, digested with SmaI, to create 
pKM1048 (A).  Plasmid pHV1249 was digested with restriction enzymes ApaLI and 
HpaI to allow isolation of the desired ~3.9 Kb fragment containing transposase and the 
mini-Tn10 cassette.  The fragment was ligated with pMTL5401F, digested with SmaI, 
to create pKM1049 (B).  Both plasmid constructs contain important features including: 
either inside (pKM1049) or outside (pKM1048) end based mini-Tn10 cassette (green 
arrow) with associated transposase gene and chloramphenicol resistance (cat), 
erythromycin resistance (ermB), ampicillin resistance (bla), repH for replication in C. 
difficile, ColE1 for replication in E. coli, the promoter Pfac (fac) and the transfer gene 
traJ.  Selected restriction sites are also highlighted. 
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4.4.2.3. Chemical transformation 
DH5! and !-select (Bioline, UK) chemically competent E. coli were 
transformed with plasmid or ligation mixtures.  Briefly: plasmid/ligation 
mixtures were added to 50 µl competent E. coli thawed on wet ice.  Bacteria 
were incubated on ice for 45-60 min before being subjected to a heat shock 
at 42oC for 45 seconds.  Cells were returned to ice for 2 minutes before 
addition of 0.8 ml of pre-warmed SOC medium.  Cultures were incubated at 
37oC with shaking (200 rpm) for 1 hour in 1.5 ml tubes.  Bacteria were spread 
onto pre-warmed LB agar plates containing appropriate antibiotics before 
incubation at 37oC for 16-18 hours.   
 
4.4.2.4. Transformation by electroporation 
Generation of electrocompetent CA434 bacteria:  Bacteria were grown in 50-
100 ml LB broth in 250-500 ml conical flasks at 37oC with shaking to an OD 
of between 0.5-1.0.  Cultures were chilled on ice for 30 minutes and 
centrifuged at 4000 x g for 15 min.  Bacterial pellets were gently re-suspend 
in pre-chilled sterile water and centrifuged at 4000 x g for 15 min.  Pellets 
were re-suspended in pre-chilled sterile 10% glycerol solution and 
centrifuged at 4000 x g for 15 min, pellets were then re-suspend in pre-chilled 
sterile 10% glycerol solution.  Bacteria were divided into 50 !l aliquots and 
snap frozen in a dry ice and ethanol bath prior to storage at -80oC.   
 
Transformations using electrocompetent CA434 and ElectroSHOX E. coli 
(Bioline, UK) were carried out according to manufacturers guidelines (Bioline, 
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UK).  Briefly 50 µl of E. coli was thawed on ice, 10-20 pmol of ligation mixture 
or plasmid was added and mixed gently.  The transformation mixture was 
transferred to pre-cooled 0.1 cm gap electroporation cuvettes (Bio-Rad 
Laboratories, UK).  Samples were placed in the electroporator and shocked 
under the following settings low range = 200 ohms, high range = 500 ohms, 
capacitance 25 µF, and 1.70 kV (Bio-Rad Laboratories, UK).  0.9 ml of pre-
warmed SOC medium (Invitrogen, UK) was added to the bacteria followed by 
incubation at 37oC with shaking (200 rpm) for 1-1.5 hours in 1.5 ml tubes.  
Bacteria were spread onto pre-warmed LB agar plates containing 50 µg ml-1 
Kan, 100 µg ml-1 Ap, 12.5 µg ml-1 Cm, 25 µg ml-1 Cm or 50 µg ml-1 Cm as 
appropriate, with aerobic incubation at 37oC for 18 hours.  All transformations 
were accompanied by control transformation using pUC19 (supplied with the 
ElectroSHOX cells, Bioline, UK). 
 
4.4.3. Confirmation of constructs 
4.4.3.1. pKM1048  
Twenty transformants were picked from the 12.5 or 25 µg ml-1 Cm selective 
LB plates and inoculated into 10 ml LB broth containing 12.5 µg ml-1 Cm.  
Cultures were incubated with shaking (200 rpm) for 16 hours at 37oC.  
Plasmid was extracted from 3 ml of culture using a Mini-prep kit and eluted in 
molH2O.  Plasmids were assessed by restriction digest and PCR before the 
correct construct was selected and stored at -20 or -70oC.  Putative 
pKM1048 plasmids were digested with both HindIII and EcoRV in separate 
reactions.  Approximately 400 to 800 ng of plasmid DNA was digested with 
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100 U (HindIII) or 80 U (EcoRV) of enzyme with appropriate 1X reaction 
buffer in a final volume of 25 µl for 16 hours at 37oC.  Digested DNA was 
separated on a 1% agarose gel with an appropriate marker; fragments were 
visualized on a transilluminator after staining with ethidium bromide. 
 
Plasmid DNA was amplified using primer pair Tn10F/Tn10R (Table 4.2) in a 
standard PCR reaction containing 10-30 ng template, 2.5 U Taq DNA 
polymerase, 100 µM dNTPs, 1X standard Taq buffer, 0.1 µM of each primer 
(F & R) in a final volume of 50 µl.  PCR conditions [94oC 4 min] x 1 cycle, 
[94oC 30 sec, 50-58oC 1.5 min, 72oC 45 sec - 2 min] x 25-30 cycles [72oC 10 
min] x1 cycle, hold 4oC.  Samples were separated on a 0.8% agarose gel 
with an appropriate marker; bands were visualised on a transilluminator after 
staining with ethidium bromide.  Desired constructs were stored at -20 or -
70oC. 
 
4.4.3.2. pKM1049  
Twelve transformants were picked from the 12.5 µg ml-1 Cm or 100 µg ml-1 
Ap LB plates and inoculated into 10 ml LB broth containing 100 µg ml-1 Ap.  
Cultures were incubated with shaking (200 rpm) for 16 hours at 37oC.  
Plasmid was extracted from 3 ml of culture using a Mini-prep kit and eluted in 
molH2O.  Plasmids were checked by digestion with EcoRV.  Approximately 
400 to 800 ng of plasmid DNA was digested with 80 U of EcoRV with 1X 
reaction buffer in a final volume of 25 µl at 37oC for 16 hrs.  Digested DNA 
was separated on a 1% agarose gel with an appropriate marker; bands were 
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visualized on a transilluminator after staining with ethidium bromide.  Desired 
constructs were stored at -20 or -70oC. 
 
4.4.4.  Plasmid sequencing 
Samples of each plasmid construct were sent for sequencing at the 
University of Cambridge where an Applied Biosystems 3730xl DNA Analyser 
was used to generate approximately 800 bp of sequence 385.  Electronic 
sequence results were analysed by eye using DNAMAN and by comparison 
to Vector NTI generated sequence files of the expected construct.  In some 
cases the ClustalW2 alignment tool was used to compare sequencing data to 
expected sequence 386. 
 
4.4.5. Mating experiments 
Recipient C. difficile strains R20291, 630, 630!erm and CD37 were grown in 
10 ml BHI broth for 18-20 hours in anaerobic conditions at 37oC.  These 
starter cultures were inoculated into 35-140 ml BHI broth (1% inoculum) and 
incubated without shaking in 50 ml universals (maximum 35 ml per tube) for 
12-24 hours in anaerobic conditions at 37oC.  Or starter cultures were 
inoculated into 35-50 ml BHI broth with 0.05% cysteine in 75 cm3 vented 
tissue culture flasks and incubated with shaking (50 rpm) for 4-10 hours in 
anaerobic conditions at 37oC.  If bacteria were grown with cysteine they were 
washed before mating: cells were centrifuged at 4000 x g for 10 min and re-
suspended in 20 ml BHI broth, the process was repeated once.   
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Donor E. coli strains CA434-48 or CA434-49 were grown in 10 ml LB broth 
supplemented with 100 µg ml-1 Ap for 16-18 hours with shaking (200 rpm) at 
37oC.  These starter cultures were used to inoculate (2%) 100 ml of LB 
containing 100 µg ml-1 Ap in a 500 ml conical flask.  Cultures were incubated 
for 4-5 hours with shaking (200 rpm) at 37oC.   
 
E. coli cultures were centrifuged for 5 min at 5000 x g and washed twice with 
LB broth.  C. difficile cultures were centrifuged at 3000 x g for 10-15 min in 
anaerobic conditions.  The donor and recipient pellets were combined in 
anaerobic conditions and mixed gently but thoroughly with addition of 600 !l 
of BHI broth.  The mating mixture was either a) spread over 3-15 cellulose 
nitrate filters (0.45 !m pore size, Sartorius stedim Biotech, UK) placed on 
pre-reduced BHIB agar; b) 15-25 !l of mating mixture was spotted directly 
onto the surface of pre-reduced BHIB agar.  Plates were incubated for 20-24 
hours in anaerobic conditions at 37oC.  Filters were transferred to sterile 20 
ml universals and thoroughly washed with 0.6 ml of BHI broth, spot plates 
were washed with 1-1.2 ml of BHI broth.  Cultures were then subjected to 
either a one-step or two-step selection protocol.  One-step – culture was 
plated on 3-4 BHIBS selective plates containing 20, 50 or 100 !g ml-1 Tm per 
filter or spot mating plate.  Plates were incubated for between 72 to 168 
hours, and examined for transconjugants.  Transconjugants were picked and 
re-streaked onto BHIBS agar plus 50 or 100 !g ml-1 Tm.  Genomic DNA was 
extracted from the transconjugants and PCR was used to confirm the 
presence of cat and amp using the appropriate primers (Table 4.2).  Two-
step - culture was plated on BHIBS agar selective plates containing 100 !g 
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ml-1 Lm.  Plates were incubated for between 72 to 168 hours, and examined 
for transconjugants at 24 hours intervals.  Control plates were also included 
in initial experiments containing either E. coli or C. difficile alone and 
incubated alongside experimental plates.  They were processed in the same 
manner as experimental plates post incubation.  Transconjugants were 
replica plated onto BHIBS agar, incubated for 48 hours in anaerobic 
conditions before replica plating on BHIBS agar plus 100 !g ml-1 Tm and 
incubated for 48 hours in anaerobic conditions.   
 
4.4.6. PCR and Southern hybridisation 
4.4.6.1. PCR 
PCR reactions were carried out using Taq DNA polymerase and standard 
Taq buffer as described previously under the following conditions: [94oC 4 
min] x 1 cycle, [94oC 30 sec, 50-58oC 1.5 min, 72oC 45 sec-3 min] x 25-35 
cycles [72oC 10 min] x1, hold 4oC.  Annealing temperatures and extension 
times were adjusted according to the primer set and expected product length 
(Table 4.2).  Primers were designed with the aid of DNAMAN (Lynnon, USA), 
VectorNTI (Invitrogen, UK) and checked using SigmaAcustom 
oligonucleotide design/ordering online software (Sigma-Aldrich, UK) 387.  
Figure 4.7 shows the location of primers used for probe generation. 
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Figure 4.7 Location of primers on plasmid pKM1048. 
Primer details can be found in Table 4.2. 
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4.4.6.2. Southern blotting and hybridisation  
DNA was extracted from C. difficile transconjugants and digested with HindIII 
at 37oC for 18 hours (see section 2.4.6.1).  Approximately 300-500 ng of 
genomic DNA was digested with 200 U enzyme, approximately 250 ng of 
plasmid DNA was digested with 100 U of enzyme.  Southern blotting was 
carried out according to the manufacturer’s instructions in the ECL kit (GE 
Healthcare, UK) as described in section 2.4.6.3. 
 
Four probes Pb-cat, Pb-catH, Pb-amp and Pb-Tn10 were generated using 
the appropriate primers in a standard PCR reaction (Table 4.2).  The PCR 
reaction was separated on a 1% agarose gel and the probe fragment were 
extracted using a gel extraction kit.  The probes and ladder were labelled with 
the Amersham ECL direct nucleic acid labelling and detection system as 
described in section 2.4.6.5.  Hybridisation and detection was carried out 
according to the methods described in section 2.4.6.6 (GE Healthcare, UK). 
 
4.4.7. Minimum inhibitory concentration (MIC) assay 
BHIB agar plates containing appropriate concentrations of Tm, Cm or Lm 
ranging from 0 to 1024 !g ml-1 were inoculated using a 36 pin automatic 
multipoint replicator (Mast Laboratories Ltd, Liverpool, UK) delivering 
approximately 1 x 104 cfu spot-1 of 16-20 hour culture of C. difficile 
standardized to an OD600 nm of 0.8 prior to inoculation.  Plates were 
incubated for 48 hours in anaerobic conditions at 37oC.  Biological replicates 
were performed in duplicate, experimental replicates were done in triplicate.  
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A control BHIB agar plate without antibiotics was inoculated with culture and 
incubated in aerobic conditions at 37oC for 24 hours. 
 
4.4.8. Serial passage and replica plating 
C. difficile transconjugant cultures were grown for 24 hours in 10 ml BHI 
broth containing 100 µg ml-1 Tm at 37oC in anaerobic conditions.  200 !l of 
this culture was used to inoculate 10 ml of fresh BHI broth containing 100 µg 
ml-1 Tm or BHI alone and grown for 24 hours as described above.  This 
process was repeated 3 times.  After the third passage a sample was taken 
and serially diluted 10-fold before onto BHIBS agar or BHIBS agar plus 100 
µg ml-1 Tm.  Plates were incubated for approximately 48 hours or until 
defined colonies were observed at 37oC in anaerobic conditions.  Plates were 
replica plated onto selective plates using sterile velvet squares.  Three 
different replica plating experiments were performed; i) cultures grown 
without thiamphenicol selection and plated onto BHIBS plus 100 µg ml-1 Tm 
were replica plated onto BHIBS agar plus 100 µg ml-1 Tm and 100 µg ml-1 
Lm; ii) cultures grown with thiamphenicol selection and plated onto BHIBS 
only agar were replicated onto BHIBS (control), BHIBS plus 100 µg ml-1 Tm 
and BHIBS plus 100 µg ml-1 Lm; iii) cultures grown with thiamphenicol 
selection and plated onto BHIBS plus 100 µg ml-1 Tm agar were replicated 
onto BHIBS plus 100 µg ml-1 Tm (control) and BHIBS plus 100 µg ml-1 Lm.  
All plates were incubated for 48 hours at 37oC in anaerobic conditions before 
analysis. 
 
  
 
261 
4.4.9. Promotion of transposition by induction of Pfac with IPTG  
10 ml BHI broth containing 100 !g ml-1 Tm and 100 mM IPTG were 
inoculated with a colony from four transconjugants (numbers 2, 7, 9 and 12), 
cultures were incubated for 24 hours in anaerobic conditions at 37oC.  These 
cultures were then serially passaged (2% inocula) into BHI broth containing 
100 !g ml-1 Tm and 100 mM IPTG 10 times.  After passage 10 the cultures 
were serially diluted and plated on BHIBS agar containing 100 !g ml-1 Tm.  
10 random colonies were picked and grown in BHI both containing 100 !g 
ml-1 Tm for 16-18 hours at 37oC.  Genomic DNA was extracted (see section 
2.4.6.1) and digested with HindIII, digests were separated on agarose gel 
using a suitable voltage.  DNA was transferred to nitrocellulose membrane 
and probed with Pb-cat and Pb-amp, as described previously (section 
2.4.6.3). 
 
4.4.10.  PCR for determining site of integration  
PCRs were carried out using primers covering specific genes and regions of 
pKM1048.  These included bla, ermB, transposase, and the Pfac region 
(Table 4.2).  PCR conditions were as follows:  10-30 ng template, 2.5 U Taq 
DNA polymerase, 100 µM dNTPs, 1X standard Taq buffer, 0.1 µM of each 
primer (F & R) in a final volume of 50 µl.  PCR conditions [94oC 4 min] x 1 
cycle, [94oC 30 sec, 54oC 45 sec, 72oC 1 min] x 30 cycles, [72oC 10 min] x 1 
cycle, hold 4oC.  Samples were separated on 0.8-1% agarose gels with an 
appropriate marker; bands were visualised on a transilluminator after staining 
with ethidium bromide. 
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4.4.11.  Plasmid stability assay 
Three transconjugants were cultured independently in 10 ml BHI broth 
containing 100 !g ml-1 Tm for 16-18 hours in anaerobic conditions at 37oC.  
10 ml BHI broth was inoculated with each culture and incubated for 16-18 
hours at 37oC.  Each culture was passaged, by 10-fold dilution (1 ml culture 
in 9 ml BHI broth) a further 4 times.  Each culture from passage 1 to 5, 
including the original culture grown with antibiotic selection was serial diluted 
and plated onto BHIBS agar and BHIBS agar with 100 !g ml-1 Tm.  Plates 
were incubated for 48 hours before enumeration of cfu ml-1. 
 
4.4.12. Plasmid isolation from C. difficile  
2 ml of 630!erm::pKM1049 culture grown in 10 ml BHI broth with 100 !g ml-1 
Tm for 16 hours at 37oC was centrifuged to harvest the bacteria.  Bacteria 
were digested with 5 !l ml-1 lytic enzyme solution (Qiagen, UK) and 20 !g ml-
1 lysozyme for 30 min at 37°C.  Plasmid was extracted using a Mini-prep kit 
with plasmid eluted in 20 !l molH2O.  10 !l of the elute was transformed into 
"-select chemical competent E. coli (Bioline, UK) (see section 4.4.2.3).  
Transformants were plated onto LB agar with 100 !g ml-1 Ap and incubated 
at 37oC for 16 hours.  5 to 10 colonies were selected and inoculated into 5 ml 
LB broth plus 100 !g ml-1 Ap; cultures were incubated at 37oC with shaking 
(200 rpm).  Plasmid was extracted from 3 ml of culture using the Mini-prep kit 
with plasmid eluted in 30 !l molH2O.  10 !l of this elute was digested with 
EcoRV for 18 hours at 37oC.  The digest was separated on a 1% agarose gel 
with an appropriate marker. 
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4.4.13. Measurement of transposase expression – RT-PCR 
4.4.13.1.  Sample culture 
R20291::pKM1048 was cultured in 10 ml BHI broth containing 100 !g ml-1 
Tm for 18 hours without shaking at 37oC.  This culture was used to inoculate 
10 ml of BHI broth in vented 25 cm3 tissue culture flasks containing 0.05% 
cysteine, 100 !g ml-1 Tm (control) or 10 ml BHI broth containing 0.05% 
cysteine, 100 !g ml-1 Tm and 100 !g ml-1 IPTG, to a final OD of 0.1 at 600 
nm. Cultures were incubated with shaking (50 rpm) in aerobic conditions for 
4-4.5 hours at 37oC.  
 
4.4.13.2.  RNA extraction  
RNA was extracted as described previously using the Fast RNA pro blue 
extraction kit (see section 3.4.2.2).  RNA was treated with DNA-free DNase 
as described previously (see section 3.4.2.3).  Unless used immediately RNA 
was stored at -80oC. 
 
4.4.13.3. Real-Time RT-PCR 
RT-PCR (Reverse transcriptase-PCR) was carried out using the one-step 
Rotor-Gene SYBR Green PCR Kit (Qiagen, UK) according to the 
manufacturer’s instructions.  A master mix of 2X Rotor-Gene SYBR Green 
PCR Master Mix, 0.1X volume of Rotor-Gene RT Mix, 0.25-2.5 µM of forward 
and reverse primer was distributed to 0.1 ml tubes (Qiagen, UK).  1 to 100 ng 
of RNA was added and the volume adjusted to 10 µl using RNase-free water.  
RT-PCR for each sample was performed in triplicate and three independent 
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experiments were performed.  Two primer pairs were designed against 
constitutively expressed genes GyrA and 16S and two primer pairs against 
target genes cat and transposase by Sigma-Aldrich (UK) to generate 
products of approximately 100 bp (Table 4.2).  The cycling conditions were 
as follows: Reverse transcription 10 min 55°C.  PCR initial activation step 5 
min 95°C, Two-step cycling-denaturation 5 sec at 95°C, combined 
annealing/extension 10 sec 58°C, Number of cycles 35–40 carried out using 
a Rotor-gene 3000 (Corbett Robotics, Australia).  Control samples were 
included in each run these consisted of samples without template and 
samples without RT enzyme. 
 
4.4.13.4.  Reaction optimization  
RT-PCR was carried out using 0.125 mM, 0.25 mM and 0.75 mM of GyrA 
and 16S primer pairs with varying quantities of template 1 ng, 10 ng and 100 
ng.  Results were analysed to determine the appropriate primer and template 
concentrations. 
 
4.4.13.5.  Calibration curve 
700 ng of RNA was serially diluted 10-fold and added to standard optimized 
RT-PCR master mix with qGyrA, q16S or qTpase primers (at 0.25 mM) in 
triplicate.  Rotor gene software was used to establish a threshold value for 
each reaction; the threshold value was then used to find the repCT value for 
the test RNA samples.   
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4.5.  Results 
 
4.5.1.  Vector construction and validation 
Plasmids pHV1248 and pHV1249, generated by Petit et al. (1990) were 
identified as suitable plasmids from which to obtain the mini-Tn10 cassette 
and associated transposase 197.  Each plasmid contained a different version 
of the mini-Tn10 containing either inside-end or outside-end IS10 repeat 
sequences.  Secondly the E. coli-Clostridium shuttle plasmid pMTL5401F 
(Figure 4.5) created by Heap et al. (2007) was chosen as the delivery 
plasmid as this is unstable in C. difficile 130, 388.  To create the desired 
construct, the mini-Tn10 and associated transposase was cloned into the 
multiple cloning site (MCS) of pMTL5401F downstream of the Pfac promoter 
(a composite of the ferredoxin gene fd promoter fused to the operator of the 
lacZ operon).  Pfac is reported to be inducible through the addition of IPTG 
however, this has not been determined in C. difficile.   
 
4.5.1.1. pKM1048 
Initially, the desired region was amplified by PCR using primers KM1F and 
KM1R  designed to amplify the ~3 Kb region including the transposase gene 
with its promoter and ribosome binding site (RBS) and the complete mini-
Tn10 cassette (Figure 4.6).  Amplification of the fragment did not generate a 
single product (data not shown).  Attempts to optimise the amplification, 
including redesigning the primers and altering the reaction conditions, did not 
result in amplification of the expected product with multiple bands observed 
(data not shown). 
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In parallel, a wholly restriction digest-based construction of the plasmid was 
attempted.  pHV1248 was digested with ApaLI and ClaI to isolate a 3.4 Kb 
region containing the transposase gene (including the promoter and RBS) 
and mini-Tn10.  The fragment was cloned into the unique SmaI site of 
pMTL5401F to create pKM1048 (Figure 4.6).  pKM1048 was transformed 
into competent E. coil and after growth, the plasmid was recovered and 
digested with EcoRV.  Digestion with EcoRV enabled confirmation of the 
direction of the fragment insertion with respect to Pfac (Figure 4.6).  The 
restriction profile of two plasmids revealed insertion of the fragment into the 
desired orientation (fragments of 7550 bp & 3835 bp) (Figure  4.8 lanes 1 & 
4).  PCR for the cat gene and sequencing of a section of the plasmid also 
confirmed the presence of mini-Tn10 in these plasmids. 
 
pKM1048 was transformed into chemical competent E. coli strain CA434 
alongside two control transformations using pHV1248 and pUC19.  Plasmid 
from fourteen colonies was digested with EcoRV with nine transformants 
showing an identical restriction fragment profile to the original plasmid 
(Figure 4.9 lanes 1, 6-12 &14).  A HindIII digest was performed to confirm the 
presence of the mini-Tn10 transposon in the construct; again all of the nine 
plasmids observed in the EcoRV digest were positive for mini-Tn10 (Figure 
4.10 lanes 1, 5-6, 8-12 & 14, note that due to an error plasmid in lane 5 and 
7 were swapped in this gel).  The expected fragment sizes were 9736, 1260 
and 389 bp, however some of these fragments are very faint and are difficult 
to see.  No plasmid is observed in lane three for either of the digests.   
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Figure  4.8 Digestion of putative pKM1048 plasmids. 
Plasmid from 18 transformants was digested with EcoRV to identify plasmid 
constructs that contained the mini-Tn10 insertion in the correct orientation.  
The digested plasmids in lanes 1 and 4 show the correct banding pattern with 
two fragments of 7550 and 3835 bp.  M = 1 Kb ladder. 
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268 
M        1   2   3   4   5   6   7   8   9  10 11 12 13 14                M 
10 Kb 
8 Kb 
 
4 Kb 
 
3Kb 
 
2 Kb 
 
1.5 Kb 
 
1 Kb 
 
 
0.5 Kb 
10 Kb 
8 Kb 
 
3Kb 
 
2 Kb 
 
1.5 Kb 
 
1 Kb 
 
 
0.5 Kb 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 EcoRV digestion of plasmids from the transformation of CA434 
with pKM1048.  
Plasmids extracted from 14 transformants were digested with EcoRV to confirm the presence 
of pKM1048.  9 of the 14 plasmids have the expected restriction profile with two fragments of 
7550 and 3835 bp in lanes 1, 6-12 and 14.  No plasmid is seen in lane 3 and incomplete 
digestion of the plasmid is visible in lane 10 and 11.  Plasmids in lane 2, 4 and 5 may 
represent incompletely digested plasmids or plasmid without the mini-Tn10 insertion.  The 
plasmid in lane 13 has an unexpected banding pattern.  M = 1 Kb ladder. 
Figure 4.10 HindIII digestion of plasmids from the transformation of 
CA434 with pKM1048. 
Plasmids extracted from 14 transformants were digested with EcoRV to confirm the presence 
of pKM1048.  9 of the 14 plasmids have the expected restriction profile with three fragments of 
9736, 1260 and 389 bp in lanes 1, 5-6, 8-12 & 14.  Note that due to a technical error plasmids 
in lanes 5 and 7 were swapped in this gel compared to the one for the EcoRV digest.  As with 
the EcoRV digest no plasmid is seen in lane 3 and an unexpected banding pattern is seen for 
the plasmid in lane 13.  The digest of plasmids in lane 2,4 and 7 reveals that the mini-Tn10 
fragment is not present in these plasmids.  M = 1 Kb ladder. 
M      1   2   3   4   5   6   7   8  9  10 11 12 13 14                M 
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4.5.1.2. pKM1049 
pHV1249 was digested with ApaLI and HpaI to isolate a fragment containing 
the transposase gene (including the RBS and promoter) and mini-Tn10 
(Figure 4.6).  The fragment was cloned into pMTL5401F to generate 
pKM1049 and transformed into E. coli (Figure 4.6).  Plasmid was extracted 
and digested with EcoRV to allow assessment of the orientation of the 
insertion (Figure 4.11 lane 9 & 12).  Due to blunt ended ligation the fragment 
could ligate into the vector in two orientations with respect to Pfac.  Four 
bands are expected in both cases, however the two high molecular weight 
bands were different depending on the orientation.  One plasmid produced 
fragments of the expected size (6089 bp and 3835 bp) for insertion in the 
desired orientation (Figure 4.11 lane 9), and one plasmid produced 
fragments of the expected size (6609 bp and 3315 bp) for insertion in the 
opposite orientation (Figure 4.11 lane 12).  Plasmids 9 (pKM1049-A) and 12 
(pKM1049-B) were transformed into CA434 and confirmed by extraction and 
digestion with EcoRV (Figure 4.12).   
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Figure 4.11 Agarose gel showing restriction digest fragments of 
putative pKM1049 transformants. 
12 colonies were picked from Cm (lanes 1-6) or Ap (7-12) selective plates.  Two 
colonies show the expected digest patterns indicating the insertion of the mini-Tn10 
fragment.  Lane 9 contains plasmid with the insert ligated in the same direction of Pfac 
and the plasmid in lane 12 shows insertion in the opposite direction to Pfac.  M = 1 Kb 
ladder. 
Figure 4.12 EcoRV digestion of plasmids pKM1049-A and pKM1049-B 
transformed into CA434  
Six random colonies were picked from each transformation of pKM1049-A and pKM1049-B 
with electrocompetent CA434 E. coli.  Plasmid DNA was extracted and digested with EcoRV 
before separation on 1% agarose gel with an appropriate marker.  M = 1 Kb ladder, lane 1-6 
= pKM1049-A transformants; 7-12 pKM1049-B transformants. 
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4.5.2. Mating of CA434-48 and CA434-49 with C. difficile 
4.5.2.1. CA434-48 
CA434-48 (CA434 E. coli strain containing plasmid pKM1048) was mated 
with C. difficile strains 630, CD37, 630!erm and R20291.  Between two and 
seven independent mating experiments were performed depending on the 
strain.  In one experiment strains were grown with the addition of cysteine 
and with shaking.  Viable counts were conducted for each experiment, and 
the ratio of C. difficile to E. coli was calculated (ranging from 1:1 to 1:20) 
(Table 4.3). 
 
In total nine independent mating experiments were performed with various 
strains, the appropriate level of thiamphenicol (Tm) for transconjugant 
selection was not known and therefore various levels were tested to ensure 
minimal background and maximum transconjugant retrieval.  In the first 
experiment one putative transconjugant arose from the R20291 recipient and 
six arose from the 630 recipient.  PCR initially confirmed the presence of the 
cat gene, however after subculture in nonselective and low level Tm selective 
broth (10 !g ml-1) all of the samples were PCR-negative for cat.  Freezer 
stocks were made for all of these putative transconjugants after the initial 
PCR positive result.  In experiments two, four, five, six, seven and nine no 
transconjugants were obtained. 
 
In the third mating experiment with 630!erm, R20291 and CD37 
transconjugants were initially selected with 20 or 50 !g ml-1 Tm.  On the 
plates with 20 !g ml-1 Tm a large number of pin-prick colonies were observed 
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whereas larger defined colonies were observed on 50 !g ml-1 Tm selective 
plates.  A total of fourteen putative transconjugants were picked and 
subcultured onto 20 and 50 !g ml-1 Tm selective plates.  Of these, eight 
R20291 putative transconjugants only grew on 20 !g ml-1 Tm, three 630!erm 
and three CD37 putative transconjugants grew on both 20 and 50 !g ml-1 Tm.  
All of these putative transconjugants were PCR positive for the presence of 
the cat and bla gene.  The conjugation frequency per donor in these 
experiments was 5.1 x 10-10 for CD37 and 630!erm, and 1.37 x 10-9 for 
R20291. 
 
In experiment seven an alternate approach was used for selection of 
transconjugants, selection on Lm rather than Tm directly selected for the 
plasmid backbone rather than mini-Tn10.  In experiment eight fourteen 
putative transconjugants were generated in strain R20291 from selection in 
100 !g ml-1 Tm.  The conjugation efficiency was 1.84 x 10-10 per CA434-48 
donor and all of the transconjugants were PCR positive for the cat and bla 
genes. 
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Experiment  Recipient strain  No. of filters 
Total E. coli cells 
per filter 
(approximately) 
Total C. difficile 
cells per filter 
(approximately) 
Approximate 
ratio C. 
difficile to E. 
coli 
Level of 
selection 
!g ml-1 
No. of 
transcon
jugants 
Conjugation 
efficiency (per 
donor) 
Supplementary 
info 
R20291 5 2.10E+09 2.24E+08 1:10 Tm 20 1 9.52E-11 
1 
630 5 2.10E+09 4.20E+08 1:5 Tm 20 6 5.71E-10 
 
630!erm 3 6.10E+07 6.93E+06 1:10 Tm 50 ND ND   
R20291 3 6.10E+07 8.13E+06 1:10 Tm 50 ND ND   
2  
CD37 3 6.10E+07 5.87E+07 1:1 Tm 50 ND ND   
630!erm 3 1.95E+09 3.03E+08 1:7 Tm 20 + 50 3 5.13E-10  
R20291 3 1.95E+09 4.47E+08 1:4 Tm 20 + 50 8 1.37E-09  3 
CD37 3 1.95E+09 1.89E+08 1:10 Tm 20 + 50 3 5.13E-10  
630!erm 10 6.15E+09 7.46E+08 1:10 Tm 100 ND ND   4 
R20291 10 6.15E+09 3.15E+08 1:20 Tm 100 ND ND   
630!erm 6 3.33E+09 1.63E+09 1:2 Tm 100 ND ND   5 
!"#$% &% #'##()*+% $',+()*+% ,-.% /0%.**% ND% ND%   
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Experiment  Recipient 
strain  
No. of 
filters 
Total E. coli 
cells per filter 
(approximately) 
Total C. difficile 
cells per filter 
(approximately) 
Approximate 
ratio C. 
difficile to E. 
coli 
Level of 
selection 
!g ml-1 
No. of 
transcon
jugants 
Conjugation 
efficiency (per 
donor) 
Supplementary 
info 
R20291 5 2.28E+09 3.57E+08 1:6 Tm 100 ND ND   6 
CD37 5 2.28E+09 2.59E+09 1:1 Tm 100 ND ND  
CD37 3 8.22E+09 3.09E+09 1:3 Lm 100 ND ND   7 
R20291 6 8.22E+09 2.18E+09 1:4 Lm 100 ND ND   
8 R20291 15 5.07E+09 2.11E+09 2:5 Tm 100 14 1.84E-10 
  
R20291 10 4.1E+09  9.2E+08 1:4 Tm 100 ND ND 
Growth with 
additional 
cysteine 9 
630!erm 5 4.1E+09 2.3E+09 1:2 Tm 100 ND ND   
Table 4.3 Mating experiments between C. difficile and CA434-48. 
In total 9 filter mating experiments were performed with strains CD37, 630, 630!erm and R20291 and CA434-48.  Transconjugants were generated in each of 
these strains.  In initial experiments low levels of Tm selection or no continued selection led to loss of the plasmid.  14 transconjugants generated in 
experiment 8 in the R20291 recipient were maintained for further analysis.  The presence of plasmid pKM1048 was confirmed by PCR for each transconjugant.  
For each experiment the number and ratio of cells mated is shown alongside the level of Tm selection and conjugation efficiency. ND = Not detected. 
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4.5.2.2. CA434-49 
CA434-49 (E. coli strain CA434 containing plasmid construct pKM1049-A) was 
mated with C. difficile strains 630!erm and R20291 in filter and spot mating.  
Four independent filter mating experiments were carried out for both C. difficile 
strains (Table 4.4).  In each experiment the ratio of C. difficile to E. coli has 
been calculated, ranging from 1:10 to 4:1.  All but one of the mating 
experiments failed to generate transconjugants.  Fourteen transconjugants were 
generated in experiment three in the 630!erm recipient strain.  Spot mating was 
performed a total of five times with mating mixtures spotted directly onto agar 
rather than filters (Table 4.5).  In experiments one to four no transconjugants 
were observed.  In experiment five a 2-step selection procedure was attempted 
whereby the mating mixture was inoculated onto Lm rather than Tm agar.  No 
transconjugants were observed. 
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Experiment  Recipient strain  
No. of 
filters per 
strain 
Total E. coli 
cells per 
filter 
Total C. 
difficile cells 
per filter 
Approximate 
ratio C. difficile 
to E. coli 
No. of 
transconjugants 
Conjugation 
efficiency 
(per donor) 
R20291 7.00E+08 1:2 ND ND 
1 
630!erm 
10 1.50E+09 
1.95E+09 1:1 ND ND 
R20291 4.34E+08 1:10 ND ND 
2 
630!erm 
15 5.65E+09 
5.93E+09 1:1 ND ND 
R20291 7.70E+08 7:10 ND ND 
3 
630!erm 
5 1.05E+09 
1.07E+09 1:1 14 1.33E-08 
R20291 3.05E+08 1:3 ND ND 
4 
630!erm 
5 1.05E+09 
9.45E+08 1:1 ND ND 
 
 
Experiment  Recipient strain  
No. of 
filters per 
strain 
Total E. coli 
cells per 
filter 
Total C. 
difficile cells 
per filter 
Approximate 
ratio C. difficile 
to E. coli 
No. of putative 
transconjugants 
Conjugation 
efficiency 
(per donor) 
R20291 1.38E+09 2:1 0 0 
1 
630!erm 
4 7.50E+08 
2.75E+09 4:1 0 0 
R20291 1.16E+09 1:1 0 0 
2 
630!erm 
5 1.21E+09 
9.50E+08 4:5 0 0 
R20291 7.70E+08 3:4 0 0 
3 
630!erm 
5 1.05E+09 
1.07E+09 1:1 0 0 
R20291 5.39E+08 1:4 0 0 4 
630!erm 
5 1.92E+09 
5.81E+08 1:3 0 0 
R20291 3.05E+08 1:3 0 0 
5 
630!erm 
5 1.05E+09 
9.45E+08 1:1 0 0 
 
 
Table 4.4  Results of filter mating between 
CA434-49 and C. difficile strains R20291 
and 630!erm. 
4 filter mating experiments were performed for each 
strain.  Transconjugants were selected on 100 !g ml-1 
Tm.  For each experiment viable counts were taken, the 
approximate ratio of donor to recipient cells is shown.  
14 transconjugants were generated in experiment 3 for 
the recipient 630"erm. ND = Not detected 
Table 4.5  Results of spot mating between 
CA434-49 and C. difficile strains R20291 and 
630!erm. 
5 spot mating experiments were performed for each 
strain.  In experiment 1-4 transconjugants were selected 
on 100 !g ml-1 Tm, for experiment 5 transconjugants were 
selected on 100 !g ml-1 Lm.  In each experiment viable 
counts were taken and the approximate ratio of donor to 
recipient cells calculated.  No transconjugants were 
generated from the spot mating experiments. ND = Not 
detected 
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4.5.3. Analysis of transconjugants 
 
4.5.3.1. Minimum inhibitory concentrations (MIC) of C. 
difficile to various antibiotics 
Both strain 630 and R20291 are resistant to Em, strain 630 has the Em 
resistance determinant ermB, but this is not present in R20291.  Em belongs 
to the MLSB class of antibiotics which includes Lm and clindamycin (Cli), it 
has been documented that some clinical isolates show high resistance to Em 
but not to other MLSB compounds such as Cli 389.  Investigation of these 
strains revealed a nucleotide substitution within the 23S rDNA copy on the 
genome, this is likely to have resulted in resistance to Em.  Therefore, it may 
be possible to use Lm or Cli to select for R20291 strains, which have 
acquired pKM1048/49 by conjugation.  To investigate this, the MIC for these 
antibiotics was established for the recipient strains (Table 4.6).  As 
anticipated, strain R20291 shows a comparable level of resistance to Em as 
strain 630 at >1024 µg ml-1 (the highest concentration tested).  R20291 is 
sensitive to Lm at a significantly lower concentration than strain 630, 32 µg 
ml-1 and 512 µg ml-1, respectively.  Similarly, R20291 is sensitive to Cli at 
concentrations above 4 µg ml-1, whereas strain 630 is sensitive to 
concentrations above 256 µg ml-1.  The profile of 630!erm is similar to that of 
R20291 except that this strain was almost completely sensitive to Em (<2 µg 
ml-1).  
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 Strain 
Antibiotic CD37 630 630!erm R20291 R20291::pKM1048  
Em < 2 µg ml-1 >1024 µg ml-1 < 2 µg ml-1 >1024 µg ml-1 nt 
Lm 32 µg ml-1 512 µg ml-1 32 µg ml-1 32 µg ml-1 100 µg ml-1* 
Cli 16 µg ml-1 256 µg ml-1 4 µg ml-1 4 µg ml-1 nt 
Tc < 2 µg ml-1 128 µg ml-1 128 µg ml-1 < 2 µg ml-1 nt 
Cm 8 µg ml-1 4 µg ml-1 8 µg ml-1 < 2 µg ml-1 >1024 µg ml-1 
Tm 4 µg ml-1 4 µg ml-1 4 µg ml-1 4 µg ml-1 >1024 µg ml-1 
 
Table 4.6 MICs for C. difficile strains and transconjugants to antibiotics. 
The MIC of strains CD37, 630, 630!erm and R20291, and 6 R20291::pKM1048 transconjugants to the MLSB group 
antibiotics erythromycin (Em), lincomycin (Lm) and clindamycin (Cli); and tetracycline (Tc), chloramphenicol (Cm) and 
thiamphenicol (Tm) were established using the agar dilution method.  The MICs given represent the average of three 
independent experiments.  * = a full MIC was not completed for the transconjugants to Lm, only concentrations of 20, 50 
and 100 µg ml-1 were examined. nt = not tested. 
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The resistance of all the strains to Tc, Cm and Tm was also tested.  Strain 
CD37 and R20291 were sensitive to the lowest concentration of Tc tested (2 µg 
ml-1), however, 630 and 630!erm were both sensitive to concentrations above 
128 µg ml-1.   All C. difficile strains were sensitive to Cm and Tm at 
concentrations above 8 µg ml-1.  Assessment of 13 R20291 transconjugants 
containing pKM1048 to Lm revealed that presence of the ermB gene on the 
plasmid conferred resistance up to 100 µg ml-1.  For this assay only 
concentrations of 20, 50 and 100 µg ml-1 were tested.  The MIC of the 
transconjugants to Cm and Tm revealed that the presence of the cat gene 
conferred resistance to concentrations over 1024 µg ml-1.  
 
4.5.3.1. Analysis of R20291::pKM1048 transconjugants 
PCR was carried out on each of the putative transconjugants to identify the cat 
in mini-Tn10 and bla on the plasmid backbone (data not shown).  Putative 
transconjugants from experiment 1, 3 and 8 were all PCR positive for both the 
cat and bla gene upon initial isolation.  All PCR positive putative 
transconjugants were subjected to Southern hybridisation.  EcoRV digests were 
blotted onto nitrocellulose membrane and probed using Pb-cat to identify the 
presence of mini-Tn10 (Figure 4.13).  The blot shows no hybridisation of Pb-cat 
to the wild type DNA and positive hybridisation to pKM1048 plasmid DNA.  
Positive hybridisation is seen at approximately 10 Kb in lane 1, 2 and 4. 
 
In a second blot, PCR positive transconjugants from experiment three were 
assayed.  DNA digested with EcoRV from nine transconjugants, three from 
each of the recipient strains CD37, R20291, and 630!erm were probed with Pb-
cat (Figure 4.14).  A putative 630 transconjugant previously probed in first blot 
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(Figure 4.13, lane 4) was also included due to the poor quality of the original 
blot.  Hybridisation of the probe is seen for this transconjugant at approximately 
9 Kb.  There is no hybridisation of Pb-cat to any of the remaining transconjugant 
samples, however positive hybridisation is seen to pKM1048. 
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Figure 4.13 Digest of putative strain 630 transconjugants and Southern 
blot probed with Pb-cat  
DNA from 4 putative 630::pKM1048 transconjugants was digested with EcoRV and transferred 
to a nitrocellulose membrane.  The membrane was probed with labelled Pb-cat and exposed to 
photographic film for 15 hours.  Faint bands of hybridisation can be seen at approximately 10 
Kb for sample 1, 2 and 4.  Faint hybridisation is also seen for the positive control (pKM1048) at 
approximately 8 Kb.  No hybridisation of the probe is seen for any of the recipient strains.  
Lane M = 1 Kb ladder, + = pKM1048; wt1 = wild type CD37, wt2 = wild type R20291, wt3 = 
wild type 630, wt4 = wild type 630!erm, lane 1-4 = 630 putative transconjugants.  
M    wt1     wt2    wt3     wt4       1        2         3        4         +        M 
 M     wt1     wt2     wt3     wt4        1         2        3          4        +        M 
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Figure 4.14  Digest and Southern hybridisation of putative 
transconjugants.  
DNA digested with EcoRV was transferred to a nitrocellulose membrane and probed with 
Pb-cat.  Positive hybridisation is seen for the plasmid control at approximately 8 Kb.  No 
hybridisation of the probe is seen for any of the wild type strains.  Positive hybridisation is 
seen in lane 9 at approximately 10 Kb.  Lane M = 1 Kb ladder; + = pKM1048; wt1 = wild type 
CD37, wt2 = wild type R20291, wt3 = 630!erm, lane 1-3 = CD37 putative transconjugants; 
lane 4-6 = R20291 putative transconjugants; 7-9 = 630!erm putative transconjugants; 10 =  
630 putative transconjugant that showed positive hybridisation in the first blot (Figure 4.13). 
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DNA from transconjugants generated in experiment one and three was digested 
with HindIII, including six R20291, one CD37 and two 630 recipient strains, and 
subject to Southern hybridisation (Figure 4.15A).  The membrane was probed 
with two probes, Pb-cat for the cat gene on mini-Tn10, and Pb-amp for the bla 
gene on the plasmid backbone (Figure 4.15B & C).  One of the putative 
transconjugants (Figure 4.15 B & C lane 6) showed hybridisation of both probes 
indicating the presence of cat and amp.  The DNA is derived from a 
transconjugant in the CD37 recipient generated in experiment three.  
Hybridisation of Pb-cat to the positive control occurs on a fragment of 
approximately 1.2 Kb, this corresponds to the mini-Tn10 fragment which is 
flanked by HindIII restriction sites.  Similarly, hybridisation of Pb-amp to DNA 
from the positive control occurs on a fragment of approximately 10 Kb, this 
corresponds to the second fragment generated from HindIII digestion of 
pKM1048 (Figure 4.6A).  An identical hybridisation pattern is seen in lane 6 for 
both probes.  No hybridisation is observed to DNA from the recipient strains.  
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Figure 4.15  Digest of putative transconjugant DNA from experiment 
1 and 3 on agarose gel (A) and hybridisation of Pb-cat (B) and Pb-
amp (C). 
Genomic DNA was digested with HindIII and separated on a 1% agarose gel (figure A).  
DNA was transferred to a nitrocellulose membrane and probed with Pb-cat (figure B) or    
Pb-amp (figure C).  Positive hybridisation for Pb-cat and Pb-amp is seen in lane 6 at 
approximately 1.2 Kb and 10 Kb, respectively.  Positive hybridisation is also seen for the 
plasmid positive control in lane +.  Lane M = 1 Kb ladder, + = pKM1048, lane 1-5 = 
R20291 putative transconjugants, lane 6 = CD37 putative transconjugant, lane 7= 
R20291 putative transconjugant (revived from experiment 1), lane 8-9 = 630 putative 
transconjugants (revived from experiment 1).  wt1 = wild type CD37, wt2 = wild type 630, 
wt3 = R20291 wt4 = R20291 (alternative stock) 
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HindIII digested DNA from fourteen R20291 putative transconjugants from 
experiment eight was probed with Pb-cat and Pb-amp (Figure 4.16).  The 
DNA extracted from one of the transconjugants (lane 13) is degraded and 
should be ignored.  The remaining thirteen transconjugants were positive for 
both Pb-cat and Pb-amp hybridisation (Figure 4.16 B & C respectively).  For 
Pb-cat, strong hybridisation can be seen at approximately 1.2 Kb identical to 
the plasmid control and for Pb-amp, hybridisation is seen at approximately 10 
Kb, again identical to that seen for the plasmid. 
 
4.5.3.1. 630!erm::pKM1049 transconjugants 
The presence of mini-Tn10 (cat gene) and the plasmid backbone (bla gene) 
was confirmed by PCR for all fourteen of the putative 630!erm 
transconjugants generated in experiment three (Figure  4.17).  Southern 
hybridisation was not performed using DNA from these transconjugants.  The 
positive band seen in the wild type control lane at approximately 800 bp (lane 
wt) for amplification of the bla gene is a non-specific product and does not 
represent a positive result. 
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Figure 4.16  Restriction digest and Southern blot of putative R20291 transconjugants. 
Figure A shows the HindIII digestion of DNA from 14 putative R20291 transconjugants containing pKM1048 separated on agarose gel.  The DNA was 
transferred to a nitrocellulose membrane and probed with Pb-cat (figure B) and Pb-amp (figure C).  Thirteen of fourteen putative transconjugants were 
positive for both cat (B) and bla (C).  The DNA in lane 13 appears to have degraded producing a large smear on the gel and after hybridisation, this 
transconjugant was not subjected to any further analysis.  Lane M1 = 1Kb ladder; M2 = 100 bp marker; 1-14 = R20291 putative transconjugants; + = 
pKM1048; wt = wild type R20291. 
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Figure  4.17 PCR amplification of 
630!erm putative transconjugants 
for presence of the cat gene(A) and 
bla gene (B). 
Genomic DNA extracted from each 
transconjugant was used as template for a 
PCR reaction to amplify cat and bla to confirm 
the presence of both genes.  PCR products 
were separated on 1% agarose gel.  Lane M 
= 100 bp ladder; lane 1-14 = 630!erm 
putative transconjugants; + = pKM1049; wt = 
wild type 630!erm; H2O = H2O control. 
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4.5.4. Investigation of plasmid fate in C. difficile transconjugants 
4.5.4.1. Sequence and PCR analysis 
The hybridisation results provide evidence of the presence of cat in the C. 
difficile transconjugants, which was supported by resistance to Tm.  
However, bla is also present, indicating maintenance of the plasmid.  Two 
possible explanations could explain this result, either the plasmid has been 
maintained in its original form or the plasmid has been integrated by 
homologous recombination into the genome of R20291. The plasmid 
sequence was analysed for regions of homology to the R20291 or 630 
genome.  Blastn analysis against the genome sequence of R20291 
(Accession No. NC_013316) showed no regions of homology suggesting 
that recombination was unlikely to have occurred.  Analysis of strain 630 
(Accession No AM180355 (chromosome) & AM180356 (plasmid)) again 
revealed no sequence similarities except for the predicted identity to ermB.  
PCR was also carried out to assess whether regions of the plasmid had been 
broken to facilitate homologous recombination.  PCRs covering the entire bla, 
ermB, transposase genes and Pfac revealed that all of these regions were 
intact (data not shown). 
 
4.5.4.2. Southern hybridisation analysis 
The second possible explanation may be that the plasmid is being 
maintained in the host cell with or without transposition of the transposon.  To 
assess this hypothesis transconjugant and control DNA was digested with 
HindIIl or left undigested and separated on agarose gel.  The DNA was 
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transferred to nitrocellulose and probed with Pb-cat.  Figure 4.18 shows the 
hybridisation pattern giving the same results as the previous blots for the 
digested DNA.  The results are inconclusive for undigested DNA as it is 
impossible to distinguish the plasmid DNA from the genomic DNA in the 
hybridising band.  In addition to the hybridisation, plasmid rescue was 
attempted to assess the fate of the plasmid.  The standard Mini-prep 
procedure failed to generate visible plasmid from the transconjugants.  
Therefore, to amplify the plasmid the primary elute from a standard Mini-prep 
of a 630!erm::pKM1049 transconjugant was transformed into competent E. 
coli.  Plasmids isolated from transformants were then digested with EcoRV 
(Figure 4.19).  The plasmid obtained from four transformant colonies 
produced a digest pattern identical to pKM1049. 
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Figure 4.18  Southern hybridisation analysis of R20291 
transconjugant DNA (pKM1048) undigested or digested 
with HindIII. 
Transconjugant and plasmid DNA undigested or digested with HindIII was 
separated by gel electrophoresis and transferred to a nitrocellulose 
membrane.  The membrane was then probed with Pb-cat.  Dark bands 
represent hybridisation of the probe to DNA.  The hybridisation of the 
digested DNA corresponds to previous blots, one band at approximately 1.2 
Kb is seen.  Hybridisation of the undigested DNA appears to be localised to a 
high molecular weight smear of a similar size to the undigested plasmid 
control (U) but show little discrimination between the predicted plasmid 
forms.  Lanes: M = 1 Kb ladder; 1 = digested transconjugant DNA a.; 2 =   
undigested transconjugant DNA a.; 3 = digested transconjugant DNA b.; 4 =  
undigested transconjugant DNA b.; 5 = digested transconjugant DNA c.; 6 =  
undigested transconjugant DNA c.; 7 = digested transconjugant DNA d.; 8 =  
undigested transconjugant DNA d; wt = wild type C. difficile R20291, +D =  
digested pKM1048; +U = undigested pKM1048. 
 M      1       2       3       4       5       6       7       8      M            wt      +D     +U 
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Figure 4.19  Digest of plasmid rescued from C. difficile 
630!erm transconjugants. 
Plasmid DNA from four transconjugants was transformed into 
competent E. coli before extraction.   Plasmids were digested with 
EcoRV and fragments separated on 1% agarose gel.  Plasmid isolated 
from each transformant gave 4 fragments that are identical to the 
fragments generated from digestion of pKM1049.  Lane1-4 = 
transformants; + = pKM1049; M = 1 Kb ladder. 
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4.5.4.3. Plasmid stability assay 
pMTL5401F is described as an unstable plasmid within C. difficile due to the 
presence the repH replicon from pCB102, highly unstable in both strain 630 
and in 027/NAP1 strains 177.  The plasmid may be maintained by the 
presence of antibiotics in the medium.  To assess the stability of pMTL5401F 
and pKM1048 within R20291 a stability assay was conducted.  Three 
independent transconjugants were cultured without antibiotic selection, and 
passaged four times.  After each passage cultures were plated onto non-
selective plates and selective plates.  The number of colony forming units 
(cfu) was established for non-selective and selective plates and compared.  
After three passages in non-selective medium 99.9% of the transconjugant 
colonies did not contain the plasmid or mini-Tn10 showing sensitivity to Tm 
(Table 4.7).  An attempt was made to introduce pMTL5401F into R20291 by 
filter mating however, this failed to produce transconjugants and 
consequently no comparison can be made between the stability of 
pMTL5401F and pKM1048. 
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 passage 1 passage 2 passage 3 
Transconjugant 1 77.9% 98.2% 99.9% 
Transconjugant 2 74.8% 98.0% 99.9% 
Transconjugant 3 77.9% 99.3% 99.9% 
 
 
 
 
Table 4.7  Plasmid loss after serial passage in the absence of 
selection. 
Three R20291 transconjugants were serially passaged in the absence of selective 
antibiotic and plated onto Tm selective agar.  The number of colonies that were able to 
grow on selective media were enumerated and compared to the total number of cfu ml-
1 in the inoculum to generate a percentage of cfu/ml which contained the plasmid.  
After three passages in non-selective medium 99.9% of the cfu had lost plasmid 
pKM1048 and associated Tm resistance. 
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4.5.5. Promotion of transposition 
To assess whether transposition would occur after several generations, three 
R20291 transconjugants were inoculated into broth with and without 
thiamphenicol (a total of 30 cultures).  Each broth was passaged three times 
in fresh media of the same constitution.  Cultures grown without (1) or with 
(2) thiamphenicol were plated onto thiamphenicol selective agar plates, after 
growth of colonies each plate was replicated onto Lm selective agar.  One 
set of cultures grown in Tm selection (3) were plated onto non-selective agar 
before replica plating onto Lm and Tm selective agar.  The total number of 
colonies that grew on the Tm selective plates was enumerated and 
compared to the Lm replica plates (Table 4.8).  All of the colonies were found 
to be Tm and Lm resistant. 
 
The transposase and mini-Tn10 fragment cloned from plasmids pHV1248 
and pHV1249 included the promoter region of the transposase (Ptat), active in 
B. subtilis.  It was not known whether this would be functional in C. difficile 
and thus the mini-Tn10 delivery plasmid was designed so that Pfac could also 
be used to drive transcription of the transposase gene.  Four 
R20291::pKM1048 transconjugants were cultured in broth with addition of 
IPTG and Tm.  The cultures were passaged nine times in the same 
conditions.  After ten passages, samples were plated and three random 
colonies chosen from each sample for further analysis.  Digested DNA was 
probed with Pb-cat (Figure 4.20).  The blot revealed that after ten passages 
in IPTG, transposition of mini-Tn10 did not occur.   
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Table 4.8  Results of transconjugant replica plating assay. 
Three R20291 pKM1048 transconjugant cultures (A, B, & C) were grown in non-
selective broth (1); Tm selective broth (2 & 3) and plated onto either Tm selective plates 
(1 & 2) or non-selective plates (3).  Plates were incubated for 36 hours before plates 
were replica plated onto selective agar containing wither 100 µg ml-1 Tm or 100 µg ml-1 
Lm and incubated for 48 hours.  The total number of colonies on both plates was 
enumerated and plates were assessed for any difference in colony growth.  No 
difference in the number of colonies that grew on the Tm plates compared to the Lm 
plates was observed for any of the experimental conditions. 
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To confirm that the intact plasmid had been maintained in the 
transconjugants after serial passage with IPTG, the membrane was re-
probed with Pb-catH (Figure 4.21).  Pb-catH covers a section of the plasmid 
backbone and part of mini-Tn10 including one of the HindIII sites present in 
pKM1048.  The blot shows hybridisation of the probe for all 12 of the 
transconjugants at two positions, approximately 10 Kb and 1.2 Kb.  The 
hybridisation pattern for the transconjugants is identical to that for the positive 
(plasmid) control.  The gel is slightly skewed however the lower bands in 
each lane are at the same position as the control band.   
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A 
   
B 
Figure 4.20  Agarose gel of IPTG passaged transconjugants digested 
with HindIII (A) and Southern hybridisation of digested DNA probed 
with Pb-cat (B). 
Four transconjugants were grown in selective medium containing IPTG, passage was 
repeated a further 9 times.  Cultures were plated on selective medium and 3 random 
colonies from each culture were selected and DNA extracted.  The DNA was digested 
with HindIII and separated on a 0.8% agarose gel.  DNA was transferred to nitrocellulose 
membrane and fixed by UV cross linking.   The membrane was probed with labelled Pb-
cat and appropriate marker.  M = 1 Kb ladder; 1-3 = transconjugant 1; 4-6 = 
transconjugant 2; 7-9 = transconjugant 3.; 10-12 = transconjugant 4; wt = wild type   
R20291, + = pKM1048. 
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Figure 4.21  Southern hybridisation probed with Pb-catH. 
Probe Pb-catH covers the HindIII restriction site downstream of the mini-
Tn10 element (see Figure 4.7).  There is positive hybridisation of the 
probe for all 12 of the IPTG passaged R20291::pKM1048 transconjugants at 
two positions approximately 10 Kb and 1.2 Kb.  Although the gel is slightly 
skewed and the first marker is faint the lower bands in each lane are at the 
same position.  The hybridisation pattern for the transconjugants matches 
that seen for the positive control.  As predicted two areas of hybridisation are 
observed as the probe binds to both the mini-Tn10 and plasmid backbone on 
either side of a HindIII site meaning half of the probe will bind to one of the 
two main plasmid fragments and the other half will bind to the remaining 
fragment.  The nonspecific ghost banding is likely to be due to non-specific 
hybridisation and/or insufficient washing before detection. 
  M      1        2      3      4      5      6     7      8      9    10   11    12     wt     M     + 
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4.5.6. RT-PCR 
Pfac is reported to be induced by IPTG, however inclusion of IPTG in the 
growth medium failed to promote the transposition of mini-Tn10 in C. difficile 
strain R20291 to a detectable level.  The expression of the transposase gene 
in the presence of IPTG was therefore investigated by RT-PCR.  RNA was 
extracted from one R20291::pKM1048 transconjugant grown with and without 
IPTG.  Two control primers pairs were designed to amplify the 16S gene and 
GyrA gene as constitutively expressed standards.  Two further primer pairs, 
qCat and qTpase, were designed to amplify the cat and transposase gene 
respectively.  All of the primers were tested in control experiments to allow 
optimum design of the RT-PCR parameters, including establishing primer 
and RNA concentrations.  
 
Positive amplification of each gene was observed in each RNA concentration 
tested, 100, 10 and 1 ng.  A calibration curve was established for the 16S, 
GyrA and transposase gene; the reaction efficiencies are within the 
acceptable range (from 86-100%) allowing real conclusions to be drawn form 
the test data (Table 4.9).  The threshold values obtained from the calibration 
curve were used to establish the average CT value (rep CT) for expression of 
each gene in each experiment (Table 4.10).  Three independent experiments 
were performed to assess the expression of the transposase gene with and 
without addition of IPTG.  There was no significant difference in the 
expression.  Assessment of the two constitutively expressed housekeeping 
genes showed almost identical expression in the two samples, supporting the 
results observed for the transposase gene. 
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  Gene 
Experiment 1 Tpase 16S GyrA 
Threshold Value 0.334 0.128 0.313 
repCT value for samples with IPTG 12.52 5.56 20.77 
repCT value for samples without IPTG 12.33 5.75 20.45 
        
Experiment 2       
Threshold Value 0.334 0.128 0.313 
repCT value for samples with IPTG 13.12 6.55 21.61 
repCT value for samples without IPTG 13.39 6.70 21.45 
        
Experiment 3       
Threshold Value 0.334 0.128 0.313 
repCT value for samples with IPTG 12.80 6.45 21.90 
repCT value for samples without IPTG 12.89 6.42 21.19 
        
Average repCT for samples with IPTG 12.81 6.19 21.43 
Average repCT for samples without IPTG 12.87 6.29 21.03 
    
 
 
 
Table 4.9  Quantitation information for 
calibration curve. 
The values for the efficiency of the reaction (E) and 
R2 (coefficient of determination) are listed for each 
primer.  Both measures are critical to evaluate the 
PCR efficiency. 
Calibration curve values 
16S E 0.857 
  R2 0.996 
Tpase E 0.913 
  R2 0.994 
GyrA E 1.020 
  R2 0.996 
Table 4.10  Expression of transposase and with and without IPTG 
induction. 
The repCT values (from triplicate samples) for the transposase, 16S and GyrA gene 
were calculated using the threshold values obtained from the calibration curve for 
each gene.  The average repCT of three independent experiments is also shown.  
There is no significant difference between the expression in induced and non-
induced samples.  All threshold values were taken from the same RNA dilution with 
approximately 7 ng of template RNA.  
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4.6. Discussion 
 
Reliable tools to generate random insertions in the genome of C. difficile 
were not available when this study began, however there was a clear need 
for their development to investigate the molecular pathogenicity of this 
important nosocomial pathogen.  Transposon mutagenesis is a widely used 
technique allowing the generation of large libraries of insertion mutants that 
can be screened to identify genes involved in the specific functions.  Petit et 
al. (1990) describe the adaptation and use of a Tn10 derivative, mini-Tn10, 
for use in the Gram-positive bacterium B. subtilis 197.  Mini-Tn10 was shown 
to generate random and stable insertions throughout the genome with one to 
two copies per clone.  These experiments highlighted mini-Tn10 as an 
attractive potential random mutagen of C. difficile. 
 
Introduction of DNA into C. difficile is only possible through conjugative 
transfer from a suitable donor bacterium.  Previous studies have shown that 
an E. coli strain CA434 could be used to deliver plasmids to C. difficile by 
direct filter mating 347.  The investigation of mini-Tn10 insertion in C. difficile 
required the development of a suitable delivery plasmid.  Several key 
attributes were required including a replicon for replication in E. coli, a 
replicon for replication in C. difficile, a selectable marker(s), transfer genes to 
work with the R702 plasmid, and a promoter active in C. difficile to drive 
expression of the Tn10 transposase.  Plasmid pMTL5401F is an E. coil-
Clostridium shuttle plasmid and has been shown to be unstable in some 
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clostridia, there is also the potential to allow inducible expression of genes 
cloned downstream of Pfac 130.   
 
Initially two methods, PCR and restriction digest were performed concurrently 
to create the construct pKM1048.  PCR amplification of mini-Tn10 failed to 
generate the desired fragment, it is possible that this was due to sub-optimal 
reaction conditions or primers.  These possibilities were not investigated 
further to allow progression of the project.  The restriction digest approach 
appeared to be relatively straightforward allowing direct insertion of a 
fragment containing the transposase gene and mini-Tn10 into pMTL5401F.  
This method was thus repeated for the second mini-Tn10 derivative 
(pKM1049).   
 
Confirmation of the construct was achieved through PCR and restriction 
digest analysis.  The plasmid construct was then transformed to the donor E. 
coli strain CA434.  Problems were encountered when using the cat selection 
marker in E. coli, which significantly delayed the isolation of CA434-48. 
Selection with Cm at various concentrations was seen to be unreliable and 
failed to allow consistent growth of colonies thought to contain mini-Tn10.  
Further investigation of the use of cat in pervious studies revealed that weak 
expression of this gene in E. coli has been documented 390. 
 
Filter mating experiments were performed with CA434-48/49 donor and C. 
difficile strains CD37, 630!erm, 630 and R20291.  Spot mating is usually 
performed for E. coli-Clostridium mating, whereas filter mating is used for 
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Bacillus-Clostridium mating as the filter aids the conjugation process 337.  
Spot mating experiments between CA434-48 and strains R20291 and 630 
failed to generate transconjugants, whereas filter mating did.  The 
appropriate level of Tm selection for the transconjugants was initially 
unknown; therefore there was a degree of trial and error in determining the 
most appropriate parameters.  Once transconjugants had been isolated an 
MIC was conducted to determine the level of resistance shown by C. difficile 
transconjugants containing the cat gene.  High levels of resistance were 
observed for the transconjugants compared to the wild type strains allowing a 
standard concentration to be determined.  Transconjugants were selected at 
various concentrations of Tm, although 100 !g ml-1 was used for the majority 
of experiments.  This is significantly higher than the concentration 
recommended for selection for C. difficile containing catP (15 !g ml-1) 130.  
However, the MIC and selection level used in this study are based on the 
resistance conveyed by expression of the gene from the plasmid, it was not 
possible to determine the level of resistance shown by a chromosomally 
expressed cat gene.  The resistance profiles of the transconjugants 
containing cat suggest that this is a useful marker in C. difficile however, the 
inconsistent results seen here and the previous demonstration of the low 
level of resistance conferred by this gene in E. coil, reveal that this is not a 
suitable maker for this study.  Ideally other markers, including catP (derived 
from C. perfringens plasmids pIP401 & pJIR27) should be examined for their 
usefulness in the mini-Tn10 element within both organisms.  
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The generation of transconjugants was extremely inefficient as no 
transconjugants were generated in the majority of mating experiments.  
Alterations to the protocol were investigated including initially selecting for the 
plasmid backbone through Lm selection before a secondary selection for 
mini-Tn10 using Tm.  No transconjugants were observed in this experiment.  
It is possible that the standard level of Tm used to select transconjugants 
was too high to identify those with the transposon on the chromosome, thus 
primary selection for the plasmid with Lm would evade this issue.  A 
subsequent selection for Tm resistance at a lower level may allow 
identification of transconjugants with insertions of mini-Tn10 on the 
chromosome.  
 
Putative transconjugants were all assessed by PCR for the presence of the 
cat and bla gene, and all were initially positive.  A number of transconjugants 
were not maintained in selective broth and were subsequently negative for 
cat and bla, confirmed by Southern hybridisation.  This indicated that the 
plasmid and the element had been lost after removal of Tm selection.  This 
result is consistent with the conclusion that the transposon had either not 
transposed or was not stably maintained in the chromosome of the recipient 
bacterium.  If mini-Tn10 had remained on the plasmid the reported instability 
of the repH replicon and the lack of selective pressure is likely to have led to 
the loss of the plasmid 130, 177.  Instability of the plasmid was confirmed after 
serial passage in non-selective media, proving pCB102 to be a suitable 
replicon for this system.  
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Hybridisation results for R20921::pKM1048 revealed that both mini-Tn10 and 
the plasmid were present.  The hybridisation profile was identical to the 
plasmid control suggesting that the complete plasmid had been maintained.  
It was also possible, but unlikely, that the plasmid had inserted into the 
genome of R20291 through homologous recombination.  Investigation of the 
plasmid sequence revealed no significant regions of homology.  Several 
PCRs were conducted to check for the presence of intact features of the 
plasmid including ermB and Pfac.  A Southern blot of digested and undigested 
R20291::pKM1048 transconjugant DNA was probed with Pb-cat to assess 
whether the intact plasmid could be observed, unfortunately the result do not 
confirm the presence of intact plasmid.  However, it was possible to obtain 
the original plasmid from the R20291::pKM1048 transconjugants confirming 
the presence of intact plasmid. 
 
Plasmids containing two versions of mini-Tn10 were generated by Petit et al. 
(1990), the element present on pHV1248 contained the cat gene flanked by 
two outside ends of IS10 and the element from pHV1249 contained the cat 
gene flanked by the inside ends of IS10 197.  Host factors IHF and HU are 
known to be required for transposition of the element containing OEs but not 
for IEs in E. coli.  Petit et al., showed that both elements were able to 
transpose in B. subtilis, therefore both elements were examined in C. difficile.  
From PCR and hybridisation analysis it appeared that there had been no 
transposition events, however it is possible that these events did occur but 
were not detected.  Therefore, experiments aiming to promote transposition 
were performed.  A replica platting assay was conducted with the aim of 
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identifying cells after serial passage that had retained Tm resistance yet lost 
Lm resistance, thus indicating the presence of mini-Tn10 and loss of the 
plasmid.  Unfortunately, no colonies were identified with this phenotype.  
Several hundred colonies were examined as transposition events might 
occur at very low frequencies.  It is possible that an insufficient number of 
colonies were screened.   
 
The promoter Pfac, a composite of the ferredoxin gene fd promoter fused to 
the operator of the lacZ operon, is present in pMTL5401F and was expected 
to allow IPTG inducible expression of downstream cloned genes 391.  This 
promoter was shown to be inducible in C. sporogenes; however it has not 
previously been investigated in C. difficile 130.  The cloned transposase and 
mini-Tn10 element were placed downstream of this promoter potentially to 
allow inducible expression.  The cloned fragments from pHV1248 and 
pHV1249 both contained the promoter Ptac and RBS region upstream of the 
transposase, which are active in B. subtilis.  It was unknown whether these 
would be active in C. difficile and therefore the existence of the Pfac promoter 
would act as a backup to this to ensure the transposase was expressed 
allowing transposition of mini-Tn10.  Transconjugants were therefore grown 
in the presence of IPTG to assess whether this would lead to transposition of 
the element.  There was no evidence of transposition to the chromosome 
from the hybridisation analysis, blots were identical to those performed on 
transconjugants grown without IPTG.  RT-PCR was then conducted to see 
whether the transposase was being expressed and whether the addition of 
IPTG had affected of the level of expression.  The results revealed that the 
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transposase was being expressed and that addition of IPTG had no effect on 
the level of expression.  As there was clearly expression of the transposase it 
is not clear why transposition of mini-Tn10 did not occur.  The element and 
the transposase gene are identical to those used in B. subtilis as the 
fragment was directly cloned into pMTL5401F, it is possible that it is not 
functional in C. difficile.  Investigation of the codon usage in C. difficile 
revealed that there might be a shortage of codons for the cognate tRNA in C. 
difficile (Appendix ) (personal communication Professor Mike Young, 2011).  
To overcome this issue the transposase gene could be re-synthesised for 
use specifically in C. difficile; unfortunately, this was not fully investigated due 
to time constraints. 
 
During the design of this project both mini-Tn10 and mariner were considered 
as potential elements for the random mutagenesis of C. difficile.  Mini-Tn10 
was chosen as the preferred element to investigate due to the success seen 
in B. subtilis, with a view to investigate mariner-based transposon systems at 
a later date.  Shortly after the end of this project Cartman and Minton (2010) 
published a paper describing the generation of random insertions of the 
mariner-transposable element Himar1, in the genome of C. difficile strain 
R20291 388.  Cartman and Minton were able to show stable insertions of the 
element that were, in the majority, single insertions which occurred at a 
relatively high frequency (~4.5 x 10-4).  After generation of a library of 
undefined size they isolated two mutants, a sporulation/germination-defective 
clone with an insertion in cspBA and an auxotroph with an insertion in the 
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pyrimidine biosynthesis gene pryB. However, neither of these mutations has 
been complemented.  
 
The pMTL-SC1 delivery vector for the Himar1 element appears to be simpler 
and is significantly smaller (7.4 Kb) than the construct used in the present 
study.  It contains catP as the selectable marker, which may be a more useful 
marker in E. coli and C. difficile.  One of the potentially significant problems 
with the design of pKM1048/49 was that the plasmid vector was unmodified 
except for the addition of the transposase and mini-Tn10, largely due to 
unfeasible cloning options, thus Pfac, an unverified promoter in C. difficile was 
relied upon for expression of the transposase should its native promoter be 
non-functional.  
 
By using the C. difficile promoter from TcdB, Cartman and Minton are able to 
express genes under its control in C. difficile.  pMTL-SC1 contains pBP1 
derived form C. botulinum, the authors assessed the efficiency of conjugation 
of the plasmid containing this replicon, and the segregational stability of the 
plasmid alongside the clostridial replicons pCB102 (C. butyricum) and pCD6 
(C. difficile) in R20291.  pBP1 was shown to have approximately the same 
segregational stability as pCB102, however, the element showed 
approximately 10-fold higher conjugation frequencies.  These data suggest 
that the stability of the replicon used in the mini-Tn10 delivery vector is 
comparable to the one used in this study although this is expressed per 
generation.  The conjugation frequencies observed with the plasmids 
described are also significantly higher than the frequencies observed for 
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pKM1048/49, this may be due in part to the large size of these plasmids 
(approximately 11 Kb) compared to the plasmids assessed by Cartman and 
Minton which range from 3 Kb to 5.3 Kb and 7.4 Kb 392 
 
The development of a mariner-based random mutagenesis tool for C. difficile 
will hopefully enable a further understanding of the molecular pathogenesis 
of this organism.  Mariner has been shown to enter the genome at AT sites, 
thus as C. difficile is AT rich this preference for AT insertion sites may not be 
a significant issue.  It would also be useful to investigate the insertion sites in 
a larger sample to ensure the randomness of the system and confirm that 
predominantly single insertions occur.  This initial study certainly suggested 
that this is an effective tool, however, further investigation of the use and 
efficiency of this tool will confirm whether it will be suitable for the generation 
of large stable insertion libraries, and whether it may be used in other C. 
difficile strains. 
 
  
 
313 
4.7. Conclusions and future perspective 
 
A novel tool for the potential random mutagenesis of C. difficile has been 
developed based on an E. coli-C. difficile shuttle plasmid and mini-Tn10.  The 
plasmid has been shown to transfer from the donor cell via conjugation to 
four C. difficile strains including the clinically relevant 027/NAP1 strain 
R20291.  Low conjugation frequencies were observed however, once inside 
the recipient cell the plasmid conferred high levels of resistance to 
thiamphenicol.  The plasmid was shown to be unstable in the absence of 
selective pressure; this facilitates stable insertions through loss of the 
transposase.  It was not possible to demonstrate transposition of the element 
in the genome of C. difficile.  The expression of the transposase gene was 
confirmed by RT-PCR with results indicating that there was no affect of IPTG 
on expression.  It is not clear why the transposon failed to transpose in these 
bacteria, however it is possible that this is due to the very low limits of 
detection. 
 
Although insertion mutants were not generated this work shows that it is 
possible to transfer relatively large plasmids into C. difficile strains.  Clearly, 
further investigation is required to develop this potential tool and to 
understand why transposition failed to occur in these transconjugants. The 
development of a series of modular plasmids, and further characterisation of 
promoters and replicons suitable for use in C. difficile genetic systems, will 
surely aid the development and refinement of shuttle plasmids to allow 
efficient delivery of DNA.   
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The recent description of a mariner-based random mutagenesis system may 
diminish the importance of further developing the mini-Tn10 tool.  However, 
this initial report does not fully describe the usefulness of this tool and it is 
possible that other complementary tools, such as mini-transposon-based 
tools, will be equally important in the investigation of gene function and 
regulation in C. difficile.  
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Chapter 5 
 
 
5. Future work - Development of a mini-Tn916 
transposon and delivery vector for C. difficile 
mutagenesis 
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5.1. Abstract 
Transposon mutagenesis is a standard technique for the generation of 
random insertion libraries.  The conjugative transposon Tn916 has been 
used successfully to generate a library of transconjugants in the toxin 
producing strains 630!erm and R20291.  Development and testing of a mini-
Tn10 shuttle vector failed to generate transconjugants with stable genomic 
insertion of the transposon in R20291 or 630!erm.  As Tn916 has been 
shown to enter the genome of CD37, 630!erm and R20291, a ‘mini’ version 
of this transposon, containing the left and right ends of Tn916 and a cat 
antibiotic resistance cassette (encoding resistance to chloramphenicol) was 
generated by SOEing PCR.  A shuttle delivery plasmid was also designed 
and partially constructed to deliver this mini-transposon into C. difficile by 
filter mating with E. coli strain CA434.  
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5.2. Introduction 
 
5.2.1. Tn916 and mini-transposons 
Mini-transposons represent a useful alternative to their bulky full-length 
ancestors. These compact elements are generally composed of functional 
ends of their parent required for transposition and a suitable marker to allow 
selection 375.  To ensure stability, the transposase or genes required for 
excision and insertion, are placed outside the element, finally minor 
modification to the transposase gene sequence can allow reduced target site 
specificity 375, 393.  Mini-Tn10 has been used successfully in several bacteria 
including E. coli and B. subtilis, generating stable random insertions 197, 394. 
 
The conjugative transposon Tn916 has been used as an insertional mutagen 
in C. difficile strain 630!erm and R20291 (see Chapter 2).  Unfortunately, this 
is not an ideal transposon for random mutagenesis due to preferential 
insertion into AT rich sites and insertion into hot spots, for example in CD37; 
furthermore, due to it large size (18 Kb) there is a greater chance of causing 
downstream effects after insertion 193, 210.   
 
5.2.2. Shuttle vectors and filter mating 
As described earlier, one of the major issues that have limited the 
investigation of C. difficile has been the lack of efficient and reliable tools for 
genetic manipulation.  Recently, two methods have been described for the 
introduction of DNA into C. difficile and the targeted disruption of genes, 
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namely the ClosTron and the shuttle plasmid/recombination vectors 130, 132.  
This has revolutionised the study of C. difficile allowing targeted inactivation 
of specific genes to investigate their function, particularly those associated 
with virulence 117, 126, 129.  Both tools rely on conjugation of plasmids to 
introduce DNA using a filter mating method akin to that used for the transfer 
of Tn916 from a B. subtilis donor 205.   
 
Tn916, although shown to lead to insertions in the genome of C. difficile is by 
no means an optimal tool for random mutagenesis of this important 
pathogen.  Preferential insertion sites, multiple insertion and low transfer 
frequencies of this large element are major drawbacks for its use in 
generation of large insertion libraries.  The investigation of this element, also 
documented in this thesis, has further stressed these drawbacks; frequency 
of transfer to the hyper-epidemic strain R20291 is extremely low, making 
generation of large insertion library in this strain infeasible.  Investigation of 
the use of mini-Tn10 as a random mutagen in C. difficile (Chapter 4) showed 
that this element does not lead to random insertions in C. difficile strains 
630!erm and R20291 in its present form.  Therefore, refinement of Tn916 by 
creation of a mini derivative may represent an alternative tool for 
mutagenesis, which could significantly increase the utility of this transposon 
and further our understanding of the molecular pathogenicity of C. difficile.  
As with other mini-transposons, the derivative will be a fraction of the size of 
the parent and can be engineered with a more flexible resistance marker to 
facilitate its use in a variety of strains.  The xis and int genes will be placed 
outside of the transposon ends to allow stable insertion and repeated rounds 
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of mutagenesis and to allow generation of a saturating insertion library if 
desired. Only the essential sequences required for transposition will be 
maintained, specifically the left and right end of Tn916 with a length of 
flanking sequence.  It is not clear how much sequence will be required for 
transposition.  However, this can be adjusted accordingly after assessment of 
the construct in C. difficile.  Likewise, a suitable resistance marker will be 
included in the construct to allow selection of transposon insertions.  This 
may also need to be exchanged, so in this work, consideration will be given 
to the ease with which this can be achieved. 
 
To ensure that minimal redundant sequence is included in the construct, the 
derivative will be made using splicing overlap extension PCR (SOEing PCR), 
a relatively simple and efficient method for generating gene constructs 395, 396.  
The mini-transposon will be placed downstream of the xis and int genes 
essential for excision, mobilisation and insertion.  The tet(M) gene with the 
tet(M) promoter (PtetM) will be placed upstream of the xis and int genes.  
Plasmid pMTL5401F used for delivery of mini-Tn10 has been shown to 
successfully conjugate with strains 630!erm and R20291; this construct was 
also unstable upon removal of antibiotic selection (see Chapter 4).  The 
plasmid carries appropriate genes for replication in the Gram-negative and 
Gram-positive host, two selectable markers and the lacZ reporter gene to 
allow blue/white selection during cloning.  This chapter describes the steps 
conducted to generate a mini-Tn916 derivative and a suitable delivery vector.  
Although this work is not complete it sets out a rationale for the generation of 
a potentially novel tool for random mutagenesis of C. difficile.  
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5.3. Aims and objectives 
 
The aim of this study is to generate a mini version of Tn916 and a suitable 
delivery vector for use as a potential mutagenesis tool in C. difficile. 
 
Objectives:  
1. Generate a mini-Tn916 using splicing by overlap extension (SOEing) 
PCR that includes a suitable resistance marker for strains 630!erm 
and R20291. 
2. Use stepwise cloning to create a plasmid to deliver the mini-Tn916 to 
C. difficile. 
3. Transfer the plasmid to CA434 to facilitate transfer to C. difficile strains 
630!erm and R20291 using filter mating. 
4. Test the construct in C. difficile and refine if necessary. 
5. Generate a library of transconjugants and screen them for mutations 
affecting cytotoxicity, sporulation/germination, bile and p-cresol 
tolerance. 
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5.4. Materials and methods 
5.4.1. Generation of mini-Tn916  
Three 1 Kb fragments of the left and right end of Tn916 from pAM120 (Figure 
5.1, Table 5.1) and the cat gene from mini-Tn10 in pHV1248 (Figure 4.4) 
were amplified by PCR independently using chimeric primers (Table 5.2).  
Each fragment was confirmed by gel electrophoresis (0.8% agarose) and 
extracted and purified as using a gel extraction kit (Qiagen, UK).  A two step 
SOEing PCR approach was used to generate the desired 3 Kb fragment – 
Initially fragment 2 (cat) and fragment 3 (Tn916 left end) were fused using 
PCR with primers CAT-1 and 916L-2 using a standard PCR reaction with 
addition of 17.5 mM MgCl2.  The resulting 2 Kb fragment was visualised on 
agarose gel before extraction and purification.  This 2 Kb fragment was 
joined by PCR to fragment 3 (Tn916 right end) using primer 916R-1 and 
916L-2 using standard PCR with addition of 17.5 mM MgCl2.  The resulting 3 
Kb fragment contained the cat gene flaked by the right and left end of Tn916 
(Figure 5.2).  The 3 Kb PCR fragment was visualised on agarose gel before 
extraction and purification.  The fragment was cloned into pCR2.1-TOPO to 
generate pCR2.1-TOPO::mini-Tn916.  Each 1 Kb fragment and the complete 
mini-Tn916 were sequenced by the department of Biochemistry, University of 
Cambridge, UK using an Applied Biosystems 3730xl DNA Analyzer, (96 
capillary array sequencer).
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Figure 5.1 Schematic diagram of pAM120 
pAM120 was used as template for the amplification of PtetM/tet(M) and the left and right 
end of Tn916.  The primer binding sites are indicated on the map.  
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Plasmid Marker Features Reference 
pAM120 tet(M) Tn916 Gawron-Burke & Clewell; 1984 232 
pHV1248 bla, cat, ermB mini-Tn10 Petit et al., 1990 197 
pMTL5401F bla, ermB  Heap et al., 2007 130 
pMTL85141 catP  Heap et al., 2009 392 
pCR2.1-TOPO  ApR & KanR Invitrogen 
pCR2.1-TOPO::tet(M) bla, tet(M)  This work 
pCR2.1-TOPO::xis/int bla  This work  
pCR2.1-TOPO::mini-Tn916 bla, cat mini-Tn916 This work  
pKLM1.1 bla, ermB, tet(M)  This work  
pKLM1.2 bla, ermB, tet(M)  This work  
pKLM916 bla, cat, ermB, tet(M) mini-Tn916 This work  
 
Marker gene  Resistance  Abbreviation 
bla Ampicillin Ap 
cat Chloramphenicol Cm 
catP Chloramphenicol  Cm 
ermB Erythromycin/ Lincomycin Em/Lm 
tet(M) Tetracycline Tc 
 
Table 5.1 Plasmids used in the study 
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Figure 5.2 Schematic representation of mini-Tn916. 
Mini-Tn916 is composed of three sections: 500 bp of the right and left end of Tn916 together with 500 bp of adjacent plasmid sequence 
from pAM120 flank the cat gene from pHV1248.  The primer binding sites are shown for the SOEing PCR fragments 
Key 
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 Primer Sequence Length  Feature 
SOEing PCR- Mini-Tn916     
916R-1 GACCGCGGGATAGAAGATGGACATAGC 27 SacII site at 5' end 
916R-2 CATTAGGGGATTCATCAGAAGCACCACCACAATATCATC 39 
CAT-1 GATATTGTGGTGGTGCTTCTGATGAATCCCCTAATG 36 
CAT -2 CTATATCCATCACTATATCCATCCGACTGTAAAAAGTAC 39 
916L-1 GTACTTTTTACAGTCGCGTGTTGAGATTGATGGATATAG 39 
Blue sequence = cat 
gene sequence 
916L-2 GACCCGGGCCTTATAGTTAGAAATGTAATC 30 XmaI site at 5' end 
tet(M) gene with RBS and PtetM     
TetM-1 CTCTCGAGGAAATCAATGAGTTTTTAACGAC 31 XhoI at 5' end 
TetM-2 CACTCGAGGCACTAGTCAACATAAAATACACTAAG 35 XhoI and SpeI at 5' end 
xis/int genes     
XI-1 CGACTAGTAAAGCTGTTCGATTGCTGG 27 SpeI site at 5' end 
XI-2 CATCTAGATATCCGCGGTCATTTGTACTACTAAGC 35 XbaI and SacII at 5' end 
 
Table 5.2 Primers for 
SOEing PCR and vector 
construction. 
The table lists the primer 
sequences used in construction 
of min-Tn916 and for cloning of 
the tet(M) and xis/int fragments. 
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Fragment 1 - Primers were designed to amplify approximately 500 bp of the 
right end of Tn916 along with 500bp of plasmid pAM120 to generate a 1 Kb 
fragment.  To facilitate cloning primer 916R-1 was designed with a SacII 
restriction site at the 5’-end.  The sequence of primer 916R-2 contains 18 bp 
of the cat gene and 21 bp of the right end of Tn916. 
 
Fragment 2 – Primers were designed to amplify the 1 Kb cat gene from 
pHV1248.  Primer CAT-1 contains 18 bp of the right end of Tn916 and 18 bp 
of the start of the cat gene.  Primer CAT-2 contains 22 bp of the left end of 
Tn916 and 16 bp of the start of the cat gene. 
 
Fragment 3 - Primers 916L-1 and 916L-2 were designed to amplify 
approximately 500 bp of the left end of Tn916 and 500bp of the plasmid 
pAM120 to generate a 1 Kb fragment.  The sequence of primer 916L-1 
contains 16 bp of the cat gene and 23 bp of the left end of Tn916.  To 
facilitate cloning a XmaI restriction site was included in primer 916L-2.  
 
PCR reactions were carried out using Taq DNA polymerase and standard 
buffer according to manufacturer’s instructions under the following conditions: 
[94oC 4 min] x 1 cycle, [94oC 30 sec, 50-60oC 1.5 min, 72oC 1-3 min] x 25-35 
cycles [72oC 10 min] x1, hold 4oC.  Annealing temperatures and extension 
times were adjusted according to the primer set and expected product length. 
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5.4.2. Gene cloning  
5.4.2.1. TOPO cloning 
After purification 3’ A overhangs were added to the PCR fragments mini-
Tn916, PtetM/tet(M) and xis/int.  Fragments were incubated with dATP and 0.5 
units Taq DNA polymerase in standard Taq buffer (New England Biolabs, 
UK) for 12 minutes at 72oC.  The fragments were ligated into the pCR2.1-
TOPO! vector according to the manufacturers protocol for chemically 
competent E. coli transformation (Invitrogen, UK). This led to generation of 
plasmids pCR2.1-TOPO::mini-Tn916, pCR2.1-TOPO::tet(M) and pCR2.1-
TOPO::xis/int. 
 
5.4.2.2. Transformations 
TOPO cloning: 2 !l of the TOPO cloning reaction was added to one vial of 
one-shot chemically competent TOP10 E. coli (Invitrogen, UK).  Cells were 
incubated for 5-10 minutes on ice and heat-shocked for 30 seconds at 42oC.  
Cells were immediately placed on ice before addition of 250 µl SOC medium 
(Invitrogen, UK) and incubated at 37oC with shaking (200 rpm).  Cells were 
spread on pre-warmed LB agar containing 50 µg ml-1 Ap and 40 mg ml-1 X-
gal and incubated for 15 hours at 37oC (both Sigma-Aldrich, UK). 
 
Chemical transformation: the ligation mixture was added to 50 µl of "-select 
chemically competent cells (Bioline, UK) thawed on ice.  Cells were 
incubated on ice for 45-60 min before heat shock at 42oC for 45 seconds and 
returned to ice for 2 minutes.  0.8 ml of pre-warmed SOC medium was added 
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and cultures were incubated at 37oC with shaking (200 rpm) for 1 hour.  Cells 
were spread on LB agar plates containing appropriate antibiotics before 
incubation at 37oC for 18 hours.   
a.  
5.4.2.3. Analysis of transformants 
After incubation 10-20 white colonies were selected for analysis.  Colonies 
were inoculated into 10 ml of LB broth containing 50 µg ml-1 Ap and 
incubated for 15 hours with shaking at 37oC.  Plasmids were extracted from 
each of the cultures using a Mini-prep kit and digested with EcoRI in standard 
buffer for 4 hours at 37oC.  Digested plasmid and an appropriate molecular 
weight marker were separated on a 0.8% agarose gel and stained with 
ethidium bromide to visualise the inserted fragments.  Plasmids that 
appeared to contain the correct insertion (based on size) were sent for 
sequencing (University of Cambridge).   
 
5.4.3. Generation of the tet(M) and xis/int fragments 
The tet(M) gene including the ribosome binding site and promoter region was 
PCR amplified from plasmid pAM120 using primers TetM-1 and TetM-2, the 
xis/int fragment was amplified from pAM120 using primers XI-1 and XI-2 
using the standard PCR conditions.  The fragments were separated on a 
0.8% agarose gel before extraction and purification.  3’ A overhangs were 
added by incubation of the fragment with dATP and 0.5 units Taq DNA 
polymerase in standard Taq buffer for 12 minutes at 72oC.  The fragments 
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were ligated into the TOPO vector and transformed into competent TOP10 E. 
coli as described above. 
 
5.4.4. Generation of plasmid pKLM1.1 (Figure 5.3) 
pMTL5401F and pCR2.1-TOPO::tet(M) (TOPO vector containing the tet(M) 
fragment) were digested with XhoI in appropriate buffer for 4 hours at 37oC.  
The pCR2.1-TOPO::tet(M) plasmid digest was separated on a 1% agarose 
gel and the desired 2.6 Kb fragment extracted and purified.  The digested 
plasmid and tet(M) fragment were ligated with T4 DNA ligase and ligase 
reaction buffer at 20-22oC for 16 hours (New England Biolabs, UK).  Ligated 
plasmids were transformed into competent !-select E. coli as described 
above.  Plasmids were selected on LB agar containing 100 !g ml-1 Ap and 40 
mg ml-1 X-gal, with incubation for 16 hours at 37oC.  20 colonies were picked 
and inoculated into LB broth containing 100 !g ml-1 Ap and incubated with 
shaking at 37oC for 6-8 hours.  Plasmids were extracted using a Mini-prep kit 
and digested with ApaLI to confirm the ligation of the PtetM/tet(M) fragment in 
the desired orientation. 
 
5.4.5. Generation of plasmid pKLM1.2 (Figure 5.4) 
pCR2.1-TOPO::xis/int (TOPO vector containing the xis/int fragment) and 
pKLM1.1 were digested with SpeI and XbaI for 4 hours at 37oC in an 
appropriate buffer.  Both digests were separated on an agarose gel and the 
desired fragments (xis/int ~1.5 Kb; pKLM1.1 ~10 Kb) were extracted and 
purified.  The xis/int fragment was ligated to linearised pKLM1.1 using T4 
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DNA ligase and ligase reaction buffer at 20-22oC for 16 hours.  The ligation 
mixture was transformed into competent !-select E. coli (Bioline, UK) and 
transformants selected on LB agar containing 100 !g ml-1 Ap and 40 mg ml-1 
X-gal.  20-100 colonies were inoculated in to LB broth containing 100 !g ml-1 
Ap and incubated with or without shaking at 37oC for 6-16 hours.  Plasmids 
were extracted using a Mini-prep kit and plasmids digested with XhoI and 
SacII to confirm the ligation. 
 
5.4.6. Generation of the plasmid pKLM916 (Figure 5.5) 
Plasmid pKLM1.2 was digested with SmaI at 25oC for 4 hours and pCR2.1-
TOPO::mini-Tn916 was digested with BsrBI for 4 hours at 37oC.  Digested 
plasmids were separated on agarose gel and the desired fragments 
extracted and purified (mini-Tn916 ~ 3 Kb; pKLM1.2 ~ 12 Kb).  The two 
fragments were ligated using T4 DNA ligase in T4 reaction buffer at 20-22oC 
for 16 hours.  The ligation mixture was transformed into competent !-select 
E. coli and transformants selected on LB agar containing 100 !g ml-1 Ap and 
40 mg ml-1 X-gal. 
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Figure 5.3 Schematic representation of pKLM1.1. 
pKLM1.1 is composed of the pMTL5401F backbone with insertion of 
the PtetM promoter and the tet(M) antibiotic resistance determinant 
Figure 5.4 Schematic representation of pKLM1.2 
pKLM1.2 is composed of the pKLM1.1 with the addition of the xis and 
int genes downstream of the PtetM promoter and tet(M). 
 
  
 
332 
 
 
 
 
 
 
 
Figure 5.5 Schematic representation of plasmid pKLM916. 
pKLM916 is composed of the pKLM1.2 with addition of mini-Tn916 downstream of 
the xis and int genes.  Confirmation of the structure of the construct was achieved 
through PCR and sequencing across the fragment joins. 
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5.4.7. Generation of mini-Tn916M 
Two approximately 1.2 Kb sections of pAM120 containing either the left or 
right end of Tn916 were amplified by primers 916L-3 & 916L-4 and 916R-3 & 
916R-4 respectively (Table 5.3) using standard PCR conditions described 
above except that Taq DNA polymerase and Taq buffer were replaced by 
Vent polymerase and buffer (New England Biolabs, UK) to increase fidelity.  
These fragments were used as template to amplify each of the two mini-
Tn916M sections – right and left end with primers 916M-1 and 916M-2 and 
916M-3 and 916M-4 respectively.  Primers 916M-1 and 916M-4 were used to 
SOE the two fragments together (template in equal ratio) to create a 2 Kb 
fragment (Figure 5.6).  The fragment was cloned into PCR2.1-
TOPO::Tn916M. 
 
Plasmid pMTL82141 was transformed into !-select competent E. coli and 
transformants were selected on LB agar supplemented with 25 µg ml-1 Cm.  
Plasmid was extracted using a Mini-prep kit 392.  pMTL85141 and pCR2.1-
TOPO::Tn916M were digested with FseI and PmeI.  The pMTL82141 digest 
was separated on agarose gel and the catP fragment extracted and purified.  
Linearised pCR2.1-TOPO::Tn916M and the catP fragment were ligated with 
T4 DNA ligase in ligase buffer at 20-22oC for 15 hours.  The ligation mixture 
was transformed into TOP10 competent E. coli, and transformants were 
selected on LB agar supplemented with 25 µg ml-1 Cm.  
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Primer Sequence 5' - 3' Length  Feature 
916L-3 GGTTGAAGAAGCCTATCAAG 20   
916L-4 CAAAGCGTACCGTTCAAG 18   
916R-3 GTACCTGCATTTCCATGG 18   
916R-4 GACGTAGAGCAGAGAATTTC 20   
916M-1 GATCTAGAGATAGAAGATGGACATAGC 27 XbaI 
916M-2 CTTTCGATTCGCTAACACTCGCGTTTAAACATATTGGCCGGCCGCCCTCTGCGGTAATACGTGG 64 PmeI & FseI 
916M-3 CCACGTATTACCGCAGAGGGCGGCCGGCCAATATGTTTAAACGCGAGTGTTAGCGAATCGAAAG 64 FseI & PmeI 
916M-4 GATCTAGAGCCTTATAGTTAGAAATGTAATC 31 XbaI 
 
 
Table 5.3 Primers used for generation of mini-Tn916M 
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Figure 5.6 Schematic representation of mini-Tn916M 
SOEing PCR was used to construct the mini-Tn916M transposon for use in pKLM1.2. 
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5.5. Results and discussion 
 
There is a clear need for a random mutagenesis system in C. difficile.  
Attempts to develop a mini-Tn10 based system failed to lead to demonstrable 
insertions in the genome of C. difficile strains 630!erm and R20291.  Thus, 
as Tn916 has been shown to insert into the genome of C. difficile at multiple 
sites, attention turned to the modification of Tn916 to generate a mini version 
termed mini-Tn916.  Like other transposons, Tn916 contains certain 
sequences that are essential to their function, while others perform more 
ancillary functions and can be considered non-essential.  Therefore it is 
possible to make a functional mini-transposon which is significantly smaller 
than the parent yet retains the ability to excise and insert into DNA.  
 
5.5.1. Design and construction of mini-Tn916 
A mini-Tn916 was designed to include a section of each end of Tn916, which 
are required to work with the xis and int genes to allow insertion and excision 
of the transposon.  Sequence from plasmid pAM120 flanking either side of 
Tn916 was also included to aid mobilisation of the transposon.  Initially 500 
bp of flanking and transposon sequence was chosen as this was believed to 
be a suitable length to maintain the small size of the construct and provide 
sufficient sequence for the actions of Xis and Int to promote transposition.  To 
allow selection of transconjugants containing mini-Tn916 insertions, the cat 
gene from mini-Tn10 was included in the initial construct.  Each fragment 
was independently generated before being used as template for SOEing 
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PCR.  Initially a one-step approach was used to generate the 3 Kb construct, 
this failed to generate the desired fragment although a faint product was 
observed in repeated reactions containing supplementary MgCl2 (Figure 5.7 
& Figure 5.8 lanes 1-4).  A PCR using this fragment as template also failed to 
generate a sufficient quantity of the desired fragment.  Modifications to 
optimise the PCR reaction such as changing the annealing temperature, 
changing the Mg2+ concentration and addition of DMSO failed to sufficiently 
improve the yield.  A two-step approach was then attempted to first ligate two 
fragments, either one and two, or two and three before addition of the final 
section.  Again various PCR reactions were performed to optimise the yield 
of the desired fragment.  Amplification of fragments two and three led to a 
high yield of the required 2 Kb fragment, whereas amplification of fragments 
one and two did not lead to generation of the ligated 2 Kb fragment (Figure 
5.8).  In general, addition of MgCl2 seems to have improved the stringency of 
the reactions leading to a greater predominance of the higher molecular 
weight products in the SOEing PCR reactions.  Mg2+ ions form a complex 
with the dNTPs and are required as a co-factor for Taq DNA polymerase 
stabilising the interaction of the primer with the template.  The fragment 
containing sections two and three was then ligated to the final section to 
generate mini-Tn916.  SOEing PCR reactions are known to be difficult to 
optimize and for these reactions an increase in Mg2+ ions and a two-step 
approach enabled successful formation of the chimeric fragment.   
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Figure 5.7 Generation of mini-
Tn916 using a 1-step SOEing 
PCR approach. 
All three fragments were used a template 
to generate the 3 Kb mini-Tn916 
transposon.  A 3 Kb was not amplified 
with a 1 Kb product predominating.  A 
faint 2 Kb product can also be seen.  PCR 
was carried out using standard conditions 
with a 3 minute extension time. 
Figure 5.8 Generation of mini-Tn916 using SOEing PCR in a 1-step and 
2-step approach  
SOEing PCR was performed with i) equal ratios of all three fragments in a 1-step reaction 
(lanes 1-4), ii) equal ratios of fragment 2 and 3 for step 1 in a 2-step approach (lanes 5-8) 
and iii) equal ratios of fragment 1 and 2 for step 1 in a 2-step approach (lanes 9-12).  For 
each group 4 reactions were performed with varying MgCl concentration, either 1.5 mM 
(lane 1, 5 & 9), 2.5 mM (lane 2, 6 & 10), 5 mM (lane 3, 7 & 11) or 7.5 mM (lane 4, 8 & 12).  
M = 1 Kb ladder.  PCR was performed using standard conditions with an extension time of 3 
minutes for reaction i and 2 minutes for reactions ii and iii.  The 1-step reaction failed to 
produce the desired 3 Kb product in reactions 1, 2 & 4, however a 3 Kb product is seen for 
reaction 3 (lane 3).  In the 2-step approach a 2 Kb product is seen for all 4 reactions with 
fragment 2 and 3 as template, for reaction 3 the desired 2 Kb fragment is not specifically 
amplified using fragments 1 and 2 as template, although a faint band is seen in lanes 11 & 
12 the 1 Kb fragments predominates. 
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5.5.2. Design and generation of mini-Tn916M 
The inclusion of the cat gene in the initial construct was based on concurrent 
work with mini-Tn10.  This gene was shown to be a useful marker in C. 
difficile however, difficulties were encountered during selection in E. coli.  
Additionally, a publication from Heap et al. (2009) described the generation of 
a series of plasmids based on a four unit module construction to allow 
generation of a range of shuttle plasmids for use in C. difficile 392.  This 
helped to form an alternative design for mini-Tn916 where the antibiotic 
resistance cassette could be exchanged simply and quickly.  Mini-Tn916M 
was made in a similar manner to mini-Tn916 using SOEing PCR, however 
this construct was made with two sections, the left and right end of Tn916, 
but contained two unique restriction sites in the centre.  The relatively rare 
restriction sites PmeI and FseI are used in the pMTL80000 modular plasmid 
series to allow exchange of the antibiotic resistance genes (Figure 5.6).  
Thus, inclusion of these sites means that any of the resistance genes 
including catP (chloramphenicol/thiamphenicol), aad9 (spectinomycin), tetA 
(tetracycline) and ermB (erythromycin) can be included in the mini-Tn916M 
through a simple digestion and ligation reaction.  Samples of these plasmids 
were obtained and initially the catP gene was cloned.  catP appears to be 
superior to cat and has been included in the modular plasmids and in the 
ClosTron plasmids 392.  Unfortunately, due to time constraints construction of 
mini-Tn916M was not completed. 
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5.5.3. Design and construction of the delivery plasmid 
The initial design of mini-Tn916 was based on the assumption that this would 
be delivered on a modified version of pMTL5401F, previously used as the 
vector for delivery of mini-Tn10.  This appeared to be a suitable delivery 
plasmid as it contained the relevant features for replication in E. coli and C. 
difficile, a selectable marker, transfer genes to allow mobilisation of the 
plasmid from E. coli during mating and an unstable replicon, to facilitate loss 
of the delivery plasmid after transposition of the element. 
 
In addition to the features present on pMTL5401F, a sufficiently strong 
promoter was required to allow expression of the xis and int genes to 
mobilise mini-Tn916.  PtetM has been shown to be functional and de-
repressible in C. difficile, the tet(M) gene also offered a secondary means of 
selection and therefore both elements were included in the design.  Finally, 
the xis and int genes were placed downstream of the PtetM promoter, as int is 
essential for integration and xis enhances excision of mini-Tn916.  Restriction 
enzyme cleavage sites were placed into the primer sequences to facilitate 
cloning of these sections to generate the plasmids pKLM1.1 and pKLM1.2 
(Figure 5.4 & Figure 5.3).  This was relatively straightforward although a large 
number of transformant colonies had to be screened to isolate pKLM1.2.  
Confirmation of the constructs was achieved through restriction digestion and 
sequencing.   
 
Unfortunately, problems were encountered when attempts were made to 
clone the mini-Tn916 section into pKLM1.2.  Digestion of pKLM1.2 with the 
restriction enzyme SacII, chosen as this was not found in pMTL5401F or the 
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PtetM/tet(M) and xis/int fragment sequence, generated two fragments.  The 
sequence of pMTL5401F was provided with the plasmid from the Minton 
Laboratory (University of Nottingham, UK).  The sequence did not contain a 
SacII site however this site was present in the plasmid, confirmed through 
restriction digestion.  This meant that this enzyme could not be used to clone 
in the mini-Tn916 fragment.  Initially several attempts were made to blunt the 
SacII-cut end of the mini-Tn916 fragment from pCR2.1-TOPO::Tn916 using 
mung bean nuclease.  This would have allowed blunt-ended ligation of the 
fragment into a SmaI site present in pKLM1.2.  This failed to generate the 
desired construct.  Investigation of the sequence of pKLM1.2 and pCR2.1-
TOPO::Tn916 revealed that enzyme BsrBI could be used to allow blunt-
ended ligation into the pKLM1.2 vector.  Unfortunately, due to time 
constraints generation of pKLM1.3 was not completed and verified, and 
therefore no experiments were performed in C. difficile. 
 
When designing the primers for mini-Tn916M the exterior primers were 
generated with an XbaI site rather than a SacII site.  Although this would 
mean that the fragment could insert in either direction, the plasmid constructs 
could easily be screened for this insertion through restriction analysis.  
Additionally, the choice of suitable restriction sites was limited due to the 
sites present on the plasmid backbone and the mini-Tn916 fragment.  
Unfortunately, due to time constraints this section of cloning was not 
completed, the final construct made was plasmid pKLM1.2 (Figure 5.3), this 
can be further developed to allow delivery of the element into C. difficile.   
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5.6. Conclusions 
 
The initial design of the mini-Tn916 element was based on information 
present at the time.  Molecular tools for the investigation of C. difficile are 
continually developing and expanding and, as such, the design of both the 
element and the delivery vector evolved quite rapidly during the relatively 
slow cloning procedures.   
 
The major development for this idea will be to adapt the restriction sites at 
the end of the mini-Tn916 element and the PtetM/tet(M) fragment for use with 
the pMTL80000 modular system 392.  This system was designed to facilitate 
easy cloning in Clostridia without the need to redesign plasmids for each 
cloning experiment.  The modules allow the user to insert the appropriate 
sections for each specific project.  In the case of this project, these would 
include a Gram-negative replicon (ColE1), a Gram-positive replicon (RepH 
from pCB102), a multiple cloning site (MCS), an ermB gene for selection and 
tra genes to mediate transfer of the plasmid from the donor to recipient cell.  
All of these features are available on the plasmids in this series and can be 
easily cloned to generate the desired vector.  The MCS would then allow 
insertion of the three sections – PtetM/tet(M), xis/int and mini-Tn916, 
potentially as a single fragment.  After construction this could then be tested 
in a range of C. difficile strains to assess whether mini-Tn916 is functional 
and to characterise its behaviour.  Unfortunately, time contains prevented 
completion of this project.  However, it represents a potentially useful 
mutagenesis system for C. difficile.  
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6.  General conclusions 
 
The investigation of the molecular pathogenicity of C. difficile has been 
severely hindered by the lack of available tools.  Prior to the commencement 
of this thesis tools for the random mutagenesis of C. difficile were not 
available.  Introduction of DNA is only possible through conjugative transfer, 
demonstrated by the use of conjugative transposons such as Tn916 and 
using E. coli-Clostridium shuttle plasmids.  Previous investigation of the 
behaviour of Tn916 in strain CD37 and 630!erm found that insertion occurs 
at a specific hot spot in the former strain, and apparently at random in the 
latter strain.   This thesis describes the generation of a Tn916 insertion library 
in the epidemic strain R20291 and investigation of the insertion sites of this 
conjugative transposon in this strain and in 630!erm.  Sequencing of the 
insertion sites revealed that Tn916 inserts into an AT rich 15 bp sequence.  
This motif is found predominantly in intergenic regions of the genome of 
strain 630 leading to an insertion bias of this element into these regions.  
Insertion of Tn916 into the genome of the epidemic strain R20291 was also 
found to occur predominantly in intergenic regions.  This insertion bias limits 
the use of this transposon as a random mutagen in these C. difficile strains, 
however, it has the potential to be used to gain a further understanding of 
these poorly described regions of the genome. 
 
The R20291::Tn916 insertion library was screened using four assays to 
identify defects in the ability of the bacterium to cause cytotoxicity, tolerate 
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bile and p-cresol, and in its ability to sporulate/germinate due to insertion of 
the transposon.  Although no non-wild type phenotypes were observed this 
library is available for further scrutiny with a variety as biological assays to 
elucidate upon the molecular pathogenesis of C. difficile. 
 
The bile screening assays suggest that R20291 is inherently more tolerant to 
high concentrations of bile than 630!erm.  It was found that low 
concentrations of bile were more inhibitory than medium to high levels for 
both strains, which may be due to the inability of low bile levels to elicited the 
protective response(s) utilised by the bacterium.  This was supported by data 
showing that pre-exposure of cultures to bile could enhance the growth of 
cultures in bile containing broth.  However, bile is reported to act as a 
germinant for C. difficile spores and it is not known whether this can account 
for the increased growth observed after pre-exposure.  Thus this study could 
be further developed to gain a better understanding of the tolerance of C. 
difficile to bile and the effects of pre-exposure on vegetative cells and spores 
independently.   
 
To investigate the mechanisms involved in the tolerance of, and response to 
bile shock, the transcription profile of 630!erm grown in several bile 
concentrations was examined.  The results of these experiments did not 
show significant changes in gene expression in bile exposed cultures 
compared to non-exposed cultures.  Reducing the statistical stringency for 
one of these experiments produced a list of genes whose expression was 
altered between these two conditions.  Interestingly, genes associated with 
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stress responses failed to show significant changes in expression.  As these 
changes would have been expected, it may suggest that the parameters of 
the experiment were not optimal; therefore optimisation of the exposure 
duration and bile concentration are required.  Significant differences were 
observed between R20291 and 630!erm’s ability to tolerate high bile levels 
therefore, one could carry out similar expression analysis using an R20291 
microarray.  These data could provide potential insights into the stress 
response, specific bile tolerance mechanisms and the germination process of 
C. difficile, which can be further investigated by gene knockout studies.  
 
The lack of tools available for the random mutagenesis of C. difficile 
prompted the development of novel tools to generate insertion libraries.  A 
vector has been developed to allow the delivery of mini-Tn10 to various C. 
difficile strains.  It was possible, with low efficiency, to conjugate this vector 
into strain R20921 and 630!erm, however transposition of mini-Tn10 was not 
demonstrated.  Several possible reasons for this outcome have been 
suggested including problems with expression of the transposase, a lack of 
activity of the transposase in C. difficile, sub-optimal selection of 
transconjugants or a low frequency transposition.  Unfortunately, the precise 
reason for the apparent lack of transposition events has not been determined 
and requires further investigation. 
 
A second transposon-based tool has also been partially constructed with a 
mini derivative of Tn916, mini-Tn916.  The identification of an insertion bias 
of Tn916 limits the usefulness of this transposon, however, a mini-version 
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may prove easier to manipulate and introduce into C. difficile.  Importantly, 
preferential insertion into intergenic regions would facilitate investigation of 
these poorly described regions, potentially providing useful information about 
gene regulation and genome architecture.   
 
The recent description of a mariner-based random mutagenesis tool for C. 
difficile should not detract from the need to develop further tools for the 
random mutagenesis of C. difficile.  The availability of multiple tools will 
facilitate comprehensive investigation of the molecular genetics of this 
important pathogen.  
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9. Appendix 
9.1. Statistical analysis of extended range bile assay  
Kruskal-Wallis test  
P value < 0.0001 
Exact or approximate P value? 
Gaussian 
Approximation 
P value summary **** 
Do the medians vary significantly     
(P < 0.05) Yes 
Number of groups 29 
Kruskal-Wallis statistic 208.3 
 
Dunn's Multiple 
Comparison 
Test 
Difference 
in rank sum 
Significant? 
P < 0.05? Summary 
0 vs 0.1% 51.82 No ns 
0 vs 0.3% 232.9 Yes *** 
0 vs 0.5% 224.9 Yes *** 
0 vs 0.8% 204.3 Yes *** 
0 vs 1.0% 185.7 Yes *** 
0 vs 1.3% 185.8 Yes *** 
0 vs 1.5% 154.5 Yes ** 
0 vs 2.0% 124.9 Yes * 
0 vs 2.5% 110.9 No ns 
0 vs 3.0% 94.71 No ns 
0 vs 3.5% 106.2 No ns 
0 vs 4.0% 83.04 No ns 
0 vs 4.5% 87.1 No ns 
0 vs 5.0% 75.21 No ns 
0 vs 5.5% 68.43 No ns 
0 vs 6.0% 73.04 No ns 
0 vs 6.5% 74.24 No ns 
0 vs 7.0% 81.6 No ns 
0 vs 7.5% 113.7 No ns 
0 vs 8.0% 165.3 Yes *** 
0 vs 8.5% 150.3 Yes ** 
0 vs 9.0% 122.9 Yes * 
0 vs 9.5% 146 Yes ** 
0 vs 10.0% 180.8 Yes *** 
0 vs 10.5% 180 Yes *** 
0 vs 11.0% 223.7 Yes *** 
0 vs 11.5% 203.1 Yes *** 
0 vs 12.0% 240.9 Yes *** 
0.1% vs 0.3% 181.1 Yes ** 
0.1% vs 0.5% 173.1 Yes ** 
0.1% vs 0.8% 152.5 Yes * 
0.1% vs 1.0% 133.9 No ns 
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0.1% vs 1.3% 134 No ns 
0.1% vs 1.5% 102.7 No ns 
0.1% vs 2.0% 73.06 No ns 
0.1% vs 2.5% 59.06 No ns 
0.1% vs 3.0% 42.89 No ns 
0.1% vs 3.5% 54.39 No ns 
0.1% vs 4.0% 31.22 No ns 
0.1% vs 4.5% 35.28 No ns 
0.1% vs 5.0% 23.39 No ns 
0.1% vs 5.5% 16.61 No ns 
0.1% vs 6.0% 21.22 No ns 
0.1% vs 6.5% 22.42 No ns 
0.1% vs 7.0% 29.78 No ns 
0.1% vs 7.5% 61.83 No ns 
0.1% vs 8.0% 113.5 No ns 
0.1% vs 8.5% 98.44 No ns 
0.1% vs 9.0% 71.06 No ns 
0.1% vs 9.5% 94.22 No ns 
0.1% vs 10.0% 129 No ns 
0.1% vs 10.5% 128.2 No ns 
0.1% vs 11.0% 171.8 Yes ** 
0.1% vs 11.5% 151.3 Yes * 
0.1% vs 12.0% 189.1 Yes ** 
0.3% vs 0.5% -8 No ns 
0.3% vs 0.8% -28.61 No ns 
0.3% vs 1.0% -47.22 No ns 
0.3% vs 1.3% -47.11 No ns 
0.3% vs 1.5% -78.39 No ns 
0.3% vs 2.0% -108.1 No ns 
0.3% vs 2.5% -122.1 No ns 
0.3% vs 3.0% -138.2 No ns 
0.3% vs 3.5% -126.7 No ns 
0.3% vs 4.0% -149.9 No ns 
0.3% vs 4.5% -145.8 No ns 
0.3% vs 5.0% -157.7 Yes * 
0.3% vs 5.5% -164.5 Yes * 
0.3% vs 6.0% -159.9 Yes * 
0.3% vs 6.5% -158.7 Yes * 
0.3% vs 7.0% -151.3 Yes * 
0.3% vs 7.5% -119.3 No ns 
0.3% vs 8.0% -67.61 No ns 
0.3% vs 8.5% -82.67 No ns 
0.3% vs 9.0% -110.1 No ns 
0.3% vs 9.5% -86.89 No ns 
0.3% vs 10.0% -52.11 No ns 
0.3% vs 10.5% -52.89 No ns 
0.3% vs 11.0% -9.278 No ns 
0.3% vs 11.5% -29.83 No ns 
0.3% vs 12.0% 8 No ns 
0.5% vs 0.8% -20.61 No ns 
0.5% vs 1.0% -39.22 No ns 
0.5% vs 1.3% -39.11 No ns 
0.5% vs 1.5% -70.39 No ns 
0.5% vs 2.0% -100.1 No ns 
0.5% vs 2.5% -114.1 No ns 
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0.5% vs 3.0% -130.2 No ns 
0.5% vs 3.5% -118.7 No ns 
0.5% vs 4.0% -141.9 No ns 
0.5% vs 4.5% -137.8 No ns 
0.5% vs 5.0% -149.7 No ns 
0.5% vs 5.5% -156.5 Yes * 
0.5% vs 6.0% -151.9 Yes * 
0.5% vs 6.5% -150.7 No ns 
0.5% vs 7.0% -143.3 No ns 
0.5% vs 7.5% -111.3 No ns 
0.5% vs 8.0% -59.61 No ns 
0.5% vs 8.5% -74.67 No ns 
0.5% vs 9.0% -102.1 No ns 
0.5% vs 9.5% -78.89 No ns 
0.5% vs 10.0% -44.11 No ns 
0.5% vs 10.5% -44.89 No ns 
0.5% vs 11.0% -1.278 No ns 
0.5% vs 11.5% -21.83 No ns 
0.5% vs 12.0% 16 No ns 
0.8% vs 1.0% -18.61 No ns 
0.8% vs 1.3% -18.5 No ns 
0.8% vs 1.5% -49.78 No ns 
0.8% vs 2.0% -79.44 No ns 
0.8% vs 2.5% -93.44 No ns 
0.8% vs 3.0% -109.6 No ns 
0.8% vs 3.5% -98.11 No ns 
0.8% vs 4.0% -121.3 No ns 
0.8% vs 4.5% -117.2 No ns 
0.8% vs 5.0% -129.1 No ns 
0.8% vs 5.5% -135.9 No ns 
0.8% vs 6.0% -131.3 No ns 
0.8% vs 6.5% -130.1 No ns 
0.8% vs 7.0% -122.7 No ns 
0.8% vs 7.5% -90.67 No ns 
0.8% vs 8.0% -39 No ns 
0.8% vs 8.5% -54.06 No ns 
0.8% vs 9.0% -81.44 No ns 
0.8% vs 9.5% -58.28 No ns 
0.8% vs 10.0% -23.5 No ns 
0.8% vs 10.5% -24.28 No ns 
0.8% vs 11.0% 19.33 No ns 
0.8% vs 11.5% -1.222 No ns 
0.8% vs 12.0% 36.61 No ns 
1.0% vs 1.3% 0.1111 No ns 
1.0% vs 1.5% -31.17 No ns 
1.0% vs 2.0% -60.83 No ns 
1.0% vs 2.5% -74.83 No ns 
1.0% vs 3.0% -91 No ns 
1.0% vs 3.5% -79.5 No ns 
1.0% vs 4.0% -102.7 No ns 
1.0% vs 4.5% -98.61 No ns 
1.0% vs 5.0% -110.5 No ns 
1.0% vs 5.5% -117.3 No ns 
1.0% vs 6.0% -112.7 No ns 
1.0% vs 6.5% -111.5 No ns 
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1.0% vs 7.0% -104.1 No ns 
1.0% vs 7.5% -72.06 No ns 
1.0% vs 8.0% -20.39 No ns 
1.0% vs 8.5% -35.44 No ns 
1.0% vs 9.0% -62.83 No ns 
1.0% vs 9.5% -39.67 No ns 
1.0% vs 10.0% -4.889 No ns 
1.0% vs 10.5% -5.667 No ns 
1.0% vs 11.0% 37.94 No ns 
1.0% vs 11.5% 17.39 No ns 
1.0% vs 12.0% 55.22 No ns 
1.3% vs 1.5% -31.28 No ns 
1.3% vs 2.0% -60.94 No ns 
1.3% vs 2.5% -74.94 No ns 
1.3% vs 3.0% -91.11 No ns 
1.3% vs 3.5% -79.61 No ns 
1.3% vs 4.0% -102.8 No ns 
1.3% vs 4.5% -98.72 No ns 
1.3% vs 5.0% -110.6 No ns 
1.3% vs 5.5% -117.4 No ns 
1.3% vs 6.0% -112.8 No ns 
1.3% vs 6.5% -111.6 No ns 
1.3% vs 7.0% -104.2 No ns 
1.3% vs 7.5% -72.17 No ns 
1.3% vs 8.0% -20.5 No ns 
1.3% vs 8.5% -35.56 No ns 
1.3% vs 9.0% -62.94 No ns 
1.3% vs 9.5% -39.78 No ns 
1.3% vs 10.0% -5 No ns 
1.3% vs 10.5% -5.778 No ns 
1.3% vs 11.0% 37.83 No ns 
1.3% vs 11.5% 17.28 No ns 
1.3% vs 12.0% 55.11 No ns 
1.5% vs 2.0% -29.67 No ns 
1.5% vs 2.5% -43.67 No ns 
1.5% vs 3.0% -59.83 No ns 
1.5% vs 3.5% -48.33 No ns 
1.5% vs 4.0% -71.5 No ns 
1.5% vs 4.5% -67.44 No ns 
1.5% vs 5.0% -79.33 No ns 
1.5% vs 5.5% -86.11 No ns 
1.5% vs 6.0% -81.5 No ns 
1.5% vs 6.5% -80.31 No ns 
1.5% vs 7.0% -72.94 No ns 
1.5% vs 7.5% -40.89 No ns 
1.5% vs 8.0% 10.78 No ns 
1.5% vs 8.5% -4.278 No ns 
1.5% vs 9.0% -31.67 No ns 
1.5% vs 9.5% -8.5 No ns 
1.5% vs 10.0% 26.28 No ns 
1.5% vs 10.5% 25.5 No ns 
1.5% vs 11.0% 69.11 No ns 
1.5% vs 11.5% 48.56 No ns 
1.5% vs 12.0% 86.39 No ns 
2.0% vs 2.5% -14 No ns 
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2.0% vs 3.0% -30.17 No ns 
2.0% vs 3.5% -18.67 No ns 
2.0% vs 4.0% -41.83 No ns 
2.0% vs 4.5% -37.78 No ns 
2.0% vs 5.0% -49.67 No ns 
2.0% vs 5.5% -56.44 No ns 
2.0% vs 6.0% -51.83 No ns 
2.0% vs 6.5% -50.64 No ns 
2.0% vs 7.0% -43.28 No ns 
2.0% vs 7.5% -11.22 No ns 
2.0% vs 8.0% 40.44 No ns 
2.0% vs 8.5% 25.39 No ns 
2.0% vs 9.0% -2 No ns 
2.0% vs 9.5% 21.17 No ns 
2.0% vs 10.0% 55.94 No ns 
2.0% vs 10.5% 55.17 No ns 
2.0% vs 11.0% 98.78 No ns 
2.0% vs 11.5% 78.22 No ns 
2.0% vs 12.0% 116.1 No ns 
2.5% vs 3.0% -16.17 No ns 
2.5% vs 3.5% -4.667 No ns 
2.5% vs 4.0% -27.83 No ns 
2.5% vs 4.5% -23.78 No ns 
2.5% vs 5.0% -35.67 No ns 
2.5% vs 5.5% -42.44 No ns 
2.5% vs 6.0% -37.83 No ns 
2.5% vs 6.5% -36.64 No ns 
2.5% vs 7.0% -29.28 No ns 
2.5% vs 7.5% 2.778 No ns 
2.5% vs 8.0% 54.44 No ns 
2.5% vs 8.5% 39.39 No ns 
2.5% vs 9.0% 12 No ns 
2.5% vs 9.5% 35.17 No ns 
2.5% vs 10.0% 69.94 No ns 
2.5% vs 10.5% 69.17 No ns 
2.5% vs 11.0% 112.8 No ns 
2.5% vs 11.5% 92.22 No ns 
2.5% vs 12.0% 130.1 No ns 
3.0% vs 3.5% 11.5 No ns 
3.0% vs 4.0% -11.67 No ns 
3.0% vs 4.5% -7.611 No ns 
3.0% vs 5.0% -19.5 No ns 
3.0% vs 5.5% -26.28 No ns 
3.0% vs 6.0% -21.67 No ns 
3.0% vs 6.5% -20.47 No ns 
3.0% vs 7.0% -13.11 No ns 
3.0% vs 7.5% 18.94 No ns 
3.0% vs 8.0% 70.61 No ns 
3.0% vs 8.5% 55.56 No ns 
3.0% vs 9.0% 28.17 No ns 
3.0% vs 9.5% 51.33 No ns 
3.0% vs 10.0% 86.11 No ns 
3.0% vs 10.5% 85.33 No ns 
3.0% vs 11.0% 128.9 No ns 
3.0% vs 11.5% 108.4 No ns 
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3.0% vs 12.0% 146.2 No ns 
3.5% vs 4.0% -23.17 No ns 
3.5% vs 4.5% -19.11 No ns 
3.5% vs 5.0% -31 No ns 
3.5% vs 5.5% -37.78 No ns 
3.5% vs 6.0% -33.17 No ns 
3.5% vs 6.5% -31.97 No ns 
3.5% vs 7.0% -24.61 No ns 
3.5% vs 7.5% 7.444 No ns 
3.5% vs 8.0% 59.11 No ns 
3.5% vs 8.5% 44.06 No ns 
3.5% vs 9.0% 16.67 No ns 
3.5% vs 9.5% 39.83 No ns 
3.5% vs 10.0% 74.61 No ns 
3.5% vs 10.5% 73.83 No ns 
3.5% vs 11.0% 117.4 No ns 
3.5% vs 11.5% 96.89 No ns 
3.5% vs 12.0% 134.7 No ns 
4.0% vs 4.5% 4.056 No ns 
4.0% vs 5.0% -7.833 No ns 
4.0% vs 5.5% -14.61 No ns 
4.0% vs 6.0% -10 No ns 
4.0% vs 6.5% -8.806 No ns 
4.0% vs 7.0% -1.444 No ns 
4.0% vs 7.5% 30.61 No ns 
4.0% vs 8.0% 82.28 No ns 
4.0% vs 8.5% 67.22 No ns 
4.0% vs 9.0% 39.83 No ns 
4.0% vs 9.5% 63 No ns 
4.0% vs 10.0% 97.78 No ns 
4.0% vs 10.5% 97 No ns 
4.0% vs 11.0% 140.6 No ns 
4.0% vs 11.5% 120.1 No ns 
4.0% vs 12.0% 157.9 Yes * 
4.5% vs 5.0% -11.89 No ns 
4.5% vs 5.5% -18.67 No ns 
4.5% vs 6.0% -14.06 No ns 
4.5% vs 6.5% -12.86 No ns 
4.5% vs 7.0% -5.5 No ns 
4.5% vs 7.5% 26.56 No ns 
4.5% vs 8.0% 78.22 No ns 
4.5% vs 8.5% 63.17 No ns 
4.5% vs 9.0% 35.78 No ns 
4.5% vs 9.5% 58.94 No ns 
4.5% vs 10.0% 93.72 No ns 
4.5% vs 10.5% 92.94 No ns 
4.5% vs 11.0% 136.6 No ns 
4.5% vs 11.5% 116 No ns 
4.5% vs 12.0% 153.8 Yes * 
5.0% vs 5.5% -6.778 No ns 
5.0% vs 6.0% -2.167 No ns 
5.0% vs 6.5% -0.9722 No ns 
5.0% vs 7.0% 6.389 No ns 
5.0% vs 7.5% 38.44 No ns 
5.0% vs 8.0% 90.11 No ns 
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5.0% vs 8.5% 75.06 No ns 
5.0% vs 9.0% 47.67 No ns 
5.0% vs 9.5% 70.83 No ns 
5.0% vs 10.0% 105.6 No ns 
5.0% vs 10.5% 104.8 No ns 
5.0% vs 11.0% 148.4 No ns 
5.0% vs 11.5% 127.9 No ns 
5.0% vs 12.0% 165.7 Yes ** 
5.5% vs 6.0% 4.611 No ns 
5.5% vs 6.5% 5.806 No ns 
5.5% vs 7.0% 13.17 No ns 
5.5% vs 7.5% 45.22 No ns 
5.5% vs 8.0% 96.89 No ns 
5.5% vs 8.5% 81.83 No ns 
5.5% vs 9.0% 54.44 No ns 
5.5% vs 9.5% 77.61 No ns 
5.5% vs 10.0% 112.4 No ns 
5.5% vs 10.5% 111.6 No ns 
5.5% vs 11.0% 155.2 Yes * 
5.5% vs 11.5% 134.7 No ns 
5.5% vs 12.0% 172.5 Yes ** 
6.0% vs 6.5% 1.194 No ns 
6.0% vs 7.0% 8.556 No ns 
6.0% vs 7.5% 40.61 No ns 
6.0% vs 8.0% 92.28 No ns 
6.0% vs 8.5% 77.22 No ns 
6.0% vs 9.0% 49.83 No ns 
6.0% vs 9.5% 73 No ns 
6.0% vs 10.0% 107.8 No ns 
6.0% vs 10.5% 107 No ns 
6.0% vs 11.0% 150.6 Yes * 
6.0% vs 11.5% 130.1 No ns 
6.0% vs 12.0% 167.9 Yes ** 
6.5% vs 7.0% 7.361 No ns 
6.5% vs 7.5% 39.42 No ns 
6.5% vs 8.0% 91.08 No ns 
6.5% vs 8.5% 76.03 No ns 
6.5% vs 9.0% 48.64 No ns 
6.5% vs 9.5% 71.81 No ns 
6.5% vs 10.0% 106.6 No ns 
6.5% vs 10.5% 105.8 No ns 
6.5% vs 11.0% 149.4 No ns 
6.5% vs 11.5% 128.9 No ns 
6.5% vs 12.0% 166.7 Yes * 
7.0% vs 7.5% 32.06 No ns 
7.0% vs 8.0% 83.72 No ns 
7.0% vs 8.5% 68.67 No ns 
7.0% vs 9.0% 41.28 No ns 
7.0% vs 9.5% 64.44 No ns 
7.0% vs 10.0% 99.22 No ns 
7.0% vs 10.5% 98.44 No ns 
7.0% vs 11.0% 142.1 No ns 
7.0% vs 11.5% 121.5 No ns 
7.0% vs 12.0% 159.3 Yes * 
7.5% vs 8.0% 51.67 No ns 
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7.5% vs 8.5% 36.61 No ns 
7.5% vs 9.0% 9.222 No ns 
7.5% vs 9.5% 32.39 No ns 
7.5% vs 10.0% 67.17 No ns 
7.5% vs 10.5% 66.39 No ns 
7.5% vs 11.0% 110 No ns 
7.5% vs 11.5% 89.44 No ns 
7.5% vs 12.0% 127.3 No ns 
8.0% vs 8.5% -15.06 No ns 
8.0% vs 9.0% -42.44 No ns 
8.0% vs 9.5% -19.28 No ns 
8.0% vs 10.0% 15.5 No ns 
8.0% vs 10.5% 14.72 No ns 
8.0% vs 11.0% 58.33 No ns 
8.0% vs 11.5% 37.78 No ns 
8.0% vs 12.0% 75.61 No ns 
8.5% vs 9.0% -27.39 No ns 
8.5% vs 9.5% -4.222 No ns 
8.5% vs 10.0% 30.56 No ns 
8.5% vs 10.5% 29.78 No ns 
8.5% vs 11.0% 73.39 No ns 
8.5% vs 11.5% 52.83 No ns 
8.5% vs 12.0% 90.67 No ns 
9.0% vs 9.5% 23.17 No ns 
9.0% vs 10.0% 57.94 No ns 
9.0% vs 10.5% 57.17 No ns 
9.0% vs 11.0% 100.8 No ns 
9.0% vs 11.5% 80.22 No ns 
9.0% vs 12.0% 118.1 No ns 
9.5% vs 10.0% 34.78 No ns 
9.5% vs 10.5% 34 No ns 
9.5% vs 11.0% 77.61 No ns 
9.5% vs 11.5% 57.06 No ns 
9.5% vs 12.0% 94.89 No ns 
10.0% vs 10.5% -0.7778 No ns 
10.0% vs 11.0% 42.83 No ns 
10.0% vs 11.5% 22.28 No ns 
10.0% vs 12.0% 60.11 No ns 
10.5% vs 11.0% 43.61 No ns 
10.5% vs 11.5% 23.06 No ns 
10.5% vs 12.0% 60.89 No ns 
11.0% vs 11.5% -20.56 No ns 
11.0% vs 12.0% 17.28 No ns 
11.5% vs 12.0% 37.83 No ns 
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Table Analyzed 
Extended range 
630deltaerm 
  
Kruskal-Wallis test  
P value < 0.0001 
Exact or approximate P value? Gaussian Approximation 
P value summary **** 
Do the medians vary significantly 
(P < 0.05) Yes 
Number of groups 29 
Kruskal-Wallis statistic 242.7 
 
Dunn's Multiple 
Comparison 
Test 
Difference 
in rank 
sum 
Significant? 
P < 0.05? Summary 
0 vs 0.1% 23.78 No ns 
0 vs 0.3% 208.9 Yes *** 
0 vs 0.5% 155.8 Yes *** 
0 vs 0.8% 135.3 Yes ** 
0 vs 1.0% 124.7 Yes * 
0 vs 1.3% 81.54 No ns 
0 vs 1.5% 67.93 No ns 
0 vs 2.0% 38.6 No ns 
0 vs 2.5% 48.72 No ns 
0 vs 3.0% 53.93 No ns 
0 vs 3.5% 75.03 No ns 
0 vs 4.0% 84.43 No ns 
0 vs 4.5% 100.4 No ns 
0 vs 5.0% 83.99 No ns 
0 vs 5.5% 127.2 Yes * 
0 vs 6.0% 141 Yes ** 
0 vs 6.5% 160.8 Yes *** 
0 vs 7.0% 159.5 Yes *** 
0 vs 7.5% 182 Yes *** 
0 vs 8.0% 184.5 Yes *** 
0 vs 8.5% 177.8 Yes *** 
0 vs 9.0% 203.4 Yes *** 
0 vs 9.5% 210.7 Yes *** 
0 vs 10.0% 226 Yes *** 
0 vs 10.5% 219.7 Yes *** 
0 vs 11.0% 227.7 Yes *** 
0 vs 11.5% 219.5 Yes *** 
0 vs 12.0% 225.2 Yes *** 
0.1% vs 0.3% 185.2 Yes ** 
0.1% vs 0.5% 132 No ns 
0.1% vs 0.8% 111.5 No ns 
0.1% vs 1.0% 100.9 No ns 
0.1% vs 1.3% 57.76 No ns 
0.1% vs 1.5% 44.15 No ns 
0.1% vs 2.0% 14.82 No ns 
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0.1% vs 2.5% 24.94 No ns 
0.1% vs 3.0% 30.15 No ns 
0.1% vs 3.5% 51.25 No ns 
0.1% vs 4.0% 60.65 No ns 
0.1% vs 4.5% 76.6 No ns 
0.1% vs 5.0% 60.21 No ns 
0.1% vs 5.5% 103.4 No ns 
0.1% vs 6.0% 117.3 No ns 
0.1% vs 6.5% 137 No ns 
0.1% vs 7.0% 135.7 No ns 
0.1% vs 7.5% 158.3 Yes * 
0.1% vs 8.0% 160.7 Yes * 
0.1% vs 8.5% 154 Yes * 
0.1% vs 9.0% 179.7 Yes ** 
0.1% vs 9.5% 186.9 Yes ** 
0.1% vs 10.0% 202.2 Yes *** 
0.1% vs 10.5% 195.9 Yes ** 
0.1% vs 11.0% 203.9 Yes *** 
0.1% vs 11.5% 195.8 Yes ** 
0.1% vs 12.0% 201.4 Yes *** 
0.3% vs 0.5% -53.17 No ns 
0.3% vs 0.8% -73.61 No ns 
0.3% vs 1.0% -84.28 No ns 
0.3% vs 1.3% -127.4 No ns 
0.3% vs 1.5% -141 No ns 
0.3% vs 2.0% -170.3 Yes ** 
0.3% vs 2.5% -160.2 Yes * 
0.3% vs 3.0% -155 Yes * 
0.3% vs 3.5% -133.9 No ns 
0.3% vs 4.0% -124.5 No ns 
0.3% vs 4.5% -108.6 No ns 
0.3% vs 5.0% -124.9 No ns 
0.3% vs 5.5% -81.78 No ns 
0.3% vs 6.0% -67.89 No ns 
0.3% vs 6.5% -48.11 No ns 
0.3% vs 7.0% -49.44 No ns 
0.3% vs 7.5% -26.89 No ns 
0.3% vs 8.0% -24.44 No ns 
0.3% vs 8.5% -31.17 No ns 
0.3% vs 9.0% -5.5 No ns 
0.3% vs 9.5% 1.722 No ns 
0.3% vs 10.0% 17.06 No ns 
0.3% vs 10.5% 10.78 No ns 
0.3% vs 11.0% 18.72 No ns 
0.3% vs 11.5% 10.61 No ns 
0.3% vs 12.0% 16.22 No ns 
0.5% vs 0.8% -20.44 No ns 
0.5% vs 1.0% -31.11 No ns 
0.5% vs 1.3% -74.22 No ns 
0.5% vs 1.5% -87.83 No ns 
0.5% vs 2.0% -117.2 No ns 
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0.5% vs 2.5% -107 No ns 
0.5% vs 3.0% -101.8 No ns 
0.5% vs 3.5% -80.74 No ns 
0.5% vs 4.0% -71.33 No ns 
0.5% vs 4.5% -55.39 No ns 
0.5% vs 5.0% -71.78 No ns 
0.5% vs 5.5% -28.61 No ns 
0.5% vs 6.0% -14.72 No ns 
0.5% vs 6.5% 5.056 No ns 
0.5% vs 7.0% 3.722 No ns 
0.5% vs 7.5% 26.28 No ns 
0.5% vs 8.0% 28.72 No ns 
0.5% vs 8.5% 22 No ns 
0.5% vs 9.0% 47.67 No ns 
0.5% vs 9.5% 54.89 No ns 
0.5% vs 10.0% 70.22 No ns 
0.5% vs 10.5% 63.94 No ns 
0.5% vs 11.0% 71.89 No ns 
0.5% vs 11.5% 63.78 No ns 
0.5% vs 12.0% 69.39 No ns 
0.8% vs 1.0% -10.67 No ns 
0.8% vs 1.3% -53.78 No ns 
0.8% vs 1.5% -67.39 No ns 
0.8% vs 2.0% -96.72 No ns 
0.8% vs 2.5% -86.6 No ns 
0.8% vs 3.0% -81.39 No ns 
0.8% vs 3.5% -60.29 No ns 
0.8% vs 4.0% -50.89 No ns 
0.8% vs 4.5% -34.94 No ns 
0.8% vs 5.0% -51.33 No ns 
0.8% vs 5.5% -8.167 No ns 
0.8% vs 6.0% 5.722 No ns 
0.8% vs 6.5% 25.5 No ns 
0.8% vs 7.0% 24.17 No ns 
0.8% vs 7.5% 46.72 No ns 
0.8% vs 8.0% 49.17 No ns 
0.8% vs 8.5% 42.44 No ns 
0.8% vs 9.0% 68.11 No ns 
0.8% vs 9.5% 75.33 No ns 
0.8% vs 10.0% 90.67 No ns 
0.8% vs 10.5% 84.39 No ns 
0.8% vs 11.0% 92.33 No ns 
0.8% vs 11.5% 84.22 No ns 
0.8% vs 12.0% 89.83 No ns 
1.0% vs 1.3% -43.11 No ns 
1.0% vs 1.5% -56.72 No ns 
1.0% vs 2.0% -86.06 No ns 
1.0% vs 2.5% -75.94 No ns 
1.0% vs 3.0% -70.72 No ns 
1.0% vs 3.5% -49.63 No ns 
1.0% vs 4.0% -40.22 No ns 
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1.0% vs 4.5% -24.28 No ns 
1.0% vs 5.0% -40.67 No ns 
1.0% vs 5.5% 2.5 No ns 
1.0% vs 6.0% 16.39 No ns 
1.0% vs 6.5% 36.17 No ns 
1.0% vs 7.0% 34.83 No ns 
1.0% vs 7.5% 57.39 No ns 
1.0% vs 8.0% 59.83 No ns 
1.0% vs 8.5% 53.11 No ns 
1.0% vs 9.0% 78.78 No ns 
1.0% vs 9.5% 86 No ns 
1.0% vs 10.0% 101.3 No ns 
1.0% vs 10.5% 95.06 No ns 
1.0% vs 11.0% 103 No ns 
1.0% vs 11.5% 94.89 No ns 
1.0% vs 12.0% 100.5 No ns 
1.3% vs 1.5% -13.61 No ns 
1.3% vs 2.0% -42.94 No ns 
1.3% vs 2.5% -32.83 No ns 
1.3% vs 3.0% -27.61 No ns 
1.3% vs 3.5% -6.514 No ns 
1.3% vs 4.0% 2.889 No ns 
1.3% vs 4.5% 18.83 No ns 
1.3% vs 5.0% 2.444 No ns 
1.3% vs 5.5% 45.61 No ns 
1.3% vs 6.0% 59.5 No ns 
1.3% vs 6.5% 79.28 No ns 
1.3% vs 7.0% 77.94 No ns 
1.3% vs 7.5% 100.5 No ns 
1.3% vs 8.0% 102.9 No ns 
1.3% vs 8.5% 96.22 No ns 
1.3% vs 9.0% 121.9 No ns 
1.3% vs 9.5% 129.1 No ns 
1.3% vs 10.0% 144.4 No ns 
1.3% vs 10.5% 138.2 No ns 
1.3% vs 11.0% 146.1 No ns 
1.3% vs 11.5% 138 No ns 
1.3% vs 12.0% 143.6 No ns 
1.5% vs 2.0% -29.33 No ns 
1.5% vs 2.5% -19.22 No ns 
1.5% vs 3.0% -14 No ns 
1.5% vs 3.5% 7.097 No ns 
1.5% vs 4.0% 16.5 No ns 
1.5% vs 4.5% 32.44 No ns 
1.5% vs 5.0% 16.06 No ns 
1.5% vs 5.5% 59.22 No ns 
1.5% vs 6.0% 73.11 No ns 
1.5% vs 6.5% 92.89 No ns 
1.5% vs 7.0% 91.56 No ns 
1.5% vs 7.5% 114.1 No ns 
1.5% vs 8.0% 116.6 No ns 
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1.5% vs 8.5% 109.8 No ns 
1.5% vs 9.0% 135.5 No ns 
1.5% vs 9.5% 142.7 No ns 
1.5% vs 10.0% 158.1 Yes * 
1.5% vs 10.5% 151.8 Yes * 
1.5% vs 11.0% 159.7 Yes * 
1.5% vs 11.5% 151.6 Yes * 
1.5% vs 12.0% 157.2 Yes * 
2.0% vs 2.5% 10.12 No ns 
2.0% vs 3.0% 15.33 No ns 
2.0% vs 3.5% 36.43 No ns 
2.0% vs 4.0% 45.83 No ns 
2.0% vs 4.5% 61.78 No ns 
2.0% vs 5.0% 45.39 No ns 
2.0% vs 5.5% 88.56 No ns 
2.0% vs 6.0% 102.4 No ns 
2.0% vs 6.5% 122.2 No ns 
2.0% vs 7.0% 120.9 No ns 
2.0% vs 7.5% 143.4 No ns 
2.0% vs 8.0% 145.9 No ns 
2.0% vs 8.5% 139.2 No ns 
2.0% vs 9.0% 164.8 Yes ** 
2.0% vs 9.5% 172.1 Yes ** 
2.0% vs 10.0% 187.4 Yes ** 
2.0% vs 10.5% 181.1 Yes ** 
2.0% vs 11.0% 189.1 Yes ** 
2.0% vs 11.5% 180.9 Yes ** 
2.0% vs 12.0% 186.6 Yes ** 
2.5% vs 3.0% 5.215 No ns 
2.5% vs 3.5% 26.31 No ns 
2.5% vs 4.0% 35.72 No ns 
2.5% vs 4.5% 51.66 No ns 
2.5% vs 5.0% 35.27 No ns 
2.5% vs 5.5% 78.44 No ns 
2.5% vs 6.0% 92.33 No ns 
2.5% vs 6.5% 112.1 No ns 
2.5% vs 7.0% 110.8 No ns 
2.5% vs 7.5% 133.3 No ns 
2.5% vs 8.0% 135.8 No ns 
2.5% vs 8.5% 129 No ns 
2.5% vs 9.0% 154.7 Yes * 
2.5% vs 9.5% 161.9 Yes * 
2.5% vs 10.0% 177.3 Yes ** 
2.5% vs 10.5% 171 Yes ** 
2.5% vs 11.0% 178.9 Yes ** 
2.5% vs 11.5% 170.8 Yes ** 
2.5% vs 12.0% 176.4 Yes ** 
3.0% vs 3.5% 21.1 No ns 
3.0% vs 4.0% 30.5 No ns 
3.0% vs 4.5% 46.44 No ns 
3.0% vs 5.0% 30.06 No ns 
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3.0% vs 5.5% 73.22 No ns 
3.0% vs 6.0% 87.11 No ns 
3.0% vs 6.5% 106.9 No ns 
3.0% vs 7.0% 105.6 No ns 
3.0% vs 7.5% 128.1 No ns 
3.0% vs 8.0% 130.6 No ns 
3.0% vs 8.5% 123.8 No ns 
3.0% vs 9.0% 149.5 Yes * 
3.0% vs 9.5% 156.7 Yes * 
3.0% vs 10.0% 172.1 Yes ** 
3.0% vs 10.5% 165.8 Yes ** 
3.0% vs 11.0% 173.7 Yes ** 
3.0% vs 11.5% 165.6 Yes ** 
3.0% vs 12.0% 171.2 Yes ** 
3.5% vs 4.0% 9.403 No ns 
3.5% vs 4.5% 25.35 No ns 
3.5% vs 5.0% 8.958 No ns 
3.5% vs 5.5% 52.13 No ns 
3.5% vs 6.0% 66.01 No ns 
3.5% vs 6.5% 85.79 No ns 
3.5% vs 7.0% 84.46 No ns 
3.5% vs 7.5% 107 No ns 
3.5% vs 8.0% 109.5 No ns 
3.5% vs 8.5% 102.7 No ns 
3.5% vs 9.0% 128.4 No ns 
3.5% vs 9.5% 135.6 No ns 
3.5% vs 10.0% 151 No ns 
3.5% vs 10.5% 144.7 No ns 
3.5% vs 11.0% 152.6 No ns 
3.5% vs 11.5% 144.5 No ns 
3.5% vs 12.0% 150.1 No ns 
4.0% vs 4.5% 15.94 No ns 
4.0% vs 5.0% -0.4444 No ns 
4.0% vs 5.5% 42.72 No ns 
4.0% vs 6.0% 56.61 No ns 
4.0% vs 6.5% 76.39 No ns 
4.0% vs 7.0% 75.06 No ns 
4.0% vs 7.5% 97.61 No ns 
4.0% vs 8.0% 100.1 No ns 
4.0% vs 8.5% 93.33 No ns 
4.0% vs 9.0% 119 No ns 
4.0% vs 9.5% 126.2 No ns 
4.0% vs 10.0% 141.6 No ns 
4.0% vs 10.5% 135.3 No ns 
4.0% vs 11.0% 143.2 No ns 
4.0% vs 11.5% 135.1 No ns 
4.0% vs 12.0% 140.7 No ns 
4.5% vs 5.0% -16.39 No ns 
4.5% vs 5.5% 26.78 No ns 
4.5% vs 6.0% 40.67 No ns 
4.5% vs 6.5% 60.44 No ns 
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4.5% vs 7.0% 59.11 No ns 
4.5% vs 7.5% 81.67 No ns 
4.5% vs 8.0% 84.11 No ns 
4.5% vs 8.5% 77.39 No ns 
4.5% vs 9.0% 103.1 No ns 
4.5% vs 9.5% 110.3 No ns 
4.5% vs 10.0% 125.6 No ns 
4.5% vs 10.5% 119.3 No ns 
4.5% vs 11.0% 127.3 No ns 
4.5% vs 11.5% 119.2 No ns 
4.5% vs 12.0% 124.8 No ns 
5.0% vs 5.5% 43.17 No ns 
5.0% vs 6.0% 57.06 No ns 
5.0% vs 6.5% 76.83 No ns 
5.0% vs 7.0% 75.5 No ns 
5.0% vs 7.5% 98.06 No ns 
5.0% vs 8.0% 100.5 No ns 
5.0% vs 8.5% 93.78 No ns 
5.0% vs 9.0% 119.4 No ns 
5.0% vs 9.5% 126.7 No ns 
5.0% vs 10.0% 142 No ns 
5.0% vs 10.5% 135.7 No ns 
5.0% vs 11.0% 143.7 No ns 
5.0% vs 11.5% 135.6 No ns 
5.0% vs 12.0% 141.2 No ns 
5.5% vs 6.0% 13.89 No ns 
5.5% vs 6.5% 33.67 No ns 
5.5% vs 7.0% 32.33 No ns 
5.5% vs 7.5% 54.89 No ns 
5.5% vs 8.0% 57.33 No ns 
5.5% vs 8.5% 50.61 No ns 
5.5% vs 9.0% 76.28 No ns 
5.5% vs 9.5% 83.5 No ns 
5.5% vs 10.0% 98.83 No ns 
5.5% vs 10.5% 92.56 No ns 
5.5% vs 11.0% 100.5 No ns 
5.5% vs 11.5% 92.39 No ns 
5.5% vs 12.0% 98 No ns 
6.0% vs 6.5% 19.78 No ns 
6.0% vs 7.0% 18.44 No ns 
6.0% vs 7.5% 41 No ns 
6.0% vs 8.0% 43.44 No ns 
6.0% vs 8.5% 36.72 No ns 
6.0% vs 9.0% 62.39 No ns 
6.0% vs 9.5% 69.61 No ns 
6.0% vs 10.0% 84.94 No ns 
6.0% vs 10.5% 78.67 No ns 
6.0% vs 11.0% 86.61 No ns 
6.0% vs 11.5% 78.5 No ns 
6.0% vs 12.0% 84.11 No ns 
6.5% vs 7.0% -1.333 No ns 
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6.5% vs 7.5% 21.22 No ns 
6.5% vs 8.0% 23.67 No ns 
6.5% vs 8.5% 16.94 No ns 
6.5% vs 9.0% 42.61 No ns 
6.5% vs 9.5% 49.83 No ns 
6.5% vs 10.0% 65.17 No ns 
6.5% vs 10.5% 58.89 No ns 
6.5% vs 11.0% 66.83 No ns 
6.5% vs 11.5% 58.72 No ns 
6.5% vs 12.0% 64.33 No ns 
7.0% vs 7.5% 22.56 No ns 
7.0% vs 8.0% 25 No ns 
7.0% vs 8.5% 18.28 No ns 
7.0% vs 9.0% 43.94 No ns 
7.0% vs 9.5% 51.17 No ns 
7.0% vs 10.0% 66.5 No ns 
7.0% vs 10.5% 60.22 No ns 
7.0% vs 11.0% 68.17 No ns 
7.0% vs 11.5% 60.06 No ns 
7.0% vs 12.0% 65.67 No ns 
7.5% vs 8.0% 2.444 No ns 
7.5% vs 8.5% -4.278 No ns 
7.5% vs 9.0% 21.39 No ns 
7.5% vs 9.5% 28.61 No ns 
7.5% vs 10.0% 43.94 No ns 
7.5% vs 10.5% 37.67 No ns 
7.5% vs 11.0% 45.61 No ns 
7.5% vs 11.5% 37.5 No ns 
7.5% vs 12.0% 43.11 No ns 
8.0% vs 8.5% -6.722 No ns 
8.0% vs 9.0% 18.94 No ns 
8.0% vs 9.5% 26.17 No ns 
8.0% vs 10.0% 41.5 No ns 
8.0% vs 10.5% 35.22 No ns 
8.0% vs 11.0% 43.17 No ns 
8.0% vs 11.5% 35.06 No ns 
8.0% vs 12.0% 40.67 No ns 
8.5% vs 9.0% 25.67 No ns 
8.5% vs 9.5% 32.89 No ns 
8.5% vs 10.0% 48.22 No ns 
8.5% vs 10.5% 41.94 No ns 
8.5% vs 11.0% 49.89 No ns 
8.5% vs 11.5% 41.78 No ns 
8.5% vs 12.0% 47.39 No ns 
9.0% vs 9.5% 7.222 No ns 
9.0% vs 10.0% 22.56 No ns 
9.0% vs 10.5% 16.28 No ns 
9.0% vs 11.0% 24.22 No ns 
9.0% vs 11.5% 16.11 No ns 
9.0% vs 12.0% 21.72 No ns 
9.5% vs 10.0% 15.33 No ns 
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9.5% vs 10.5% 9.056 No ns 
9.5% vs 11.0% 17 No ns 
9.5% vs 11.5% 8.889 No ns 
9.5% vs 12.0% 14.5 No ns 
10.0% vs 10.5% -6.278 No ns 
10.0% vs 11.0% 1.667 No ns 
10.0% vs 11.5% -6.444 No ns 
10.0% vs 12.0% -0.8333 No ns 
10.5% vs 11.0% 7.944 No ns 
10.5% vs 11.5% -0.1667 No ns 
10.5% vs 12.0% 5.444 No ns 
11.0% vs 11.5% -8.111 No ns 
11.0% vs 12.0% -2.5 No ns 
11.5% vs 12.0% 5.611 No ns 
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9.2. Raw transcriptomics data  
Test 0.1% p=0.05          
Kat's Bile MAVI 
Norm          
 Control Test  
 0.10% 0.10%  
Systematic ID Normalized t-test P-value Raw Control 
Fold 
change 
t-test P 
value    Test  Control Product 
Cd630-0067 (1K9) 1.1 0.468 5445 4820 1.9 0.004 5143 2848 DNA-directed RNA polymerase beta' chain 
Cd630-0070 (1N9) 1.0 0.667 1716 1724 1.5 0.011 1129 757 translation elongation factor G 
Cd630-0087 (1O11) 1.1 0.557 7738 7123 2.0 0.027 8265 4252 50S ribosomal protein L18 
Cd630-0092 (1L12) 1.1 0.592 3800 3323 2.4 0.000 3901 1567 methionine aminopeptidase 
Cd630-0096 (1P12) 1.1 0.562 96705 77653 1.5 0.048 89662 60882 30S ribosomal protein S11 
Cd630-0126 (2F16) 1.0 0.991 791 810 0.7 0.011 538 729 stage III sporulation protein D 
Cd630-0138 (2B18) 1.5 0.398 82 34 3.2 0.020 58 18 conserved hypothetical protein 
Cd630-0140 (2D18) 0.8 0.572 372 397 0.6 0.029 128 207 putative peptidase 
Cd630-0144 (2H18) 1.1 0.619 1659 1573 1.4 0.036 1257 927 peptide chain release factor 2 
Cd630-0166 (2F21) 1.2 0.539 126 100 2.3 0.012 105 47 putative amidohydrolase/peptidase 
Cd630-0180 (2D23) 0.9 0.722 104 99 0.6 0.038 57 94 hypothetical protein 
Cd630-0181 (2E23) 0.9 0.575 825 848 0.3 0.019 259 727 putative membrane-associated metalloprotease 
Cd630-0184 (2H23) 1.0 0.991 546 513 0.4 0.042 189 351 aspartate carbamoyltransferase catalytic chain 
Cd630-0186 (2B24) 1.0 0.890 7181 7131 0.6 0.006 3987 6558 dihydroorotate dehydrogenase, catalytic subunit 
Cd630-0188 (2D24) 0.9 0.403 1413 1506 0.5 0.012 656 1142 putative ketopantoate reductase 
Cd630-0201 (4A2) 1.0 0.885 1121 1118 0.7 0.040 450 620 putative chromate transporter 
Cd630-0202 (4B2) 1.0 0.675 886 855 0.8 0.049 335 439 conserved hypothetical protein 
Cd630-0215 (4G3) 0.9 0.728 650 664 0.4 0.020 175 375 transposase 
Cd630-0217 (4A4) 1.1 0.754 981 850 0.5 0.044 319 581 putative nitroreductase 
Cd630-0219 (4C4) 0.8 0.463 916 1012 0.5 0.027 325 652 phosphoribosylaminoimidazole-succinocarboxamide synthase 
Cd630-0230 (4F5) 1.0 0.638 4033 3950 0.6 0.050 1928 2841 putative flagellar biosynthesis protein 
Cd630-0235 (4C6) 1.0 0.925 12046 11954 0.8 0.009 7540 9354 flagellar protein FliS 
Cd630-0241 (4A7) 1.0 0.933 12746 12360 0.7 0.023 6565 9128 phosphoserine phosphatase 
Cd630-0247 (4G7) 1.0 0.909 8943 9004 0.5 0.023 4709 7647 flagellar hook-basal body complex protein 
Cd630-0251 (4C8) 1.0 0.713 49203 51295 0.6 0.015 33109 50395 flagellum-specific ATP synthase 
Cd630-0253 (4E8) 1.0 0.937 15899 15870 0.5 0.049 7828 13067 putative flagellar hook-length control protein 
Cd630-0254 (4F8) 1.0 0.661 22850 23297 0.6 0.048 13141 20850 putative basal-body rod modification protein 
Cd630-0256 (4H8) 1.0 0.697 28011 28251 0.6 0.043 15376 24126 chemotaxis protein 
Cd630-0295 (2G1) 1.0 0.874 66 64 3.8 0.025 76 21 putative iron-sulfur-binding protein 
  
 
391 
Cd630-0332 (2D6) 0.9 0.432 1523 1663 0.6 0.026 802 1308 putative exosporium glycoprotein 
Cd630-0334 (2F6) 1.1 0.611 2007 1973 1.5 0.008 1934 1283 
aldehyde-alcohol dehydrogenase [includes: alcohol dehydrogenase; 
acetaldehyde dehydrogenase [acetylating]; pyruvate-formate-lyase 
deactivase 
Cd630-0335 (2G6) 0.5 0.663 25 28 0.4 0.009 19 51 hypothetical protein 
Cd630-0356 (2D9) 1.0 0.574 1156 1105 1.3 0.009 1026 779 excisionase 
Cd630-0382 (2F12) 1.1 0.724 43 38 3.3 0.014 73 22 hypothetical protein 
Cd630-0397 (2M2) 1.1 0.612 24574 21243 1.2 0.011 18251 14933 R-phenyllactate dehydratase medium subunit 
Cd630-0406 (2N3) 1.0 0.775 1995 2152 1.3 0.041 1345 1046 putative tRNA (Uracil-5-)-methyltransferase 
Cd630-0407 (2O3) 1.5 0.368 92 59 4.4 0.038 86 25 hypothetical protein 
Cd630-0409 (2I4) 1.0 0.921 479 475 0.6 0.043 194 306 putative replication initiation protein 
Cd630-0447 (2P8) 0.9 0.659 571 578 0.5 0.018 258 472 methylaspartate mutase 
Cd630-0460 
(2M10) 0.8 0.473 577 676 0.6 0.033 215 319 ABC transporter, permease protein 
Cd630-0467 (2L11) 0.9 0.672 228 247 0.7 0.022 83 124 putative hydrolase 
Cd630-0482 (1C1) 1.2 0.644 54 43 3.3 0.015 92 25 putative lantibiotic resistance two-component sensor kinase 
Cd630-0491 (1D2) 1.1 0.742 44 41 4.8 0.046 154 31 PTS system, IIa component 
Cd630-0494 (1G2) 0.9 0.843 46 41 2.5 0.048 41 16 PTS system, IId component 
Cd630-0515 (1E5) 0.7 0.385 1542 2278 0.4 0.001 444 1056 D-alanyl-D-alanine carboxypeptidase 
Cd630-0516 (1F5) 1.7 0.525 70 28 7.0 0.015 70 10 putative transcription antiterminator 
Cd630-0524 (1F6) 1.0 0.868 2079 2046 0.7 0.037 1051 1401 putative peptidase 
Cd630-0525 (1G6) 1.0 0.701 3785 3824 0.7 0.029 2490 3434 putative aminobenzoyl-glutamate transporter (pseudogene) 
Cd630-0533 (1G7) 0.9 0.477 617 655 0.3 0.032 215 512 chemotaxis protein 
Cd630-0535 (1A8) 0.9 0.684 892 939 0.2 0.034 251 886 chemotaxis protein 
Cd630-0539 (1E8) 1.0 0.808 3599 3638 0.4 0.045 1702 3419 chemotaxis protein 
Cd630-0541 (1G8) 1.0 0.858 1134 1098 0.3 0.028 289 681 chemotaxis protein methyltransferase 
Cd630-0542 (1H8) 1.0 0.610 2109 2157 0.5 0.022 1072 1857 putative chemotaxis-related protein-glutamate methylesterase 
Cd630-0588 (2N14) 0.6 0.433 307 403 0.4 0.042 144 310 hypothetical protein 
Cd630-0592 (2J15) 1.3 0.514 102 63 3.6 0.004 137 38 putative membrane protein 
Cd630-0638 (2N20) 1.0 0.954 45 41 3.9 0.040 67 20 hypothetical protein 
Cd630-0644 (2L21) 0.9 0.839 158 169 0.7 0.018 77 116 two-component sensor histidine kinase 
Cd630-0663g (3B1) 1.0 0.430 13200 12889 1.2 0.027 8309 7127 toxin A 
Cd630-0666 (3F1) 1.0 0.655 8029 7853 1.2 0.029 5129 4436 putative lantibiotic ABC transporter, peremase protein 
Cd630-0670 (3B2) 1.0 0.735 4531 4597 1.6 0.002 3285 2050 putative regulatory protein 
Cd630-0707 (3G6) 1.0 0.990 2724 2794 0.7 0.019 1240 1701 putative signaling protein 
Cd630-0716 (3H7) 0.9 0.434 8394 8927 0.7 0.016 5628 7676 putative bifunctional carbon monoxide dehydrogenase/acetyl-CoA synthase 
Cd630-0777 (1E15) 1.0 0.807 69 73 0.5 0.045 31 59 putative membrane protein 
Cd630-0779 (1G15) 1.0 0.944 740 719 0.6 0.004 251 456 putative amidohydrolase 
Cd630-0791 (1C17) 1.4 0.464 69 54 6.7 0.018 98 14 conserved hypothetical protein 
Cd630-0799 (1C18) 1.1 0.784 40 35 8.1 0.015 194 15 putative CoA-transferase 
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Cd630-0802 (1F18) 1.0 0.872 622 591 0.6 0.012 156 283 putative CoA-transferase 
Cd630-0809 (1E19) 1.0 0.528 1109 1087 0.7 0.034 367 524 conserved hypothetical protein 
Cd630-0815 (1C20) 1.2 0.722 50 42 5.7 0.019 85 18 probable transporter 
Cd630-0820 (1H20) 1.0 0.868 806 776 1.4 0.043 751 512 two-component response regulator 
Cd630-0839 (1C23) 1.0 0.901 233 258 0.8 0.002 263 314 putative membrane-associated CAAX amino terminal protease 
Cd630-0846 (1B24) 1.1 0.439 222 189 1.4 0.036 170 122 hypothetical protein 
Cd630-0868 (3P2) 1.1 0.427 3828 3424 1.4 0.042 2268 1652 conserved hypothetical protein 
Cd630-0875 (3O3) 1.0 0.389 15567 16470 0.9 0.008 9035 10436 ABC transporter, permease protein 
Cd630-0891 (3O5) 0.9 0.576 4594 4973 0.8 0.045 2354 3087 putative agmatinase 
Cd630-0907 (3O7) 1.0 0.977 110 107 1.5 0.045 97 65 putative phage regulatory protein 
Cd630-0917 (3I9) 1.1 0.633 20 20 3.5 0.048 41 11 putative phage recombination protein 
Cd630-0930 (3N10) 0.9 0.404 397 423 0.6 0.025 143 229 phage protein 
Cd630-0939 (3O11) 1.1 0.416 3676 3453 1.4 0.017 3121 2260 hypothetical phage protein 
Cd630-0963 (4O14) 1.1 0.667 261 192 1.6 0.030 185 107 phage protein 
Cd630-0964 (4P14) 0.9 0.499 1002 1057 0.7 0.041 602 818 phage protein 
Cd630-0967 (4K15) 0.9 0.551 813 875 0.6 0.012 436 666 hypothetical phage protein 
Cd630-0974 (4J16) 2.2 0.429 147 74 4.4 0.020 203 39 hypothetical phage protein 
Cd630-0991 (4K18) 1.0 0.669 550 568 0.7 0.049 212 304 3-isopropylmalate dehydratase small subunit 
Cd630-1009 
(4M20) 0.9 0.838 1426 1492 1.6 0.008 1140 728 GntR-family transcriptional regulator 
Cd630-1017 
(4M21) 1.3 0.539 249 139 1.8 0.047 132 76 putative ABC transporter, permease/ATP-binding protein 
Cd630-1019 (4O21) 1.1 0.517 41 39 4.9 0.045 69 16 conserved hypothetical protein 
Cd630-1036b 
(4J24) 1.1 0.533 379 314 0.6 0.047 177 317 putative cell surface N-acetylmuramoyl-L-alanine amidase 
Cd630-1039 
(4M24) 0.3 0.641 53 279 0.1 0.027 31 554 conserved hypothetical protein 
Cd630-1054 (4D14) 0.8 0.434 376 505 0.4 0.037 235 505 butyryl-CoA dehydrogenase 
Cd630-1064 (4F15) 0.9 0.673 518 579 0.8 0.040 416 523 LacI-family transcriptional regulator (catabolite control protein) 
Cd630-1094 (4D19) 0.8 0.457 58 70 2.1 0.017 122 54 conjugative transposon protein 
Cd630-1107 (4A21) 1.1 0.906 16 6 9.2 0.004 35 4 putative membrane protein 
Cd630-1110 (4D21) 2.8 0.548 423 23 2.5 0.027 73 25 putative conjugal transfer protein 
Cd630-1138 (4H24) 1.0 0.854 21421 20221 0.8 0.031 14316 17773 electron transport complex protein 
Cd630-1147 (3A14) 1.0 0.980 9599 9565 0.8 0.017 4786 5944 putative membrane protein 
Cd630-1168 (3F16) 0.9 0.507 552 586 0.8 0.002 365 482 putative membrane protein 
Cd630-1175 (3E17) 1.0 0.418 25067 25787 1.2 0.016 15614 13459 acetate kinase 
Cd630-1176 (3F17) 1.1 0.619 18563 17833 1.4 0.006 13079 9516 conserved hypothetical protein 
Cd630-1185 (3G18) 1.1 0.572 2044 1836 1.6 0.045 1596 1026 putative signaling protein 
Cd630-1191 (3E19) 1.0 0.762 6370 6278 1.5 0.004 3779 2523 putative fructose-1,6-bisphosphatase 
Cd630-1211 (3A22) 0.9 0.488 2725 2849 0.8 0.004 1362 1747 putative acetyltransferase 
Cd630-1219 (3A23) 0.9 0.530 6867 7126 0.6 0.018 3189 5049 conserved hypothetical protein 
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Cd630-1222 (3D23) 1.0 0.576 5129 5348 0.5 0.043 2639 4417 putative tyrosine recombinase 
Cd630-1249 (3P14) 1.0 0.916 571 528 0.7 0.032 234 344 radical SAM-superfamily protein 
Cd630-1253 (3L15) 0.8 0.399 1620 2028 0.5 0.042 783 1450 30S ribosomal protein S16 
Cd630-1257 (3P15) 1.0 0.684 3417 3457 0.7 0.028 1662 2486 50S ribosomal protein L19 
Cd630-1258 (3I16) 1.0 0.624 1628 1656 0.6 0.040 789 1229 putative GTPase 
Cd630-1261 (3L16) 1.0 0.842 7150 6786 0.8 0.031 4455 5477 putative ribonucleotide-diphosphate reductase 
Cd630-1271 (3N17) 0.9 0.523 5807 6353 1.4 0.034 3832 2720 conserved hypothetical protein 
Cd630-1305 (3P21) 1.1 0.672 16633 14732 1.7 0.024 15287 9464 DNA polymerase III PolC-type 
Cd630-1318 
(3M23) 1.0 0.715 11338 10793 0.8 0.006 6604 8190 polyribonucleotide nucleotidyltransferase 
Cd630-1319 (3N23) 1.0 0.794 338 329 0.5 0.035 176 301 putative polysaccharide deacetylase 
Cd630-1322 (3I24) 1.0 0.963 456 389 0.7 0.039 247 370 aspartokinase 
Cd630-1370 (4I6) 1.5 0.578 57 30 5.0 0.036 67 16 phage protein 
Cd630-1376 (4O6) 0.8 0.639 119 122 0.7 0.039 66 93 putative membrane protein 
Cd630-1390 (4M8) 1.2 0.760 32 22 1.4 0.033 33 24 putative membrane protein 
Cd630-1404 (4K10) 1.0 0.563 16830 15969 1.5 0.006 15587 10338 putative oligopeptide transporter 
Cd630-1412 (4K11) 0.9 0.622 492 519 0.5 0.001 181 350 sigma-54 dependent regulatory protein 
Cd630-1417 (4P11) 0.9 0.518 1334 1521 0.4 0.026 300 703 putative ATP-binding protein 
Cd630-1438 (5E2) 1.4 0.459 152 131 1.3 0.039 115 84 putative multiprotein complex assembly protein 
Cd630-1449 (5H3) 1.1 0.862 871 893 0.6 0.017 373 596 putative GTP cyclohydrolase I 
Cd630-1497 (5A10) 1.0 0.886 3536 3652 1.2 0.011 2453 2008 hypothetical protein 
Cd630-1543 (5O3) 1.5 0.576 77 42 2.4 0.016 63 27 putative acyl carrier protein phosphodiesterase 
Cd630-1550 (5N4) 1.0 0.969 3072 3178 0.6 0.028 1260 1831 imidazoleglycerol-phosphate dehydratase 
Cd630-1576 (5P7) 1.1 0.550 3248 2765 0.5 0.011 1436 2524 putative arylesterase 
Cd630-1578 (5J8) 0.9 0.410 1077 1146 0.7 0.034 620 877 putative membrane-associated ribonuclease 
Cd630-1582 (5N8) 0.8 0.525 77 85 0.4 0.006 59 135 histidinol dehydrogenase 
Cd630-1592 (5P9) 0.8 0.495 73 79 3.0 0.022 98 38 potassium-transporting ATPase B chain 
Cd630-1607 (5O11) 0.8 0.482 58 62 3.1 0.019 85 29 ABC transporter, ATP-binding protein 
Cd630-1610 (5J12) 1.1 0.814 220 121 4.2 0.027 136 35 putative membrane protein 
Cd630-1611 (5K12) 1.0 0.885 101 98 2.1 0.026 76 34 putative exported protein 
Cd630-1645 (5E16) 1.0 0.741 6091 5616 0.7 0.006 3515 4941 putative membrane protein 
Cd630-1646 (5F16) 1.0 0.746 4347 4027 0.7 0.045 2113 2943 putative dipeptidase 
Cd630-1657 (5A18) 1.0 0.701 1906 1877 1.3 0.049 1025 746 
putative bi-functional glycine dehydrogenase/aminomethyl transferase 
protein 
Cd630-1661 (5E18) 1.0 0.804 7646 7512 1.8 0.012 5456 3156 transposase-like protein B 
Cd630-1663 (5G18) 1.1 0.462 1327 1208 1.5 0.017 846 556 guanine deaminase 
Cd630-1673 (5A20) 1.0 0.952 1935 1815 0.7 0.003 637 908 putative membrane protein 
Cd630-1675 (5C20) 1.0 0.863 1897 1971 1.6 0.033 923 614 putative transcriptional regulator 
Cd630-1677 (5E20) 0.7 0.512 1874 2063 0.4 0.006 438 1177 putative membrane protein 
Cd630-1696 (5H22) 1.1 0.549 283 271 1.5 0.014 263 185 putative sodium:amino acid symporter 
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Cd630-1709 (5E24) 1.0 0.867 3891 3845 0.7 0.001 2210 3084 putative molybdopterin-guanine biosynthesis protein 
Cd630-1710 (5F24) 1.0 0.471 2085 2052 0.7 0.023 1215 1637 hypothetical protein 
Cd630-1760 (5I19) 1.0 0.911 1229 1220 0.5 0.004 236 438 putative iron-sulfur protein 
Cd630-1767 (5P19) 1.0 0.887 52 48 3.5 0.034 88 29 glyceraldehyde-3-phosphate dehydrogenase 1 
Cd630-1768 (5I20) 1.0 0.863 40183 42545 1.6 0.017 34810 22585 putative membrane protein 
Cd630-1774 (5O20) 1.3 0.651 140 124 2.4 0.024 108 47 ABC transporter, substrate-binding protein 
Cd630-1779 (5L21) 1.1 0.561 2600 2543 0.7 0.049 1499 1954 conserved hypothetical protein 
Cd630-1802 (5K24) 1.0 0.769 461 484 0.7 0.039 288 403 putative hydrolase 
Cd630-1803a 
(5L24) 1.3 0.493 92 55 3.6 0.017 86 28 putative cell surface protein 
Cd630-1812 (1N13) 1.2 0.496 375 350 2.3 0.046 1421 447 putative two-somponent system response regulator (partial) 
Cd630-1838 (1P16) 1.2 0.417 1158 988 0.8 0.041 726 864 shikimate kinase 
Cd630-1846 (1P17) 0.7 0.648 108 96 2.5 0.011 134 50 conserved hypothetical protein 
Cd630-1850 (1L18) 1.1 0.551 125 94 3.2 0.014 149 47 AraC-family transcriptional regulator 
Cd630-1854 (1P18) 1.7 0.456 109 37 3.9 0.045 96 24 putative conjugative transposon membrane exported protein 
Cd630-1880 (1J22) 1.1 0.755 93 83 2.3 0.018 97 42 hypothetical protein 
Cd630-1885 (1O22) 1.0 0.948 42 42 3.1 0.014 63 20 putative acetyl xylan esterase 
Cd630-1895 (1I24) 1.0 0.863 3871 3531 0.7 0.002 1954 2890 putative membrane protein 
Cd630-1927 (6A4) 1.1 0.915 675 264 0.3 0.010 28 79 ABC transporter, ATP-binding protein (pseudogene) 
Cd630-1931 (6E4) 0.9 0.698 5033 5823 1.4 0.014 2388 1689 SOS regulatory protein 
Cd630-1936 (6B5) 1.0 0.878 3155 3086 1.3 0.036 2456 1816 acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha 
Cd630-1937 (6C5) 0.9 0.604 11864 12489 0.8 0.020 7491 10047 acetyl-coenzyme A carboxylase carboxyl transferase subunit beta 
Cd630-1943 (6A6) 1.0 0.532 1700 1623 1.6 0.010 1571 990 conserved hypothetical protein 
Cd630-1946 (6D6) 1.0 0.937 555 510 0.5 0.026 232 400 AraC-family transcriptional regulator 
Cd630-2003 (6N1) 1.0 0.981 1664 1656 1.2 0.030 1151 942 putative efflux pump 
Cd630-2004 (6O1) 1.2 0.473 341 293 1.9 0.016 303 165 hypothetical protein 
Cd630-2043 (6I7) 0.9 0.370 781 841 0.6 0.021 369 565 putative hydrolase 
Cd630-2051 (6I8) 1.0 0.756 1792 1791 0.8 0.044 1003 1228 putative membrane protein 
Cd630-2052 (6J8) 1.1 0.381 4894 4541 0.8 0.011 2959 3733 putative lipoprotein 
Cd630-2065 (6O9) 1.1 0.524 2277 2164 1.4 0.013 1809 1227 putative regulatory protein 
Cd630-2075 (6I11) 0.9 0.692 562 584 0.7 0.049 207 307 xanthine permease 
Cd630-2079 
(6M11) 1.1 0.680 333 268 0.5 0.036 95 169 xanthine dehydrogenase, molybdenum binding subunit 
Cd630-2081 (6O11) 0.8 0.513 33 39 2.1 0.027 49 25 xanthine dehydrogenase iron-sulfur binding subunit 
Cd630-2108 (6B15) 1.1 0.452 4160 3466 0.9 0.001 2319 2747 putative drug/sodium antiporter 
Cd630-2120 (6F16) 1.1 0.547 13070 11286 0.8 0.044 7460 9364 putative 2-nitropropane dioxygenase 
Cd630-2122 (6H16) 1.2 0.541 116 94 3.8 0.022 164 47 putative cations transporter 
Cd630-2123 (6A17) 1.0 0.792 2329 2291 1.1 0.015 1521 1367 putative multiprotein-complex assembly protein 
Cd630-2129 (6G17) 1.4 0.502 56 48 4.8 0.039 97 21 putative membrane-associated protease 
Cd630-2144 (6F19) 1.0 0.870 295 280 0.5 0.047 70 154 putative membrane protein 
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Cd630-2172 (6B23) 1.0 0.568 5203 5300 0.8 0.011 2775 3561 probable amino-acid ABC transporter, ATP-binding protein 
Cd630-2173 (6C23) 1.0 0.745 4239 3945 0.7 0.040 2232 3069 putative peptidase 
Cd630-2174 (6D23) 1.1 0.812 1549 1430 0.7 0.042 891 1221 probable amino-acid ABC transporter, substrate-binding protein 
Cd630-2179 (6A24) 1.0 0.948 2524 2436 0.5 0.006 985 1751 putative oxidoreductase, molybdopterin-binding subunit 
Cd630-2181 (6C24) 1.0 0.911 7696 7272 0.6 0.017 3516 5743 putative aromatic compounds hydrolase 
Cd630-2208 (8O3) 0.9 0.722 239 261 0.4 0.037 75 171 MarR-family transcriptional regulator 
Cd630-2235 (8J7) 0.9 0.838 505 454 0.6 0.012 194 304 RpiR-family transcriptional regulator 
Cd630-2252 (8K9) 1.0 0.756 1676 1630 1.6 0.039 1188 716 L-lysine 2,3-aminomutase 
Cd630-2322 (6I18) 1.0 0.984 9611 9337 1.5 0.013 7433 5137 transketolase 
Cd630-2335 (6N19) 1.1 0.693 4926 4569 1.5 0.002 4274 2842 inosine-5'-monophosphate dehydrogenase 
Cd630-2363 (6J23) 1.0 0.854 10042 9471 0.7 0.041 4514 6239 hypothetical protein 
Cd630-2365 (6L23) 1.1 0.553 23546 21263 0.7 0.007 12372 16524 putative sulfonate ABC transporter, solute-binding lipoprotein 
Cd630-2371 (6J24) 1.0 0.927 2576 2542 0.8 0.041 1663 2287 L-aspartate oxidase 
Cd630-2374 
(6M24) 1.1 0.576 611 536 0.4 0.009 207 423 hypothetical protein 
Cd630-2388 (7C2) 0.9 0.750 691 806 0.6 0.037 225 375 putative peptidoglycan- binding/hydrolysing protein 
Cd630-2435 (7B8) 1.0 0.793 5792 5873 0.7 0.016 3070 4144 DNA repair protein 
Cd630-2438 (7E8) 1.0 0.926 4413 4369 0.7 0.021 2366 3216 cytidine deaminase 
Cd630-2442 (7A9) 0.9 0.497 955 1072 0.6 0.015 341 561 putative stage IV sporulation protein 
Cd630-2444 (7C9) 1.0 0.867 9047 9387 1.6 0.047 9584 6463 putative sigma 54 modulation protein 
Cd630-2456 (7G10) 1.0 0.545 1508 1428 1.6 0.035 1282 752 ABC transporter, ATP-binding protein 
Cd630-2459 (7B11) 1.1 0.483 2455 2184 1.5 0.007 1696 1123 glucokinase 
Cd630-2468 (7C12) 1.1 0.701 64 58 2.1 0.039 63 31 putative exported protein 
Cd630-2473 (7H12) 1.0 0.754 9150 8941 0.7 0.030 7693 10723 30S ribosomal protein S20 
Cd630-2493 (7D15) 1.3 0.609 161 139 2.1 0.047 165 80 selenocysteine-specific elongation factor 
Cd630-2496 (7G15) 0.9 0.412 2624 2774 1.4 0.043 1602 1183 selenide,water dikinase selenide,water dikinase 
Cd630-2500 (7C16) 1.0 0.959 1710 1627 0.6 0.022 838 1197 argininosuccinate lyase 
Cd630-2517 (7D18) 0.9 0.557 637 659 1.6 0.043 570 352 putative regulatory protein 
Cd630-2521 (7A19) 1.1 0.656 369 355 2.4 0.001 255 106 leucyl-tRNA synthetase 
Cd630-2526 (7F19) 0.9 0.548 405 456 0.4 0.044 158 352 glycogen branching enzyme 
Cd630-2541 (7E21) 1.1 0.527 21384 19986 1.3 0.007 12065 9388 sodium:dicarboxylate symporter family protein 
Cd630-2544 (7H21) 0.9 0.588 912 908 0.6 0.007 269 470 putative membrane protein 
Cd630-2545 (7A22) 1.0 0.480 2324 2384 0.6 0.020 947 1412 cellulose synthase catalytic subunit [UDP-forming] 
Cd630-2549 (7E22) 1.0 0.540 13036 13357 0.8 0.014 6707 8390 putative sugar transporter, permease protein 
Cd630-2553 (7A23) 1.0 0.875 3380 3129 0.7 0.041 1579 2289 phosphotransferase system, C component 
Cd630-2556 (7D23) 1.0 0.946 1379 1358 0.6 0.016 724 1048 
putative bifunctional protein [includes B component of phosphotransferase 
system and transcriptional antiterminator] 
Cd630-2561 (7A24) 0.9 0.512 13261 14148 0.7 0.012 8592 12160 putative phosphatase 
Cd630-2570 (7J13) 1.3 0.789 463 655 2.7 0.020 266 87 two-component sensor histidine kinase 
Cd630-2591 (7O15) 1.0 0.623 3217 3126 0.9 0.046 1755 2009 low-specificity L-threonine aldolase 
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Cd630-2604f0 
(7L17) 1.0 0.924 130 144 0.5 0.041 50 111 binary ADP-ribosyltransferase Cdt toxin (pseudogene) 
Cd630-2611 (7N18) 1.1 0.607 2449 2368 1.9 0.022 2081 1107 5'-methylthioadenosine/S- adenosylhomocysteine nucleosidase 
Cd630-2612 (7O18) 1.0 0.997 4638 4560 1.3 0.008 2706 2107 putative amino acid permease 
Cd630-2630 (7I21) 1.0 0.945 6582 6405 1.3 0.036 3509 2759 glycerol-3-phosphate dehydrogenase [NAD(P)+] 
Cd630-2640 (7K22) 0.9 0.686 905 1006 0.3 0.012 206 532 putative ATP-binding protein 
Cd630-2644 (7O22) 0.5 0.440 397 480 0.3 0.028 125 371 sporulation sigma-E factor processing peptidase 
Cd630-2650 
(7M23) 2.0 0.442 3328 690 0.5 0.015 223 403 putative cell division protein 
Cd630-2655 (7J24) 1.0 0.988 3763 3698 0.7 0.030 1823 2410 UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase 
Cd630-2656 (7K24) 1.0 0.854 1567 1558 0.8 0.030 855 1217 stage V sporulation protein D (sporulation specific penicillin-binding protein) 
Cd630-2664 (7K1) 1.0 0.513 3770 3529 1.5 0.020 2640 1738 
putative UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate 
ligase 
Cd630-2665 (7L1) 1.0 0.999 3319 3215 1.4 0.035 2467 1714 AraC-family transcriptional regulator 
Cd630-2666 (7M1) 1.0 0.511 6497 6270 1.7 0.022 5746 3476 PTS system, glucose-specific IIa component 
Cd630-2667 (7N1) 0.9 0.673 9688 10733 1.3 0.001 7871 5992 PTS system, glucose-specific IIbc component 
Cd630-2670 (7I2) 1.0 0.755 3107 3038 1.4 0.014 2329 1674 oligopeptide ABC transporter, ATP-binding protein 
Cd630-2701 (7P5) 0.8 0.490 2336 2283 1.5 0.007 2173 1406 putative lipoprotein 
Cd630-2710 (7I7) 1.1 0.709 594 435 0.7 0.027 203 284 conserved hypothetical protein 
Cd630-2734 (7J10) 1.2 0.633 177 106 2.4 0.043 82 39 putative malate-2H(+)/Na(+)-lactate antiporter 
Cd630-2738 (7O10) 0.9 0.499 977 1040 0.5 0.001 446 855 putative cytosine permease 
Cd630-2740 (7I11) 0.9 0.508 6394 7152 1.3 0.029 4221 3356 putative histidyl-tRNA synthetase 
Cd630-2757 (8B1) 1.0 0.871 4141 4241 1.3 0.001 2791 2225 putative phospholipase 
Cd630-2776 (8F3) 1.0 0.670 4001 3933 1.2 0.047 2542 2118 putative glycosyl transferase 
Cd630-2778 (8H3) 1.1 0.610 6191 5860 1.2 0.048 3895 3339 putative polysaccharide biosynthesis protein 
Cd630-2796b (8C7) 0.9 0.447 7627 8252 0.7 0.000 4465 6716 putative cell surface protein 
Cd630-2805 (8F8) 1.0 0.575 2321 2180 0.8 0.009 1383 1793 holliday junction DNA helicase 
Cd630-2806 (8G8) 1.0 0.876 1722 1698 0.6 0.024 832 1235 holliday junction DNA helicase 
Cd630-2817 (8B10) 1.0 0.654 1149 1126 1.3 0.023 674 521 ABC transporter, ATP-binding/permease protein 
Cd630-2820 (8E10) 0.9 0.794 427 429 0.6 0.000 161 254 putative membrane protein 
Cd630-2821 (8F10) 0.9 0.401 542 592 0.8 0.036 288 358 putative membrane protein 
Cd630-2841 
(10B13) 1.1 0.569 277 224 1.8 0.028 190 111 putative amidohydrolase 
Cd630-2863 
(10H15) 1.5 0.389 47 23 4.3 0.012 61 16 putative sigma-54-dependent transcriptional regulator 
Cd630-2866 
(10C16) 1.0 0.787 112 106 1.5 0.009 109 72 putative regulatory protease 
Cd630-2871 
(10H16) 1.1 0.908 113 56 4.2 0.004 133 34 altronate hydrolase (N-terminus) 
Cd630-2874 
(10C17) 1.1 0.515 53 41 2.0 0.040 62 27 putative drug/sodium antiporter 
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Cd630-2879 
(10H17) 1.1 0.514 596 492 1.7 0.036 411 256 hypothetical protein 
Cd630-2883 
(10D18) 1.1 0.789 127 88 3.0 0.003 166 51 PTS system, lichenan-specific IIc component 
Cd630-2888 
(10A19) 1.3 0.629 64 43 1.5 0.029 38 25 ABC transporter, permease protein 
Cd630-2899 
(10D20) 1.7 0.608 6840 1587 0.5 0.019 169 315 phage protein 
Cd630-2948 (8D14) 1.3 0.505 32 24 4.1 0.040 77 18 putative phage anti-repressor 
Cd630-2962 (8B16) 1.0 0.709 690 664 0.7 0.032 433 583 hypothetical protein 
Cd630-2979 (8C18) 1.0 0.794 296 298 0.6 0.027 121 196 conserved hypothetical protein 
Cd630-3003 (8C21) 0.9 0.649 15 16 5.7 0.005 46 8 probable carbohydrate hydrolase (N-terminus) 
Cd630-3010 (8B22) 1.1 0.678 63 52 2.5 0.026 76 31 putative cytochrome C biogenesis protein 
Cd630-3018 (8B23) 1.0 0.752 2087 2004 1.4 0.044 2390 1721 conserved hypothetical protein 
Cd630-3030 (8F24) 0.8 0.710 110 114 1.7 0.002 95 54 PTS system, maltose and glucose-specific IIbc component 
Cd630-3031 (8G24) 1.0 0.706 927 963 1.6 0.049 1000 640 transcription antiterminator 
Cd630-3040 (8P13) 1.2 0.460 1342 1251 1.7 0.015 1126 659 conserved hypothetical protein 
Cd630-3055 (8O15) 1.0 0.559 1591 1635 0.7 0.025 792 1027 putative ABC transporter, permease protein 
Cd630-3060 (8L16) 1.0 0.858 905 900 0.7 0.005 657 909 putative maltose-6'-phosphate glucosidase 
Cd630-3069 
(8M17) 1.1 0.476 3343 3207 1.3 0.014 1943 1508 PTS system, IId component 
Cd630-3089 (8I20) 0.9 0.417 34185 36982 0.5 0.025 14314 26188 PTS system, IIabc component 
Cd630-3100 (8L21) 1.0 0.975 12614 12561 0.7 0.035 9360 12705 putative C4-dicarboxylate anaerobic carrier 
Cd630-3102 (8N21) 1.1 0.472 814 693 1.4 0.047 549 383 putative dipeptidase 
Cd630-3107 (8K22) 1.0 0.571 1270 1188 0.7 0.039 690 890 putative transcription antiterminator 
Cd630-3110 (8N22) 0.9 0.666 459 443 0.8 0.012 227 284 putative phosphofructokinase 
Cd630-3112 (8P22) 1.2 0.446 758 594 0.7 0.048 425 535 putative amidohydrolase 
Cd630-3116 (8L23) 1.1 0.447 1738 1543 0.7 0.009 1120 1602 PTS system, beta-glucoside-specific IIabc component 
Cd630-3119 (8O23) 1.0 0.960 582 535 0.7 0.044 295 406 putative glycosyltransferase 
Cd630-3143 (9G2) 1.0 0.527 800 818 0.6 0.009 324 527 conserved hypothetical protein 
Cd630-3159 (9B5) 1.2 0.485 203 138 2.5 0.020 158 62 putative acetyltransferase 
Cd630-3161 (9D5) 0.8 0.428 632 729 0.6 0.011 232 383 putative ABC transporter, permease permease 
Cd630-3181 (9H7) 0.9 0.861 538 515 0.4 0.023 129 326 putative amidohydrolase 
Cd630-3200 (9D10) 1.4 0.442 129 65 2.5 0.040 90 33 putative ABC transporter, permease protein 
Cd630-3204 (9H10) 1.2 0.461 148 109 2.3 0.017 155 69 putative membrane protein 
Cd630-3207 (9C11) 0.8 0.526 697 783 0.3 0.027 154 419 putative Na+ driven multidrug efflux pump 
Cd630-3211 (9G11) 1.0 0.965 608 609 0.5 0.017 186 330 conserved hypothetical protein 
Cd630-3222 (9J1) 1.0 0.865 99 99 1.6 0.025 78 53 L-serine dehydratase 
Cd630-3223 (9K1) 0.9 0.535 241 248 1.3 0.026 190 140 dihydrodipicolinate synthase 
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Cd630-3224 (9L1) 1.0 
no 
replicates 64 64 3.9 0.008 133 33 aspartate-semialdehyde dehydrogenase 
Cd630-3241 (9M3) 0.9 0.819 55 58 2.2 0.015 85 38 proline reductase 
Cd630-3244 (9P3) 1.2 0.396 94 82 3.3 0.011 195 64 proline reductase subunit proprotein 
Cd630-3257 (9M5) 1.0 0.693 1148 1178 0.6 0.030 330 514 putative polysaccharide deacetylase 
Cd630-3258 (9N5) 2.8 0.460 1386 1248 0.6 0.003 714 1148 iron-only hydrogenase 
Cd630-3259 (9O5) 0.9 0.487 1340 1401 0.7 0.024 676 923 putative membrane protein 
Cd630-3277 (9I8) 1.0 0.880 684 643 0.5 0.047 263 525 PTS system, IIc component 
Cd630-3283 (9O8) 1.0 0.869 3925 3934 0.6 0.020 2017 3255 putative pyruvate formate-lyase 3 activating enzyme 
Cd630-3285 (9I9) 0.8 0.591 432 433 0.4 0.024 180 556 glucose-6-phosphate isomerase 
Cd630-3290 (9N9) 1.1 0.591 6214 6015 1.2 0.022 3718 3055 putative protein translocase 
Cd630-3297 
(9M10) 0.9 0.405 656 690 0.6 0.023 209 335 putative membrane protein 
Cd630-3301 (9I11) 1.2 0.466 433 377 1.8 0.006 237 133 ATP-dependent protease La 
Cd630-3322 (9F13) 1.1 0.581 1484 1447 0.6 0.016 791 1359 hypothetical protein 
Cd630-3328 (9D14) 0.9 0.658 794 824 0.6 0.042 380 633 congative transposon conserved hypothetical protein 
Cd630-3329 (9E14) 0.9 0.494 1029 1142 0.5 0.032 454 858 conjugative transposon conserved hypothetical protein 
Cd630-3335 (9C15) 0.9 0.581 2045 2109 0.6 0.014 1166 1836 conjugative tyransposon conserved hypothetical protein 
Cd630-3339 (9G15) 1.1 0.826 389 303 0.5 0.023 154 271 conjugative transposon membrane protein 
Cd630-3342 (9B16) 1.0 
no 
replicates 55 55 6.5 0.025 105 16 putative phage membrane protein 
Cd630-3380 (9H20) 0.7 0.394 588 797 0.3 0.009 225 602 conjugative transposon protein 
Cd630-3384 (9D21) 1.0 0.952 376 358 0.6 0.017 141 233 conjugative transposon membrane protein 
Cd630-3386 (9F21) 1.5 0.518 224 69 2.6 0.014 115 42 conjugative transposon protein 
Cd630-3392 (9D22) 0.7 0.389 30 37 2.1 0.046 57 27 putative collagen-binding surface protein 
Cd630-3403 (9G23) 1.0 0.792 5560 5534 0.7 0.009 2894 4154 putative formate/nitrite transporter 
Cd630-3413 (9I13) 1.6 0.506 40 33 5.0 0.013 48 9 putative nucleotide pyrophosphatase 
Cd630-3421 (9I14) 1.0 0.687 4424 4647 0.7 0.013 2159 3149 porphobilinogen deaminase 
Cd630-3456 (9L18) 0.9 0.583 721 747 0.8 0.036 379 491 putative 5-formyltetrahydrofolate cyclo-ligase 
Cd630-3457 
(9M18) 1.0 0.773 773 722 0.6 0.022 279 478 putative exported protein 
Cd630-3472 (9L20) 1.1 0.621 16182 14866 1.5 0.025 10961 7522 ATP synthase B chain 
Cd630-3488 (9L22) 1.0 0.872 6215 6195 0.7 0.014 3239 4877 utp--glucose-1-phosphate uridylyltransferase (general stress protein 33) 
Cd630-3490 (9N22) 1.0 0.914 1247 1239 0.8 0.008 604 824 stage II sporulation protein e 
Cd630-3491 (9O22) 0.9 0.536 2152 2208 0.6 0.017 857 1480 putative exopolyphosphatase 
Cd630-3498 (9N23) 1.0 0.748 9579 9056 0.7 0.006 5289 7178 stage V sporulation protein B 
Cd630-3499 (9O23) 1.0 0.813 1723 1735 0.7 0.032 923 1266 stage V sporulation protein T 
Cd630-3512 (10D1) 1.0 0.905 422 415 1.4 0.001 389 271 type IV pilus assembly protein 
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Cd630-3525 (10A3) 1.1 0.520 2393 2284 1.4 0.036 1582 1051 putative iron ABC transporter, solute-binding protein 
Cd630-3549 (10A6) 0.9 0.415 1340 1559 0.6 0.037 679 1092 putative DNA polymerase III, delta' subunit 
Cd630-3561 (10E7) 0.9 0.545 775 859 0.7 0.046 491 657 conserved hypothetical protein 
Cd630-3565 (10A8) 1.0 0.760 4851 4651 0.8 0.007 3167 4153 GntR-family transcriptional regulator 
Cd630-3574 (10B9) 0.7 0.518 97 109 0.5 0.002 31 54 putative membrane protein 
Cd630-3601 
(10E12) 0.9 0.796 771 790 0.5 0.013 272 449 D-alanyl-D-alanine carboxypeptidase 
Cd630-3610 (10N1) 0.9 0.461 1314 1511 0.7 0.042 599 856 putative glyoxalase 
Cd630-3623 (10K3) 1.0 0.572 924 892 0.8 0.048 447 528 putative ABC transporter, ATP-binding protein 
Cd630-3627 (10O3) 1.1 0.607 550 462 0.6 0.008 155 262 putative dihydrodipicolinate synthase 
Cd630-3632 (10L4) 0.9 0.599 368 394 0.5 0.042 98 191 putative isochorismatase 
Cd630-3650 (10N6) 1.0 0.774 2120 2147 0.7 0.010 1195 1705 putative signaling protein 
Cd630-3670 (10J9) 1.0 0.928 3799 4021 1.4 0.004 3017 2129 putative selenocysteine lyase 
 
Bile 2.4% p=0.05         
Kat's Bile MAVI Norm         
 Control Test  
 2.40% 2.40%  
Systematic ID Normalized t-test P-value Raw Control 
Fold 
change 
t-test 
P 
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Cd630-3238 (9J3) 1.2 0.510 62 59 3.4 0.050 90 30 conserved hypothetical protein 
Cd630-2460 (7C11) 1.0 0.758 7952 7768 1.6 0.050 7666 5345 chaperone protein 
Cd630-1318 (3M23) 1.0 0.811 6650 6971 0.7 0.050 4113 5591 polyribonucleotide nucleotidyltransferase 
Cd630-3138 (9B2) 1.0 0.616 8907 9256 0.8 0.049 5026 6248 transcription antiterminator 
Cd630-1038 (4L24) 1.0 0.791 422 382 0.5 0.049 112 198 putative helicase 
Cd630-0044 (1L6) 1.1 0.906 57 37 2.3 0.048 43 20 putative membrane protein 
Cd630-0592 (2J15) 1.0 0.936 457 445 0.4 0.048 119 320 putative membrane protein 
Cd630-2759 (8D1) 1.0 0.991 764 765 0.6 0.048 221 380 conserved hypothetical protein 
Cd630-1230 (3D24) 0.9 0.625 426 497 0.5 0.048 110 220 sigma K 
Cd630-1616 (5P12) 1.1 0.714 2119 1931 0.5 0.048 442 895 putative signaling protein 
Cd630-2654 (7I24) 1.0 0.945 4701 4854 0.6 0.048 2053 3487 phospho-N-acetylmuramoyl-pentapeptide-transferase 
Cd630-1438 (5E2) 0.7 0.656 90 90 2.2 0.048 222 96 putative multiprotein complex assembly protein 
Cd630-3595 
(10G11) 1.0 0.955 125 125 1.7 0.048 122 74 aminopeptidase 
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Cd630-0295 (2G1) 1.0 0.874 60 64 6.0 0.048 113 19 putative iron-sulfur-binding protein 
Cd630-0517 (1G5) 1.0 0.860 1553 1575 1.7 0.048 1837 1064 putative membrane protein 
Cd630-0290 (2B1) 1.4 0.537 55 30 7.1 0.048 92 15 hypothetical protein 
Cd630-2459 (7B11) 1.0 0.966 2315 2337 1.3 0.047 1563 1267 glucokinase 
Cd630-0618 (2J18) 1.0 0.864 425 414 0.3 0.047 79 214 putative transcriptional regulator 
Cd630-0875 (3O3) 1.0 0.648 20752 21377 0.6 0.047 8740 14913 ABC transporter, permease protein 
Cd630-0255 (4G8) 1.1 0.670 6902 6833 0.5 0.047 1818 3476 flagellar hook protein 
Cd630-1979 (6E10) 1.0 0.855 433 433 1.4 0.046 350 228 ABC transporter, substrate-binding protein 
Cd630-0818 (1F20) 1.0 0.980 343 333 1.7 0.046 172 99 putative 6-phospho-beta-glucosidase 
Cd630-1309 (3L22) 1.1 0.608 1542 1393 1.5 0.046 1209 843 translation initiation factor IF-2 
Cd630-1873 (1K21) 0.9 0.843 45 61 11.3 0.046 1529 158 ABC transporter, permease protein 
Cd630-0604 (2L16) 1.0 0.804 1069 1080 1.5 0.046 845 582 conserved hypothetical protein 
Cd630-1091 (4A19) 1.0 0.913 180 176 2.3 0.046 209 114 integrase 
Cd630-1681 (5A21) 1.0 0.770 1846 1880 1.2 0.046 1502 1278 TetR-family transcriptional regulator 
Cd630-0536 (1B8) 1.0 0.919 943 917 0.3 0.045 168 550 chemotaxis protein 
Cd630-2605f4 
(7J18) 0.9 0.801 382 378 0.5 0.045 95 193 ADP-ribosyltransferase (pseudogene) 
Cd630-1148 (3B14) 1.0 0.940 11758 11729 0.6 0.045 5174 8544 putative penicillin-binding protein 
Cd630-2527 (7G19) 1.0 0.942 4226 4267 1.3 0.045 3996 3025 TetR-family transcriptional regulator 
Cd630-1780 (5M21) 1.1 0.514 192 162 1.9 0.045 93 48 putative methylase 
Cd630-2681 (7L3) 1.3 0.587 1388 1137 2.4 0.045 1546 562 putative Calcium-chelating exported protein 
Cd630-2943 (8G13) 1.2 0.863 41 41 2.3 0.045 40 15 putative phage replication protein 
Cd630-0388 (2L1) 1.0 0.573 3043 2972 1.3 0.045 2261 1743 PTS system, beta-glucoside-specific IIabc component 
Cd630-1339 (4J2) 1.1 0.701 7561 6978 1.5 0.044 5802 4244 aspartate aminotransferase 
Cd630-0588 (2N14) 0.9 0.670 314 300 0.6 0.044 131 224 hypothetical protein 
Cd630-3099 (8K21) 1.0 0.757 17078 17545 0.7 0.044 8225 11204 putative amidohydrolase 
Cd630-1421 (4L12) 0.9 0.659 2133 2239 0.5 0.044 814 1399 putative signaling protein 
Cd630-2220 (8K5) 1.0 0.878 473 480 1.5 0.044 396 243 putative cAMP-binding regulatory protein 
Cd630-0375 (2G11) 1.6 0.659 16 7 24.6 0.044 54 3 conjugative transposon protein 
Cd630-2830 (8G11) 1.0 0.961 17200 17363 1.1 0.044 13564 11957 putative exported protein 
Cd630-1977 (6C10) 1.0 0.808 491 523 0.4 0.044 94 278 DNA mismatch repair protein 
Cd630-1645 (5E16) 1.0 0.991 5536 5583 1.6 0.043 5527 3212 putative membrane protein 
Cd630-3423 (9K14) 1.0 0.934 548 535 0.3 0.043 131 307 cobalt-precorrin-6a reductase precorrin-6x reductase 
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Cd630-2564 (7D24) 0.9 0.765 487 529 1.3 0.043 426 327 MerR-family transcriptional regulator 
Cd630-0381 (2E12) 1.2 0.603 57 48 2.5 0.043 55 26 putative conjugative transposon replication initiation factor 
Cd630-3044 (8L14) 1.0 0.824 5243 5329 1.2 0.043 3758 3015 putative phosphosugar-binding transcriptional regulator 
Cd630-0744 (3D11) 1.0 0.781 5173 5006 1.5 0.042 4250 2776 putative chemotaxis protein 
Cd630-1168 (3F16) 0.9 0.512 475 474 1.2 0.042 411 348 putative membrane protein 
Cd630-3536 (10D4) 1.0 0.972 135 133 0.7 0.042 67 88 putative phosphonate metabolism protein 
Cd630-2437 (7D8) 1.0 0.487 14254 14947 0.5 0.042 4345 8446 GTP-binding protein 
Cd630-0236 (4D6) 1.0 0.940 17735 17724 0.6 0.042 6549 10402 flagellar protein 
Cd630-0422 (2N5) 1.1 0.474 907 855 2.6 0.042 1272 437 conserved hypothetical protein 
Cd630-3488 (9L22) 1.0 0.940 5231 5284 0.7 0.042 2215 3252 utp--glucose-1-phosphate uridylyltransferase (general stress protein 33) 
Cd630-0987 (4O17) 1.0 0.775 638 648 0.6 0.042 243 396 putative phosphoesterase 
Cd630-0410 (2J4) 0.9 0.782 278 265 1.9 0.042 321 141 putative DNA replication protein 
Cd630-1350 (4M3) 1.1 0.560 214 202 0.5 0.041 67 135 putative lantibiotic ABC transporter, permease protein 
Cd630-2876 
(10E17) 1.0 0.834 34 35 4.1 0.041 75 18 putative ferrichrome ABC transporter, permease protein 
Cd630-2086 (6L12) 0.9 0.408 1240 1365 0.5 0.041 499 931 putative iron-sulfur flavoprotein 
Cd630-0403 (2K3) 1.1 0.547 4230 4015 1.8 0.041 4716 2421 putative fructose-bisphosphate aldolase 
Cd630-1471 (5G6) 1.0 0.451 2535 2435 1.9 0.041 3255 1737 putative membrane protein (putative phage infection protein) 
Cd630-1254 (3M15) 1.0 0.933 7763 7779 1.2 0.041 5712 4821 conserved hypothetical protein 
Cd630-3581 
(10A10) 0.8 0.430 1977 2437 0.5 0.040 550 1225 conserved hypothetical protein 
Cd630-1592 (5P9) 1.2 0.453 35 27 6.4 0.040 112 18 potassium-transporting ATPase B chain 
Cd630-1458 (5A5) 0.9 0.481 625 641 0.7 0.039 292 408 putative flavoprotein 
Cd630-0941 (3I12) 1.0 0.911 3741 3749 1.4 0.039 3208 2178 phage protein 
Cd630-2406 (7E4) 1.0 0.976 1146 1084 1.5 0.039 794 544 putative lipoprotein 
Cd630-2922 
(10B23) 0.8 0.423 570 670 0.8 0.039 318 430 phage terminase large subunit 
Cd630-3217 (9E12) 1.4 0.440 221 114 2.3 0.039 137 62 putative nogalamycin resistance protein 
Cd630-0239 (4G6) 1.1 0.632 65526 55031 1.6 0.039 88983 52720 flagellin subunit 
Cd630-3650 (10N6) 1.0 0.946 2499 2496 0.7 0.039 1093 1418 putative signaling protein 
Cd630-0820 (1H20) 1.1 0.628 945 867 1.6 0.038 699 441 two-component response regulator 
Cd630-2980 (8D18) 0.9 0.485 751 788 0.4 0.038 154 415 conserved hypothetical protein 
Cd630-3048 (8P14) 0.9 0.747 668 750 0.7 0.038 277 437 PTS system, IIc component 
Cd630-0441 (2J8) 0.9 0.429 503 617 0.5 0.038 197 432 putative arginine utilization sigma-54 dependent regulatory protein 
Cd630-2604f2 1.0 0.859 215 197 0.2 0.038 20 124 binary ADP-ribosyltransferase Cdt toxin (pseudogene) 
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(7M17) 
Cd630-3088 (8P19) 1.0 0.777 12983 13040 1.8 0.038 12786 7139 putative cellobiose-phosphate degrading protein 
Cd630-0257 (4A9) 1.1 0.698 24713 22854 0.5 0.037 9270 16317 chemotaxis protein 
Cd630-0332 (2D6) 0.9 0.504 1390 1610 1.3 0.037 1426 1137 putative exosporium glycoprotein 
Cd630-0396 (2L2) 0.9 0.597 40487 43202 0.6 0.037 16893 31439 R-phenyllactate dehydratase activator 
Cd630-2161 (6G21) 0.8 0.398 1122 1443 0.4 0.037 360 795 putative membrane protein 
Cd630-3168 (9C6) 1.0 0.868 470 429 1.7 0.037 361 235 conserved hypothetical protein 
Cd630-1903 (6A1) 0.6 0.531 34 39 3.8 0.036 49 13 putative lipoprotein signal peptidase 
Cd630-2682 (7M3) 1.0 0.767 70554 72927 1.2 0.036 80886 69065 pyruvate-flavodoxin oxidoreductase 
Cd630-3432 (9L15) 1.0 0.946 2144 2125 0.3 0.036 214 911 pthreonine-phosphate decarboxylase 
Cd630-1032 (4L23) 1.0 0.998 62 65 4.0 0.036 57 15 putative exported protein 
Cd630-1167 (3E16) 1.1 0.718 830 753 1.8 0.036 912 481 putative phage-related integrase/recombinase 
Cd630-2827 (8D11) 1.0 0.990 1299 1244 0.3 0.035 256 745 putative MarR-family regulatory protein 
Cd630-0001 (1I1) 1.0 0.959 352 334 0.5 0.035 110 221 chromosomal replication initiator protein 
Cd630-3420 (9P13) 1.0 0.958 3233 3351 0.7 0.035 1308 1705 
porphyrin biosynthesis protein includes: uroporphyrinogen-III 
methyltransferase and uroporphyrinogen-III synthase] 
Cd630-1688 (5H21) 1.0 0.802 5212 5259 0.9 0.035 2714 3083 two-component response regulator 
Cd630-0663a 
(2L24) 1.0 0.929 2457 2492 0.6 0.035 1022 1763 toxin A 
Cd630-3101 (8M21) 0.9 0.773 2152 2485 0.6 0.035 738 1296 PTS system, IIbc component 
Cd630-0663h (3C1) 1.0 0.630 2582 2535 1.2 0.035 1701 1439 toxin A 
Cd630-1698 (5B23) 1.0 0.796 1318 1316 1.1 0.035 931 838 riboflavin biosynthesis protein 
Cd630-3310 (9J12) 1.0 0.970 2287 2294 1.4 0.035 1868 1327 putative D-isomer specific 2-hydroxyacid dehydrogenase 
Cd630-0163 (2C21) 0.9 0.816 155 158 0.2 0.034 32 165 hypothetical protein 
Cd630-0530 (1D7) 1.0 0.867 110 101 0.6 0.034 33 56 putative membrane protein 
Cd630-0157 (2E20) 1.0 0.732 305 284 0.6 0.034 95 155 putative membrane protein (pseudogene) 
Cd630-0051 (1K7) 1.1 0.403 3754 3565 1.5 0.034 3230 1950 glutamyl-tRNA synthetase 
Cd630-1955 (6E7) 1.0 0.757 638 630 0.7 0.034 280 385 ABC transporter, ATP-binding protein 
Cd630-2807 (8H8) 1.0 0.592 1404 1397 0.8 0.033 645 807 crossover junction endodeoxyribonuclease RuvC 
Cd630-2105 (6G14) 1.4 0.417 41 23 3.1 0.033 43 14 ABC transporter, ATP-binding protein 
Cd630-1108 (4B21) 1.5 0.517 48 28 2.4 0.033 60 26 putative DNA-repair protein 
Cd630-1754 (5K18) 1.0 0.991 20 20 0.1 0.033 3 18 putative ABC transporter, permease protein 
Cd630-2269 (8L11) 0.8 0.474 136 143 2.2 0.033 197 92 PTS system, IIbc component 
Cd630-2101 (6C14) 1.0 0.908 982 981 0.5 0.033 254 602 putative FAD-binding subunit of oxidoreductase 
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Cd630-2678 (7I3) 1.1 0.905 42 37 2.4 0.033 47 19 butyrate--acetoacetate CoA-transferase subunit B 
Cd630-1694 (5F22) 0.9 0.582 1295 1446 1.9 0.033 1457 716 hypothetical protein 
Cd630-2653 (7P23) 1.0 0.979 5707 5640 0.5 0.033 1534 4012 UDP-N-acetylmuramoylalanine--D-glutamate ligase 
Cd630-0904 (3L7) 1.0 0.899 867 831 0.5 0.033 326 566 phage integrase 
Cd630-0079 (1O10) 0.9 0.608 37802 40851 0.8 0.032 16366 22192 30S ribosomal protein S3 
Cd630-1445 (5D3) 1.0 0.790 4142 4134 0.3 0.032 755 2440 para-aminobenzoate synthase glutamine amidotransferase component II 
Cd630-0308 (2D3) 1.0 0.455 1346 1413 1.3 0.032 1034 782 putative membrane protein 
Cd630-1745 (5I17) 1.0 0.918 665 640 0.6 0.032 230 392 hypothetical protein 
Cd630-0228 (4D5) 1.1 0.440 2129 1915 0.6 0.032 754 1323 flagellar motor switch protein 
Cd630-2849 
(10B14) 1.1 0.503 305 258 0.5 0.032 70 140 
putative bifunctional protein [includes phosphonoacetaldehyde 
phosphonohydrolase; 2-aminoethylphosphonate:pyruvate 
aminotransferase] 
Cd630-1866 (1L20) 1.0 0.842 440 417 0.5 0.032 105 241 putative conjugative transposon conserved hypothetical protein 
Cd630-1117 (4C22) 1.3 0.724 45 25 4.0 0.032 58 16 conserved hypothetical protein 
Cd630-0646 (2N21) 1.3 0.535 93 49 2.1 0.031 62 30 putative lantibiotic ABC transporter, permease protein 
Cd630-2624 (7K20) 1.1 0.794 3418 3541 0.5 0.031 998 2032 putative exported protein 
Cd630-0116 (2D15) 1.1 0.409 3337 3164 2.2 0.031 3720 1756 putative oxidoreductase, thiamine diP-binding subunit 
Cd630-2393 (7H2) 1.0 0.930 1182 1196 0.6 0.031 409 721 putative transglycosylase 
Cd630-1195 (3A20) 0.8 0.516 357 405 0.4 0.031 97 218 stage III sporulation protein AD 
Cd630-1413 (4L11) 0.9 0.455 872 932 0.6 0.031 391 611 putative membrane protein 
Cd630-0686 (3B4) 1.0 0.862 6290 6343 0.5 0.031 2741 4677 50S ribosomal protein L35 
Cd630-2963 (8C16) 1.1 0.473 2921 2787 0.4 0.031 638 1518 putative peptidoglycan-binding exported protein 
Cd630-2030 (6L5) 1.0 0.667 1158 1197 1.3 0.031 953 710 ornithine carbamoyltransferase 
Cd630-2786b (8B5) 1.0 0.629 902 946 2.0 0.031 977 488 putative cell surface protein 
Cd630-1303 (3N21) 1.1 0.471 1652 1496 2.1 0.030 1758 891 putative NAD-dependent deacetylase (Sir2-family regulatory) 
Cd630-2259 (8J10) 1.0 0.915 1483 1454 0.4 0.030 485 1075 conserved hypothetical protein 
Cd630-1009 (4M20) 1.0 0.739 1823 1984 1.6 0.030 1449 989 GntR-family transcriptional regulator 
Cd630-2962 (8B16) 1.0 0.919 767 824 0.5 0.030 218 441 hypothetical protein 
Cd630-1625 (5A14) 1.1 0.546 1771 1620 1.8 0.030 1605 948 two-component sensor histidine kinase 
Cd630-2927 
(10G23) 1.0 0.803 2694 2632 1.9 0.030 2763 1677 putative phage DNA-binding protein 
Cd630-1802 (5K24) 1.0 0.990 790 784 0.5 0.030 274 521 putative hydrolase 
Cd630-1575 (5O7) 1.0 0.985 327 337 0.3 0.029 69 213 putative exported protein 
Cd630-1746 (5J17) 1.0 0.953 55 50 3.4 0.029 80 27 sodium/glutamate symporter 
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Cd630-0508 (1E4) 1.0 0.627 44252 45147 0.8 0.029 24928 30726 conjugative transposon tetracycline resistance protein 
Cd630-2476 (7C13) 1.0 0.729 3168 3434 1.6 0.029 3434 1980 conserved hypothetical protein 
Cd630-0894 (3J6) 1.0 0.783 6715 6675 0.6 0.029 2744 4564 iron-dependent hydrogenase 
Cd630-3078 (8N18) 1.4 0.412 310 172 2.1 0.029 214 107 putative membrane protein 
Cd630-2866 
(10C16) 1.0 0.876 173 181 1.4 0.029 110 76 putative regulatory protease 
Cd630-2828 (8E11) 1.0 0.731 2571 2494 1.3 0.029 1778 1363 putative aromatic amino acid aminotransferase 
Cd630-2346 (6I21) 0.8 0.399 835 987 0.5 0.029 464 1069 putative membrane protein 
Cd630-3330 (9F14) 1.0 0.885 1245 1262 1.4 0.029 1196 871 putative transposon-related DNA-binding protein 
Cd630-1545 (5I4) 1.1 0.530 2467 2372 1.7 0.029 2140 1167 conserved hypothetical protein 
Cd630-0351 (2G8) 1.0 0.421 3112 3321 1.3 0.029 2757 2120 hypothetical protein 
Cd630-1474 (5B7) 1.1 0.769 2379 2195 1.8 0.029 2581 1279 putative ruberythrin 
Cd630-0193 (4A1) 1.0 0.839 3204 3258 1.3 0.028 2751 2062 10 kDa chaperonin 
Cd630-3027 (8C24) 1.0 0.864 4511 4496 1.4 0.028 3333 2491 PTS system, glucose-specific IIa component 
Cd630-3188 (9G8) 1.0 0.780 758 786 0.7 0.028 353 533 hypothetical protein 
Cd630-0202 (4B2) 1.0 0.993 643 645 0.5 0.028 210 388 conserved hypothetical protein 
Cd630-0349 (2E8) 1.1 0.586 1589 1494 1.6 0.028 1448 856 conserved hypothetical protein (pseudogene) 
Cd630-3033 (8I13) 1.1 0.709 153 147 1.6 0.028 130 81 thioredoxin 
Cd630-2648 (7K23) 1.2 0.438 1799 1402 0.7 0.028 616 943 putative exported protein 
Cd630-2276 (8K12) 1.0 0.903 1417 1448 2.1 0.028 1848 1050 putative sodium:solute symporter 
Cd630-1301 (3L21) 1.0 0.928 1732 1710 1.1 0.028 1162 1001 putative membrane protein 
Cd630-2553 (7A23) 1.0 0.829 3243 3227 1.2 0.027 2268 1881 phosphotransferase system, C component 
Cd630-3392 (9D22) 1.1 0.824 32 29 3.3 0.027 62 22 putative collagen-binding surface protein 
Cd630-3067 (8K17) 1.0 0.786 1863 1869 1.4 0.027 1543 1051 PTS system, IIa component 
Cd630-1256 (3O15) 0.9 0.493 801 891 0.4 0.027 242 566 tRNA (Guanine-n(1)-)-methyltransferase 
Cd630-1007 (4K20) 1.0 0.923 260 269 2.3 0.027 561 206 conserved hypothetical protein 
Cd630-0562 (1D11) 1.0 0.950 642 635 0.5 0.027 163 350 putative endonuclease 
Cd630-3373 (9A20) 1.4 0.409 1540 948 2.2 0.027 1113 488 magnesium transporting ATPase, P-type 
Cd630-2463 (7F11) 1.0 0.863 9219 9344 1.7 0.027 8907 5534 heat-inducible transcription repressor 
Cd630-3523 (10G2) 0.9 0.593 590 594 0.5 0.027 164 354 dimethyladenosine transferase 
Cd630-1848 (1J18) 1.3 0.793 31 13 3.6 0.027 31 9 putative conjugative transposon protein 
Cd630-3419 (9O13) 0.9 0.637 3313 3638 1.6 0.026 3865 2283 delta-aminolevulinic acid dehydratase 
Cd630-0899 (3O6) 0.9 0.469 1451 1586 1.4 0.026 1497 1066 DNA polymerase IV 
Cd630-3628 (10P3) 0.9 0.452 637 730 0.4 0.026 182 392 putative sugar-phosphate isomerase 
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Cd630-1177 (3G17) 1.0 0.932 13890 13888 0.8 0.026 6827 9086 
DeoR-family transcriptional regulator (fatty acid and phospholipid 
biosynthesis regulator) 
Cd630-2128 (6F17) 1.5 0.582 77 57 2.6 0.026 67 28 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase 
Cd630-1253 (3L15) 1.0 0.832 1900 1880 0.5 0.026 629 1244 30S ribosomal protein S16 
Cd630-2500 (7C16) 1.0 0.778 1625 1600 0.5 0.026 489 958 argininosuccinate lyase 
Cd630-3139 (9C2) 1.0 0.926 188 181 1.6 0.026 176 109 putative transcriptional regulator 
Cd630-0056 (1P7) 1.0 0.592 4341 4306 1.3 0.026 3177 2390 conserved hypothetical protein 
Cd630-0222 (4F4) 1.0 0.866 4456 4526 0.6 0.026 1948 3088 phosphoribosylglycinamide formyltransferase 
Cd630-0889 (3M5) 1.1 0.584 15507 12930 0.7 0.026 6437 8961 S-adenosylmethionine decarboxylase proenzyme 
Cd630-3149 (9H3) 1.0 0.994 1855 1853 0.4 0.026 355 1031 putative DNA helicase 
Cd630-0271 (4G10) 1.0 0.805 3625 3713 0.6 0.026 1364 2239 putative flagellar motor switch protein 
Cd630-2784b (8G4) 1.0 0.794 5993 5944 0.5 0.026 2268 4533 putative cell surface protein 
Cd630-2386 (7A2) 1.3 0.591 50 34 4.3 0.026 59 15 conserved hypothetical protein 
Cd630-2462 (7E11) 1.0 0.820 15476 14813 1.2 0.025 9454 7910 heat shock protein 
Cd630-0817 (1E20) 1.0 0.975 6991 6964 1.3 0.025 5848 4252 putative transposase-like protein B 
Cd630-3393 (9E22) 1.0 
no 
replicates 13 13 3.1 0.025 50 14 putative RNA methyltransferase 
Cd630-2432 (7G7) 1.0 0.999 5014 4901 1.6 0.025 5120 3329 glycyl-tRNA synthetase beta chain 
Cd630-0077 (1M10) 0.9 0.468 17053 19724 0.8 0.025 11064 14611 30S ribosomal protein S19 
Cd630-1579 (5K8) 0.9 0.543 2290 2646 0.7 0.025 963 1354 putative two-component histidine kinase 
Cd630-1909 (6G1) 1.0 0.954 26 28 4.8 0.025 75 17 putative ethanolamine/propanediol utilization protein 
Cd630-1391 (4N8) 0.8 0.660 74 80 0.4 0.025 28 92 putative esterase 
Cd630-2701 (7P5) 1.0 0.998 3307 3282 1.3 0.025 2221 1805 putative lipoprotein 
Cd630-2640 (7K22) 1.1 0.496 917 902 0.3 0.025 194 576 putative ATP-binding protein 
Cd630-0224 (4H4) 1.0 0.965 6799 6775 0.5 0.025 2329 4436 phosphoribosylamine--glycine ligase 
Cd630-3239 (9K3) 1.0 0.523 950 961 4.3 0.024 2573 583 conserved hypothetical protein 
Cd630-1964 (6F8) 0.9 0.576 338 380 1.4 0.024 298 206 conserved hypothetical protein 
Cd630-0326 (2F5) 1.0 0.915 486 542 0.3 0.024 121 500 cobalt transport protein 
Cd630-3651 (10O6) 1.0 0.939 3065 3049 0.9 0.024 1753 2052 putative metallo-beta-lactamase superfamily protein 
Cd630-0215 (4G3) 0.9 0.637 556 638 0.4 0.024 161 364 transposase 
Cd630-1934 (6H4) 0.9 0.551 1479 1624 0.6 0.024 530 980 conserved hypothetical protein 
Cd630-0258 (4B9) 1.0 0.926 7814 7799 0.6 0.024 3265 5469 flagellar basal body-associated protein 
Cd630-0924 (3P9) 1.5 0.471 39 20 8.5 0.023 68 9 hypothetical phage protein 
Cd630-1220 (3B23) 1.1 0.487 3897 3673 0.4 0.023 1276 2835 ADP-ribose pyrophosphatase 
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Cd630-3377 (9E20) 1.0 0.834 5519 5277 1.8 0.023 4994 2748 magnesium transporting ATPase, P-type 1 
Cd630-1047 (4E13) 1.1 0.595 2235 2051 0.7 0.023 1089 1544 putative cell surface protein 
Cd630-2004 (6O1) 1.0 0.872 424 424 3.3 0.023 885 234 hypothetical protein 
Cd630-1651 (5C17) 1.0 0.946 526 538 0.5 0.023 178 319 putative signaling protein 
Cd630-0729 (3E9) 1.0 0.614 2048 2097 0.3 0.023 489 1341 putative glycine cleavage system H protein 
Cd630-3633 (10M4) 0.9 0.680 782 770 0.4 0.023 212 521 putative membrane protein 
Cd630-1837 (1O16) 0.9 0.685 1567 1801 0.4 0.023 531 1181 shikimate dehydrogenase 
Cd630-2285 (6L13) 0.8 0.471 845 901 0.2 0.023 99 446 GntR-family transcriptional regulator 
Cd630-2452 (7C10) 1.0 0.983 1189 1277 0.3 0.023 198 646 hypothetical protein 
Cd630-2018 (6P3) 1.0 0.623 1374 1359 0.7 0.022 538 776 AraC-family transcriptional regulator 
Cd630-2540 (7D21) 1.0 0.555 15184 15407 1.6 0.022 16547 10110 NADH oxidase 
Cd630-0171 (2C22) 1.0 0.600 1697 1658 1.8 0.022 1941 1062 putative DNA-binding protein 
Cd630-3335 (9C15) 1.0 0.749 1933 1960 1.3 0.022 1678 1312 conjugative tyransposon conserved hypothetical protein 
Cd630-3620 (10P2) 1.0 0.917 1792 1776 0.8 0.022 864 1042 hypothetical protein 
Cd630-2450 (7A10) 1.0 0.465 1653 1682 0.7 0.022 930 1213 putative ribosomal protein L11 methyltransferase 
Cd630-2545 (7A22) 1.0 0.933 1972 1968 0.8 0.022 988 1287 cellulose synthase catalytic subunit [UDP-forming] 
Cd630-2933 
(10E24) 1.1 0.387 276 219 2.0 0.022 274 146 hypothetical phage protein 
Cd630-1975 (6A10) 1.0 0.555 1466 1533 0.7 0.022 727 927 tRNA delta(2)-isopentenylpyrophosphate transferase 
Cd630-2461 (7D11) 0.9 0.375 15557 16844 1.4 0.022 12127 8839 chaperone protein 
Cd630-2605f1 
(7O17) 0.9 0.471 525 548 0.5 0.022 148 327 ADP-ribosyltransferase (pseudogene) 
Cd630-1011 (4O20) 1.2 0.495 595 510 1.9 0.022 439 218 glucosamine-6-phosphate deaminase 
Cd630-3425 (9M14) 1.0 0.719 2951 3184 0.5 0.022 1155 2455 putative cobalamin biosynthesis protein 
Cd630-0179 (2C23) 1.0 0.506 5942 5805 1.7 0.021 8185 5031 NAD-specific glutamate dehydrogenase 
Cd630-0942 (3J12) 1.0 0.735 1855 1786 1.8 0.021 2444 1315 hypothetical phage protein 
Cd630-0902 (3J7) 1.0 0.815 1126 1147 1.7 0.021 1199 703 putative cation efflux rotein 
Cd630-2616 (7K19) 1.0 0.771 1514 1511 1.3 0.021 1328 1023 hypothetical protein 
Cd630-1145 (3G13) 1.0 0.975 34555 34637 0.5 0.021 12485 23295 rod shape-determining protein 
Cd630-2172 (6B23) 1.1 0.430 5946 5580 0.6 0.021 2454 4076 probable amino-acid ABC transporter, ATP-binding protein 
Cd630-1550 (5N4) 1.0 0.701 3007 3040 0.5 0.021 1013 2168 imidazoleglycerol-phosphate dehydratase 
Cd630-0353 (2A9) 1.1 0.673 2207 2121 1.3 0.021 1357 1038 hypothetical protein 
Cd630-3356 (9H17) 1.0 0.631 2336 2382 1.3 0.021 1630 1250 putative transcriptional regulator 
Cd630-0809 (1E19) 1.0 0.919 937 959 0.7 0.021 440 581 conserved hypothetical protein 
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Cd630-0327 (2G5) 1.1 0.412 9809 8852 0.4 0.021 2544 5753 cobalt ABC transporter, ATP-binding protein 
Cd630-1589 (5M9) 1.1 0.571 646 557 1.4 0.021 438 321 putative ribose ABC transporter, substrate-binding lipoprotein 
Cd630-2363 (6J23) 1.0 0.648 9275 9178 0.5 0.020 3756 7576 hypothetical protein 
Cd630-0183 (2G23) 1.0 0.798 701 745 0.3 0.020 157 533 putative exported protein 
Cd630-0452 (2M9) 0.9 0.612 3257 3409 1.3 0.020 2324 1716 putative DNA repair protein 
Cd630-2823 (8H10) 1.0 0.839 923 934 0.4 0.020 223 486 conserved hypothetical protein 
Cd630-1119 (4E22) 0.7 0.774 20 18 8.8 0.020 81 9 putative lipoprotein 
Cd630-0272 (4H10) 1.0 0.665 4486 4760 0.4 0.020 1712 3682 conserved hypothetical protein 
Cd630-0204 (4D2) 1.0 0.950 2017 1960 0.5 0.020 647 1141 putative signaling protein 
Cd630-1751b 
(5P17) 1.0 0.991 83 88 3.1 0.020 110 36 putative cell surface-associated cysteine protease 
Cd630-1551 (5O4) 1.0 0.897 54 51 2.0 0.020 42 21 putative imidazole glycerol phosphate synthase subunit 
Cd630-1503 (5G10) 1.0 0.815 751 771 0.5 0.020 258 483 putative transcriptional regulator 
Cd630-1088 (4F18) 1.2 0.378 81 67 2.3 0.019 83 32 putative membrane protein 
Cd630-0249 (4A8) 1.0 0.713 27605 28534 0.4 0.019 8723 20400 flagellar motor switch protein 
Cd630-0413 (2M4) 0.7 0.581 44 54 3.4 0.019 57 17 putative single-strand binding protein 
Cd630-3578 (10F9) 0.9 0.485 1159 1261 1.4 0.019 1010 726 putative resolvase 
Cd630-3621 (10I3) 1.0 0.983 1394 1354 0.4 0.019 296 759 conserved hypothetical protein 
Cd630-1761 (5J19) 1.0 0.945 1587 1604 1.3 0.019 1407 1051 conserved hypothetical protein 
Cd630-0254 (4F8) 1.0 0.833 18882 21094 0.5 0.019 7344 14992 putative basal-body rod modification protein 
Cd630-3375 (9C20) 1.0 0.996 931 936 2.3 0.019 1035 472 Mabnesium transporting ATPase protein C 
Cd630-2536 (7H20) 0.9 0.452 1284 1325 0.5 0.019 344 741 two-component response regulator 
Cd630-3111 (8O22) 1.0 0.973 868 853 0.5 0.019 256 537 conserved hypothetical protein 
Cd630-1099 (4A20) 1.0 0.857 57 58 3.6 0.019 67 22 two-component response regulator 
Cd630-2345 (6P20) 1.0 0.762 2850 2908 0.6 0.019 1143 1862 LysR-family regulatory protein 
Cd630-1783 (5P21) 1.0 0.722 847 905 0.3 0.019 167 474 two component sensor histidine kinase 
Cd630-1210 (3H21) 1.0 0.415 1678 1650 0.6 0.019 589 1036 putative exported protein 
Cd630-1720 (5P13) 1.0 0.795 11371 11311 0.6 0.019 4840 7593 putative hydantoinase 
Cd630-0220 (4D4) 1.0 0.964 11615 11514 0.5 0.019 4168 7850 amidophosphoribosyltransferase 
Cd630-3337 (9E15) 1.5 0.554 37 19 4.1 0.019 49 13 conjugative transposon membrane protein 
Cd630-2413 (7D5) 1.5 0.422 113 78 2.2 0.019 107 51 conserved hypothetical protein 
Cd630-2169 (6G22) 0.9 0.573 224 259 1.7 0.019 301 167 iron-sulfur binding protein 
Cd630-0379 (2C12) 0.9 0.768 216 202 1.6 0.019 177 112 conjugative transposon protein 
Cd630-3608 (10L1) 0.9 0.665 418 419 0.3 0.018 89 286 ABC transporter, ATP-binding protein 
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Cd630-1143 (3E13) 1.0 0.782 14702 14879 0.7 0.018 6418 8944 septum formation protein 
Cd630-3271 (9K7) 1.0 0.829 2493 2565 0.4 0.018 917 2168 hypothetical protein 
Cd630-1236 (3K13) 1.0 0.942 6091 6335 0.8 0.018 3141 3959 putative exported protein 
Cd630-3622 (10J3) 1.0 0.654 937 890 0.6 0.018 361 625 putative phosphonoacetate hydrolase 
Cd630-3490 (9N22) 0.9 0.626 1062 1112 0.8 0.018 618 784 stage II sporulation protein e 
Cd630-1071 (4E16) 0.9 0.779 425 520 0.5 0.018 152 296 conserved hypothetical protein 
Cd630-3524 (10H2) 0.9 0.592 825 830 0.4 0.018 199 465 putative DNA-binding protein 
Cd630-0550 (1H9) 1.0 0.880 586 579 1.3 0.018 453 347 putative membrane protein 
Cd630-0395 (2K2) 1.0 0.814 43426 44207 0.4 0.018 9570 24011 E-cinnamoyl-CoA:R-phenyllactate CoA transferase large subunit 
Cd630-2958 (8F15) 1.0 0.933 895 860 0.6 0.018 407 666 V-type sodium ATP synthase subunit E 
Cd630-3280 (9L8) 0.9 0.432 1216 1356 0.8 0.018 522 675 putative transcription antiterminator 
Cd630-3584 
(10D10) 1.0 0.995 162 124 3.0 0.018 129 43 putative ABC transporter, permease protein 
Cd630-1599 (5O10) 0.9 0.593 264 269 0.3 0.018 60 194 putative phosphomethylpyrimidine kinase 
Cd630-3247 (9K4) 1.1 0.575 148 130 3.4 0.017 386 102 putative electron transfer protein 
Cd630-0325 (2E5) 1.0 0.895 6212 6156 0.4 0.017 1580 3463 cobalt transport protein 
Cd630-1147 (3A14) 1.0 0.971 7977 8008 0.5 0.017 3189 5922 putative membrane protein 
Cd630-2445 (7D9) 1.2 0.551 1648 1491 2.8 0.017 2349 780 probale sensory protein 
Cd630-3544 (10D5) 1.0 0.889 902 920 1.8 0.017 863 500 AsnC-family transcriptional regulator 
Cd630-0908 (3P7) 0.9 0.619 55 55 3.9 0.017 87 24 phage protein 
Cd630-2439 (7F8) 1.0 0.795 343 355 0.4 0.017 73 223 putative membrane-associated kinase and phosphatase 
Cd630-1384 (4O7) 1.0 0.984 888 881 0.3 0.016 217 616 conserved hypothetical protein 
Cd630-3531 (10G3) 1.0 0.727 113 111 2.5 0.016 105 42 putative phophoesterase 
Cd630-0177 (2A23) 1.0 0.838 928 919 2.1 0.016 1286 596 cyclopropane-fatty-acyl-phospholipid synthase 
Cd630-3185 (9D8) 1.1 0.435 881 823 0.5 0.016 252 463 conserved hypothetical protein (pseudogene) 
Cd630-2772 (8B3) 0.7 0.397 256 353 0.3 0.016 85 313 putative teichuronic acid biosynthesis glycosyl transferase 
Cd630-1166 (3D16) 1.0 0.897 4222 4476 1.3 0.016 3772 2701 homoserine dehydrogenase 
Cd630-0758 (1B13) 0.9 0.632 492 527 1.8 0.016 459 261 pyruvate formate-lyase activating enzyme 
Cd630-1607 (5O11) 1.3 0.708 41 32 2.6 0.016 64 21 ABC transporter, ATP-binding protein 
Cd630-1215 (3E22) 1.0 0.984 5426 5470 0.7 0.016 2195 3114 putative pyrophosphokinase 
Cd630-1935 (6A5) 1.1 0.557 2030 1883 1.9 0.016 1788 970 stage V sporulation protein S 
Cd630-0197 (4E1) 1.0 0.408 1556 1643 1.4 0.016 1329 961 conserved hypothetical protein (pseudogene) 
Cd630-2173 (6C23) 1.0 0.987 5682 5633 0.4 0.016 1443 3948 putative peptidase 
Cd630-3347 (9G16) 1.0 0.825 1666 1655 0.7 0.016 775 1085 putative membrane protein 
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Cd630-0821 (1A21) 1.0 0.989 676 680 1.7 0.016 753 428 two-component sensor histidine kinase 
Cd630-2013 (6K3) 1.0 0.573 1514 1428 0.6 0.016 554 842 TetR-family transcriptional regulator 
Cd630-0218 (4B4) 1.0 0.994 3733 3726 0.5 0.015 1293 2763 phosphoribosylaminoimidazole carboxylase catalytic subunit 
Cd630-3061 (8M16) 1.1 0.437 609 492 1.7 0.015 463 265 PTS system, IIbc component 
Cd630-0230 (4F5) 1.0 0.970 4966 5076 0.5 0.015 1856 3494 putative flagellar biosynthesis protein 
Cd630-2509 (7D17) 1.0 0.860 3568 3526 0.4 0.015 891 2180 probable 6-phospho-alpha-glucosidase 
Cd630-0739 (3G10) 1.0 0.980 4958 5095 0.8 0.015 2467 3156 putative exported protein 
Cd630-2067 (6I10) 1.0 0.552 2294 2243 0.7 0.015 1009 1396 putative exported protein 
Cd630-0192 (2H24) 1.1 0.458 2574 2443 1.3 0.015 1868 1378 cardiolipin synthetase 
Cd630-2454 (7E10) 0.9 0.451 1295 1373 0.4 0.015 335 775 hypothetical protein 
Cd630-0975 (4K16) 1.0 0.938 5192 5443 0.5 0.015 1623 3005 hypothetical phage protein 
Cd630-1841 (1K17) 1.0 0.785 881 882 0.3 0.015 111 468 putative signaling protein 
Cd630-1294 (3M20) 1.1 0.659 3579 3282 1.6 0.015 2888 1894 putative membrane-associated peptidase 
Cd630-1096 (4F19) 1.0 0.839 194 197 2.1 0.015 206 102 putative lantibiotic ABC transporter, permease protein 
Cd630-0253 (4E8) 0.9 0.436 13153 15136 0.4 0.015 4611 12281 putative flagellar hook-length control protein 
Cd630-3354 (9F17) 1.0 0.651 976 1002 0.7 0.014 401 613 conserved hypothetical protein 
Cd630-1765 (5N19) 1.0 0.887 299 288 1.4 0.014 266 199 Nudix-family hydrolase 
Cd630-0307 (2C3) 1.0 0.997 1848 1914 1.5 0.014 1706 1117 putative 'four-disulfide core' protein 
Cd630-1665 (5A19) 1.0 0.932 4634 4486 1.4 0.014 3630 2652 cysteine synthase A 
Cd630-0250 (4B8) 0.9 0.612 14677 16779 0.4 0.014 5187 11932 flagellar assembly protein 
Cd630-0334 (2F6) 1.2 0.436 2301 2033 2.0 0.013 2827 1456 
aldehyde-alcohol dehydrogenase [includes: alcohol dehydrogenase; 
acetaldehyde dehydrogenase [acetylating]; pyruvate-formate-lyase 
deactivase 
Cd630-2228 (8K6) 1.2 0.426 1287 1162 1.6 0.013 1101 703 putative membrane protein 
Cd630-0270 (4F10) 1.0 0.942 7106 7692 0.6 0.013 3519 5501 putative flagellar motor switch protein 
Cd630-2656 (7K24) 1.0 0.846 1391 1381 1.4 0.013 1092 798 
stage V sporulation protein D (sporulation specific penicillin-binding 
protein) 
Cd630-0003 (1K1) 1.1 0.442 506 442 0.5 0.013 152 294 putative RNA-binding mediating protein 
Cd630-3670 (10J9) 1.0 0.834 4413 4348 1.2 0.013 3151 2581 putative selenocysteine lyase 
Cd630-2639 (7J22) 0.9 0.604 1354 1390 0.3 0.013 301 785 conserved hypothetical protein 
Cd630-0266 (4B10) 1.0 0.851 6735 6819 0.3 0.013 1289 4680 RNA polymerase sigma factor for flagellar operon 
Cd630-2361 (6P22) 1.0 0.753 12332 12418 0.4 0.013 3450 8576 putative aliphatic sulfonate ABC transporter, ATP-binding protein 
Cd630-1556 (5L5) 1.0 0.785 1108 1106 0.5 0.013 298 620 putative polysaccharide deacetylase 
Cd630-0394 (2J2) 1.0 0.710 15020 15492 0.5 0.013 5508 12124 D-lactate dehydrogenase 
  
 
410 
Cd630-3117 (8M23) 1.0 0.977 1777 1743 0.7 0.013 617 870 putative beta-glucoside bgl operon transcription antiterminator 
Cd630-1863 (1I20) 1.0 0.956 66 60 2.2 0.013 72 32 putative conjugative transposon conserved hypothetical protein 
Cd630-2705 (7L6) 1.0 0.803 2463 2508 0.3 0.013 439 1467 putative amidohydrolas 
Cd630-0740 (3H10) 1.0 0.857 3338 3394 0.5 0.013 963 1985 putative aminotransferase 
Cd630-1239 (3N13) 1.1 0.454 2691 2464 0.8 0.013 1435 1720 putative regulatory protein 
Cd630-3327 (9C14) 1.0 0.849 8824 8864 1.6 0.013 8453 5493 conjugative transposon conserved hypothetical protein 
Cd630-0243 (4C7) 1.0 0.817 11133 11514 0.3 0.013 4437 12516 conserved hypothetical protein 
Cd630-2001 (6L1) 0.9 0.513 743 819 1.5 0.012 798 517 conserved hypothetical protein 
Cd630-3208 (9D11) 0.9 0.472 762 785 0.5 0.012 226 435 MarR-family transcriptional regulator 
Cd630-2990 (8F19) 0.9 0.555 962 1080 0.4 0.012 235 640 ABC transporter, ATP-binding protein 
Cd630-0499 (1D3) 1.0 0.991 1748 1694 1.5 0.012 1488 995 putative conjugative transposon replication initiation factor 
Cd630-3332 (9H14) 1.0 0.897 6635 6635 0.8 0.012 3435 4530 TetR-family transcriptional regulator 
Cd630-1171 (3A17) 1.0 0.876 885 940 1.5 0.012 849 562 electron transfer flavoprotein beta-subunit 
Cd630-0158 (2F20) 1.0 0.825 900 887 0.3 0.012 199 645 putative membrane protein (pseudogene) 
Cd630-1526 (5N1) 1.0 0.689 5730 5766 1.3 0.012 4778 3567 dihydroorotase 
Cd630-2773 (8C3) 0.9 0.461 352 431 0.2 0.012 111 437 putative beta-glycosyltransferase 
Cd630-0713 (3E7) 1.0 0.786 3894 3894 1.4 0.012 3653 2544 putative adenosylcobamide-dependent radical SAM superfamily protein 
Cd630-3075 (8K18) 1.5 0.516 4074 1866 6.2 0.012 8901 1276 PTS system, IIabc component 
Cd630-1307 (3J22) 1.0 0.979 1178 1162 1.3 0.012 976 782 transcription elongation protein 
Cd630-1548 (5L4) 1.0 0.958 819 822 0.4 0.012 218 509 putative ATP phosphoribosyltransferase 
Cd630-2534 (7F20) 1.1 0.535 978 857 0.5 0.011 293 563 ABC transporter ATP-binding protein 
Cd630-1690 (5B22) 1.0 0.937 6184 6260 1.6 0.011 6062 3689 thioredoxin 
Cd630-0687 (3C4) 1.1 0.494 2816 2652 0.6 0.011 1016 1705 50S ribosomal protein L20 
Cd630-1185 (3G18) 1.1 0.378 2363 2198 1.7 0.011 2129 1164 putative signaling protein 
Cd630-0434 (2J7) 1.1 0.621 442 387 1.7 0.011 333 203 putative drug/sodium antiporter 
Cd630-1655 (5G17) 0.9 0.471 6799 7445 0.7 0.011 3756 5197 putative Na+/H+ antiporter 
Cd630-2389 (7D2) 1.0 0.826 663 676 0.4 0.011 175 508 putative beta-lactamase inducer 
Cd630-1212 (3B22) 1.0 0.513 1873 1890 0.5 0.011 727 1367 spermine/spermidine acetyltransferase 
Cd630-1216 (3F22) 1.0 0.902 3451 3441 0.5 0.011 986 2091 putative exported protein 
Cd630-0539 (1E8) 1.1 0.409 3802 3368 0.3 0.011 788 2130 chemotaxis protein 
Cd630-0195 (4C1) 1.0 0.978 2056 2094 1.6 0.011 1853 1186 putative membrane protein 
Cd630-2992 (8H19) 1.0 0.806 600 556 0.6 0.011 254 444 hypothetical protein 
Cd630-1538 (5J3) 1.0 0.855 1683 1682 0.8 0.010 863 1017 putative signaling protein 
  
 
411 
Cd630-1483 (5C8) 1.2 0.574 192 140 0.7 0.010 44 67 putative aliphatic sulfonates ABC transporter, ATP-binding protein 
Cd630-0153 (2A20) 0.9 0.732 53 56 2.7 0.010 86 30 4-hydroxyphenylacetate decarboxylase, catalytic subunit 
Cd630-1024 (4L22) 1.0 0.444 839 787 2.1 0.010 950 425 spermidine/putrescine ABC transporter, ATP-binding protein 
Cd630-2447 (7F9) 1.0 0.796 10176 10055 1.5 0.010 10331 6748 histidine triad nucleotide-binding protein 
Cd630-0522 (1D6) 1.1 0.543 736 647 0.3 0.010 78 285 putative signaling protein 
Cd630-3671 (10K9) 1.1 0.426 3599 3460 0.8 0.010 1622 2038 stage 0 sporulation protein J 
Cd630-2127 (6E17) 1.0 0.803 21891 22040 0.5 0.010 7032 12999 putative membrane protein 
Cd630-1282 (3I19) 1.0 0.980 25039 25453 1.7 0.010 26768 15173 putative alanyl-tRNA synthetase 
Cd630-0735 (3C10) 1.1 0.393 7334 7040 1.5 0.010 5867 3943 hypothetical protein 
Cd630-0473 (2J12) 1.0 0.735 1354 1340 0.2 0.010 232 919 MarR-family transcriptional regulator 
Cd630-0917 (3I9) 1.1 0.709 35 30 3.3 0.010 76 21 putative phage recombination protein 
Cd630-3461 (9I19) 0.9 0.407 4235 4667 1.2 0.010 3300 2874 putative regulator of cell growth 
Cd630-3236 (9P2) 1.2 0.641 105 91 6.3 0.010 236 31 putative membrane protein 
Cd630-0103 (2G13) 1.0 0.767 3528 3662 1.7 0.010 3703 2124 tRNA pseudouridine synthase 1 
Cd630-2716 (7P7) 0.9 0.762 2152 2349 0.4 0.009 611 1495 hypothetical protein 
Cd630-2674 (7M2) 1.0 0.699 4331 4006 1.6 0.009 3946 2623 oligopeptide ABC transporter, permease protein 
Cd630-3283 (9O8) 1.0 0.916 3477 3654 0.7 0.009 1622 2296 putative pyruvate formate-lyase 3 activating enzyme 
Cd630-0240 (4H6) 1.1 0.755 7222 7122 0.5 0.009 3344 5938 putative glycosyltransferase 
Cd630-0732 (3H9) 1.0 0.500 1959 1864 1.6 0.009 1545 951 putative radical SAM superfamily protein 
Cd630-3439 (9K16) 1.0 0.757 4489 4933 0.5 0.009 1345 2829 nicotinate-nucleotide--dimethylbenzimidazole phosphoribosyltransferase 
Cd630-0028 (1L4) 1.0 0.864 4233 4152 0.5 0.009 1302 2674 putative DNA-binding protein 
Cd630-3674 (10N9) 1.0 0.592 4690 4580 1.5 0.009 4206 2814 
methyltransferase (putative glucose inhibited division protein B) 
(pseudogene) 
Cd630-2649 (7L23) 1.0 0.684 2347 2471 0.5 0.009 671 1299 putative exported protein 
Cd630-3097 (8I21) 1.0 0.883 2782 2786 1.2 0.009 1370 1130 PTS system, IIabc component 
Cd630-1933 (6G4) 1.1 0.518 1805 1752 0.3 0.009 349 1170 putative membrane protein 
Cd630-3299 (9O10) 1.0 0.759 1737 1757 1.2 0.009 1403 1173 probable transporter 
Cd630-0262 (4F9) 1.0 0.988 12992 12994 0.7 0.009 5272 7703 flagellar export protein 
Cd630-3416 (9L13) 1.1 0.794 1375 1401 2.0 0.009 1403 699 ABC transporter, permease protein 
Cd630-0910 (3J8) 1.0 0.530 3070 3104 1.7 0.009 3520 2113 putative phage protein 
Cd630-2181 (6C24) 0.9 0.537 6769 7523 0.5 0.009 3088 5375 putative aromatic compounds hydrolase 
Cd630-0246 (4F7) 1.0 0.757 9969 9981 0.4 0.009 3249 7584 flagellar basal-body rod protein 
Cd630-3258 (9N5) 0.9 0.425 1061 1225 0.8 0.009 566 727 iron-only hydrogenase 
Cd630-3041 (8I14) 0.9 0.530 7521 8094 1.4 0.009 7237 5001 proline iminopeptidase 
  
 
412 
Cd630-3613 (10I2) 1.1 0.475 1361 1236 1.4 0.008 965 694 conserved hypothetical protein 
Cd630-2149 (6C20) 1.0 0.724 5698 5971 1.7 0.008 7596 4301 putative exported protein 
Cd630-3453 (9I18) 1.0 0.850 2175 2157 0.5 0.008 578 1277 N-acetylglucosamine-6-phosphate deacetylase 
Cd630-2009 (6N2) 1.0 0.873 111 102 2.4 0.008 156 60 putative topoisomerase (partial) 
Cd630-1693 (5E22) 1.0 0.519 8323 7952 3.9 0.008 17264 4117 putative dinitrogenase iron-molybdenum cofactor 
Cd630-0472 (2I12) 0.9 0.528 2513 2630 0.4 0.008 586 1541 putative iron-sulfur flavoprotein 
Cd630-1695 (5G22) 1.0 0.699 3963 4084 1.5 0.008 4399 2804 putative arsenical pump membrane protein 
Cd630-2983 (8G18) 0.7 0.645 342 321 0.3 0.008 64 255 conserved hypothetical protein 
Cd630-1587 (5K9) 1.0 0.853 111 101 2.2 0.008 107 50 putative ribose ABC transporter, ATP-binding protein 
Cd630-2533 (7E20) 1.5 0.439 64 35 20.0 0.008 206 7 ABC transporter, permease protein 
Cd630-0703 (3C6) 1.0 0.740 5420 5470 1.4 0.008 7633 5202 protease 
Cd630-3087 (8O19) 1.1 0.665 1614 1525 1.7 0.008 1551 952 phosphosugar-binding transcriptional regulator 
Cd630-3374 (9B20) 1.8 0.394 336 95 3.6 0.008 176 51 putative membrane protein 
Cd630-2360 (6O22) 1.0 0.879 5896 5815 0.3 0.007 1475 5045 hypothetical protein 
Cd630-2542 (7F21) 1.1 0.430 4347 4122 1.5 0.007 4517 2969 putative exported protein 
Cd630-1404 (4K10) 1.0 0.774 17621 17915 1.4 0.007 14477 10199 putative oligopeptide transporter 
Cd630-1284 (3K19) 1.0 0.754 4723 4638 0.8 0.007 2323 2831 putative membrane protein 
Cd630-0252 (4D8) 0.9 0.591 20547 23724 0.2 0.007 3439 13614 flagellar protein 
Cd630-0232 (4H5) 1.0 0.650 33064 34086 0.4 0.007 10159 25969 flagellar hook-associated protein 
Cd630-1489 (5A9) 1.0 0.888 1541 1496 0.5 0.007 489 900 D-methionine ABC transporter, ATP-binding protein 
Cd630-1485 (5E8) 1.0 0.879 805 783 3.6 0.007 1912 501 conserved hypothetical protein 
Cd630-2024 (6N4) 1.0 0.810 1912 1914 1.4 0.007 1529 1025 ABC transporter, ATP-binding protein 
Cd630-2416 (7G5) 1.2 0.558 13 9 34.4 0.007 526 8 putative transcription antiterminator 
Cd630-3547 (10G5) 0.9 0.542 301 292 0.4 0.007 53 143 conserved hypothetical protein 
Cd630-1172 (3B17) 1.0 0.995 1103 1099 1.5 0.007 1092 724 electron transfer flavoprotein alpha-subunit 
Cd630-0245 (4E7) 1.0 0.824 11530 12364 0.3 0.007 2367 7627 flagellar basal-body rod protein 
Cd630-1844 (1N17) 1.0 
no 
replicates 86 86 1.4 0.007 103 73 putative cell surface protein (pseudogene) 
Cd630-2789b (8G5) 1.0 0.694 9279 9138 0.7 0.007 4194 5821 cell surface protein 
Cd630-0211 (4C3) 1.0 0.825 2082 2080 0.2 0.007 301 1333 CTP:phosphocholine cytidylyltransferase 
Cd630-0438 (2N7) 0.9 0.442 1155 1291 0.4 0.007 431 1071 putative exported protein 
Cd630-1151 (3E14) 1.0 0.802 4677 4637 1.3 0.007 4087 3016 cell division topological specificity factor 
Cd630-3076 (8L18) 1.5 0.527 3325 1462 5.6 0.007 4547 764 putative tagatose (1)-phosphate-kinase 
Cd630-1389 (4L8) 0.9 0.730 491 512 0.4 0.007 136 327 putative chloromuconate cycloisomerase 
  
 
413 
Cd630-1828 (1N15) 1.0 0.842 4470 4634 1.9 0.007 5506 2749 cell division protein 
Cd630-1275 (3J18) 1.0 0.901 2751 2733 1.4 0.007 2307 1654 GTP-sensing transcriptional pleiotropic repressor 
Cd630-3467 (9O19) 1.0 0.992 4735 4731 1.5 0.007 4544 3130 ATP synthase epsilon chain (partial) 
Cd630-3098 (8J21) 0.9 0.518 1420 1686 0.7 0.006 746 1137 transcription antiterminator 
Cd630-2471 (7F12) 1.1 0.469 894 796 2.6 0.006 1010 410 conserved hypothetical protein 
Cd630-1417 (4P11) 1.0 0.941 1510 1498 0.4 0.006 475 1009 putative ATP-binding protein 
Cd630-2362 (6I23) 1.0 0.862 9160 9403 0.5 0.006 4187 8909 
putative aliphatic sulfonates ABC transporter, permease protein 
(pseudogene) 
Cd630-1999 (6J1) 1.0 0.915 736 732 2.1 0.006 996 462 flavodoxin 
Cd630-0227 (4C5) 1.0 0.628 6072 5921 0.4 0.006 2254 5241 conserved hypothetical protein 
Cd630-2737 (7N10) 1.1 0.594 980 811 0.6 0.006 309 530 putative carbon-nitrogen hydrolase 
Cd630-1261 (3L16) 1.1 0.407 9985 9546 1.6 0.006 8662 5229 putative ribonucleotide-diphosphate reductase 
Cd630-3376 (9D20) 1.0 0.982 2713 2499 2.4 0.006 2798 1165 putative transcriptional regulator 
Cd630-0184 (2H23) 1.2 0.446 690 522 0.5 0.006 152 334 aspartate carbamoyltransferase catalytic chain 
Cd630-0985 (4M17) 1.0 0.818 2551 2563 0.7 0.006 1110 1553 putative drug/sodium antiporter 
Cd630-3010 (8B22) 0.9 0.607 63 66 2.5 0.006 65 25 putative cytochrome C biogenesis protein 
Cd630-1304 (3O21) 1.1 0.526 3430 3236 1.8 0.006 3052 1663 putative mannosyl-glycoprotein endo-beta-N-acetylglucosamidase 
Cd630-0607 (2O16) 1.0 0.910 2227 2229 1.6 0.006 2021 1288 putative transposase-like protein B 
Cd630-0358 (2F9) 1.2 0.382 373 308 1.5 0.005 271 188 conjugative transposon conserved hypothetical protein 
Cd630-0878 (3J4) 1.0 0.976 23143 23199 0.6 0.005 11645 20522 ABC transporter, permease protein 
Cd630-1630 (5F14) 0.9 0.569 483 512 0.3 0.005 147 507 putative membrane-associated metal-dependent hydrolase 
Cd630-3157 (9H4) 1.0 0.877 3697 3861 1.8 0.005 4122 2285 SsrA-binding protein 
Cd630-2358 (6M22) 1.0 0.813 538 496 0.6 0.005 172 283 putative oligoendopeptidase 
Cd630-3091 (8K20) 1.0 0.749 17477 18059 0.4 0.005 5694 14087 trehalose-6-phosphate hydrolase 
Cd630-1785 (5J22) 1.0 0.664 3560 3451 0.7 0.005 1789 2636 argininosuccinate synthase 
Cd630-1943 (6A6) 1.0 0.606 1785 1832 1.4 0.005 2464 1723 conserved hypothetical protein 
Cd630-2374 (6M24) 0.8 0.411 640 645 0.5 0.005 216 392 hypothetical protein 
Cd630-3428 (9P14) 1.1 0.421 2563 2397 0.2 0.005 306 1471 probable cobalt-precorrin-6y C(5)-methyltransferase 
Cd630-3103 (8O21) 1.0 0.495 1388 1333 1.4 0.005 1129 780 putative PTS syste, IIa component 
Cd630-3430 (9J15) 1.0 0.795 1104 1139 0.2 0.005 243 894 cobalt-precorrin-8x methylmutase 
Cd630-3426 (9N14) 1.1 0.680 1344 1239 0.2 0.005 174 793 precorrin-4 C(11)-methyltransferase 
Cd630-1397 (4L9) 1.0 0.896 513 516 0.4 0.005 125 289 conserved hypothetical protein 
Cd630-2543 (7G21) 1.0 0.946 1897 1973 0.6 0.005 917 1475 putative polysaccharide O-acetylase 
Cd630-2492 (7C15) 0.9 0.573 526 592 0.2 0.005 91 383 putative sensor histidine kinase 
  
 
414 
Cd630-2666 (7M1) 1.0 0.807 9675 9865 1.2 0.005 7535 6181 PTS system, glucose-specific IIa component 
Cd630-1170 (3H16) 0.9 0.582 535 577 2.4 0.005 773 322 conserved hypothetical protein 
Cd630-2531 (7C20) 1.1 0.374 5066 4651 0.6 0.005 2241 3410 putative membrane protein 
Cd630-3438 (9J16) 1.0 0.790 1647 1797 0.2 0.005 296 1151 
bifunctional adenosylcobalamin biosynthesis protein [includes: 
adenosylcobinamide kinase and adenosylcobinamide-phosphate 
guanylyltransferase] 
Cd630-0256 (4H8) 1.1 0.627 30258 29247 0.5 0.005 9096 17545 chemotaxis protein 
Cd630-2234 (8I7) 1.0 0.931 177 178 0.4 0.005 40 106 cAMP-binding regulatory protein 
Cd630-0840 (1D23) 1.0 0.918 474 483 0.4 0.005 138 330 putative hydrolase 
Cd630-1594 (5J10) 1.0 0.964 914 897 1.5 0.004 742 483 putative O-acetylserine sulfhydrylase 
Cd630-2262 (8M10) 0.9 0.883 750 711 1.6 0.004 653 446 probable proton-dependent oligopeptide transporter 
Cd630-0606 (2N16) 0.9 0.465 2754 3269 1.6 0.004 3045 1931 chloride ion channel protein 
Cd630-0393 (2I2) 1.1 0.437 3579 3337 0.6 0.004 1406 2459 putative membrane protein 
Cd630-2012 (6J3) 1.0 0.908 2287 2251 0.7 0.004 1019 1465 putative hydrolase 
Cd630-2138 (6H18) 0.9 0.557 1078 1164 0.4 0.004 350 880 uridylate kinase 
Cd630-2750 (7K12) 1.1 0.412 1021 912 0.5 0.004 361 760 accessory gene regulator 
Cd630-2371 (6J24) 1.0 0.674 1868 1860 1.3 0.004 1273 979 L-aspartate oxidase 
Cd630-2444 (7C9) 1.0 0.859 8400 8787 3.2 0.004 17033 5041 putative sigma 54 modulation protein 
Cd630-2334 (6M19) 1.1 0.469 1507 1373 1.4 0.004 1165 843 PTS system, mannitol-specific IIbc component 
Cd630-2055 (6M8) 1.0 0.898 690 669 1.8 0.004 893 477 hypothetical protein 
Cd630-2179 (6A24) 1.0 0.944 1937 2003 0.4 0.004 439 1106 putative oxidoreductase, molybdopterin-binding subunit 
Cd630-1279 (3N18) 1.0 0.834 7072 6952 0.7 0.004 2991 4356 cysteine desulfurase 
Cd630-3284 (9P8) 1.0 0.905 5723 5991 2.3 0.004 7278 2978 probable protease 
Cd630-0654 (2N22) 0.9 0.425 343 368 0.4 0.004 116 293 putative ABC transporter, permease protein 
Cd630-1627 (5C14) 1.0 0.809 335 328 0.4 0.004 93 194 putative D-alanyl-D-alanine carboxypeptidase 
Cd630-0059 (1K8) 1.0 0.854 7358 7811 0.7 0.004 3762 5684 preprotein translocase SecE subunit 
Cd630-1963 (6E8) 1.1 0.439 517 469 2.2 0.004 746 335 conserved hypothetical protein 
Cd630-2819 (8D10) 1.0 0.906 3058 3034 1.9 0.004 3416 1694 putative amino acid racemase 
Cd630-0541 (1G8) 1.0 0.810 1103 1145 0.2 0.004 131 677 chemotaxis protein methyltransferase 
Cd630-0540 (1F8) 1.0 0.960 555 538 0.2 0.004 84 330 chemotaxis protein 
Cd630-2757 (8B1) 1.0 0.512 4020 4159 0.8 0.004 2147 2708 putative phospholipase 
Cd630-2641 (7L22) 1.0 0.889 963 938 0.3 0.004 178 580 conserved hypothetical protein 
Cd630-2815 (8H9) 1.0 0.907 1246 1217 1.7 0.004 1200 674 hypothetical protein 
Cd630-1778 (5K21) 1.0 0.538 1772 1739 0.6 0.004 622 1073 conserved hypothetical protein 
  
 
415 
Cd630-2455 (7F10) 0.9 0.596 838 901 0.3 0.004 105 415 conserved hypothetical protein 
Cd630-1614 (5N12) 1.0 0.997 2554 2544 0.4 0.003 636 1330 putative sodium extrusion ABC transporter, ATP-binding protein 
Cd630-2039 (6M6) 0.9 0.629 306 307 1.6 0.003 288 183 conserved hypothetical protein 
Cd630-0688 (3D4) 1.0 0.786 2616 2512 0.2 0.003 445 1903 conserved hypothetical protein 
Cd630-0769 (1E14) 1.0 0.852 545 546 0.5 0.003 204 429 putative oxidoreductase 
Cd630-3254 (9J5) 1.0 0.621 3052 3208 0.4 0.003 922 2233 putative serine protease 
Cd630-3561 (10E7) 0.9 0.775 538 528 0.5 0.003 227 507 conserved hypothetical protein 
Cd630-0356 (2D9) 1.0 0.903 1422 1447 1.5 0.003 1404 964 excisionase 
Cd630-0242 (4B7) 1.0 0.832 10757 11346 0.5 0.003 5487 10365 conserved hypothetical protein 
Cd630-0881 (3M4) 1.0 0.981 9734 9544 2.7 0.003 13586 4949 putative membrane protein 
Cd630-0866 (3N2) 1.0 0.632 1890 1927 1.4 0.003 1582 1132 putative exported protein 
Cd630-2354 (6I22) 1.1 0.817 615 586 0.6 0.003 284 468 glycine reductase complex component B alpha and beta subunits 
Cd630-1747 (5K17) 1.0 0.901 2861 2904 0.7 0.003 1421 1881 adenosine deaminase 
Cd630-1686 (5F21) 1.0 0.881 724 758 0.3 0.003 112 383 putative DNA-binding protein 
Cd630-0533 (1G7) 1.0 0.869 874 891 0.1 0.003 72 495 chemotaxis protein 
Cd630-3074 (8J18) 1.4 0.457 4966 2816 8.0 0.003 15206 1799 tagatose-1,6-bisphosphate aldolase 
Cd630-0893 (3I6) 1.0 0.869 10153 10419 0.4 0.003 3499 8663 iron-dependent hydrogenase 
Cd630-0888 (3L5) 1.1 0.408 14127 12709 0.3 0.003 2909 9132 arginine decarboxylase 
Cd630-0534 (1H7) 0.9 0.699 1072 1155 0.3 0.003 166 608 chemotaxis protein CheC 
Cd630-0229 (4E5) 1.0 0.654 5536 5238 0.5 0.003 1814 3361 negative regulator of flagellin synthesis (anti-sigma-d factor) 
Cd630-2745 (7N11) 0.8 0.421 558 644 0.6 0.003 251 434 adenine phosphoribosyltransferase 
Cd630-3422 (9J14) 0.9 0.512 1189 1288 0.2 0.003 159 826 sirohydrochlorin cobaltochelatase 
Cd630-1222 (3D23) 1.0 0.833 5455 5658 0.5 0.003 1626 3310 putative tyrosine recombinase 
Cd630-2388 (7C2) 1.0 0.776 633 633 0.3 0.003 117 380 putative peptidoglycan- binding/hydrolysing protein 
Cd630-2309 (6L16) 1.1 0.754 342 327 2.3 0.002 373 169 hypothetical protein 
Cd630-1469b (5E6) 1.0 0.374 8845 8389 0.5 0.002 3002 5863 putative penicillin-binding protein 
Cd630-2063 (6M9) 1.0 0.665 5108 5187 0.6 0.002 2090 3322 putative membrane protein 
Cd630-0223 (4G4) 1.0 0.814 5855 6102 0.5 0.002 1835 3457 
bifunctional purine biosynthesis protein [includes: 
phosphoribosylaminoimidazolecarboxamide formyltransferase and IMP 
cyclohydrolase] 
Cd630-1190 (3D19) 1.0 0.726 3641 3460 0.5 0.002 994 2110 putative acetyltransferase 
Cd630-0545 (1C9) 1.0 0.623 3958 3840 0.5 0.002 1356 2590 putative lipoprotein 
Cd630-3609 (10M1) 1.1 0.467 566 505 0.4 0.002 152 385 hypothetical protein 
Cd630-0339 (2C7) 1.0 0.916 515 507 0.3 0.002 111 390 two-component response regulator 
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Cd630-3619 (10O2) 1.0 0.533 1976 1912 0.6 0.002 801 1360 putative acetyltransferase 
Cd630-2861 
(10F15) 1.0 0.939 74 68 4.6 0.002 100 22 putative membrane protein 
Cd630-0678 (3B3) 1.0 0.873 8635 8832 1.3 0.002 7022 5128 putative transcriptional regulator 
Cd630-2786a (8A5) 1.1 0.518 436 410 1.9 0.002 427 227 putative cell surface protein 
Cd630-0263 (4G9) 1.0 0.691 14384 14419 0.4 0.002 4269 11689 flagellar export protein 
Cd630-2014 (6L3) 1.0 0.972 1677 1574 0.6 0.002 554 959 dihydroxy-acid dehydratase 
Cd630-3353 (9E17) 1.1 0.562 734 614 0.5 0.002 187 372 GntR-family transcriptional regulator 
Cd630-0853 (3I1) 1.0 0.867 11760 11947 0.6 0.002 4653 7756 oligopeptide ABC transporter, permease protein 
Cd630-1027 (4O22) 1.1 0.538 1062 919 2.4 0.002 1394 541 spermidine/putrescine ABC transporter, substrate-binding lipoprotein 
Cd630-0558 (1H10) 1.0 0.800 4946 4867 0.5 0.002 1719 3095 probable glutaminase 
Cd630-2524 (7D19) 1.0 0.663 4078 3958 0.4 0.002 774 2067 nicotinate-nucleotide adenylyltransferase 
Cd630-1793 (5J23) 1.1 0.503 1066 900 2.9 0.002 1634 578 putative membrane protein 
Cd630-3614 (10J2) 1.1 0.503 2344 2218 1.7 0.002 2456 1402 conserved hypothetical protein 
Cd630-3513 (10E1) 1.1 0.405 327 286 2.3 0.002 331 144 pilin 
Cd630-0324 (2D5) 1.0 0.873 29696 30198 0.5 0.002 12590 26074 putative cobalt transport protein 
Cd630-3427 (9O14) 1.1 0.553 3601 3251 0.4 0.002 912 2343 probable cobalt-precorrin-6y C(15)-methyltransferase 
Cd630-3100 (8L21) 1.0 0.703 17939 17919 0.4 0.002 4120 10919 putative C4-dicarboxylate anaerobic carrier 
Cd630-2330 (6I19) 1.0 0.687 5338 5496 0.3 0.002 1255 3942 xanthine phosphoribosyltransferase 
Cd630-0027 (1K4) 1.0 0.918 3694 3789 0.7 0.002 1589 2297 DNA repair protein 
Cd630-3145 (9A3) 1.0 0.968 15569 15226 0.3 0.002 2394 9030 
putative serine-aspartate-rich surface anchored fibrinogen-binding 
protein 
Cd630-0591 (2I15) 1.0 0.823 2019 1957 0.3 0.002 353 1139 putative cation transporting ATPase 
Cd630-2760 (8E1) 0.9 0.442 2285 2370 0.5 0.002 864 1588 putative signaling protein 
Cd630-1221 (3C23) 1.0 0.755 2046 2085 0.3 0.001 332 967 putative membrane protein 
Cd630-1478 (5F7) 0.9 0.524 1080 1345 3.7 0.001 2629 730 putative ferrous iron transport protein A 
Cd630-1237 (3L13) 1.0 0.731 3956 4051 0.5 0.001 1268 2513 hypothetical protein (fragment) 
Cd630-1446 (5E3) 1.0 0.709 2162 2341 0.3 0.001 341 1305 para-aminobenzoate synthase component I 
Cd630-2761 (8F1) 0.9 0.467 3887 4239 0.5 0.001 1508 2813 putative N-acetylmuramoyl-L-alanine amidase 
Cd630-2510 (7E17) 1.0 0.807 3203 3228 0.6 0.001 1074 1838 PTS system, IIbc component 
Cd630-2065 (6O9) 1.0 0.943 2264 2181 2.2 0.001 2857 1300 putative regulatory protein 
Cd630-1161 (3G15) 1.1 0.630 5202 4985 1.6 0.001 7379 4365 50S ribosomal protein L21 
Cd630-1779 (5L21) 1.0 0.753 3384 3277 0.5 0.001 1178 2204 conserved hypothetical protein 
Cd630-2565 (7E24) 1.1 0.636 785 700 1.5 0.001 780 509 putative transcriptional antiterminator 
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Cd630-3143 (9G2) 1.0 0.991 691 690 0.7 0.001 287 412 conserved hypothetical protein 
Cd630-2796b (8C7) 0.9 0.454 7224 7918 0.4 0.001 2264 5178 putative cell surface protein 
Cd630-0117 (2E15) 1.1 0.429 8069 7542 2.2 0.001 11560 5416 putative subunit of oxidoreductase 
Cd630-1800 (5I24) 0.9 0.513 2968 3389 0.4 0.001 1092 2422 tellurium resistance protein 
Cd630-2229 (8L6) 0.9 0.436 125 144 4.5 0.001 349 79 putative membrane protein 
Cd630-1576 (5P7) 0.9 0.401 3485 3629 0.5 0.001 957 1931 putative arylesterase 
Cd630-3668 (10P8) 0.9 0.639 7546 8348 0.7 0.001 3277 4932 putative transcriptional regulator 
Cd630-0268 (4D10) 1.0 0.788 16216 15812 0.4 0.001 3980 9326 flagellar basal-body rod protein FlgG 
Cd630-2647 (7J23) 1.0 0.625 1823 1949 0.4 0.001 619 1655 putative membrane protein 
Cd630-0887 (3K5) 1.0 0.510 4971 5187 0.5 0.001 1818 3606 GntR-family transcriptional regulator 
Cd630-3341 (9A16) 1.0 0.870 1089 1020 1.5 0.001 898 606 conjugative transposon conserved hypothetical protein (pseudogene) 
Cd630-3642 (10N5) 1.0 0.902 2092 2111 0.6 0.001 763 1319 putative selenocysteine synthase 
Cd630-2171 (6A23) 1.0 0.901 8050 7970 0.5 0.001 2583 5235 putative Sodium:dicarboxylate symporter 
Cd630-2767b (8E2) 1.0 0.635 6104 5799 0.4 0.001 1756 3911 putative cell surface protein 
Cd630-0707 (3G6) 1.0 0.734 2727 2698 0.6 0.001 1005 1721 putative signaling protein 
Cd630-0730 (3F9) 1.0 0.999 10558 10597 2.3 0.001 15588 6686 putative iron-sulfur protein 
Cd630-0728 (3D9) 1.0 0.581 4676 4457 0.6 0.001 1507 2572 
putative carbon monoxide dehydrogenase/acetyl-CoA synthase 
complex, beta subunit 
Cd630-3077 (8M18) 1.3 0.498 1073 717 2.9 0.001 1076 379 phosphosugar-binding transcriptional regulator 
Cd630-0269 (4E10) 1.0 0.583 13488 13837 0.4 0.001 4255 9108 putative flagellar basal-body rod protein 
Cd630-2270 (8M11) 1.2 0.476 234 184 3.7 0.001 363 102 putative 1-phosphofructokinase 
Cd630-3116 (8L23) 1.0 0.806 3635 3745 0.7 0.001 1397 2114 PTS system, beta-glucoside-specific IIabc component 
Cd630-0226 (4B5) 1.0 0.956 15207 15050 0.5 0.000 5738 11783 putative transglycosylase 
Cd630-0282 (4B12) 1.0 0.854 2121 2073 2.0 0.000 2134 1041 putative phosphoesterase 
Cd630-3673 (10M9) 1.0 0.726 5057 4824 0.5 0.000 1824 3591 putative stage 0 sporulation protein 
Cd630-3241 (9M3) 1.3 0.722 78 30 3.9 0.000 78 20 proline reductase 
Cd630-2365 (6L23) 1.0 0.974 25340 25640 0.6 0.000 10829 18992 putative sulfonate ABC transporter, solute-binding lipoprotein 
Cd630-1997 (6H12) 1.1 0.430 1722 1665 2.2 0.000 1901 895 putative proline iminopeptidase 
Cd630-3625 (10M3) 0.9 0.498 2994 3102 0.4 0.000 716 1874 putative signaling protein 
Cd630-0267 (4C10) 1.0 0.945 4523 4643 0.4 0.000 1388 3244 putative exported protein 
Cd630-1692 (5D22) 1.0 0.963 4832 4865 3.0 0.000 9147 3047 ArsR-family transcriptional regulator 
Cd630-3414 (9J13) 1.4 0.445 445 302 1.7 0.000 363 210 ABC transporter, solute-binding protein 
Cd630-0341 (2E7) 1.0 0.992 2096 2073 0.4 0.000 552 1444 conserved hypothetical protein 
Cd630-1157 (3C15) 1.0 0.628 10506 10187 1.6 0.000 13531 8135 putative anaerobic nitric oxide reductase flavorubredoxin 
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Cd630-0261 (4E9) 1.0 0.882 3881 3868 0.5 0.000 1595 2945 flagellar export protein 
Cd630-0194 (4B1) 1.1 0.624 12837 12269 1.9 0.000 14495 7570 60 kDa chaperonin 
Cd630-0241 (4A7) 0.9 0.719 11324 12564 0.4 0.000 4971 12370 phosphoserine phosphatase 
Cd630-1590 (5N9) 1.0 0.979 4060 4004 2.0 0.000 4516 2296 putative membrane protein 
Cd630-0231 (4G5) 1.0 0.940 24468 24284 0.2 0.000 4941 20098 putative flagellar hook-associated protein 
Cd630-1953 (6C7) 1.0 0.995 7079 7050 0.2 0.000 977 5607 conserved hypothetical protein 
Cd630-0796 (1H17) 1.0 0.400 2787 2923 1.2 0.000 1974 1686 LacI-family transcriptional regulator 
Cd630-3272 (9L7) 1.0 0.995 4647 4724 0.6 0.000 1946 3159 putative membrane protein 
Cd630-0247 (4G7) 1.0 0.980 10454 10897 0.4 0.000 2853 7380 flagellar hook-basal body complex protein 
Cd630-2062 (6L9) 1.0 0.685 6790 6524 0.6 0.000 2643 4682 conserved hypothetical protein 
Cd630-2329 (6P18) 1.1 0.775 6248 6117 0.4 0.000 1564 3819 putative transaldolase 
Cd630-0582 (2P13) 1.0 0.849 5333 5031 2.0 0.000 6173 3108 putative PEP-utilising kinase 
Cd630-0559 (1A11) 0.9 0.474 5118 5407 0.4 0.000 1385 3842 conserved hypothetical protein 
Cd630-0549 (1G9) 1.0 0.780 2505 2565 2.0 0.000 2861 1423 putative exported protein 
Cd630-1025 (4M22) 0.9 0.512 1230 1320 1.8 0.000 1653 923 spermidine/putrescine ABC transporter, permease protein 
Cd630-0617 (2I18) 1.0 0.958 881 882 0.3 0.000 145 560 putative membrane protein 
Cd630-0538 (1D8) 0.9 0.436 2849 3169 0.1 0.000 251 1686 putative methyl accpeting chemotaxis protein 
Cd630-2366 (6M23) 1.0 0.828 18874 19989 0.2 0.000 3379 14184 putative exported protein 
Cd630-2367 (6N23) 1.0 0.784 10077 10343 0.5 0.000 4273 9224 putative permease 
Cd630-0265 (4A10) 1.0 0.941 8875 8593 0.3 0.000 1334 5133 flagellar number regulator 
Cd630-0855 (3K1) 1.0 0.983 13417 13256 0.4 0.000 3598 9622 oligopeptide ABC transporter, substrate-binding lipoprotein 
Cd630-1205 (3C21) 1.0 0.508 5206 5421 0.5 0.000 1811 3416 geranyltranstransferase 
Cd630-1479 (5G7) 0.8 0.423 3730 4606 0.4 0.000 1323 3256 ferrous iron transport protein B 
Cd630-1477 (5E7) 1.1 0.671 514 444 6.9 0.000 1959 273 putative ferrous iron transport protein 
Cd630-2806 (8G8) 1.0 0.799 1594 1587 0.6 0.000 675 1044 holliday junction DNA helicase 
Cd630-3515 (10G1) 0.9 0.474 1655 1745 0.4 0.000 454 1164 
bifunctional protein [includes: UDP-N- acetylglucosamine 
pyrophosphorylase and glucosamine-1-phosphate N-acetyltransferase] 
Cd630-0854 (3J1) 1.0 0.652 8743 8567 0.4 0.000 1985 5427 oligopeptide ABC transporter, permease protein 
Cd630-0535 (1A8) 0.8 0.618 839 782 0.2 0.000 93 601 chemotaxis protein 
Cd630-0264 (4H9) 1.0 0.640 18430 18550 0.2 0.000 3007 11798 signal recognition particle complex, GTP- binding subunit 
Cd630-2003 (6N1) 1.0 0.582 1851 1811 2.4 0.000 2785 1152 putative efflux pump 
Cd630-2768 (8F2) 1.0 0.743 9711 9858 0.3 0.000 2421 8100 putative cell-wall hydrolase 
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9.3. Codon usage in C. difficile 
The codon usage of C. difficile was compared to that of the transposase 
gene from pHV1248 using the Graphical Codon Usage Analyzer version 2.0 
(http://gcua.schoedl.de/seqoverall_v2.html) based on information from 
www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=1496&aa=1&style=N 
and the plasmid sequence of pHV1248.  The results are shown graphically 
with the percentage of codons representing each amino acid from the 
transposase gene shown in red and the C. difficile reference in black.  Where 
the usage in the transposase gene is significantly higher this highlights a 
possible shortage of the cognate tRNAs in C. difficile.  
 
